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A B S T R A C T
Background
Eczema is a chronic skin disease characterised by dry skin, intense itching, inflammatory skin lesions, and has a considerable impact
on quality of life. Moisturisation is an integral part of treatment, but it is unclear if moisturisers are effective.
Objectives
To assess the effects of moisturisers for eczema.
Search methods
We searched the following databases to December 2015: Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase,
LILACS, and GREAT. We searched five trials registers and checked references of included and excluded studies for further relevant
trials.
Selection criteria
Randomised controlled trials in people with eczema.
Data collection and analysis
We used standard Cochrane methodological procedures.
Main results
We included 77 studies (mean duration: 6.7 weeks; 6603 participants, mean age: 18.6 years). Thirty-six studies were at high risk of bias,
34 at unclear risk, and seven at low risk. Twenty-four studies assessed our primary outcome of participant-assessed disease severity, 13
assessed satisfaction, and 41 assessed adverse events. Secondary outcomes included investigator-assessed disease severity (addressed in
65 studies), skin barrier function (29), flare prevention (16), quality of life (10), and corticosteroid use (eight). Adverse events reporting
was limited (smarting, stinging, pruritus, erythema, folliculitis).
Six studies evaluated moisturiser versus no moisturiser. Participant-assessed disease severity and satisfaction were not assessed. Moisturiser
use yielded lower SCORing Atopic Dermatitis (SCORAD) scores than no moisturiser (3 studies, 276 participants; mean difference
(MD) -2.42, 95% confidence interval (CI) -4.55 to -0.28), but the minimal important difference (MID) was unmet. Moisturiser use
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resulted in fewer flares (2 studies, 87 participants; RR 0.40, 95% CI 0.23 to 0.70), prolonged time to flare (median: 180 versus 30
days), and reduced use of topical corticosteroids (2 studies, 222 participants; MD -9.30 g, 95% CI -15.3 to -3.27). There was no clear
difference in adverse events (1 study, 173 participants; risk ratio (RR) 15.34, 95% CI 0.90 to 261.64). Evidence for these outcomes
was low quality.
With Atopiclair, 174/232 participants reported improvement in disease severity versus 27/158 using vehicle (3 studies; RR 4.51, 95%
CI 2.19 to 9.29). Atopiclair decreased itching (4 studies, 396 participants; MD -2.65, 95% CI -4.21 to -1.09) and achieved more
frequent satisfaction (2 studies, 248 participants; RR 2.14, 95% CI 1.58 to 2.89), fewer flares (3 studies, 397 participants; RR 0.18,
95% CI 0.11 to 0.31), and lower Eczema Area and Severity Index (EASI) scores (4 studies, 426 participants; MD -4.0, 95% CI -5.42
to -2.57), but the MID was unmet. The number of participants reporting adverse events was not statistically different (4 studies, 430
participants; RR 1.03, 95% CI 0.79 to 1.33). Evidence for these outcomes was moderate quality.
Participants reported skin improvement more frequently with urea-containing cream than placebo (1 study, 129 participants; RR 1.28,
95% CI 1.06 to 1.53; low-quality evidence), with equal satisfaction between the two groups (1 study, 38 participants; low-quality
evidence). Urea-containing cream improved dryness (investigator-assessed) (1 study, 128 participants; RR 1.40, 95% CI 1.14 to 1.71;
moderate-quality evidence), and produced fewer flares (1 study, 44 participants; RR 0.47, 95% CI 0.24 to 0.92; low-quality evidence),
but caused more adverse events (1 study, 129 participants; RR 1.65, 95% CI 1.16 to 2.34; moderate-quality evidence).
Three studies assessed glycerol-containing moisturiser versus vehicle or placebo. More participants in the glycerol group noticed skin
improvement (1 study, 134 participants; RR 1.22, 95% CI 1.01 to 1.48; moderate-quality evidence), which also included improved
investigator-assessed SCORAD scores (1 study, 249 participants; MD -2.20, 95% CI -3.44 to -0.96; high-quality evidence), but the
MID was unmet. Participant satisfaction was not addressed. The number of adverse events reported was not statistically significant (2
studies, 385 participants; RR 0.90, 95% CI 0.68 to 1.19; moderate-quality evidence).
Four studies investigated oat-containing moisturisers versus no treatment or vehicle. No significant differences between groups were
reported for participant-assessed disease severity (1 study, 50 participants; RR 1.11, 95% CI 0.84 to 1.46; low-quality evidence),
satisfaction (1 study, 50 participants; RR 1.06, 95% CI 0.74 to 1.52; very low-quality evidence), or investigator-assessed disease severity
(3 studies, 272 participants; standardised mean difference (SMD) -0.23, 95% CI -0.66 to 0.21; low-quality evidence). In the oat
group, there were fewer flares (1 study, 43 participants; RR 0.31, 95% CI 0.12 to 0.7; low-quality evidence) and reduced use of topical
corticosteroids (2 studies, 222 participants; MD -9.30g, 95% CI 15.3 to -3.27; low-quality evidence), but more adverse events (1 study,
173 participants; Peto odds ratio (OR) 7.26, 95% CI 1.76 to 29.92; low-quality evidence).
We compared all moisturisers to placebo, vehicle, or no moisturiser. Participants considered moisturisers to be more effective for
reducing eczema (5 studies, 572 participants; RR 2.46, 95% CI 1.16 to 5.23; low-quality evidence) and itch (7 studies, 749 participants;
SMD -1.10, 95% CI -1.83 to -0.38) than control. Participants in both treatment arms reported comparable satisfaction (3 studies, 296
participants; RR 1.35, 95% CI 0.77 to 2.26; low-quality evidence). Moisturisers led to lower investigator-assessed disease severity scores
(12 studies, 1281 participants; SMD -1.04, 95% CI -1.57 to -0.51; high-quality evidence) and fewer flares (6 studies, 607 participants;
RR 0.33, 95% CI 0.17 to 0.62; moderate-quality evidence), without a difference in adverse events (10 studies, 1275 participants; RR
1.03, 95% CI 0.82 to 1.30; moderate-quality evidence).
Topical active treatment combined with moisturiser was more effective than active treatment alone in reducing investigator-assessed
disease severity scores (3 studies, 192 participants; SMD -0.87, 95% CI -1.17 to -0.57; moderate-quality evidence) and flares (1
study, 105 participants; RR 0.43, 95% CI 0.20 to 0.93), and was preferred by participants (both low-quality evidence). There was no
clear difference in number of adverse events (1 study, 125 participants; RR 0.39, 95% CI 0.13 to 1.19; very low-quality evidence).
Participant-assessed disease severity was not addressed.
Authors’ conclusions
Most moisturisers showed some beneficial effects; prolonging time to flare, reducing the number of flares and the amount of topical
corticosteroids needed to achieve similar reductions in eczema severity. Moisturisers combined with active treatment gave better results
than active treatment alone. We did not find reliable evidence that one moisturiser is better than another.
P L A I N L A N G U A G E S U M M A R Y
Emollients and moisturisers for eczema
Review question
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Do emollients and moisturisers help control eczema?
Background
Eczema is a chronic (long-lasting) skin disorder. Its main symptoms are dry skin and intense itching. Affected areas appear red, with
crusts and scratches, and may ooze fluid. Moisturisers are considered important in eczema treatment, but there is uncertainty about
how well they work, and whether any one moisturiser works better - and is preferable - to another.
Study characteristics
We searched the medical literature up to December 2015, and identified 77 relevant studies with 6603 participants, with mainly mild
to moderate eczema. Participant age ranged from four months to 84 years (mean: 18.6 years). Most studies lasted between two and six
weeks; a few lasted six months.
Forty-six studies received funding from pharmaceutical companies.
Key results
Most moisturisers appeared to be effective. Twenty-four studies reported participant-assessed eczema severity. Only 13 studies assessed
participant satisfaction with the moisturiser. Side effects (adverse events) were reported in 41 studies, although this information was
often limited (mainly smarting, stinging, itch, redness). Most studies evaluated physician-assessed severity of eczema (65 studies). Other
outcomes addressed were skin barrier function (29 studies), flare prevention (16), quality of life (10), and corticosteroid use (8).
According to physicians, moisturisers reduced eczema severity compared with no moisturiser (3 studies), but the reduction was too
small to be considered meaningful for patients. Moisturiser use resulted in fewer flares (2 studies), and reduced the need for topical
corticosteroids (2 studies). Participant-assessed eczema severity and satisfaction were not evaluated. There was no difference in the
number of adverse events reported.
Participants thought Atopiclair (containing glycyrrhetinic acid) was more than four times more effective at improving eczema-severity
than the control (i.e. identical looking, but without glycyrrhetinic acid) (3 studies). However, physicians did not identify a meaningful
difference for patients. Atopiclair led to greater reduction of itch (4 studies), more frequent participant satisfaction (2 studies), and
fewer flares (3 studies). The number of reported adverse events was similar in each group.
Four studies evaluated urea-containing cream. Participants using urea cream reported improvement more often than those using control
(1 study). Satisfaction ratings in both groups were comparably positive (1 study). Urea-containing cream improved dryness more often
(physician assessment) (1 study) and led to fewer flares (1 study), but with more adverse events reported.
Three studies assessed glycerol-containing moisturiser versus control. More participants in the glycerol group considered their skin
to be improved (1 study), as did physicians, but these differences were not meaningful for patients. Participant satisfaction was not
addressed. There was no difference in the number of adverse events reported.
Four studies investigated oat-containing moisturisers versus no treatment or control. No differences between groups were observed for
participant-assessed improvement (1 study), participant satisfaction (1 study), or physician-assessed improvement (3 studies). However,
the oat group had fewer flares (1 study), and a reduced need for topical corticosteroids (2 studies). Oat creams caused more adverse
events.
When we compared all moisturisers against no moisturiser or control, overall, participants considered moisturisers to be more than
twice as effective in improving eczema than no moisturiser or control (5 studies), and more effective for itch (7 studies). Participants
in both treatment arms reported comparable satisfaction (3 studies). According to physicians, moisturisers decreased eczema severity
more than the control (12 studies), and led to fewer flares (6 studies). There were no differences between groups for the number of
adverse events reported.
According to physicians, topical corticosteroids were more effective at improving eczema when used with a moisturiser, rather than
used alone (3 studies), and also reduced the number of flares (1 study). This combination was also favoured by participants, though
participant-assessed disease severity was not addressed. There was no difference in the number of adverse events reported.
Quality of the evidence
There was high certainty evidence for physician-assessed disease severity for glycerol-containing creams versus control and all moisturisers
versus control. For most other outcomes across comparisons, there was low to moderate certainty evidence. The most important reasons
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for lowering the certainty of evidence were risk of bias in studies (e.g. no blinding, or missing data), or too few participants, which
leads to less precise results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
M oisturisers versus no moisturiser for eczema
Patient or population: people with eczema
Setting: dermatology departments in hospitals
Intervention: moisturisers
Comparison: no treatment (no moisturiser)
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intervent ion group was






Reduct ions f rom base-
line in
Giordano-Labadie 2006
and Grimalt 2007 met
MID (= 8.7 Schram
2012) in both treat-
ment arms. There was
greater severity of dis-
ease in these studies
than in Patrizi 2014.
A MD of -2.42, although
stat ist ically signif icant,













There were fewer f lares
in the moisturiser
groups. The rate of f lare
in the control group was
3.74 t imes the rate in
the moisturiser group
(hazard rat io (HR) 3.74,
95% CI 1.86 to 7.50; P =
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ence in change f rom
baseline of quality of
lif e between the 2 treat-
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CDLQI: Children’s Dermatology Life Quality Index; CI: conf idence interval; IDQOL: Infant ’s Dermatit is Quality of Life Index; M D: mean dif ference; M ID: minimal important
dif f erence;OR: odds rat io; RR: risk rat io; SCORAD: scoring atopic dermatit is; SM D: standardised mean dif ference
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aWe had to put a value other than 0 in GRADEproGDT to calculate the risk with no moisturiser in relat ion to the RR, and we
chose 0.5 (af ter discussion with the GRADE working Group). GRADEproGDT then calculates the risk with moisturiser.
1Grimalt 2007.
2Downgraded one level due to high risk of bias because of performance and detect ion bias.
3Downgraded one level due to serious imprecision (wide conf idence interval, low occurrence of events).
4Giordano-Labadie 2006, Grimalt 2007, Patrizi 2014.
5Downgraded one level for serious inconsistency (I² = 68%), caused by Grimalt 2007.
6 Weber 2015, Wirén 2009.
7Downgraded one level for serious imprecision (small sample size).
8Giordano-Labadie 2006, Grimalt 2007.
9Downgraded one level for serious inconsistency (I² = 68%). In the study of Giordano-Labadie 2006, far more topical
cort icosteroids were used and the dif ference between the two arms was much larger.



















































































B A C K G R O U N D
We have listed relevant terms in the glossary of terms in Table 1.
Description of the condition
Definition
Atopic eczema, which is also known as atopic dermatitis, eczema,
flexural eczema or neurodermatitis, is a chronic inflammatory skin
disease that can present with frequent spontaneous flares and re-
missions (Bos 2010; Eichenfield 2014a; Weidinger 2016). It is a
heterogeneous, highly variable skin disease with a broad range of
presentations, and is characterised principally by dry skin, intense
itching, and inflammatory skin lesions (Andersen 2015; Bieber
2008; Weidinger 2016). Atopic eczema has a typical age-related
distribution (Möhrenschlager 2006), and in all of the age cate-
gories, itching can result in sleep deprivation and have a consider-
able impact on quality of life (Bieber 2008; Weidinger 2016).
There is long-standing and continuing debate as to whether atopic
eczema is truly atopic (Flohr 2004; Flohr 2008; Williams 2005;
Williams 2006). Atopy is associated with an increased level of im-
munoglobulin E (IgE) antibodies against common inhaled aller-
gens (sensitisation) (Flohr 2004), but there does not seem to be
an absolute relationship between IgE levels and atopic dermatitis,
as the percentage of people with atopic dermatitis that show aller-
gic sensitisation to aeroallergens varies widely from 30% to 80%
(Eichenfield 2014a; Flohr 2004; Flohr 2008). The development
of atopic eczema followed by the development of allergic sensi-
tisation, asthma or food allergy is often called the ’atopic march’
(Boguniewicz 2011; Eichenfield 2014a), but this is not a universal
occurrence (Eichenfield 2014a; Williams 2006), and it has been
postulated that the sequence might even be reversed (such as the
onset of asthma before the onset of eczema) (Dharmage 2014).
We will use the term ’eczema’ throughout the review in agree-
ment with the ’Revised nomenclature for allergy for global use’
(Johansson 2004).
Epidemiology
A number of recent studies have reported that the lifetime preva-
lence of eczema at the global level continues to show a steady
but measurable increase (Flohr 2014; Nutten 2015; Weidinger
2016). These findings largely concur with an earlier systematic
review of epidemiological studies, covering the period 1990 to
2010, which concluded that although there was “no consistent
overall global trend”, prevalence has increased in some parts of
the world (Deckers 2012; Haileamlak 2005). In an investigation
into whether childhood eczema prevalence was on the increase
worldwide, researchers evaluated data from Phases One (1991 to
2002) and Three (1999 to 2004) of the International Study of
Asthma and Allergies in Childhood (ISAAC), and reported that
“the epidemic of eczema seems to be levelling or decreasing in
some countries with previously high prevalence rates” (Odhiambo
2009; Williams 2008). It is generally recognised that the limi-
tations and reliability of most of these epidemiological data are
in part dependent on the complexities associated with assessing
global trends over time, as well as on the diversity of outcome and
diagnostic measures used to gather the data (Flohr 2009).
Prevalence rates vary between and within countries and are re-
ported to range between 15% and 30% in children, and be-
tween 2% and 10% in adults (Bieber 2008; Mack Correa 2012;
Silverberg 2013). Most of these data have been derived from ques-
tionnaires; however, the validity and reliability of using question-
naires to obtain prevalence data for eczema in non-English speak-
ing and low- and middle-income countries has recently been ques-
tioned (Flohr 2009; Hogewoning 2012).
The first manifestations of eczema usually occur in early infancy,
with approximately 60% of cases developing during the first year
of life (Bieber 2008; Eichenfield 2014a; Nutten 2015; Weidinger
2016), and with up to 90% of individuals experiencing an onset
of eczema before the age of five (Bieber 2008; Eichenfield 2014a;
Nutten 2015). However, eczema can also develop in adult life (late-
onset eczema) (Bieber 2008; Eichenfield 2014a). Several studies
have reported that up to 70% of affected children have either a
resolution or a marked improvement of their eczema before ado-
lescence (Bieber 2008; Eichenfield 2014a; Weidinger 2016). The
recent PEER study (Pediatric Eczema Elective Registry), which
consisted mainly of children with mild to moderate eczema, also
indicated that eczema probably does not resolve fully in the ma-
jority of children who have it to a mild or moderate degree, but is
most likely a lifelong disease (Margolis 2014).
Eczema constitutes a major public health issue, and was ranked
as the skin condition with the highest burden of disease expressed
as disability-adjusted life years (DALYs) in the Global Burden
of Disease Study 2010 (Murray 2012). Furthermore, it has been
estimated that the overall economic costs associated with eczema
are not dissimilar to those for asthma (Jenner 2004; Nutten 2015;
Williams 2005).
Symptoms
The cardinal features of eczema are dry skin and intense itch ac-
companied by persistent subsequent scratching, which become
part of a continuous itch-scratch cycle (Bieber 2008; Eichenfield
2014a). In addition, the presence of red, irritated, scaly patches
on the skin that sometimes become infected, coupled with sleep
disturbances and difficulties concentrating at school and at work,
can have a significant impact on the quality of life of affected in-
dividuals (Lewis-Jones 2006; Nutten 2015).
Risk factors and aetiology
Although the precise aetiology is yet to be determined conclu-
sively, a number of potential risk factors and possible causative
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associations have been acknowledged for eczema (Bieber 2008;
Eichenfield 2014a; Weidinger 2016). Genetic and environmental
factors have been implicated and remain a continuing subject of
debate, as does the lack of certainty regarding the balance of im-
pact of these risk factors, and whether they should be considered
as interdependent, cumulative or sequentially independent (Cork
2009; Flohr 2008; Flohr 2014). Indeed, it remains unclear how
the increased prevalence can be explained by genetic factors alone,
and whether these increases in prevalence may reflect more recent
changes at an environmental level that appear to have a key role
in the disease process (Cork 2006).
Genetic risk factors, which have been evaluated in several observa-
tional studies, showed a higher concordance rate in monozygotic
(identical) twins than dizygotic (fraternal) twins (Bieber 2008;
Nutten 2015), and people with a family history of atopic disease
are at increased risk of developing eczema (Boguniewicz 2011;
Eichenfield 2014a). Discussion of candidate gene association stud-
ies and genome-wide linkage studies, as well as the concepts of
innate and adaptive immunity is beyond the scope of this review,
but more information can be found in the literature (Bieber 2008;
Boguniewicz 2011; Weidinger 2016).
Important genetic risk factors have been identified and are the
focus of ongoing research. The most significant of these are loss-
of-function mutations in the filaggrin gene (FLG), which has the
propensity to influence skin barrier function and transepidermal
water loss (TEWL) (Flohr 2014; Palmer 2006). When the skin
barrier functions normally it prevents water loss through the skin,
and also protects against the penetration of irritants, allergens and
pathogenic microbes (Elias 2014; Moncrieff 2013). Filaggrin is a
key protein in epidermal differentiation, and is therefore crucial for
skin barrier integrity (Nutten 2015; Palmer 2006). This protein,
which is expressed in the outer layers of the epidermis, has multiple
functions, one of which is hydration of the stratum corneum (Elias
2014; Kezic 2008). Filaggrin is degraded into hygroscopic, free
amino acids, some of which generate natural moisturising factors
(NMF) that maintain epidermal hydration (Kezic 2008; Moncrieff
2013). However, not all people suffering from eczema appear to
have FLG mutations, and not all people with FLG mutations have
eczema (Eichenfield 2014a; Nutten 2015). Further breakdown of
the skin barrier can be caused by proteases - enzymes normally
involved in homeostasis and restoration of the skin barrier - in
the stratum corneum. Protease levels are increased in people with
eczema (by genetic and environmental factors) (Cork 2006; Elias
2014). Proteases released by the bacterium Staphylococcus aureus
(S aureus) can also add measurably to the disruption of the skin
barrier and enhance microbial invasion (Cork 2009; Elias 2014).
While the skin of 5% to 30% of people without eczema is colonised
with S aureus, colonisation occurs in 60% to 100% of people
with eczema (Petry 2013). In addition, the toxins produced by S
aureus can exacerbate skin inflammation, and contribute to disease
severity (Bieber 2008; Chung 2008; Elias 2011; Petry 2013).
Recent findings in skin biology suggest that skin barrier defects
might be a crucial initiator of disease activity in eczema (Palmer
2006; Simpson 2014). Researchers and eczema experts continue
to debate whether impaired barrier function is secondary to the
inflammatory response in people with eczema (inside-outside hy-
pothesis) (Leung 2000), or if xerosis, caused by barrier dysfunc-
tion, should be considered to be the driver of disease activity (out-
side-inside hypothesis) (Chamlin 2002; Cork 2006; Elias 2011;
Elias 2014). The stratum corneum is central to the normal func-
tioning of the skin barrier. In people with eczema, both lesional
skin and non-lesional skin demonstrate a reduced barrier func-
tion (Janssens 2012; van Smeden 2014b). Skin barrier function is
largely dependent on the intercellular lipid matrix in the stratum
corneum, which is composed of corneocytes (dead, flattened cells
containing NMF), which are protected externally by a cornified
cell envelope and are surrounded by a lipid matrix in what has
been described as a ’bricks and mortar’ structure (Caussin 2008;
Rawlings 2014; van Smeden 2014b). The ’bricks’ are held together
by corneodesmosomes and the intercellular matrix (lipid bilayers)
(Rawlings 2014; van Smeden 2014b, respectively). This lipid ma-
trix consists of free fatty acids, ceramides and cholesterol. Studies
have demonstrated that in eczema the amount, concentration, and
chain length of ceramide and free fatty acids - as well as the organi-
sation of the lipids within the matrix - are altered; and the amount
of lipids is reduced in both lesional and non-lesional skin (Elias
2014; Janssens 2012; van Smeden 2014a; van Smeden 2014b). In
healthy skin, three components regulate hydration by inhibiting
water loss: the intercellular lipid matrix, the fully matured corneo-
cytes bound by the corneodesmosomes, and the NMF within the
corneocytes (Rawlings 2005; Rawlings 2014). Skin barrier disrup-
tion in people with eczema makes the skin more susceptible to
the penetration of allergens, irritants and microbes (Boguniewicz
2011; Flohr 2014; van Smeden 2014a). Furthermore, TEWL is
increased when skin barrier function is impaired, and people with
eczema demonstrate elevated TEWL in both lesional and non-
lesional skin (Janssens 2012; van Smeden 2014b).
Environmental factors such as aeroallergens, microbial exposure,
diet, climate, antibiotics, smoking, pollution, skin irritants, hard
water, improved hygiene, and number of siblings have also been
implicated in the development of eczema (Eichenfield 2014a;
Hogewoning 2010; Flohr 2014; Lee 2007; Mack Correa 2012).
Clinical findings and diagnosis
Three age-related clinical phases can be observed for eczema
(Bieber 2008; Möhrenschlager 2006; Weidinger 2016). The in-
fantile phase is characterised by the appearance of lesions on the
cheeks and scalp, but the whole body may be affected (Bieber
2008; Weidinger 2016). In childhood, the flexural areas of the
knee and elbows are generally affected, but the wrists, ankles and
buttocks can also be involved (Bieber 2008; Weidinger 2016). In
adolescents and adults, the neck and face are most commonly af-
fected, with a more diffuse scaling, erythema, and lichenification
(Bieber 2008; Weidinger 2016). In people with a dark skin type
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(i.e. Asians, Carribeans or Africans) there is a predilection more
often for the extensor surfaces to be affected instead of the flexor
surfaces and “discoid (circular) or follicular (around hair follicles)
patterns may be more common” (NICE 2007). Also, the severity
of erythema might be more difficult to assess in darker skin types.
In the acute stage, eczema is characterised clinically by itching,
diffuse redness, oozing papulovesicular lesions and crusts, and is
often accompanied by secondary infection with S aureus (Mack
Correa 2012; Weidinger 2016; Williams 2005). The chronic stage
is typified by lichenification, excoriations and very dry skin with
a more specific involvement of the elbow and knee folds, wrists,
ankles, face and neck (Möhrenschlager 2006; Williams 1994).
Physical examination continues to be the best way to diagnose
eczema because diagnosis is based on an array of clinical find-
ings, and there is no single pathognomonic biomarker that can be
used to make the diagnosis (Andersen 2015; Eichenfield 2014a;
Weidinger 2016; Williams 2005). The most frequently used clini-
cal criteria for the diagnosis of eczema are those developed by Han-
ifin and Rajka in 1980 (Hanifin 1980). These criteria are based on
clinical experience and were developed via a consensus approach.
The UK Diagnostic Criteria for Atopic Dermatitis Working Party
has refined the criteria of Hanifin and Rajka further by developing
a core set of six diagnostic criteria, which are especially suitable
for use in epidemiological and clinical studies (Eichenfield 2014a;
Williams 1994; Williams 1996).
Description of the intervention
Management strategies for eczema include both active treatments
that address the inflammatory lesions and adjunctive therapies to
optimise skin barrier function and prevent flare-ups (Eichenfield
2014a; Eichenfield 2014b; Ring 2012a). Further recommended
measures include advice on: bathing practices; avoidance of trig-
gers such as irritants (e.g. wool, soap), allergens (such as aeroaller-
gens, food allergens, contact allergens), environmental factors (e.g.
humidity), and non-irritating clothing; together with education
about eczema, its treatments and how to apply these (Eichenfield
2014b; Ring 2012a; Sidbury 2014a; Weidinger 2016).
Topical corticosteroids are still the cornerstone of anti-inflamma-
tory therapy in the management of eczema (Eichenfield 2014b;
Ring 2012a). However, under-use of topical corticosteroids - out
of a fear of skin thinning or possible growth retardation - are
well-known problems (Charman 2000). Other frequently used
topical anti-inflammatory treatments include coal tar applications
and topical calcineurin inhibitors (non-steroidal immune modu-
lators) such as tacrolimus and pimecrolimus (Eichenfield 2014b;
Ring 2012a). The beneficial effects of sunlight for eczema are well
recognised, and so phototherapy or photo(chemo)therapy are pe-
riodically used as an alternate form of treatment (Ring 2012b;
Sidbury 2014b). Systemic immunosuppressive treatments such as
ciclosporin, mycophenolate mofetil, methotrexate, azathioprine,
and systemic steroids (used in the short term for severe flares)
are mainly indicated in people with moderate to severe eczema
that does not respond sufficiently well to topical treatments and
phototherapy (Haeck 2011; Ring 2012b; Sidbury 2014b). An-
timicrobials can be used to treat infected eczema, but preferably
only in the short term, as this treatment may foster the develop-
ment of antibiotic resistance, and thus far, there is no reliable evi-
dence of a beneficial effect when it is used in non-infected eczema
(Bath-Hextall 2010; Eichenfield 2014b). Although antihistamines
are widely prescribed for people with eczema, there is a lack of evi-
dence that they reduce itching (van Zuuren 2014). However, seda-
tive antihistamines may prove useful for improving sleep (Sidbury
2014b).
Some other interventions for eczema have been covered by other
Cochrane Reviews (Apfelbacher 2013; Ashcroft 2007; Bamford
2013; Bath-Hextall 2008; Bath-Hextall 2010; Bath-Hextall 2012;
Birnie 2002; Boyle 2006; Cury Martins 2015; Ersser 2014; Gu
2013; Nankervis 2015), while some topics are under development
and currently published as protocols (Calderon 2010; Futamura
2014; Jadotte 2014; Küster 2015; Moed 2012).
Emollients and moisturisers
The terms ’emollient’ and ’moisturiser’ are used interchangeably
and lack consistency in their use in the literature (Penzer 2012).
However, in essence an emollient is an ingredient of a moisturiser
(Rawlings 2004). Therefore, it would be more appropriate to use
the term ’moisturiser’, and this will be used throughout this review.
As dry skin (xerosis) is the most important disease feature for
eczema, skin moisturisation may constitute an integral part of
standard treatment for all severities of eczema (Bieber 2008;
Eichenfield 2014b). Moisturising the skin might be sufficient to
control mild eczema, but could also form part of the treatment
regimen for more severe eczema, and may have a role in the possi-
ble prevention of eczema flare-ups (Eichenfield 2014b; Moncrieff
2013; Sidbury 2014a; Weber 2015).
The functions of moisturisers are to reduce the dryness of skin,
decrease TEWL, improve comfort and reduce itch (Lodén 2012;
Rawlings 2004). Moisturising components can be hydrophilic or
lipophilic (Caussin 2008; Caussin 2009a). Hydrophilic compo-
nents are predominantly important for skin hydration (Caussin
2008), whilst lipophilic components are designed to remain on
the surface of the skin as an occlusive (waterproofing) layer that
prevents evaporation of water and assists barrier recovery (Caussin
2008). Moisturisers can include humectants (e.g. urea, glycerol,
lactic acid) which help increase the attraction and retention of
water by the stratum corneum; occlusives (e.g. petrolatum, min-
eral oil, dimethicone) that form a layer on the skin surface and
prevent TEWL; and emollients (lanolin, glycerol stearate, glyc-
eryl stearate, soy sterols) to soften the skin and make it smoother
(Eichenfield 2014b; Lodén 2003; Lodén 2012; Rawlings 2004).
Recently, the notional term ’prescription emollient devices’ (PED)
was introduced; this is a class of topical agents developed to “target
specific defects in skin barrier function” in people with eczema
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(Eichenfield 2014b). These PEDs contain various mixtures and
ratios of lipids, ceramides, fatty acids, and natural anti-inflamma-
tory agents such as glycyrrhetinic acid, as well as other ingredients
to alleviate itching and inflammation (Mack Correa 2012).
Studies to evaluate the use of moisturisers in primary prevention
of eczema in high risk (atopic) families have been conducted, and
are ongoing, but these are beyond the scope of our review (e.g.
Kvenshagen 2014; Simpson 2010; Simpson 2014).
There are a number of different formulations of moisturisers, such
as oil-in-water creams, water-in-oil creams, ointments, lotions,
oils, gels, sprays and emulsions, and the choice of formulation
used will depend on the severity of the skin condition and the
patient’s preferences (Eichenfield 2014b; Lodén 2003). Further-
more, moisturisers can be categorised as leave-on (directly applied)
moisturisers, soap substitutes and bath moisturisers. In this review
we will focus on the leave-on moisturisers.
Usually moisturisers need to be applied two to three times a day
(Eichenfield 2014b), in amounts of up to “150-200 g per week
in young children and up to 500g in adults” (Ring 2012a). It is
preferable to apply moisturisers after bathing (Eichenfield 2014b).
The repetitive application of topical treatments is time consum-
ing, and the use of adequate amounts of moisturiser is often re-
stricted due to cost, especially since there is no reimbursement in
most countries (Nutten 2015; Ring 2012a; Williams 2005). Pos-
sible side effects include irritation and contact allergy for certain
ingredients (Eichenfield 2014b; Lodén 2003; Lodén 2012; Ring
2012a). The ideal moisturiser should be pleasant to use, restore
the skin barrier and soften skin effectively, avoid additives that can
irritate or sensitise - such as fragrance and perfume - and contain
just a few ingredients (Eichenfield 2014b; Weidinger 2016).
How the intervention might work
Since Palmer 2006, a growing understanding that gene-expressed
skin barrier impairment may play a key role in the pathogenesis
of eczema has reinforced the importance of developing specific
treatments with the capacity to either restore barrier function or
to ameliorate further damage, or both (Boguniewicz 2011; Elias
2014; Moncrieff 2013).
Moisturisers are directed towards improving the skin barrier func-
tion by delivering lipids and water to the stratum corneum (Lodén
2003; Moncrieff 2013; Simpson 2010). Restoring barrier func-
tion might also improve antimicrobial defence in the skin of peo-
ple with eczema, and so have a beneficial effect on disease activ-
ity (Elias 2014). Moisturisers containing hydrophilic components
mostly include low-molecular-weight hygroscopic substances such
as glycerol and urea. It is assumed that, because of their low molecu-
lar weight, these substances penetrate the stratum corneum, where
they subsequently act as humectants (Sagiv 2003), mimicking
the role of NMF (Caussin 2008). Moisturisers containing more
lipophilic components include compounds that are water insolu-
ble, such as fatty acids, waxes, and triglycerides (Caussin 2009a).
These are unlikely to penetrate the skin due to their high molecular
weight (Caussin 2009a), so serve as occlusive agents that prevent
TEWL. However, if they penetrate into the stratum corneum, they
may restore barrier function by interacting with the lipid matrix
(Caussin 2009b; Ghadially 1992). Although adjuvant constituents
such as ceramides, cholesterol and fatty acids may be included in
moisturisers, it is unclear if these actually improve the efficacy of
the moisturisers (Moncrieff 2013).
Why it is important to do this review
Severe eczema remains difficult to treat and some of the treatments
offered can be problematic and associated with adverse side effects
(Eichenfield 2014b; Ring 2012a; Ring 2012b; Sidbury 2014b).
Moisturisers are widely prescribed as the basis of eczema manage-
ment, as they are relatively inexpensive, have a favourable safety
profile, and can improve the appearance and symptoms of the dry
skin (xerosis) (Eichenfield 2014b; Moncrieff 2013; NICE 2007;
Ring 2012a; SIGN 2011). However, their application is time con-
suming - possibly a life-long requirement - and moisturisers can
be smelly, messy and stick to clothing (Eichenfield 2014b). Some
preparations are known to cause skin reactions such as stinging
and burning, which can result in poor adherence, while others may
contain sensitising ingredients, which can lead to contact dermati-
tis (Eichenfield 2014b; Lodén 2003; Lodén 2012; Ring 2012a).
The use of moisturisers still fails to meet the expectations of people
with eczema (Rawlings 2014; Santer 2013; Santer 2016).
A perceived advantage of moisturiser use is that it may restrict the
need to use topical corticosteroids to more severe eczema only, or
during exacerbations and flare-ups, while at the same time im-
proving disease control (Harcharik 2014; Lucky 1997; Moncrieff
2013; Msika 2008; Weber 2015). Moisturisers may also reduce
the number of flares (Moncrieff 2013; Sidbury 2014a), which we
hope to confirm with this review. At present it is not clear which,
if any, moisturiser is effective at particular body sites, and whether
one moisturiser is preferable to another according to people with
eczema.
The plans for this review were published as a protocol with the
title ’Emollients and moisturisers for eczema’ (van Zuuren 2016).
O B J E C T I V E S
To assess the effects of moisturisers for eczema.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We have only included randomised controlled trials (RCTs).
Types of participants
People of any age with a clinical diagnosis of eczema (or ’atopic
eczema’ or ’atopic dermatitis’) as diagnosed by a dermatologist,
physician or other specialist healthcare practitioner using the stan-
dardised diagnostic criteria of Hanifin and Rajka (Hanifin 1980),
the UK Working Party’s diagnostic criteria for atopic dermatitis
(Williams 1994), or other recognised diagnostic criteria.
We excluded trials where the participants suffered from other
types of eczema such as contact dermatitis, nummular eczema or
dyshidrotic eczema.
Types of interventions
All types of moisturisers alone or in combination versus:
• active treatment e.g. topical corticosteroids;
• another moisturiser;
• ’placebo’ moisturiser (moisturiser, but with a different
composition and without the assumed effective ingredient);
• vehicle (has same composition as the moisturiser it is
compared with, but without the assumed effective ingredient);
• combination of moisturiser and active treatment;
• or no treatment.
Types of outcome measures
Acronyms are included in the glossary of terms in Table 1. We
have searched the website of Core Outcome Measures in Effec-
tiveness Trials (COMET) (www.comet-initiative.org) to help us
define some of the outcomes. A full set of core outcome mea-
sures has not yet been defined, although the Eczema Area and
Severity Index (EASI), the objective SCORing Atopic Dermati-
tis (SCORAD) scale, and the Patient Oriented Eczema Measure
(POEM) are the scales recommended for use in studies (Schmitt
2007; Schmitt 2014).
Primary outcomes
• Change in disease severity from baseline as assessed by study
participants using a recognised or validated rating scale (e.g.
POEM and Patient Oriented SCORAD (PO-SCORAD)), visual
analogue scale (VAS) score, Likert scale, or similar scale. If data
were available we evaluated change in scores for itch separately.
• Participant satisfaction using any generic Likert scale or
similar scale.
• Adverse events (proportion of participants reporting an
adverse event); we reviewed the nature of adverse events (e.g.
itching, stinging, sensitisation) and reported them narratively.
Secondary outcomes
• Change in disease severity from baseline as assessed by
investigators using a recognised or validated rating scale (e.g.
SCORAD and EASI), VAS score, Likert scale, or similar scale.
• Prevention of flares (measured as time to first flare).
• Change in use of topical active treatment (e.g.
corticosteroids or topical immune modulators, tar).
• Changes in skin barrier function as assessed by TEWL.
• Change in health-related quality of life (HRQoL) using a
recognised or validated rating scale (e.g. the Dermatology Life
Quality Index (DLQI), Children’s DLQI, and the Quality of
Life Index for Atopic Dermatitis (QoLIAD)).
Timing of outcomes
We considered measurements taken for up to one week to be short-
term; between one and four weeks to be medium-term; and after
four weeks to be long-term. We reported end of study data, and
there were no other data that could be cohesively grouped into
other specific time periods.
Outcomes for ’Summary of findings’ tables
We produced ’Summary of findings’ tables for the main compar-
isons that included the following outcomes (listed according to
priority):
• participant-assessed change in disease severity from baseline;
• participant satisfaction;
• adverse events;
• investigator-assessed change in disease severity from
baseline;
• prevention of flares;
• change in use of topical active treatment;
• change in HRQoL.
We produced these tables using the GRADEpro GDT program.
Search methods for identification of studies
We aimed to identify all relevant randomised controlled trials
(RCTs) regardless of language or publication status (published,
unpublished, in press, or in progress).
Electronic searches
We searched the following databases up to 17 December 2015:
• the Cochrane Skin Specialised Register using the search
strategy in Appendix 1;
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 11, in the Cochrane Library) using the
strategy in Appendix 2;
• MEDLINE via Ovid (from 1946) using the strategy in
Appendix 3;
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• Embase via Ovid (from 1974) using the strategy in
Appendix 4; and
• LILACS (Latin American and Caribbean Health Science
Information database, from 1982) using the strategy in
Appendix 5.
We searched the Global Resource of EczemA Trials (GREAT
database) on 21 December 2015 using the strategy in Appendix
6. GREAT is produced by the Centre of Evidence Based Derma-
tology, and accessed at: www.greatdatabase.org.uk.
Trials registers
Two review authors (EvZ and ZF) searched the following trials
registers on 16 February 2016 using the following search terms:
’eczema’, ’emollient’, ’ointment’, ’cream’, ’moisturizer’ and ’mois-
turiser’:
• the ISRCTN registry (www.isrctn.com/);
• ClinicalTrials.gov (www.clinicaltrials.gov);
• the Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au);
• the World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch/); and
• the EU Clinical Trials Register (
www.clinicaltrialsregister.eu).
Searching other resources
References from published studies
Two review authors (EvZ and ZF) examined the bibliographies of
the included and excluded studies for further references to poten-
tially eligible studies.
Adverse effects
We did not perform a separate search for adverse effects of the
target intervention. However, we examined and reported the data
on adverse effects from the included studies.
Correspondence
Trial investigators were contacted (by EvZ and ZF) and asked to
provide missing data or clarify study details (see Table 2).
Data collection and analysis
Some parts of the methods section of this review uses text that
was originally published in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We followed the published
protocol for this Cochrane Review (van Zuuren 2016).
Selection of studies
Two authors (EvZ and ZF) independently assessed the titles and
abstracts of studies identified from the searches and, if necessary,
obtained and reviewed them in full text to evaluate whether they
met the inclusion criteria. We resolved disagreement through dis-
cussion and, when necessary, by the judgement of a third author
(AL). We excluded studies that did not meet our inclusion criteria.
We have reported the number of reports retrieved, the number of
both included and excluded studies and the reasons for exclusion
in a flow diagram (Figure 1), as described in the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement (Liberati 2009).
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Figure 1. Study flow diagram
14Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data extraction and management
Two review authors (EvZ and ZF) collected study details and out-
come data independently with a piloted data extraction form. Dis-
agreements were resolved through discussion or a third author
(RC).
The following details were extracted.
• Methods: study design, blinding of participants,
investigators and outcome assessors, setting, date of study
conduct and study duration.
• Participants: number randomised, gender, inclusion and
exclusion criteria, number of dropouts and reasons for losses to
follow-up, baseline data.
• Interventions: description of treatment arms, dosage or
application frequency, duration of intervention.
• Outcomes: timing of assessments and outcomes as reported
by trial authors.
• Funding source as reported.
• Declarations of interest.
One review author (EvZ) added these details into the
Characteristics of included studies tables in Review Manager
(RevMan) 5 (RevMan 2014), and these were checked by another
review author (ZF).
Assessment of risk of bias in included studies
Two review authors (EvZ and ZF) independently assessed the risk
of bias of each individual included study using the Cochrane tool
for assessing risk of bias (Higgins 2011). Inconsistencies were re-
solved through discussion or by involving a third author (RC).
The ’Risk of bias’ tool addresses the following domains:
• method of sequence generation;
• method of allocation concealment;
• blinding of investigators and participants;
• blinding of outcome assessors;
• presence of incomplete outcome data;
• presence of selective reporting; and
• other bias such as, for example, baseline imbalance.
For each study we categorised each domain as being at a low risk
of bias, high risk of bias or unclear risk of bias. We determined the
overall risk of bias of each study as follows:
• low risk of bias when all domains were assessed as being at
low risk (plausible bias unlikely to seriously alter the results);
• unclear risk of bias when at least one domain was classified
as being at unclear risk (plausible bias that raises some doubt
about the results);
• high risk of bias when at least one domain was judged as
being at high risk (plausible bias that seriously weakens
confidence in the results).
Measures of treatment effect
Dichotomous data
We calculated risk ratios (RR) with their associated 95% confi-
dence interval (CI) for dichotomous data. When the RR was sta-
tistically significant (95% CI did not overlap 1) we computed
the number needed to treat for an additional beneficial outcome
(NNTB) or number needed to treat for an additional harmful out-
come (NNTH) on the basis of the combined RR value, applying
the overall event rate in the placebo groups as a proxy for baseline
risk.
Continuous data
We calculated mean differences (MD) with their associated 95%
CI for continuous data when the eligible trials used the same
instrument to measure a given construct. In cases where different
measurement instruments were used, we calculated standardised
mean differences (SMDs). Clinically, for HRQoL measures, an
effect size (SMD) of 0.2 is considered small, 0.5 is considered
moderate, and 0.8 or more is considered large (Bliddal 2009).
Time-to-event data
We expressed results for time-to-event outcome data as hazard
ratios (HR). Conducting a meta-analysis using summary infor-
mation from published papers can often be problematic. We ob-
tained the estimates of log hazard ratios and the corresponding
standard errors from the reports (either from confidence intervals
or reported P values) and applied them in meta-analyses using the
generic inverse variance method (Tierney 2007). We estimated the
corresponding standard error (from the log-scale), which enabled
us to use the generic inverse variance method in RevMan 5. In
future updates, if situations arise where we only have a contrast
between groups (e.g. a difference) with an explicit P value, we will
estimate the standard error, based on a Wald test (Wald 1943).
Unit of analysis issues
In studies with a parallel-group design, the unit of analysis was the
participant.
Cross-over studies
We only included the first treatment period of cross-over trials,
due to possible carryover effects.
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Studies with multiple treatment groups
We included studies with multiple treatment arms and these have
been included as pair-wise comparisons following the recommen-
dations in Chapter 16, section 16.5.4 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
Within-participant studies
We included within-participant studies following the recommen-
dation in Chapter 16, section 16.4.4 in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). For continuous
outcomes reported from within-participant designs we used the
mean of the paired differences (i.e. we handled the unit of analysis
as a pair of observations rather than two independent observa-
tions). We calculated the summary statistics - outside RevMan 5 -
and reported and presented these using the inverse variance prop-
erty feature. Matched group designs enrol pairs of subjects, and in
analysis, use the difference score between ’subject’ and ’sibling’. In
dermatology this study design is applied when different sides of
the body are compared; thus, it is not the ’matching subjects’ that
are compared but the matching sides of the body. The standard
deviation (SD) of the difference is computed by summing the two
SDs, and then subtracting a term that includes the correlation
(rho) between the two scores on the same individual (Borenstein
2009). For pragmatic reasons we decided a priori to assume that
the correlation between ’within-participant’ measures was 0.7 for
all studies reporting paired samples.
We had limited analyses for binary outcomes, therefore we only
reported proportions or percentages of the body sides without
calculating RRs, principally because the data could not be analysed
in a way that takes into account the within-participant nature of
the study design.
Dealing with missing data
We contacted trial investigators and sponsors for details of missing
data for studies that were less than 10 years old. Whenever possible
we used results from the intention-to-treat (ITT) population for
both continuous and dichotomous data. For dichotomous data, we
assumed that the missing participants experienced a poor outcome
(imputation on basis of the worst-case scenario).
For continuous data, we extracted the mean change from base-
line and corresponding SD, or, where applicable, the after-value
scores. When necessary, we approximated means and measures of
dispersion from figures in the reports.
Assessment of heterogeneity
We assessed both clinical and statistical diversity to determine if
data from studies could meaningfully be combined and entered
into a meta-analysis. We assessed clinical heterogeneity by explor-
ing variability in participants, interventions and outcomes. For
the meta-analysis we used standard random-effects meta-analysis
as the default option (DerSimonian 1986), and applied the fixed-
effect model for the purpose of sensitivity analysis. The random-
effects model assumes that the true treatment effect differs from
study to study and provides an estimate of the average treatment
effect, rather than assuming all studies are estimating the same
(fixed) treatment effect (Riley 2011). We assessed heterogeneity
across the studies by using the I² statistic, which describes the per-
centage of total variation across trials that is due to heterogeneity
rather than chance (Higgins 2011). An I² of 50% to 90% may rep-
resent considerable heterogeneity and 75% to 100%, represents
substantial heterogeneity. We conducted meta-analyses according
to the protocol independently of the observed I². Based on the
recommendations of the Grading of Recommendations Assess-
ment, Development and Evaluation working group (GRADE),
we considered downgrading the quality of the evidence for serious
inconsistency if I² was above 50%, and also took other consider-
ations for downgrading into account. One consequence of using
random-effects models as the default (these models weigh studies
more equally than a fixed-effect analysis) is that in the presence
of small-study effects (in which the intervention effect is more
beneficial in the smaller studies) the random-effects estimate of
the intervention effect will appear more beneficial than the fixed-
effect estimate. In order to explore whether there was evidence of
small-study effects, we performed sensitivity analyses to examine
how the results of the meta-analysis changed when we compared
the fixed-effect and random-effects estimates of the intervention
effect. If the estimates were similar, then any small-study effects
had little effect on the estimate of the intervention effect (Chapter
10.4.4.1 Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Assessment of reporting biases
There was only one outcome for which we had more than 10 stud-
ies entered in a meta-analysis (one secondary outcome in compar-
ison 2f ). We generated a funnel plot for this outcome to check
for asymmetry (which may suggest publication and small study
effect biases) (Higgins 2011), however we did not detect asymme-
try in the funnel plot for this specific outcome (disease severity as
assessed by the investigators).
Data synthesis
Two review authors (EvZ and ZF) analysed the data in RevMan
5 using a random-effects model, following the recommendations
in Chapter 9 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
Where outcomes of interest were rare, we followed the recommen-
dations of Bradburn 2007 and used Peto odds ratios to compare
the intervention and comparator groups. We planned to undertake
meta-analyses using Mantel-Haenszel risk differences. However,
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this was not required, as we had no meta-analysis for outcomes
that were rare. In future updates when we can perform meta-anal-
yses for these outcomes, we will report results with 95% CI and
forest plots for both statistical measures so that findings can be
compared.
Where we estimated results for individual studies with low num-
bers of events (fewer than 10 in total) or where the total sample
size was less than 30 participants, we reported the proportion of
events in each group, together with a P value from a Fisher’s exact
test.
We applied the GRADE approach for the main comparisons (
Schünemann 2013), in order to rate the quality of the evidence
for the prespecified outcomes (see Outcomes for ’Summary of
findings’ tables under Types of outcome measures) (Guyatt 2013a;
Guyatt 2013b).
Subgroup analysis and investigation of heterogeneity
According to our protocol we planned to undertake the following
stratified analyses for the primary outcomes to explore whether
different study characteristics could be considered as effect modi-
fiers:
• age of participants (e.g. children versus adults) (subset of
participants);
• disease severity (mild versus severe eczema) (subset of
participants);
• atopic versus non-atopic eczema (subset of participants);
and
• presence of filaggrin gene mutations versus no filaggrin gene
mutations (subset of participants).
However, we did not find enough studies to carry out any subgroup
analysis.
Sensitivity analysis
We carried out sensitivity analyses to examine the effects of ex-
cluding studies at high risk of bias, as well as different stratified
analyses to explore heterogeneity. To do this we performed strat-
ified analyses for the overall risk of bias, defined as low risk (low
for all domains), high risk (high for one or more domains), and
unclear risk (unclear for one or more domains).
In the presence of small-study effects, that is where the interven-
tion effect appears more beneficial in smaller studies, use of a ran-
dom-effects estimate of intervention effect produces a more ben-
eficial result than a fixed-effect estimate. Therefore, we assessed
the influence of small-study effects on the results of meta-analyses
in which there was evidence of between-study heterogeneity (I²
> 0), by comparing the fixed-effect and random-effects estimates
of the intervention effect (i.e. if the estimates were similar, then
any small-study effects had little effect on the intervention effect
estimate) (Chapter 10 Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011)).
Where possible, we performed a stratified analysis to compare
study results from preregistered trials (e.g. available on Clinical-
Trials.gov) with those without an available prespecified protocol.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
Our searches of the various databases retrieved 5611 records for
studies, two of which were protocols for ongoing trials. The
searches of the trials registers identified a further 29 ongoing stud-
ies, and we found 11 additional references through other resources,
including the bibliographies of included and excluded studies. Af-
ter removal of 20 duplicate records, we screened 5631 references
for eligibility. We excluded 5471 studies through assessment of
their titles and abstracts, and we obtained full-text copies of the
remaining 160 studies. Among the 160 studies there were 47 du-
plicate studies (multiple publications of the same study; i.e. stud-
ies published as well in another journal or presented as an abstract
or poster during a conference). We excluded five studies with rea-
sons detailed in Characteristics of excluded studies; a further 31
are ongoing trials (see Characteristics of ongoing studies). We in-
cluded the remaining 77 studies in the review (see Characteristics
of included studies). For details of our screening process, see the
study flow diagram (Figure 1).
Thirteen studies had to be translated into English from Chinese
(Gao 2008; Wu 2014; Yang 2010), German (Bohnsack 1997;
Gehring 1996; Puschmann 2003; Thumm 2000; Wilhelm 1998),
Japanese (Hamada 2008; Shiratori 1977), Korean (Kim 2014 (full
publication of Nho 2014) and Noh 2011), and French (Larregue
1996), prior to further assessment (see Acknowledgements).
Included studies
We included 77 studies, with a total of 6603 participants, in the
review. The number of participants for whom gender was reported
(2986 women and 2311 men) were fairly comparable, but gender
was not reported for the remaining 1306 participants.
Characteristics of the trial setting and methods
Within the 77 included RCTs:
• seven compared a moisturiser with no treatment (no
moisturiser) (Giordano-Labadie 2006; Grimalt 2007;
Hagströmer 2006; Patrizi 2014; Simpson 2013; Weber 2015;
Wirén 2009);
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• 15 were placebo- or vehicle-controlled (Abramovits 2008;
Belloni 2005; Boguniewicz 2008; Bohnsack 1997; Boralevi
2014; Breternitz 2008; Gayraud 2015; Gehring 1999; Hamada
2008; Korting 2010; Larregue 1996; Nebus 2009; Peltonen
2014; Tan 2010; Wilhelm 1998);
• four multi-armed studies made comparisons between
placebo or vehicle as well as another moisturiser (Lodén 2002;
Patrizi 2008; Shiratori 1977; Thumm 2000);
• 15 studies compared moisturisers against active treatments
(topical corticosteroids or topical immunomodulators)
(Angelova-Fischer 2014; Berth-Jones 2003; De Belilovsky 2011;
Emer 2011; Frankel 2011; Gehring 1996; Glazenburg 2009;
Hanifin 2002; Janmohamed 2014; Jirabundansuk 2014; Peserico
2008; Sugarman 2009; Takeuchi 2012; Udompataikul 2011;
Wanakul 2013);
• seven studies compared active treatment combined with
moisturisers against active treatment alone (Draelos 2008; Gao
2008; Hanifin 1998; Kircik 2009; Msika 2008; Simpson 2011;
Wu 2014);
• the remaining 29 studies compared one moisturiser with
another moisturiser.
Thirty-eight studies were conducted in a single centre, mostly der-
matology departments of hospitals, whilst 40 studies were multi-
centre studies. The majority of studies were conducted in Europe
(42), followed by the USA and Canada (20), Asia (14), and Africa
(1).
Characteristics of the participants
The studies mainly included participants with mild to moderate
eczema; the criteria of the UK Working Party (Williams 1994), and
of Hanifin and Rajka (Hanifin 1980), were the most widely used
diagnostic criteria. Sample sizes were relatively small and ranged
from six to 552 participants with the majority of studies including
between 20 and 60 participants.
The ages of the participants varied across the studies, with a range
of four months to 84 years, and an overall mean of 18.6 years.
Characteristics of the interventions
The studies evaluated a wide range of different moisturisers (see
Table 3), but very few compared similar interventions. Duration
of interventions lasted from a single 10-minute application of a
treatment to application several times a day for up to six months,
but two to six weeks was the most common duration of study,
with a mean of 6.7 weeks.
Fourteen of the 77 included studies provided no usable data (see
Table 4). The reasons for this were: that the study report was
unclear about how many participants were randomised to each
treatment arm; or reported no precise outcome data, so the data
could only be estimated from figures; or there were no separate
data for healthy participants and atopic participants; or the study
did not address our prespecified outcomes; or the reports were
posters with limited information. We were either unsuccessful in
our attempts to obtain data from the principal investigators of
these 14 cases (see Table 2), or the studies were more than 10 years
old, which made a response to enquiries unlikely.
Characteristics of the outcome measures
Our primary outcome, participant-assessed disease severity, was
addressed in only 24 studies, which mostly used a 3- to 6-point
Likert scale. However, three studies used a validated instrument.
The Gayraud 2015 study applied the Patient-Oriented SCOR-
ing Atopic Dermatitis (PO-SCORAD) scale (Stalder 2011), and
the Hlela 2015 and Janmohamed 2014 studies used the Patient
Oriented Eczema Measure (POEM) (Charman 2004). A total of
23 studies evaluated changes in itch scores, which were predom-
inantly measured with a visual analogue scale (VAS). Satisfaction
was assessed in 13 studies with either a Likert scale, VAS or a ques-
tionnaire. Adverse events were reported in 41 studies, however,
information was mostly limited or generic in nature (e.g. “Only
five adverse events were possibly or probably related to the study
products with three of them of mild intensity and all of them re-
lated to the skin” (Bissonnette 2010)).
One of our secondary outcomes, investigator-assessed disease
severity, was addressed in 65 studies and, as with the participant
assessments, was predominantly evaluated with a Likert scale alone
or in combination with validated instruments such as the Eczema
Area and Severity Index (EASI) and SCORAD. Fourteen studies
assessed disease severity with EASI (Hanifin 2001), and 25 studies
used the SCORAD (European Task Force on Atopic Dermatitis
1993). Prevention of flares (lengthening the time to first flare) was
investigated in 16 studies, mostly after eczema had been stabilised
with active treatment. The least assessed outcome was ’change in
use of topical active treatment’ which was only addressed in eight
studies. Twenty-nine studies assessed changes in skin barrier func-
tion by TEWL, followed by corneometry, to measure skin hydra-
tion. The remaining secondary outcome ’change in health-related
quality of life’ was covered in 10 studies. All of the studies used
validated instruments except Bissonnette 2010 which used a 22-
item questionnaire. De Belilovsky 2011, Grimalt 2007 and Msika
2008 used two instruments (the Infant’s Dermatitis Quality of
Life index (IDQOL) (Lewis-Jones 2001), and the Dermatitis Fam-
ily Impact questionnaire (DFI) (Lawson 1998)). Gayraud 2015
used the Children’s Dermatology Life Quality Index (CDLQI)
as an additional instrument (Lewis-Jones 1995). Hlela 2015 and
Janmohamed 2014 applied the IDQOL, Giordano-Labadie 2006
used the CDLQI, Nebus 2009 the Dermatology Quality of Life
Index (DLQI) (Finlay 1994), and Åkerström 2015 the EQ-5D
(The EuroQol Group 1990).
Many of the included studies in this review reported addi-
tional outcomes of potential clinical relevance, but they were
not directly relevant to the prespecified objectives of this re-
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view. Examples of such outcomes included reduction in S au-
reus (Angelova-Fischer 2014; Verallo-Rowell 2008), tolerability
(Bissonnette 2010; Draelos 2008; Grimalt 2007; Korting 2010;
Larregue 1996; Marseglia 2014; Puschmann 2003; Wilhelm
1998), cosmetic acceptability (Bissonnette 2010; Faergemann
2009; Fredriksson 1975), and onset and duration of itch relief
(Boguniewicz 2008).
Declaration of interest and funding
A total of 46 of the 77 studies reported the source of their fund-
ing, which was mostly from the pharmaceutical industry, and
27 of these studies declared conflicts of interest. Some stud-
ies did not report funding, although the product under inves-
tigation was manufactured by a pharmaceutical company that
employed one or more of the investigators, which would make
the prospect of pharmaceutical company funding more likely
(Abramovits 2008; Andersson 1999; Bissonnette 2010; Bohnsack
1997; Giordano-Labadie 2006).
Some studies reported that there was no conflict of interest, but
indicated that some of the investigators were employees of the
manufacturer of the moisturiser under investigation (Andersson
1999; Bohnsack 1997; De Belilovsky 2011; Giordano-Labadie
2006; Glazenburg 2009; Hanifin 1998; Hanifin 2002; Lodén
2001; Lodén 2002; Msika 2008; Thumm 2000; Wilhelm 1998;
Wirén 2009).
Nine studies did not report funding (or were not funded by
the pharmaceutical industry) and had no apparent conflict of
interest (Berents 2015; Evangelista 2014; Hagströmer 2006;
Hamada 2008; Hlela 2015; Park 2014; Shi 2015; Takeuchi 2012;
Verallo-Rowell 2008). The older studies generally did not report
funding or conflicts of interest, as these declarations were not a
requirement at that time; this made it impossible for us to draw
conclusions about whether these studies were industry sponsored
or were free of conflicts of interest (e.g. Ferreira 1998; Fredriksson
1975; Gehring 1996; Gehring 1999; Larregue 1996; Pigatto 1996;
Shiratori 1977).
Excluded studies
We excluded five studies after evaluation of their full text;
most were excluded because they were not RCTs (see details
Characteristics of excluded studies).
Risk of bias in included studies
We assessed each of the six domains of the Cochrane ’Risk of bias’
tool for every included study (see ’Risk of bias’ table corresponding
to the individual studies in Characteristics of included studies).
Risk of bias is also presented in Figure 2 (the ’Risk of bias’ graph)
and Figure 3 (the ’Risk of bias’ summary).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Seven studies received an overall assessment of low risk of bias as
we judged all domains in the ’Risk of bias’ tool to be at low risk
(plausible bias unlikely to alter the results seriously) (Åkerström
2015; Belloni 2005; Boralevi 2014; Gayraud 2015; Miller 2011;
Nebus 2009; Tan 2010). We assessed 36 studies as being at high
risk of bias because we considered one or more domains to be at
a high risk of bias (plausible bias that weakens confidence in the
results seriously). We classified the remaining 34 studies as being
at an unclear risk of bias (plausible bias that raises some doubt
about the results).
Allocation
In 44 studies the method used to generate the allocation sequence
was clearly described, and allowed a clear assessment of whether the
method would produce comparable groups; most of these studies
used computer-generated randomisation codes. The remaining
33 studies were reported to be randomised, but did not provide
further details about the methods of random sequence generation
used.
Allocation concealment was ensured in 32 studies. Central alloca-
tion by pharmaceutical companies and deliveries of sequentially
numbered, de-identified containers or tubes of identical appear-
ance were the most frequently used methods to secure this. We
considered allocation concealment to be at a high risk of bias in
one study, as the principal investigator informed us that there was
no concealment of allocation (Danby 2011). We judged this do-
main to be at unclear risk of bias for the other 44 studies, as these
did not report the method of allocation concealment used.
Blinding
Lack of blinding was the single most important reason for which
we judged studies to be at a high risk of bias.
Sixteen studies had no blinding, or incomplete or inadequate
blinding, and we therefore judged the domain for performance
bias as being at high risk. We judged 21 studies to be at low risk
of bias for this domain, as these provided sufficient detail about
the measures used to blind study participants and personnel from
knowledge of which intervention a participant received. Methods
we considered to provide adequate blinding included the use of
similar containers, tubes or boxes with similar looking moisturis-
ers, and comparative treatments and similar application frequen-
cies. Forty studies did not describe the method of blinding, or
described it inadequately, and therefore we considered the domain
as being at unclear risk of bias.
Twenty-three studies ensured blinding of the outcomes assessors,
and it was unlikely that the blinding could have been broken.
For 29 studies we judged blinding of outcome assessors as being
at high risk of bias. This number is clearly higher than for the
domain of performance bias. This was mainly due to the fact
that although some studies were labelled as investigator-blinded,
the participants were not blinded, yet the study design included
participant-assessed outcomes. We judged 25 studies to be at an
unclear risk of detection bias, largely due to the lack of detail
reported about the methods of blinding.
Incomplete outcome data
For 52 studies there was no evidence of incomplete reporting of
outcome data, or missing data were limited and balanced between
the treatment arms, therefore we judged this domain to be at a
low risk of bias. For six studies we considered this domain to be
at a high risk of bias (Abramovits 2008; Berents 2015; Grimalt
2007; Noh 2011; Tripodi 2009; Wu 2014), mainly because of high
dropout rates combined with per-protocol analysis, an unbalanced
number of dropouts, or because outcome data were missing (such
as incomplete outcome data from questionnaires). We assessed the
remaining 19 studies as being at an unclear risk of bias.
Selective reporting
The prespecified outcomes and those mentioned in the Methods
section appeared to have been reported adequately in the majority
of studies (66). In four studies one or more predefined outcomes
were not addressed in the Results section (Draelos 2011; Larregue
1996; Laumann 2006; Takeuchi 2012), and we considered that
this presented a high risk of bias for this domain. For the other
seven studies there was either limited reporting of an outcome, or
insufficient information available to permit us to make a ’Risk of
bias’ judgement.
Other potential sources of bias
We considered the domain of other bias to be at low risk of bias
in 67 studies. We assessed this domain as being at unclear risk of
bias for 10 studies; there was some baseline imbalance in three
studies (Breternitz 2008; Hlela 2015; Verallo-Rowell 2008), and,
in the remaining seven studies, there was insufficient information
available to permit us to make a clear judgement (e.g. poster ab-
stract) (Danby 2011; Gao 2008; Kircik 2009; Laumann 2006;
Nho 2014; Nuñez 2013; Pigatto 1996).
Effects of interventions
See: Summary of findings for the main comparison Moisturisers
versus no treatment (no moisturiser); Summary of findings 2
Atopiclair versus vehicle; Summary of findings 3 Urea-containing
moisturisers versus vehicle, placebo or no moisturiser; Summary
of findings 4 Glycerin/glycerol-containing moisturisers versus
vehicle or placebo; Summary of findings 5 Oat-containing
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moisturisers versus vehicle or no moisturiser; Summary of
findings 6 All moisturisers compared to vehicle, placebo or no
moisturiser for eczema; Summary of findings 7 Licochalcone-
containing moisturiser versus hydrocortisone acetate 1% cream
for eczema; Summary of findings 8 Vehicle treatment + daily
moisturiser compared to fluticasone propionate twice weekly +
daily moisturiser; Summary of findings 9 Topical active treatment
in combination with moisturiser compared to topical active
treatment alone
A total of 63 studies contributed to comparisons as listed below.
Some studies contributed to more than one comparison. As stated
above, 14 studies provided no usable data (Table 4).
We provide a summary of the comparisons we made, and the
categories within them, below for ease of navigation (see Table 3).
Some studies appear in more than one category.
Comparison 1: moisturisers versus no treatment (i.e. no mois-
turiser) (six studies)
Comparison 2: moisturisers versus vehicle, placebo or no treat-
ment (2a to 2g): subdivided as follows.
• 2a - Atopiclair (glycyrrhetinic acid-containing moisturiser)
versus vehicle (four studies);
• 2b - Urea-containing moisturisers versus vehicle, placebo or
no treatment (i.e. no moisturiser) (four studies);
• 2c - Glycerol (glycerine)-containing moisturisers versus
vehicle or placebo (three studies);
• 2d - Oat-containing moisturisers versus vehicle or no
treatment (four studies);
• 2e-I to 2e-VI - Remainder of moisturisers versus vehicle or
placebo (five studies, one reference included three treatment
arms (Thumm 2000));
• 2f - All moisturisers versus vehicle, placebo or no treatment
(14 studies);
• 2g - Oil versus placebo (three studies (one reference:
Gehring 1999 included two studies).
To ensure consistency with the terminology used by the investi-
gators, we have used their wording and refer to ’placebo’ or ’ve-
hicle’ accordingly. It is important to know that a placebo is also
a moisturiser, but with a different composition and without the
ingredient assumed to be effective, while a vehicle has the same
composition as the moisturiser it is compared with, but without
the ingredient assumed to be effective. As both placebo and vehicle
have moisturising properties, they might have a beneficial effect
on the skin barrier and thus might decrease disease severity.
Comparison 3: one moisturiser versus another moisturiser (3a to
3x, 22 studies, one reference included two studies (Fredriksson
1975), and one reference included three treatment arms (Miller
2011)).
Comparison 4: moisturisers versus active treatment:
• 4a - Licochalcone-containing cream versus hydrocortisone
acetate 1% cream (three studies);
• 4b-I to 4b-VI - Other moisturisers versus topical
corticosteroids (six studies);
• 4c- Moisturisers versus topical immunomodulators (three
studies).
Comparison 5: vehicle in combination with a moisturiser versus
topical corticosteroids in combination with a moisturiser (three
studies, one reference included four treatment arms (Berth-Jones
2003)).
Comparison 6: topical active treatment in combination with a
moisturiser versus topical active treatment only (six studies).
Where small-study bias was suspected in the meta-analyses, we
used a fixed-effect model sensitivity analyses for pooled data and
we present the estimates in Table 5. We also performed stratified
analyses for ’Risk of bias’ domain for pooled data (where there
were three or more studies) and the results are presented in Table
6. We could not perform a stratified analysis to compare study
results from trials that were preregistered (e.g. available on Clini-
calTrials.gov (www.clinicaltrials.gov)) with those without an avail-
able prespecified protocol because, a limited number of studies
included in the meta-analyses were preregistered.
Analyses are only shown when we were able to pool data of at least
two studies.
(1) Moisturisers versus no treatment (i.e. no
moisturiser)
Six studies (413 participants) evaluated this comparison (
Giordano-Labadie 2006; Grimalt 2007; Patrizi 2014; Simpson
2013; Weber 2015; Wirén 2009); however, in Patrizi 2014 and
Weber 2015, the comparator consisted of a cleaning product
only. Study duration varied from four weeks in the Patrizi 2014
and Simpson 2013 studies, to six months in the Weber 2015
and Wirén 2009 studies. Four studies were conducted in chil-
dren (Giordano-Labadie 2006; Grimalt 2007; Patrizi 2014; Weber
2015), and the other two, in adults (Simpson 2013; Wirén 2009).
The participants in these studies had predominantly mild to mod-
erate eczema.
The Simpson 2013 study, which was reported only as ’investi-
gator-blinded’, included mainly investigator-assessed outcomes,
but because the method of blinding was not clearly specified, we
judged it to be at unclear risk of bias. None of the other studies
were blinded; therefore, we assessed them as being at a high risk
of bias.
In Giordano-Labadie 2006 and Grimalt 2007, application of mod-
erate to strong topical corticosteroids was allowed in both treat-
ment arms, whilst in Weber 2015, ’Eucerin Eczema Relief Instant
Therapy’ was allowed on active lesions, and Wirén 2009 allowed
topical corticosteroids on areas other than the target lesions.
See also Summary of findings for the main comparison.
Primary outcomes
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Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed in any of the studies; however, ’itch’
was evaluated in Patrizi 2014 (54 participants) on a 4-point Likert
scale (0 to 3), with a higher score indicating more severe itch. The
mean change from baseline in itch in the emollient balm group (28
participants) was -1.24 (standard deviation (SD) 0.77) compared
to -0.76 (SD 1.05) in the control group (26 participants), with a
mean difference (MD) of -0.48 (95% confidence interval (CI) -
0.97 to 0.01; P = 0.06).
Participant satisfaction
This outcome was not assessed in any of the studies.
Adverse events
Two studies reported some data on adverse events (Grimalt 2007;
Simpson 2013). In Grimalt 2007, 8/91 participants reported ad-
verse events in the active treatment group compared to 0/82 in
the control group after six weeks (Peto odds ratio (OR) 7.26, 95%
CI 1.76 to 29.92; P = 0.006). The P value of Fisher’s Exact Test
was 0.0071. Three adverse events were reported to be mild, three
moderate, and two were severe, which led to treatment discontin-
uation. No further details were provided other than “all the ad-
verse events spontaneously resolved without sequel.” The Simpson
2013 study had a within-participant design, in which the legs of
20 participants were randomised, and there were no treatment-
related adverse events experienced on either leg.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Disease severity was assessed using the SCORing Atopic Der-
matitis (SCORAD) index (scale: 0 to 103, higher scores indicate
worse eczema) in three studies, with a total of 276 participants
(Giordano-Labadie 2006; Grimalt 2007; Patrizi 2014). In both
Giordano-Labadie 2006 and Grimalt 2007, moderate to strong
topical corticosteroids were allowed in both treatment arms, and
the participants in these two studies had higher baseline SCO-
RAD scores, which indicated more severe disease, than those in
Patrizi 2014. The baseline SCORAD values in Giordano-Labadie
2006 were 25.96 (SD 7.67) in the moisturiser group and 23.3 (SD
7.63) in the non-treated group; in Grimalt 2007, these baseline
values were 35.63 (SD 11.92) versus 35.96 (SD 10.50) and in
Patrizi 2014, 11.7 (SD 3.1) versus 10.2 (SD 3.3), which explains
the considerable heterogeneity observed with the pooled data. The
MD between the pooled moisturiser groups and control groups
was -2.42 (95% CI -4.55 to -0.28; P = 0.03; I² = 68%; Analysis
1.1), favouring the moisturiser group. However, the minimal im-
portant difference (MID) for the SCORAD is estimated to be 8.7
(Schram 2012), and therefore this difference, although statistically
significant, is not clinically relevant. As Giordano-Labadie 2006
and Grimalt 2007 used topical corticosteroids in both treatment
arms, the SCORAD decreased in each arm in a very substantial
way and met the MID in both arms (but without meeting MID
between arms). Grimalt 2007 was the only study that did not show
a difference between the two treatments, while the other two stud-
ies with smaller sample sizes did show a difference (although did
not meet MID). However, baseline differences in eczema severity
as well as the use of topical corticosteroids might be responsible
for this difference. All three studies were assessed as being at an
overall high risk of bias due to lack of blinding, therefore, we did
not conduct sensitivity analyses for overall risk of bias. However,
when we conducted further stratified analyses for the individual
domains of risk of bias, our repeat analysis showed no heterogene-
ity following the exclusion of Grimalt 2007, which was also judged
to be at high risk of bias for incomplete outcome data (MD -3.39,
95% CI -4.73 to -2.05; P < 0.00001; I² = 0%; Table 6).
The Simpson 2013 study, which had a within-participant design
(20 participants), used a dryness scale (0 to 4, with higher scores
being worse) for assessment of this outcome. The mean change
from baseline was -1.15 (SD 0.41) on the side treated with mois-
turiser versus -0.91 (SD 0.58) on the side that received no treat-
ment. The mean of the paired differences was statistically signif-
icant at -0.24 (95% CI -0.42 to -0.06). This small difference in
favour of moisturiser is unlikely to be clinically important.
Prevention of flares (lengthening the time to first flare)
Both Weber 2015 and Wirén 2009 (total of 87 participants) had a
study duration of six months and assessed the efficacy of reducing
the risk of flare. Combining data from the two studies, a total of 11/
42 participants experienced a flare in the moisturiser group over a
period of six months compared to 30/45 in the control group (risk
ratio (RR) 0.40, 95% CI 0.23 to 0.70; P = 0.001; number needed
to treat for an additional beneficial outcome (NNTB) = 3, 95%
CI 2 to 5; Analysis 1.2). The RR showed a significant difference in
favour of the moisturiser group. In both studies, the median time
to flare in the moisturiser group was more than 180 days versus 28
days and 30 days for the control groups (Weber 2015 and Wirén
2009, respectively). The rate of flare in the control group was 3.74
times the rate in the moisturiser group (hazard ratio (HR) 3.74,
95% CI 1.86 to 7.50; P = 0.0002, I²= 0%; Analysis 1.3). These
data indicate that with the use of moisturisers there are fewer flares,
and the time to flare is lengthened.
Change in use of topical active treatment
Two of the studies in this comparison measured the amount of
topical corticosteroids used (Giordano-Labadie 2006; Grimalt
2007).
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In Giordano-Labadie 2006, data were available from 35/37 par-
ticipants in the moisturiser group. The mean amount of topical
corticosteroids (moderate and strong, class 2 and 3 respectively)
used in the first part of the study (days 0 to 28) was 24.5 g (SD
12.51) in the moisturiser group, compared to 38 g (SD 18.63)
in the control group (39 participants) (MD -13.50 g, 95% CI -
20.67 to -6.33; P = 0.0002), which was a 35% reduction in the
use of topical corticosteroids in the moisturiser group. This cor-
responded with a 50% reduction in SCORAD in the moisturiser
group and a 48.7% reduction in SCORAD in the control group,
demonstrating that the control group had to apply more topical
corticosteroids to reach a similar reduction in SCORAD. From
day 28 until day 56, 24.6 g (SD 9.89) was used in the moisturiser
group versus 24.1 g (SD 12.85) in the control group, which is
almost identical for both groups (MD 0.50 g, 95% CI -4.70 to
5.70; P = 0.85). The reduction in SCORAD was greater in the
moisturiser group (Analysis 1.1), but the difference was not clini-
cally relevant (see the ’Change from baseline in disease severity as
assessed by the investigators’ section).
In the first three weeks of the Grimalt 2007 study, 4.86 g (SD
8.57) of high-potency topical corticosteroids was used in the mois-
turiser group (based on 78/91 participants) compared to 8.87 g
(SD 11.46) in the control group (based on 70/82 participants)
(MD -4.01 g, 95% CI -7.30 to -0.72; P = 0.02), which corre-
sponds to a 45.2% reduction in the use of strong-potency topical
corticosteroids in the moisturiser group compared to the control
group. The amount of moderate-potency topical corticosteroids
used was 4.66 g (SD 5.74) in the moisturiser group versus 4.91
g (SD 6.27) in the control group (MD -0.25 g, 95% CI -2.19 to
1.69; P = 0.80), which, in contrast to the use of strong-potency
topical corticosteroids, was not statistically significant. The total
amount of high-potency corticosteroids used over six weeks was
8.56 g (SD 15.37) in the moisturiser group and 14.7 g (SD 17.47)
in the control group (MD -6.14 g, 95% CI -11.47 to -0.81; P =
0.02). Although this is a statistically significant difference, it did
not hold true for the moderate-potency topical corticosteroids, for
which the amount used in the moisturiser group was 7.43 g (SD
9.98) versus 8.03 g (SD 10.29) in the control group (MD -0.60 g,
95% CI -3.87 to 2.67; P = 0.72). The amount of topical corticos-
teroids used from weeks three to six was not specified separately.
Analysis 1.4 is subgrouped by length of treatment. In the first few
weeks, both studies showed a non-statistically significant differ-
ence in favour of the moisturiser groups for the amount of corti-
costeroids used (MD -8.25 g, 95% CI -17.22 to 0.72; P = 0.07; I²
= 82%), but no difference was seen in the last three to four weeks
(MD 0.50 g, 95% CI -4.70 to 5.70) (data from Giordano-Labadie
2006 only). However, the mean difference in the total amount of
corticosteroids used over six to eight weeks was -9.30 g (95% CI -
15.33 to -3.27; P = 0.003; I² = 68%). This is a statistically signifi-
cant difference showing that the use of moisturisers decreased the
need for topical corticosteroids. For this analysis in Grimalt 2007,
data for both the moderate- and high-potency corticosteroids were
combined. The amount of total topical corticosteroids used in
both treatment groups was much higher in Giordano-Labadie
2006, which may explain the substantial heterogeneity.
Changes in skin barrier function
Three studies reported data on transepidermal water loss (TEWL) (
Patrizi 2014; Simpson 2013; Wirén 2009). The Wirén 2009 study
only reported that “the difference in TEWL between the groups
after three weeks of maintenance treatment did not reach statistical
significance.” Simpson 2013 had a within-participant design, and
therefore we did not pool the data with Patrizi 2014. A reduction in
TEWL score equates to an improvement in skin barrier function.
In Patrizi 2014, the mean change from baseline in TEWL at day
28 was -12.50 g/m²/h (SD 12.81) in the moisturiser group (28
participants) compared to 1.13 g/m²/h (SD 12.09) in the control
group (26 participants), with a MD of -13.63 g/m²/h (95% CI -
20.27 to -6.99; P < 0.0001).
In Simpson 2013 (a within-participant design with 20 partici-
pants), the mean changes from baseline in TEWL were -1.59 g/m²/
h (SD 0.97) on the moisturiser side and -0.42 g/m²/h (SD 1.13)
on the control side, which were both minimal changes (statistically
significant mean of the paired differences: -1.17 g/m²/h (95% CI
-1.52 to -0.82)). In this study, measurement of skin capacitance
was evaluated with a corneometer and showed an improvement
of 16.91 units (SD 6.31) on the moisturiser side and 3.3 units
(SD 3.86) on the control side (statistically significant mean of the
paired differences: 13.61 units, 95% CI 11.60 to 15.60).
Change in health-related quality of life
Change in health-related quality of life was assessed in two studies (
Giordano-Labadie 2006; Grimalt 2007). Giordano-Labadie 2006
used the Children’s Dermatology Life Quality Index (CDLQI)
with scoring ranging from 0 to 30. Scores between 0 and 1 indicate
no effect on quality of life, while scores between 19 and 30 indicate
an extremely large negative effect on quality of life (Lewis-Jones
1995). In the moisturiser group the score had changed by -0.84
(SD 0.43) at day 56 and by -0.41 (1.50) in the control group.
Grimalt 2007 used the Infant’s Dermatitis Quality of Life Index
(IDQOL) (Lewis-Jones 2001), and the Dermatitis Family Impact
(DFI) questionnaires (Lawson 1998), with scores in both rang-
ing from 0 (no quality of life impairment) to 30 (most serious
quality of life impairment). The mean change from baseline on
the IDQOL was -2.57 (SD 35.51) in the moisturiser group (data
only available for 49/91 participants) and -3.41 (SD 26.70) in the
control group (data for 54/82 participants only). The standardised
mean difference (SMD) in change from baseline quality of life
between the moisturiser group and the control group was -0.15
(95% CI -0.55 to 0.24; P = 0.44; I² = 42%; Analysis 1.5). The
reductions in scores in each treatment arm for both studies were
small and not clinically important with no statistically significant
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difference between groups. The data from the second question-
naire in Grimalt 2007 (DFI) were in agreement with this analy-
sis. For the DFI, the mean changes were -2.82 (SD 35.79) in the
moisturiser group and -2.89 (SD 30.10) in the control group with
a MD of 0.07 (95% CI -12.77 to 12.91; P = 0.99). A possible
explanation for the statistical heterogeneity (I² = 42%) between
the two treatments might be that in Grimalt 2007 40% of the
participants did not complete the questionnaires, and this domain
was therefore assessed as being at high risk of attrition bias.
(2) Moisturisers versus vehicle, placebo or no
treatment (i.e. no moisturiser)
2a Atopiclair (containing glycyrrhetinic acid) three times a
day versus vehicle three times a day
Four studies with a total of 450 participants reported data on this
comparison (Abramovits 2008; Belloni 2005; Boguniewicz 2008;
Patrizi 2008). We assessed the Belloni 2005 study as being at a low
risk of bias, Abramovits 2008 at high risk of bias, and the other two
at unclear risk of bias. Study duration ranged from 21 days (Belloni
2005), through 43 days (Boguniewicz 2008; Patrizi 2008), up to
50 days (Abramovits 2008). Both Boguniewicz 2008 and Patrizi
2008 were conducted in children, Belloni 2005 included children
and adults, and Abramovits 2008 only investigated adults. All of
the participants included in these studies had mild to moderate
eczema.
In Boguniewicz 2008 and Patrizi 2008, low-potency topical corti-
costeroids were allowed in both treatment arms, but only if really
needed. Patrizi 2008 was a three-arm study (see also comparison
3a, we did not consider Atopiclair light versus vehicle, as Atopi-
clair light was never marketed).
See also Summary of findings 2.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Three studies reported the number of participants who experi-
enced improvement rated as good improvement to total resolution
(Abramovits 2008; Belloni 2005; Boguniewicz 2008); this showed
that 174/232 in the Atopiclair group experienced good improve-
ment to total resolution versus 27/158 in the vehicle group (RR
4.51, 95% CI 2.19 to 9.29; P < 0.0001; I² = 64%; NNTB = 2,
95% CI 1 to 2; Analysis 2.1). When we removed the study with the
smallest sample size (Belloni 2005), the effect estimate increased
slightly showing that the meta-analysis findings were robust. We
conducted a sensitivity analysis based on these three studies. When
we excluded the Abramovits 2008 study (which was at high risk
of bias) from the analysis, our repeat analysis showed no residual
heterogeneity (RR 6.95, 95% CI 3.69 to 13.07; P < 0.00001; I²
= 0%; NNTB = 2, 95% CI 1 to 2).
Itch was addressed in all four studies via a visual analogue scale
(VAS) that ran from 0 cm to 10 cm, with score of 0 indicating
no itch. There was a significant reduction in itch in favour of the
Atopiclair moisturiser group with a MD of -2.65 cm (95% CI -
4.21 to -1.09; P = 0.0008; I² = 97%; Analysis 2.2). The only study
at low risk of bias, Belloni 2005, showed a smaller effect, which
might have been caused by the shorter treatment duration (three
weeks versus six to seven weeks in the other studies). None of the
sensitivity analyses (stratified by risk of bias or effect size) reduced
the heterogeneity to a minimum.
Participant satisfaction
At the end of the Abramovits 2008 study, 119/145 participants
were willing to continue treatment with Atopiclair, while only 28/
73 wished to continue with vehicle (RR 2.14, 95% CI 1.58 to 2.89;
P < 0.00001; NNTB = 2, 95% CI 2 to 3). In Belloni 2005, the
participants were asked about their willingness to use the treatment
again; 9/15 in both groups indicated that they ’might’ (RR 1.00,
95% CI 0.56 to 1.79; P = 1.00), and 5/15 in the Atopiclair group
indicated that they ’would’ use it again versus 0/15 in the vehicle
group (Peto OR 10.18, 95% CI 1.54 to 67.23; P = 0.02). The P
value of the Fisher’s Exact Test was 0.0421. This outcome was not
assessed in Boguniewicz 2008, and in Patrizi 2008, no data were
reported other than P values indicating the participants’ desire to
continue on the treatment, which read “P < 0.001 in favour of
Atopiclair”.
Adverse events
All four studies addressed adverse events. There was no statistically
significant difference in the number reporting an adverse event in
either group with 84/252 adverse events in the Atopiclair group
and 59/178 in the vehicle group (RR 1.03, 95% CI 0.79 to 1.33; P
= 0.83; I² = 0%; Analysis 2.3). As no adverse events were reported
in either group in Belloni 2005, we repeated our analysis adding
one adverse event in each group for this study, and the RR was
1.03 (95% CI 0.79 to 1.33), which made no difference.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
This outcome was assessed in all four studies with the EASI (for
which the score rating runs from 0 to 72, with higher scores being
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worse (Hanifin 2001)), with a MD of -4.00 (95% CI -5.42 to -
2.57; P < 0.00001; I² = 51%; Analysis 2.4) in favour of Atopiclair.
The MID for the EASI is estimated at 6.6 (Schram 2012), and
therefore the difference was not clinically relevant. Removing both
of the studies with smaller sample sizes did slightly increase the
MD (Belloni 2005; Patrizi 2008), therefore, we can conclude that
the meta-analysis is robust. The stratified sensitivity analyses per
domain of risk of bias concluded that Boguniewicz 2008 demon-
strated the greatest effect size, as well as being the only study in
which there was uncertainty regarding the efficacy of the alloca-
tion concealment and of the blinding (see Table 6).
Prevention of flares (lengthening the time to first flare)
Occurrence of flares was measured as the number of partici-
pants who needed rescue medication in three of the four stud-
ies (Abramovits 2008; Boguniewicz 2008; Patrizi 2008). In the
Atopiclair treatment arm, 15/237 of the participants experienced
a flare versus 56/160 in the vehicle group, showing benefit in the
treatment arm (RR 0.18, 95% CI 0.11 to 0.31; P < 0.00001; I² =
0%; NNTB = 3, 95% CI 3 to 5; Analysis 2.5). The study at high
risk of bias, Abramovits 2008, did not appreciably alter the effect
estimate In the sensitivity analysis (Analysis 2.5).
Change in use of topical active treatment
This outcome was not assessed in any of the studies.
Changes in skin barrier function
This outcome was not assessed in any of the studies.
Change in health-related quality of life
This outcome was not assessed in any of the studies.
2b Urea-containing moisturisers versus vehicle, placebo or
no treatment (i.e. no moisturiser)
Four studies, with a total of 362 adult participants, examined
urea-containing cream versus vehicle, placebo, or no treatment
(Bohnsack 1997; Lodén 2002; Wilhelm 1998; Wirén 2009). We
assessed three of these as being at an unclear risk of bias (Bohnsack
1997; Lodén 2002; Wilhelm 1998), and the fourth as being at high
risk of bias due to lack of blinding (Wirén 2009). The Bohnsack
1997, Lodén 2002, and Wilhelm 1998 studies were four weeks
long, and Wirén 2009 had a duration of six months (this study
is featured in Comparison 1 also). The objective of the Wirén
2009 study was to explore time to flare after treatment; treatment
success was obtained in certain target areas with betamethasone
valerate 0.1% (a steroid) and moisturiser, and Canoderm cream
(containing urea) was compared with no treatment in the subse-
quent maintenance phase. Bohnsack 1997 and Wilhelm 1998 had
a within-participant design and did not allow topical treatments,
while Lodén 2002 and Wirén 2009 did allow topical steroids in
either treatment arm (though in Wirén 2009 they were permitted
at areas other than the target areas during the maintenance phase).
Lodén 2002 was a three-armed study (see Comparisons 2c and
3o).
See Summary of findings 3.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed in Bohnsack 1997 and Wirén
2009. In Lodén 2002, 56/63 participants in the group treated with
urea-containing cream (4% urea and 4% sodium chloride) rated
the dryness of their skin as improved versus 46/66 in the group
treated with placebo (for ingredients, see Notes in Characteristics
of included studies for Lodén 2002), with a statistically significant
difference in favour of the urea-containing cream (RR 1.28, 95%
CI 1.06 to 1.53; P = 0.009; NNTB = 5, 95% CI 3 to 18).
Sixty-one per cent of the 77 participants in the Wilhelm 1998
within-participant study considered that the side treated with 10%
urea cream showed moderate to very good improvement compared
to 48.1% who felt that the side treated with vehicle showed mod-
erate to good improvement. Itch was also assessed in this study,
with 54.5% reporting improvement of itch on the side treated
with urea cream and 45.5% reporting improvement on the vehicle
side.
Participant satisfaction
Only Bohnsack 1997 assessed participant satisfaction, specifically
smell, spreadability, penetration into the skin, and the feel of the
skin, using a 4-point Likert scale (1 = unsatisfactory, 2 = satisfac-
tory, 3 = good, 4 = very good). Thirty-two of the 38 participants
thought the side treated with 10% urea cream smelt ’satisfactory
to good’, and 31/38 considered that the vehicle side smelt ’satis-
factory’ (RR 1.07, 95% CI 0.79 to 1.44; P = 0.68). Spreadability
was assessed as ’satisfactory to very good’ by 35/38 participants for
the 10% urea cream and by 37/38 for the vehicle (RR 0.94, 95%
0.78 to 1.14; P = 0.55). Penetration into the skin was assessed as
’satisfactory to very good’ by 26/38 participants for the 10% urea
cream and as ’satisfactory to good’ by 32/38 participants for the
vehicle (RR 0.81, 95% CI 0.57 to 1.17; P = 0.26). Twenty-seven
out of 38 participants considered the feel of the skin on the 10%
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urea-treated side as ’satisfactory to good’, and 32/38 considered it
to be ’satisfactory to good’ on the vehicle-treated side (RR 0.88,
95% CI 0.63 to 1.22; P = 0.43).
Adverse events
Only the Lodén 2002 trial assessed adverse events. Smarting was
reported by 41/63 participants in the urea cream group and by
26/66 participants in the placebo group (RR 1.65, 95% CI 1.16
to 2.34; P = 0.005; NNTH = 4, 95% CI 2 to 11), which is a
statistically significant difference in favour of the placebo cream.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
This outcome was not assessed in Wirén 2009. The Lodén 2002
study used the dry skin area and severity index (DASI) to assess
disease severity (score from 4 to 20, with higher scores being worse)
(Serup 1995). After four weeks, 56/63 in the urea cream-treated
group had improved, and 42/66 in the placebo cream group (RR
1.40, 95% CI 1.14 to 1.71; P = 0.001; NNTB = 4, 95% CI 3 to 9);
this result favoured the urea-containing cream and was consistent
with the participant assessments.
The within-participant Bohnsack 1997 study used a combined
score for all participants to assess dryness (4-point Likert scale (0 to
3); 0 = fine shiny skin surface, 1 = dry matte skin surface, 2 = mild
scaling, 3 = obvious mild to moderate scaling). The combined
total score for all 38 participants decreased from 91 to 63 on the
side treated with 10% urea cream and from 88 to 70 on the vehicle
side. The investigators of the study reported that this was not a
statistically significant difference.
The within-participant Wilhelm 1998 study used a sum score to
assess change in disease severity (erythema, dryness, induration,
papules, with each item scoring from 0 to 4, with higher values
being worse). The mean change from baseline in the sum score
after four weeks was -1.90 (SD 3.5) on the side treated with urea-
containing cream and -1.33 (SD 2.11) on the side treated with
vehicle, with the mean of the paired differences being -0.57 (95%
CI -1.14 to 0.0).
Prevention of flares (lengthening the time to first flare)
Only Wirén 2009 examined time to first flare. During the six-
month period of the trial, 7/22 of the 5% urea cream group expe-
rienced a flare compared with 15/22 of the no moisturiser group,
which favours the use of moisturiser (RR 0.47, 95% CI 0.24 to
0.92; P = 0.03; NNTB = 3, 95% CI 2 to 11). In this study, the
median time to flare was more than 180 days in the urea cream
group versus 30 days for the no moisturiser group. The rate of
flare in the no moisturiser group was 3.2 times that in the urea
cream group (HR 3.2, 95% CI 1.3 to 7.8; P = 0.01). (See the data
analysis for Wirén 2009 in Analysis 1.3). These data demonstrate
that urea cream reduced the number of flares and prolonged time
to flare compared to not using a moisturiser.
Change in use of topical active treatment
This outcome was not assessed in any of the studies.
Changes in skin barrier function
Bohnsack 1997 and Wilhelm 1998 (both within-participant stud-
ies) assessed skin hydration with a corneometer in a total of 115
participants. In Bohnsack 1997, hydration increased over four
weeks by 12 arbitrary units (SD 7.21) on the side treated with
10% urea cream and by 15.20 units (SD 7.92) on the vehicle-
treated side. In Wilhelm 1998 the changes were 11.80 (SD 6.90)
arbitrary units on the side treated with urea cream and 6.20 (SD
6.58) units on the side treated with vehicle (pooled data showed a
MD 1.23, 95% CI -7.39 to 9.86; P = 0.78; I² = 98%; Analysis 3.1).
Improvements in skin hydration were seen in both arms, with the
studies just showing slightly different results, with Bohnsack 1997
favouring vehicle and Wilhelm 1998 favouring the urea cream.
The Wirén 2009 study measured TEWL, and the investigators
reported that “the difference in TEWL between the groups after
three weeks of maintenance treatment did not reach statistical
significance.”
Change in health-related quality of life
This outcome was not assessed in any of the studies.
2c Glycerol-containing moisturisers versus vehicle or
placebo
The participants in the three studies that evaluated glycerol-con-
taining moisturises against vehicle or placebo had mild to mod-
erate eczema (409 participants) (Boralevi 2014; Breternitz 2008;
Lodén 2002). The duration of all three studies was four weeks.
The Boralevi 2014 study enrolled 251 children aged from two to
six years and allowed topical corticosteroids only if they were really
needed; we assessed it as being at low risk of bias. The Breternitz
2008 study was a within-participant study (24 participants), con-
ducted in people aged between 15 and 49 years, in which no con-
comitant treatments were permitted; we assessed it as being at an
unclear risk of bias. Lodén 2002 was a three-armed study of 197
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adults (see also Comparisons 2b and 3o) that did not permit ad-
ditional use of topical corticosteroids; we assessed it as being at an
unclear risk of bias.
See Summary of findings 4.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Only Lodén 2002 evaluated participant-assessed disease severity
and rated the improvement in dryness of the skin. In the group
treated with glycerol 20% cream, 58/68 participants considered
their skin to have improved in terms of dryness versus 46/66 in
the placebo cream group, with a RR of 1.22 (95% CI 1.01 to
1.48; P = 0.03; NNTB = 6, 95% CI 3 to 60), showing greater
improvement in the glycerol group.
In the Boralevi 2014 study, the participants scored itch on a 10 cm
VAS (with higher values being worse): in the 124 children treated
with glycerol 15% cream, the mean change from baseline in itch
was -1.72 cm (SD 2.01), while in the 125 children treated with
placebo cream, the mean change was -1.11 cm (SD 1.93), which
were both small changes but slightly favoured the glycerol group
(MD -0.61 cm, 95% CI -1.10 to -0.12; P = 0.01).
Participant satisfaction
This outcome was not assessed in any of the studies.
Adverse events
Two studies reported data on adverse events (Boralevi 2014; Lodén
2002). There was no statistically significant difference in the num-
ber of adverse events between the two treatment groups (RR 0.90,
95% CI 0.68 to 1.19; P = 0.45; I² = 0%; Analysis 4.1). The ad-
verse events were mild to moderate and consisted of smarting, ery-
thema, pruritus, or burning.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
In Boralevi 2014, the investigators assessed disease severity with the
objective SCORAD (Kunz 1997). The mean change from baseline
was -5.3 (SD 5.3) in the 124 participants treated with glycerol
cream versus a change of -3.1 (SD 4.7) in the 125 participants
treated with vehicle cream (MD -2.20, 95% -3.44 to -0.96; P =
0.0005), which is a statistically significant difference in favour of
the glycerol-containing cream, but this value does not meet the
MID of 8.2 for the objective SCORAD (Schram 2012).
Breternitz 2008 had a within-participant design with 24 partic-
ipants. The mean change from baseline in SCORAD was -1.10
(SD 1.57) on the side treated with glycerol 20% cream, and 0.0
(SD 1.83) on the side treated with vehicle (mean of the paired
differences: -1.10, CI 95% -1.63 to -0.57), which favoured the
glycerol-containing cream.
The investigators in Lodén 2002 evaluated skin dryness with the
DASI (Serup 1995), and stated that there were “no differences
between the groups in DASI scores”. Despite this, in the glycerol
group, 58/68 showed improvement in dryness of the skin versus
42/66 in the vehicle group (RR 1.34, 95% CI 1.09 to 1.65; P =
0.0006; NNTB = 5, 95% CI 3 to 14), which is in accordance with
the participant assessments and favoured the glycerol cream.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed in any of the studies.
Change in use of topical active treatment
This outcome was not assessed in any of the studies.
Changes in skin barrier function
In Boralevi 2014, the hydration index was measured with cor-
neometry and showed a mean change of 11.14 units (SD 10.21) in
the glycerol group (120 participants) versus 5.56 units (SD 9.88)
in the vehicle group (121 participants) (MD 5.58 units, 95% CI
3.04 to 8.12; P < 0.0001), showing glycerol was more effective at
improving hydration.
In the within-participant study (24 participants) of Breternitz
2008, the mean change in TEWL was -5.80 g/m²/h (SD 4.95) on
the side treated with glycerol cream versus 7.20 g/m²/h (SD 11.01)
on the side treated with vehicle, with a statistically significant mean
of the paired differences of -13 g/m²/h (95% CI -16.33 to -9.67)
in favour of glycerol cream. Furthermore, the mean change from
baseline in hydration was 12.40 units (SD 6.2) on the glycerol
cream side versus 5.30 units (SD 5.77) on the vehicle cream side
(statistically significant mean of the paired differences: 7.10 units,
95% CI 5.24 to 8.96).
Change in health-related quality of life
This outcome was not assessed in any of the studies.
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2d Oat-containing moisturisers versus vehicle or no
treatment (i.e. no moisturiser)
Four studies (344 participants) reported data on oat-containing
moisturisers versus no treatment or vehicle (Giordano-Labadie
2006; Grimalt 2007; Nebus 2009; Weber 2015). Three of these
four studies are also reported under Comparison 1 (Giordano-
Labadie 2006; Grimalt 2007; Weber 2015). Only Nebus 2009
compared oat-containing moisturiser versus occlusive vehicle,
whilst the comparison in the other studies was no moisturiser.
Study duration was six weeks for Grimalt 2007, eight weeks for
Giordano-Labadie 2006 and Nebus 2009, and six months for
Weber 2015.
The Giordano-Labadie 2006, Grimalt 2007, and Weber 2015
studies were conducted in children, and Nebus 2009 included
both children (above 12 years of age) and adults. All participants
had predominantly mild to moderate eczema.
We assessed Nebus 2009 as being at low risk of bias, but the other
three studies were not blinded, and we therefore assessed them as
being at a high risk of bias.
The Giordano-Labadie 2006, Grimalt 2007, and Nebus 2009
studies allowed application of moderate to strong topical corticos-
teroids in both treatment arms, and Weber 2015 allowed applica-
tion of ’Eucerin Eczema Relief Instant Therapy’ to active lesions.
See Summary of findings 5.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was only assessed in Nebus 2009, in which 50 par-
ticipants reported how effective the creams were in hydrating and
alleviating eczema. There was no difference between the two treat-
ment groups for two assessments: 21/25 participants in the oat-
containing cream group considered the moisturiser to be effective
in hydrating skin versus 19/25 in the occlusive vehicle group (RR
1.11, 95% CI 0.84 to 1.46; P = 0.45), while 18/25 in the oat-
containing cream group felt eczema was alleviated versus 16/25 in
the occlusive vehicle group (RR 1.13, 95% CI 0.77 to 1.65; P =
0.55).
Itch was assessed on a 5-point Likert scale (0 to 4, with a higher
score being worse) in Nebus 2009. The mean change from base-
line was -0.78 (SD 0.76) in the oat-containing cream group (25
participants) versus -1.20 (SD 1.01) in the occlusive vehicle group
(25 participants) (MD 0.42, 95% CI -0.08 to 0.92; P = 0.10).
Participant satisfaction
This outcome was only assessed in Nebus 2009, where there was
equal satisfaction in the two groups with the treatments; 18/25
participants in the oat-containing cream group indicated that the
cream was soothing and calmed the discomfort versus 17/25 in
the occlusive vehicle group (RR 1.06, 95% CI 0.74 to 1.52; P =
0.76).
Adverse events
At six weeks in the Grimalt 2007 trial, 8/91 participants reported
adverse events in the oat-containing cream group compared to
0/82 in the no moisturiser control group (Peto OR 7.26, 95%
CI 1.76 to 29.92; P = 0.006). The P value of Fisher’s Exact Test
was 0.0071. Three adverse events were reported to be mild, three
moderate, and two severe, which led to treatment discontinuation.
No further details were provided other than “all the adverse events
spontaneously resolved without sequel.” None of the other studies
addressed this outcome.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The investigators in three studies evaluated disease severity (
Giordano-Labadie 2006; Grimalt 2007; Nebus 2009). Two of
the studies, Giordano-Labadie 2006 and Grimalt 2007, used the
SCORAD to measure disease severity, and Nebus 2009 used the
EASI. The SMD in change from baseline in disease severity was
-0.23 (95% CI -0.66 to 0.21; P = 0.30; I² = 65%; Analysis 5.1).
However, when we conducted further analyses based on individ-
ual domains of risk of bias in addition to a stratified analysis
adjusting for effect size - which eliminated the heterogeneity -
Giordano-Labadie 2006 showed a greater effect than the other two
studies, but did not alter the conclusion (Table 6).
Prevention of flares (lengthening the time to first flare)
Only Weber 2015 evaluated flaring: 4/20 participants in the oat-
containing cream group experienced a flare versus 15/23 in the
no moisturiser control group (RR 0.31, 95% CI 0.12 to 0.77; P
= 0.01; NNTB = 2, 95% CI 1 to 5), favouring the use of oat-
containing cream. The median time to flare was more than 180
days for the group treated with oat-containing cream versus 28
days for the no moisturiser group. The HR for rate to flare was
4.74 (95% CI 1.57 to 14.34; P = 0.006; Analysis 1.3) in favour
of the oat-containing cream.
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Change in use of topical active treatment
Two of the four studies provided data for this outcome, Giordano-
Labadie 2006 and Grimalt 2007. These have been discussed under
Comparison 1, and only the conclusion is repeated here. Pooled
data that demonstrated a statistically significant reduction in use of
topical corticosteroids in the moisturiser groups, where a smaller
amount was required to achieve a similar reduction in eczema
severity, are presented in Analysis 1.4. Total topical corticosteroid
usage was much higher in both treatment groups in Giordano-
Labadie 2006, which explains the substantial heterogeneity.
Changes in skin barrier function
This outcome was not assessed in any study.
Change in health-related quality of life
Three studies assessed change from baseline in quality of life
(Giordano-Labadie 2006; Grimalt 2007; Nebus 2009) (details of
Giordano-Labadie 2006 and Grimalt 2007 appear in Comparison
1 and Analysis 1.5). Giordano-Labadie 2006 used the CDLQI;
Grimalt 2007, the IDQOL; and Nebus 2009 used the Dermatol-
ogy Quality of Life Index (DLQI) (Finlay 1994). The SMD for
changes from baseline in quality of life was -0.09 (95% CI -0.37
to 0.19; P = 0.53; I² = 12%; Analysis 5.2).
2e Remainder of moisturisers versus vehicle, placebo or no
treatment (i.e. no moisturiser)
2e-I Ammonium lactate-containing moisturiser (6%) versus
vehicle
One study compared twice daily application of ammonium lactate
(6%) in water in oil emulsion with vehicle that was also applied
twice daily (Larregue 1996). This within-participant trial had 46
participants (six to 12 years old), who had had moderate eczema
for four weeks. We assessed the study as being at a high risk of bias.
Very limited data were provided, and no additional treatment was
allowed.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Although this was a prespecified outcome and should have been
measured with a questionnaire filled in by the parents, the
data were not reported. (See the ’Risk of bias’ assessment in
Characteristics of included studies).
Participant satisfaction
The trial did not assess this outcome.
Adverse events
The trial did not assess this outcome.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Larregue 1996 assessed desquamation and xerosis, lichenification,
and hyperkeratosis on a 4-point Likert scale (0 = normal, to 3 =
severe), and summed the results for all participants into a total
score. At the start of the study, the total score for desquamation and
xerosis in 44/46 participants on the side treated with ammonium
lactate was 74, which decreased to 34 over a period of four weeks.
On the vehicle side of the body, the score was 76 at baseline and 35
at the end of the study, showing a minimal difference between the
two treatments on either side of the body. Data for lichenification
showed a decrease of 21 on the side treated with ammonium lactate
and a decrease of 19 on the vehicle side. Hyperkeratosis decreased
by 23 on the side treated with ammonium lactate and by 18 on
the vehicle side. The authors reported that both treatments were
effective in reducing erythema and papules.
Prevention of flares (lengthening the time to first flare)
The trial did not assess this outcome.
Change in use of topical active treatment
The trial did not assess this outcome.
Changes in skin barrier function
The trial did not assess this outcome.
Change in health-related quality of life
The trial did not assess this outcome.
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2e-II Pale sulfonated 4% shale oil cream versus vehicle
One study compared application of pale sulfonated 4% shale oil
(PSSO) with application of vehicle, both applied three times daily
(Korting 2010). The trial included 99 children who had had mild
to moderate eczema for four weeks. We assessed the study as being
at a high risk of bias. No other treatments for eczema were allowed
during the study period.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
The trial did not assess this outcome.
Participant satisfaction
The trial did not assess this outcome.
Adverse events
Two out of the 51 participants treated with PSSO reported adverse
events (both reported itch and erythema) versus 4/48 treated with
vehicle (Peto OR 0.46, 95% CI 0.09 to 2.40; P = 0.36). The P
value of Fisher’s Exact Test was 0.4270. The adverse events in the
vehicle group included one case each of a bacterial super-infection;
erythema and itch; erythema, itch and spreading of eczema; and
worsening of eczema.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
This outcome was assessed with EASI (score rating from 0 to 72,
with a higher score being worse) (Hanifin 2001). In the PSSO
group (50 participants), the mean change from baseline in EASI
was -8.90 (SD 4.96) compared to -1.30 (SD 6.40) in the vehicle
group (47 participants) (MD -7.60, 95% CI -9.89 to -5.31; P <
0.00001). The MID of the EASI is 6.6 (Schram 2012), and there-
fore the reduction in the PSSO group was a clinically important
reduction, as was the difference between the two groups.
Prevention of flares (lengthening the time to first flare)
The trial did not assess this outcome.
Change in use of topical active treatment
The trial did not assess this outcome.
Changes in skin barrier function
The trial did not assess this outcome.
Change in health-related quality of life
The trial did not assess this outcome.
2e-III Atoderm Intensive cream versus moisturiser base
One study compared twice daily application of Atoderm Inten-
sive cream with moisturiser base, also applied twice daily, over
six months (Gayraud 2015). The trial enrolled 130 children with
mild to moderate eczema. We assessed the study as being at a low
risk of bias. Participants were permitted to continue using their
prescribed medication for eczema, as long as the usage remained
stable.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Participants assessed disease severity with the patient-oriented
SCORAD (Stalder 2011). The mean change from baseline was -
5.70 (SD 5.59) in the 62 participants treated with Atoderm In-
tensive cream versus -2.70 (SD 5.66) in the 61 treated with the
moisturiser base, with a MD of -3.00 (95% CI -4.99 to -1.01; P
= 0.003) in favour of Atoderm Intensive cream.
Participant satisfaction
The trial did not assess this outcome.
Adverse events
Five out of the 65 participants randomised to Atoderm Intensive
cream reported adverse events (warm sensation, pruritus, stinging,
pain, erythema, flare-up) versus 7/65 in the moisturiser base group
(pruritus, mild warm sensation, mild flare-ups, mild or moderate
erythema and papules) (RR 0.71, 95% CI 0.24 to 2.13; P = 0.55).
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Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Investigators used the SCORAD (score 0 to 103, with higher
scores being worse) to assess disease severity. The mean change
from baseline was -3.70 (SD 3.79) in the 62 participants treated
with Atoderm Intensive cream versus 0 (SD 5.60) in the 61 treated
with the moisturiser base, with a MD of -3.70 (95% CI -5.39
to -2.01; P < 0.0001). Although this difference clearly favoured
Atoderm Intensive cream, it did not meet the estimated MID of
8.7 (Schram 2012).
Prevention of flares (lengthening the time to first flare)
In the Atoderm Intensive cream group, 18/62 of the participants
experienced a flare versus 22/61 in the control group (RR 0.80,
95% CI 0.48 to 1.34; P = 0.41). The time to flare was 59 days (SD
11) in the Atoderm Intensive cream group compared to 39 days
(SD 12) in the moisturiser base group (MD 20.00 days, 95% CI
15.93 to 24.07; P < 0.00001), and favoured Atoderm Intensive
cream. In addition, the investigators reported that “overall, severity
of flares had decreased by 49% in SBT [Atoderm Intensive cream]
complex group compared to 15% in the emollient base group.”
Change in use of topical active treatment
Change in use of topical active treatment was evaluated through
reporting the mean number of treatment days during flares. The
usage of topical corticosteroids was 4.3 days (SD 1.10) in the
Atoderm Intensive cream group (62 participants) versus 4.8 days
(SD 1.0) in the moisturiser base group (61 participants) (MD -
0.50 day, 95% CI -0.87 to -0.13; P = 0.008). The difference in
usage of topical immunomodulators was 1.6 days (SD 0.6) versus
3.8 days (SD 1.0) (MD -2.20 days, 95% CI -2.49 to -1.91; P <
0.00001), respectively. The usage of oral antihistamines was 0.5
days (SD 0.3) versus 3.5 days (SD 1.6), respectively (MD -3.00,
95% CI -3.41 to -2.59; P < 0.00001), which favoured the Atoderm
Intensive cream.
Changes in skin barrier function
The trial did not assess this outcome.
Change in health-related quality of life
For children under four years of age, quality of life was assessed
with the IDQOL (0 = no quality of life impairment, 30 = highest
quality of life impairment), and for children over four years of age,
it was assessed with the CDLQI (score 0 to 30: 0 to 1 = no effect
on quality of life, 19 to 30 = extremely large effect on quality of
life). In addition, the DFI questionnaire was used to assess quality
of life in all of the participants and their parents (0 = no quality
of life impairment, 30 = highest quality of life impairment).
In children under four years of age, the mean change in IDQOL
was -4.90 (SD 4.69) in the 47 children on Atoderm Intensive
cream versus -1.00 (SD 2.90) in the 36 children treated with the
moisturiser base (MD -3.90, 95% CI -5.54 to -2.26; P < 0.00001).
For children over four years of age, the mean change from baseline
in CDLQI was -0.70 (SD 1.64) in the 15 children treated with
Atoderm Intensive cream versus -0.50 (SD 2.12) in the 25 treated
with moisturiser base (MD -0.20, 95% CI -1.56 to 1.16; P =
0.77).
All children were included in the assessments of the DFI, where
the mean change from baseline was -4.40 (SD 2.49) in the 62
children treated with Atoderm Intensive cream versus -2.2 (SD
2.88) in the 61 treated with moisturiser base (MD -2.20, 95% CI
-3.78 to -0.62; P = 0.006). While this was a statistically significant
difference in favour of Atoderm Intensive cream, and although the
MID of the DFI has not yet been established, this difference is
unlikely to be clinically important.
2e-IV Triclosan 1% moisturiser twice daily versus vehicle
cream twice daily
Triclosan 1% moisturiser was evaluated in a single study we as-
sessed as being at low risk of bias, which included 60 children and
adults with mild to moderate eczema (Tan 2010). The study dura-
tion was 41 days, and usage of low-potency topical corticosteroids
was allowed in both treatment arms.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
The trial did not assess this outcome.
Participant satisfaction
The trial did not assess this outcome.
Adverse events
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Three of the 30 participants who used triclosan 1% moisturiser
experienced transient stinging pain after application compared to
1/30 of those who used the vehicle cream (Peto OR 2.87, 95% CI
0.38 to 21.44; P = 0.30). The P value of Fisher’s Exact Test was
0.6120.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The investigators measured disease severity with SCORAD. The
mean change from baseline was -12.67 (SD 7.7) in the triclosan
1% moisturiser group and -11.69 (SD 7.7) in the vehicle cream
group (MD -0.98, 95% CI -4.88 to 2.92; P = 0.62). Both reduc-
tions met the MID of 8.7 (Schram 2012), but with no important
difference between the two groups.
Prevention of flares (lengthening the time to first flare)
The trial did not assess this outcome.
Change in use of topical active treatment
The mean amount of topical corticosteroids used for the duration
of the study varied substantially between groups, with 22 g used in
the triclosan 1% moisturiser group and 44.2 g used in the vehicle
cream group; the vehicle cream group required twice the amount
of corticosteroids to achieve a reduction in SCORAD similar to
that seen in the triclosan 1% moisturiser group.
Changes in skin barrier function
The trial did not assess this outcome.
Change in health-related quality of life
The trial did not assess this outcome.
2e-V Hippophae rhamnoides 10% cream versus placebo
cream
Thumm 2000 was a three-armed study with a total of 43 adult
participants with mild to moderate eczema (see Comparisons 2e-
VI and 3t). The study compared sea buckthorn oil (Hippophae
rhamnoides) 10% cream, with H rhamnoides 20% cream, and with
placebo. H rhamnoides cream also contains beeswax, paraffin, and
glycerol and was applied for four weeks. We assessed the study as
being at an unclear risk of bias.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Disease severity was not assessed by the participants, although itch
was assessed on a VAS. No precise data were reported, other than
that there were improvements in the severity of itch in both groups,
with the H rhamnoides 10% group showing greater improvement
than the placebo group.
Participant satisfaction
The trial did not assess this outcome.
Adverse events
The trial did not assess this outcome.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The investigators assessed disease severity with the SCORAD. No
standard deviations were reported, but in the H rhamnoides 10%
cream group (17 participants) the SCORAD decreased by 9.52
and by 13.76 in the placebo cream group (19 participants). Both
scores indicate clinically relevant reductions (MID for the SCO-
RAD is 8.7 (Schram 2012)), with the placebo group apparently
doing better.
Prevention of flares (lengthening the time to first flare)
The trial did not assess this outcome.
Change in use of topical active treatment
The trial did not assess this outcome.
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Changes in skin barrier function
TEWL showed a decrease of 10.20 g/m²/h in the H rhamnoides
10% cream group and a decrease of 11.37 g/m²/h in the placebo
cream group. No standard deviations were provided. Skin hydra-
tion improved in both arms by 8 and 10.15 units, respectively.
Hence, there were only small differences between the groups for
both TEWL and skin hydration.
Change in health-related quality of life
The Thumm 2000 study used the DLQI to measure changes in
quality of life (score 0 to 30, with a higher score indicating a
greater impairment of quality of life). The mean change from
baseline was -2.74 for the H rhamnoides 10% cream group and -
3.79 in the placebo cream group. Previously, the MID of DLQI
varied between three and five, but an MID of four is the currently
recommended value for inflammatory skin diseases (Basra 2015).
2e-VI Hippophae rhamnoides 20% cream versus placebo
cream
This is the second comparison in Thumm 2000 (see Comparisons
2e-V and 3t).
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Disease severity was not assessed by the participants, but itch was
assessed on a VAS. No precise data were reported, other than that
there were improvements in the severity of itch in both groups,
with the H rhamnoides 20% group showing greater improvement
than the placebo group.
Participant satisfaction
The trial did not assess this outcome.
Adverse events
The trial did not assess this outcome.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The investigators assessed disease severity with the SCORAD. No
standard deviations were provided, but in the H rhamnoides 20%
cream group (17 participants) the SCORAD decreased by 10.98
and by 13.76 in the placebo cream group (19 participants). Both
are both clinically important reductions (MID for the SCORAD
is 8.7 (Schram 2012)). The size of reduction that was reported in
the placebo group was quite remarkable.
Prevention of flares (lengthening the time to first flare)
The trial did not assess this outcome.
Change in use of topical active treatment
The trial did not assess this outcome.
Changes in skin barrier function
TEWL showed a decrease of 10.59 g/m²/h in the H rhamnoides
20% cream group and a decrease of 11.37 g/m²/h in the placebo
cream group. No standard deviations were provided. Skin hydra-
tion improved in both arms by 14.84 and 10.15 units, respectively.
Hence, there were only small differences between the groups for
both TEWL and skin hydration.
Change in health-related quality of life
The mean change from baseline in DLQI was -3.67 for the H
rhamnoides 20% cream group and -3.79 for the placebo cream
group. Until recently the MID of DLQI varied between three and
five, but an MID of four is the currently recommended value for
inflammatory skin diseases (Basra 2015).
2f All moisturisers (2a-2e) versus vehicle, placebo, or no
treatment (i.e. no moisturiser)
All of the studies listed under Comparisons 2a up to 2e-VIII pro-
vided data for this overall comparison for at least one of the out-
comes.
See Summary of findings 6.
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Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was addressed in five studies for which the data could
be pooled (Abramovits 2008; Belloni 2005; Boguniewicz 2008;
Lodén 2002; Nebus 2009); Lodén 2002 provided data on two
different treatment arms versus placebo, and therefore we pooled
the data from the two active treatment arms and have partitioned
them in the analyses (to avoid double counting). The number of
participants who considered that their eczema had improved was
252/323 in the moisturiser group versus 92/249 in the control
group, which favoured the use of moisturiser (RR 2.46, 95% CI
1.16 to 5.23; P = 0.02; I² = 95%; NNTB = 2, 95% CI 1 to 3;
Analysis 6.1). From a clinical point of view, the result of the Nebus
2009 study appeared to be an outlier, but removing this study had
little effect on the effect estimate. Removing the study with the
smallest sample size did not alter the results (Belloni 2005).
Seven studies assessed itch (Abramovits 2008; Belloni 2005;
Boguniewicz 2008; Boralevi 2014; Nebus 2009; Patrizi 2008;
Patrizi 2014). Six of these used a VAS scale, and Patrizi 2014 used
a 4-point Likert scale. The SMD was -1.10 (95% CI -1.83 to -
0.38; P < 0.00001; I² = 94%; Analysis 6.2), and favoured mois-
turiser. Again, the Nebus 2009 study, which had a smaller sample
size, appeared to be an outlier, but the removal of this study did
not have an important effect on the overall effect estimate. The
stratified sensitivity analyses by domain of risk of bias (Table 6)
and effect size (analyses not shown) did not minimise the degree of
heterogeneity. Stratified analyses that compared study results from
the single prospectively registered trial, Boralevi 2014, with those
without a published prespecified protocol (remainder of trials in-
cluded for this outcome) did not alter the degree of heterogeneity
(analysis not shown).
Participant satisfaction
Only three studies reported data on participant satisfaction with
the treatment (Abramovits 2008; Belloni 2005; Nebus 2009). In
the moisturiser group, 146/185 expressed satisfaction to a certain
extent with the treatment and also indicated their willingness to use
it again, versus 54/113 in the control group (RR 1.35, 95% CI 0.77
to 2.36; P = 0.29; I² = 83%; Analysis 6.3). The stratified analyses
based on individual domains demonstrated that Abramovits 2008,
which was assessed as being at high risk of bias (due to high risk
of attrition bias) and also showed the greatest effect estimate, was
responsible for all of the heterogeneity (see Table 6).
The Bohnsack 1997 study (within-participant design) included 38
participants and assessed smell, spreadability, penetration into the
skin, and skin feeling. The results are summarised under Compar-
ison 2b, but there was no difference between the two treatments
for any of these features, which confirms the results from the other
three studies that we pooled (Analysis 6.3).
Adverse events
Ten studies reported on the number of participants who ex-
perienced an adverse event (Abramovits 2008; Belloni 2005;
Boguniewicz 2008; Boralevi 2014; Gayraud 2015; Grimalt 2007;
Korting 2010; Lodén 2002; Patrizi 2008; Tan 2010). We took
the number of participants who reported an adverse event in the
two active treatment arms of Lodén 2002 together and partitioned
them (numerator and denominator) to avoid double-counting. In
total, 170/680 participants treated with a moisturiser reported an
adverse event compared to 139/595 in the control arms with a RR
of 1.03 (95% CI 0.82 to 1.30; P = 0.80; I² = 21%; Analysis 6.4),
which was not a statistically significant difference. As Belloni 2005
did not report adverse events in either treatment arm, we repeated
our analysis when one adverse event was added in both groups,
which resulted in a RR of 1.03 (95% CI 0.83 to 1.27), showing no
difference between groups. Our repeat analysis no longer showed
heterogeneity when we pooled data from studies at low risk of bias
only (Table 6).
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Twelve studies provided usable data for this outcome (Abramovits
2008; Belloni 2005; Boguniewicz 2008; Boralevi 2014; Gayraud
2015; Giordano-Labadie 2006; Grimalt 2007; Korting 2010;
Nebus 2009; Patrizi 2008; Patrizi 2014; Tan 2010), measured with
different instruments, and showed a SMD of -0.65 (95% CI -
0.89 to -0.41; P < 0.00001; I² = 75%; Analysis 6.5), which is a
significant difference in favour of the moisturiser group. Further
exploration of the heterogeneity to detect publication bias and
small-study effects revealed no evidence of funnel plot asymmetry
(Figure 4). In addition, our stratified sensitivity analyses by do-
main of risk of bias did not reduce the heterogeneity to a mini-
mum (Table 6). Only the Boralevi 2014 study had a prospectively
registered protocol.
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Figure 4. Funnel plot of comparison 5: All moisturisers versus vehicle, placebo or no treatment (no
moisturiser), outcome: 5.5 Change in disease severity as assessed by the investigators
The investigators in the within-participant Bohnsack 1997 study
reported a combined total score for all 38 participants, which,
over four weeks, showed a reduction in total score of 28 on the
urea cream-treated side versus a reduction of 18 on the vehicle-
treated side. (For further details, see Comparison 2b). The within-
participant Wilhelm 1998 study used a sum score that included
erythema, dryness, induration, and papules (each item scored from
0 to 4, with higher scores being worse) in the assessment of this
outcome. The mean change from baseline in the sum score after
four weeks was -1.90 (SD 3.5) on the side treated with urea cream
and -1.33 (SD 2.11) on the side treated with vehicle, with a mean
of the paired differences of -0.57 (95% CI -1.14 to 0.0).
Prevention of flares (lengthening the time to first flare)
Six studies examined occurrence of flares (Abramovits 2008;
Boguniewicz 2008; Gayraud 2015; Patrizi 2008; Weber 2015;
Wirén 2009). The number of participants who experienced a flare
in the moisturiser group was 44/341 versus 108/266 in the control
group (RR 0.33, 95% CI 0.17 to 0.62; P = 0.0006; I² = 73%;
NNTB = 4, 95% CI 3 to 5; Analysis 6.6); this result favoured use
of moisturiser. The Gayraud 2015 study was the only one that
did not show a difference between the treatment arms. Removing
this study from the meta-analysis altered the result only slightly. In
this trial, the moisturiser base in the placebo arm appeared to be
quite effective as well, possibly because it included glycerol, which
might explain this effect.
The only two studies that addressed time to flare were Weber
2015 and Wirén 2009; both studies lasted six months, and the
results have already been discussed under Comparison 1. There
was a statistically significant difference in favour of the moisturiser
groups for risk of flare (HR 3.74, 95% CI 1.86 to 7.50; P = 0.0002;
I²= 0%; Analysis 1.3).
Change in use of topical active treatment
The assessments for this outcome have been presented in Com-
parison 1 and include two studies that evaluated the amount of
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topical steroid used (Giordano-Labadie 2006; Grimalt 2007, see
Analysis 1.4). See Comparison 2e-III too (Gayraud 2015), which
evaluated the number of treatment days and not the amount of
topical active treatment used.
Changes in skin barrier function
Seven of the studies did not provide data that could be pooled
for this outcome. Boralevi 2014 reported on the skin hydration
index; Patrizi 2014 on TEWL; Breternitz 2008 and Simpson 2013
(within-participants studies) both reported TEWL. SDs were not
reported in Thumm 2000 for TEWL and skin capacitance. Both
Bohnsack 1997 and Wilhelm 1998 evaluated skin capacitance
(Analysis 3.1). All of the results on skin barrier function have been
presented in the comparisons listed above (1, 2b, 2c, 2e-V, and 2e-
VI).
Change in health-related quality of life
Three studies provided usable data for this outcome (Gayraud
2015; Giordano-Labadie 2006; Grimalt 2007). Gayraud 2015
used three separate measuring instruments. We chose to use the
DFI, as that was the only instrument that covered the whole pop-
ulation, whilst the other two instruments assessed children on the
basis of their age. Giordano-Labadie 2006 used the CDLQI, and
Grimalt 2007 used the IDQOL. (See Comparisons 1 and 2e-III.)
In the three studies, the SMD for the change from baseline in
quality of life was -0.39 (95% CI -0.90 to 0.12; P = 0.13; I² =
79%; Analysis 6.7). We assessed Gayraud 2015 as being at a low
risk of bias, and it demonstrated the largest effect size; we assessed
the other two studies as being at a high risk of bias. Furthermore,
as already stated under Comparison 1, in Grimalt 2007, 40% of
the participants did not complete the questionnaires, and we as-
sessed this domain as being at high risk of attrition bias, which
might further explain some of the heterogeneity (Table 6).
2g Oil versus placebo
Three studies compared oil versus placebo and provided limited
data: Gehring 1999, which reported two studies, and Hamada
2008. We assessed all of the studies as being at an unclear risk
of bias. The two Gehring 1999 studies assessed evening primrose
oil in different vehicles on adults, and the Hamada 2008 study
assessed camellia oil versus water in both children and adults. The
Gehring 1999 studies had a within-participant design, with a treat-
ment period of four weeks during which no other treatments were
allowed. The Hamada 2008 study had a two-week duration, a
parallel design, and allowed all concomitant treatments.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed by any study.
Participant satisfaction
This outcome was not assessed by any study.
Adverse events
Only the Hamada 2008 study addressed this outcome; no adverse
events were reported in the 30 participants who used camellia oil
spray or in the nine who applied water spray.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
This outcome was not assessed in the Gehring 1999 studies, but
was assessed in Hamada 2008 by means of a 5-point Likert scale.
The investigators considered that the camellia oil spray treatment
was effective, or very effective, in 8/30 participants, and that water
spray was effective, or very effective, in 2/9 of the participants (RR
1.20, 95% CI 0.31 to 4.67; P = 0.79).
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed by any study.
Change in use of topical active treatment
This outcome was not assessed by any study.
Changes in skin barrier function
The two Gehring 1999 within-participant studies (data on 20 and
19 participants) evaluated TEWL and skin hydration. For TEWL,
the MD was -0.34 g/m²/h (95% CI -1.44 to 0.76; P = 0.94; I²
= 0%; Analysis 7.1), showing no difference in results between the
two treatments. The measurements with corneometry showed a
similar result with an MD of 0.34 (95% CI -2.54 to 3.21; P =
0.82; I² = 0%; Analysis 7.2).
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Change in health-related quality of life
This outcome was not assessed by any study.
(3) One moisturiser versus another moisturiser
3a Atopiclair three times daily versus Atopiclair ’light’ three
times daily (both containing glycyrrhetinic acid)
Patrizi 2008, a three-armed study with 60 children, at unclear
risk of bias, evaluated this comparison over 29 days (see Compar-
ison 2a too). Atopiclair light contains the same key ingredients as
Atopiclair, but at a lower concentration and with no preservatives.
The study included children between the ages of two and 17 years
with mild to moderate eczema. Additional low-potency topical
corticosteroids were allowed in both treatment arms as part of a
rescue regimen when really needed.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Disease severity was not assessed by the participants, but itch (pru-
ritus) was assessed on a VAS (0 cm to 10 cm, with higher values
being worse). The VAS showed a reduction of 2.6 cm (SD 0.9) in
the Atopiclair group (19 participants) versus a reduction of 0.23
cm (SD 0.9) in the Atopiclair light group (19 participants), with a
mean difference of -2.37 cm (95% CI -2.94 to -1.80; P < 0.00001)
in favour of the Atopiclair group.
Participant satisfaction
Participants’ or caregivers’ ’appraisal of acceptability of study sub-
stance’ and wish to continue was a prespecified outcome. The
principal investigators reported that there was a statistically signif-
icant difference in favour of Atopiclair, citing a P value of less than
0.0001, but provided no further details, and the contact person
for the study was unable to provide us with further information
(see Table 2).
Adverse events
In both groups, 2/20 participants reported an adverse event that
was mild or moderate in severity (Peto OR 1.00, 95% CI 0.13 to
7.69; P = 1.00). The P value of Fisher’s Exact Test was 1.000.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The review authors estimated data for this outcome from a figure
that showed a change in EASI (score from 0 to 72, with higher
scores being worse). The Atopiclair group (19 participants) showed
a reduction of -4.3 (SD 3.3) and the Atopiclair light group (19
participants) showed a reduction of -0.8 (SD 5.53), with a MD
of -3.50 (95% CI -6.40 to -0.60; P = 0.02).
Prevention of flares (lengthening the time to first flare)
This was reported as the need for rescue medication in the event
of a flare. One of the 20 participants in the Atopiclair group ex-
perienced a flare and needed rescue medication compared to 9/
18 in the Atopiclair light group (RR 0.10, 95% CI 0.01 to 0.71;
P = 0.02; NNTB = 2, 95% CI 1 to 5), which was statistically
significant in favour of Atopiclair.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
3b Atopiclair (containing glycyrrhetinic acid) three times
daily versus EpiCeram (containing ceramides, cholesterol
and free fatty acids) three times daily
Miller 2011 conducted a three-arm study (39 participants in total),
which we assessed as being at a low risk of bias, to evaluate Atopi-
clair, EpiCeram and Aquaphor Healing Ointment (Aquaphor
Healing Ointment is considered in Comparisons 3c and 3d). The
study duration was 43 days; no other eczema treatment was al-
lowed during the study. The study was conducted in children with
mild to moderate eczema.
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Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Participants did not assess disease severity, but itch was scored on
a VAS from 0 mm to 100 mm (0 = no itch and 100 = the most
intense itch imaginable). The mean change from baseline in itch
was -5.73 mm (SD 15.54) in the 13 participants treated with
Atopiclair and -20.35 mm (SD 36.21) for the 13 participants in
the EpiCeram group, with a MD of 14.62 mm (95% CI -6.80 to
36.04; P = 0.18).
Participant satisfaction
This outcome was not assessed.
Adverse events
This was not a predefined outcome in this study, but the inves-
tigators reported that there were no serious adverse events in any
group.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The mean change from baseline as measured with the EASI (score
from 0 to 72, higher being worse) was -1.36 (SD 2.22) in the
Atopiclair group and -0.95 (SD 1.91) in the EpiCeram group,
which were both minimal reductions (MD -0.41, 95% CI -2.00 to
1.18; P = 0.61). The MID for the EASI is estimated at 6.6 (Schram
2012), and therefore the reductions reported are not considered
clinically relevant.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
3c Atopiclair (containing glycyrrhetinic acid) three times
daily versus Aquaphor (containing petrolatum, cera
microcristallina, panthenol, glycerol, bisabolol) three times
daily
This comparison includes the Aquaphor Healing Ointment arm
of the Miller 2011 study, the EpiCeram arm is not considered
here, but is included in Comparisons 3b and 3d.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Disease severity was not assessed, but itch was assessed on a VAS
from 0 mm to 100 mm. The mean change from baseline for itch
was -5.73 mm (SD 15.54) in the 13 participants on Atopiclair
compared to -24.86 mm (SD 13.74) in the 13 participants treated
with Aquaphor (MD 19.13 mm, 95% CI 7.85 to 30.41; P =
0.0009), which is statistically significant in favour of Aquaphor.
Participant satisfaction
This outcome was not assessed.
Adverse events
This was not a predefined outcome in this study, but the investi-
gators reported that there were no serious adverse events in any of
the intervention groups.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Investigators assessed disease severity with the EASI. The mean
change from baseline was -1.36 (SD 2.22) in the Atopiclair group
and -2.90 (SD 2.23) in the Aquaphor group (MD 1.54, 95% CI
-0.17, 3.25; P = 0.08). These were both small improvements.
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Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
3d EpiCeram (containing ceramides, cholesterol and free
fatty acids) three time daily versus Aquaphor (containing
petrolatum, cera microcristallina, panthenol, glycerol,
bisabolol) three time daily
This is the third comparison in the Miller 2011 study (see Com-
parisons 3b and 3c too).
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Disease severity was not assessed in this study, but reduction of
itch was assessed on a VAS from 0 mm to 100 mm. The mean
change from baseline for itch was -20.35 mm (SD 36.21) in the
13 participants treated with EpiCeram compared to a change of
-24.86 mm (SD 13.74) in the 13 participants of the Aquaphor
group (MD 4.51 mm, 95% CI -16.54 to 25.56; P = 0.67).
Participant satisfaction
This outcome was not assessed.
Adverse events
This was not a predefined outcome in this study, but the investi-
gators reported that there were no serious adverse events in any of
the intervention groups.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The investigators assessed disease severity with the EASI; the re-
ductions in EASI were small in both arms and not clinically mean-
ingful. The MID for the EASI is estimated at 6.6 (Schram 2012).
The change from baseline in EASI score in the EpiCeram group
(13 participants) was -0.95 (SD 1.91) and -2.90 (SD 2.23) in the
Aquaphor group (13 participants), with a MD of 1.95 (95% CI
0.35 to 3.55; P = 0.02), which, although not a clinically important
difference, does favour Aquaphor.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
3e EpiCeram (containing ceramides, cholesterol and free
fatty acids) twice daily versus Hyalotopic (hyaluronic acid-
based emollient foam) twice daily
Only one within-participant study (20 participants) that we
judged to be at a high risk of bias compared these two interven-
tions over four weeks (Draelos 2011). Participants had to have at
least moderate eczema. No additional treatment for eczema was
allowed during the study period.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Although this was a prespecified outcome, measured on a 6-point
Likert scale, these data were not reported, and we failed in our
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attempts to receive clarification (see Table 2 and ’Risk of bias’
assessment under Characteristics of included studies). In this study,
data were available for 18 participants; 6/18 felt that EpiCeram
worked better while the remaining 12/18 felt Hyalotopic worked
better.
Participant satisfaction
The participants expressed a preference for Hyalotopic foam over
EpiCeram; 10/18 wished to continue with Hyalotopic foam, com-
pared to 8/18 who wished to continue with EpiCeram. Thirteen
thought that Hyalotopic foam had less odour, were willing to
spend more money on it, found that it rubbed in more easily,
and that it was more moisturising. In addition, 14 considered that
Hyalotopic foam spread more easily and was easier to use than
EpiCeram.
Adverse events
No adverse events occurred on either side of the participants’ bod-
ies.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Disease severity was assessed on a 6-point Likert scale (0 = none, 5
= severe). No standard deviations were reported, but we estimated
from a figure that on the EpiCeram side, the score went from 2.95
(3 = moderate) to 1.55 (minimal-mild), and on the Hyalotopic
foam side from 2.95 to 1.1, which are reductions of 47.5% and
62.7%, respectively.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
3f EpiCeram (containing ceramides, cholesterol and free
fatty acids) twice daily versus colloidal oatmeal cream twice
daily
One study, which we assessed as being at unclear risk of bias, was
reported as a poster presentation and therefore provided limited
data for this comparison (Nuñez 2013). The study was conducted
over three weeks and included 49 participants. Following email
contact, the principal investigator provided us with most of the
missing study details (see Table 2). The study was conducted in
African American children with mild to moderate eczema. No
additional treatment for eczema was allowed during the study
period.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed in this study, but itch was assessed
on a VAS (0 cm to 10 cm, with higher scores indicating more itch).
The mean change in baseline for itch was -0.20 cm (SD 2.03) in
the 24 participants treated with EpiCeram versus 0.5 cm (SD 2.3)
in the 25 participants who used the colloidal oatmeal cream, with
a MD of -0.70 cm (95% CI -1.91 to 0.51; P = 0.26).
Participant satisfaction
This outcome was not assessed.
Adverse events
This outcome was not assessed.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The change in EASI (score 0 to 72, with higher scores being worse)
over three weeks was -2.20 (SD 3.81) in the EpiCeram group (24
participants) versus -2.40 (SD 1.17) in the colloidal oatmeal cream
group (25 participants), which are both small reductions; the MD
was 0.20 (95% CI -1.39 to 1.79; P = 0.81).
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Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
3g EpiCeram (containing ceramides, cholesterol and free
fatty acids) versus Eucerin lotion (petrolatum-based)
One small within-participant pilot study evaluated these two prod-
ucts in 10 participants over a period of four weeks (Kircik 2014).
The study was assessed as being at unclear risk of bias and mainly
provided very limited data on barrier function. The application
frequency of the interventions was unclear in the report. Both chil-
dren and adults with mild to moderate eczema were included. No
other treatment for eczema was allowed during the study period.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed.
Participant satisfaction
This outcome was not assessed.
Adverse events
This outcome was not assessed.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
This outcome was not assessed.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
Barrier function assessment was based on measurement of TEWL
and corneometry. We estimated the reduction from a figure, as the
principal investigator was unable to provide more precise data (see
Table 2). TEWL decreased by 2.2 g/m²/h on the EpiCeram side
and by 1.4 g/m²/h on the Eucerin side, both of which are very
small improvements.
Hydration improved by 55% on the EpiCeram side and by 37%
on the Eucerin side; no further details were reported.
Change in health-related quality of life
This outcome was not assessed.
3h MimyX cream (barrier cream containing lipids and
palmitoylethanolamide (palmitamide MEA)) plus Eucerin
twice daily versus Eucerin only twice daily
The data for this comparison were reported in a conference ab-
stract (Laumann 2006). This was a within-participant study that
evaluated 74 participants over 12 weeks, that we assessed as being
at a high risk of bias. The outcomes reported were predominantly
assessments of participants’ experience with Mimyx. The study
included both children and adults with eczema in remission, but
with a history of frequent flares.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
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This outcome was assessed by a questionnaire and data were avail-
able for 71 of the 74 participants. Overall, 37 participants (50%)
considered Mimyx to be better than anything they had used be-
fore, 23 (31%) considered it similar to other products, and 11
(15%) considered it was not as good as other products.
Participant satisfaction
Satisfaction was also assessed with a questionnaire, with data avail-
able for 71/74 participants. Overall, 57 (77%) participants indi-
cated that they were willing to continue treatment with Mimyx,
while 14 (19%) did not want to continue. Mimyx was reported
as ’very nice to use and pleasant’ by 66 (89%) participants, while
5 (7%) considered it was ’not pleasant and too sticky’.
Adverse events
One participant at the end of the study reported mild stinging and
burning with Mimyx cream.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Although this was a prespecified outcome, this was not reported
(see the ’Risk of bias’ assessment under Characteristics of included
studies ).
Prevention of flares (lengthening the time to first flare)
The median number of days before flare was 43 days (95% CI 37
to 78) on the Mimyx plus Eucerin side versus 29 days (95% CI 15
to 43) on the Eucerin only side, which was 48% longer for Mimyx
plus Eucerin. On the Mimyx plus Eucerin side of the body, 59.5%
had a flare versus 74.3% on the Eucerin only side of the body.
Change in use of topical active treatment
Rescue medication was used in 41/74 participants on the Mimyx
plus Eucerin side of the body, and in 50/74 on the Eucerin only
side.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
3i Albolene over-the-counter (OTC) moisturiser twice daily
versus Mimyx (barrier cream containing lipids and
palmitamide MEA) twice daily
A single within-participant study of four weeks duration with
60 adult participants reported data on this comparison (Draelos
2009). We assessed this study as being at a high risk of bias. Par-
ticipants with mild eczema used the moisturisers only, while par-
ticipants with moderate eczema used 0.1% triamcinolone cream
as well on both sides.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Although the study lasted four weeks, no end-of-study data were
reported, and our attempts to receive clarification from the prin-
cipal investigator were unsuccessful (see Table 2). Therefore, we
only report data at two weeks. Disease severity was assessed on a
6-point Likert scale (0 = none, 5 = severe). Both treatment sides
started at 2.8 and reduced to 1 at two weeks, as estimated from a
figure in the report.
Participant satisfaction
This outcome was not assessed.
Adverse events
There were no adverse events at either side.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Disease severity was assessed by the investigators on the same Likert
scale used by the participants. On both sides, disease severity went
from 2.6 to 0.6 after two weeks. As with the participant data, there
were no four-week data reported, but similar to the participant-
assessed data, the investigator reported that at all time points, there
were no differences between the two moisturisers.
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Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
3j Aquacare (containing 10% urea, multisterols,
phospholipids and fatty diols) twice daily versus Calmurid
(containing 10% urea, betaine, and a high concentration of
lactic acid) twice daily
These treatments were assessed in two within-participant studies
each with 30 participants (Fredriksson 1975 reports on two stud-
ies). We assessed both of these studies as being at an unclear risk
of bias. Study duration was four weeks, and no other treatments
were allowed.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed.
Participant satisfaction
Based on preference ratings, 27/60 participants in this within-
participant study preferred Aquacare, 7/60 preferred Calmurid
(RR 3.50, 95% CI 1.30 to 9.41; P = 0.01; NNTB = 3, 95% CI 2
to 8), and 26/60 expressed no preference.
Adverse events
The 60 participants reported no adverse events on the Aquacare-
treated side, but reported 13 adverse events on the contralateral
Calmurid-treated side (RR 0.08, 95% CI 0.00 to 1.31; P = 0.08).
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The assessments of the investigators were in agreement with the
assessments of the participants. Aquacare was considered to be
the more effective treatment in 28/60 participants and Calmurid
was considered more effective in 7/60 participants (RR 3.50, 95%
CI 1.30 to 9.41; P = 0.01; NNTB = 3, 95% CI 2 to 8); both
treatments were considered equally effective in 25 participants.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
3k Locobase repair (containing ceramide III, cholesterol and
free fatty acids) twice daily versus Atoderma (containing
glycerol, ceramides, cholesterol, vitamin E) twice daily
These moisturisers were evaluated in a single study with a duration
of one year, and we assessed the study as being at a high risk of bias
(Namazova-Baranova 2012). All participants in both groups re-
ceived 0.1% hydrocortisone 17-butyrate cream one to three times
a day and oral antihistamines as needed. The study was conducted
in 44 children between six months and 12 years of age with eczema
of moderate severity.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed.
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Participant satisfaction
This outcome was not assessed.
Adverse events
None of the 44 participants reported an adverse event.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The investigators measured disease severity with SCORAD (score
0 to 103, higher score being worse). The change in SCORAD was
-29.9 (SD 8.1) in the 22 participants on Locobase repair versus -
27.1 (SD 7.9) in the 22 participants treated with Atoderm, both
of which are substantial and clinically important reductions, but
with a MD of -2.80 (95% CI -7.53 to 1.93; P = 0.25), so there
was no clear difference between the groups.
Prevention of flares (lengthening the time to first flare)
The only information reported stated: “Clinically, a decrease in
the recurrence of the disease and the severity of the current 1-year
follow-up was observed.”
Change in use of topical active treatment
Over the one-year study period, the mean daily consumption of
topical corticosteroid decreased by 1.6 g per day in the Locobase
repair group (22 participants) and 1.7 g per day in the Atoderm
group (22 participants) to achieve similar reduction in eczema
severity.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
The CDLQI was used to assess changes in quality of life (score 0
to 30: 0 to 1 = no effect on quality of life, 19 to 30 = extremely
large effect on quality of life). The investigators reported the degree
of reduction in scores as percentages without providing the exact
data. The CDLQI score reduced by -12.7% in the Locobase repair
group (22 participants) and by -11.55% in the Atoderm group
(22 participants), which indicates that the quality of life in both
groups improved over the treatment period.
3l Canoderm (containing urea 5%) twice daily versus
Miniderm (reference cream without urea) twice daily
These moisturisers were evaluated by a single study with 172
adult participants; we judged this study to be at a low risk of bias
(Åkerström 2015). The study consisted of two phases. In the sta-
bilisation phase, all participants were treated with once-daily top-
ical mometasone furoate cream 0.1% (Elocon) on the trunk and
extremities, and hydrocortisone cream 1% on the face, groin, and
armpits. In addition, in this phase of the study the participants used
a medicinal moisturiser containing 20% glycerol (Miniderm). Af-
ter (almost) clearing the eczema, participants entered the mainte-
nance phase for 180 days, one group using Canoderm (containing
5% urea) and the other using Miniderm reference cream (without
20% glycerol). No topical corticosteroids were allowed.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed.
Participant satisfaction
This outcome was not assessed.
Adverse events
In the Canoderm group, 48/87 participants reported an adverse
event compared to 44/85 in the Miniderm group (RR 1.07, 95%
CI 0.81 to 1.41; P = 0.65). These adverse events included ery-
thema, pruritus, and burning and were mainly considered to be
mild to moderate in severity and unrelated to treatment.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
At the start of the maintenance phase (after being treated with
topical corticosteroids), the SCORAD had reduced substantially
to around six in both groups. At the end of the 180 days for
those participants who remained ’eczema free’, the mean change
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in SCORAD was -3.38 (SD 4.24) in the Canoderm group (21
participants) versus 0.44 (SD 4.07) in the Miniderm group (8
participants) (MD -3.82, 95% CI -7.17 to -0.47; P = 0.03), which,
although it is a statistically significant difference, is not clinically
relevant, as the MID for the SCORAD is estimated to be 8.7
(Schram 2012).
For those who relapsed, the mean SCORAD increased to 27.45
(SD 10.32) in the Canoderm group (66 participants) and to 30.46
(SD 12.67) in the Miniderm group (77 participants) (MD -3.01,
95% CI -6.78 to 0.76; P = 0.12).
Prevention of flares (lengthening the time to first flare)
At the end of the 180-day maintenance phase, 21/87 of the partic-
ipants in the Canoderm group had not experienced a flare, com-
pared to 8/85 in the Miniderm group (RR 2.56, 95% CI 1.20 to
5.47; P = 0.01; NNTB = 7, 95% CI 3 to 26). The median time
to flare was 22 days in the Canoderm group compared to 15 days
in the Miniderm group. At day 180, 66/87 (75.8%) in the Can-
oderm group had a flare versus 77/85 (90.1%) in the Miniderm
group, which corresponds to an absolute risk reduction of flare
of 14.0% and a relative risk reduction of 15.6% with the use of
Canoderm.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was measured using the EQ-5D health question-
naire covering five dimensions (mobility, self-care, usual activities,
pain/discomfort, anxiety/depression) and a VAS that was rated
0 to 100 (100 equated to “best health you can imagine”) (The
EuroQol Group 1990). At the start of the maintenance phase in
the Canoderm group, the score was 90 (after a period of treatment
with topical corticosteroids) and 90 at the end of the study, and
for those with a flare, the score reduced to 82.5. In the Miniderm
group, it started at 89 and was 95 at the end of the study, but for
those who experienced a flare, it dropped to 74.0.
On the EQ-5D 5-item instrument, the mean score was 0.945
(SD 0.137) at the beginning of the maintenance phase and 0.951
(SD 0.093) at end of study in the Canoderm group, but this
score dropped to 0.881 (SD 0.154) in those with a flare. In the
Miniderm group, the score at the start of the maintenance phase
was 0.931 (SD 0.135), and at the end of the study and during
flare, it was 0.935 (SD 0.136) and 0.851 (SD 0.152), respectively.
These scores indicate that the quality of life remained relatively
stable during the eczema-free periods, but decreased during flares.
3m Urea 5% moisturiser twice daily versus urea 10% lotion
twice daily
These two moisturisers were compared in one six-week study with
100 adult participants; we assessed this study as being at an unclear
risk of bias (Bissonnette 2010). The use of a stable dose of topical
corticosteroids was permitted throughout the study period in both
groups.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed.
Participant satisfaction
Cosmetic acceptability was assessed with a questionnaire consist-
ing of 21 items (each scored from 0 = totally agree to 3 = totally
disagree), with a lower total score indicating better acceptability.
At the end of the study, 43/50 participants treated with urea 5%
moisturiser had a mean score of 20.52 (SD 11.93) versus 29.75
(SD 13.03) in the 44/50 participants treated with urea 10% lotion
(MD -9.23, 95% CI -14.32 to --4.14; P = 0.0004); this result
favours the urea 5% moisturiser.
Adverse events
In the urea 5% group, 12/50 participants reported adverse events
versus 10/50 in the urea 10% group, with a RR of 1.20 (95% CI
0.57 to 2.52; P = 0.63). The adverse events were reported to be of
mild intensity.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Investigators assessed disease severity with SCORAD (score from 0
to 103, higher score being worse). The mean change from baseline
was -4.52 (SD 4.63) in the urea 5% group (43 participants) versus
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-4.39 (SD 5.48) in the urea 10% group (44 participants) (MD -
0.13, 95% CI -2.26 to 2.00; P = 0.90).
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
3n Urea 4% and sodium chloride 40 mg/g in oil-in-water
emulsion twice daily versus urea 4% in oil-in-water emulsion
twice daily
These moisturisers were compared by one within-participant study
with a small sample size (22 participants), which we assessed as
being at an unclear risk of bias (Hagströmer 2001). The study
duration was two weeks, and no topical steroids were allowed.
The study was conducted in adult participants with eczema, and
only forearms were treated. There were minimal changes in barrier
function after treatment between the two treatments.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed.
Participant satisfaction
This outcome was not assessed.
Adverse events
This outcome was not assessed.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
This outcome was not assessed.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
We had to estimate data from a figure; the change from baseline in
TEWL was -0.60 g/m²/h (SD 1.90) on the urea 4% plus sodium
chloride side versus 2.50 g/m²/h (SD 2.5) on the urea 4% only
side, with a mean of the paired differences of -3.10 g/m²/h (95%
CI -3.84 to -2.36), which is a statistically significant difference in
favour of urea 4% plus sodium chloride.
Skin barrier function was also assessed with a corneometer (0 to
120, with higher measurements indicating greater hydration); the
mean change from baseline was 8 arbitrary units (SD 3) on the
urea 4% plus sodium chloride side versus 14 arbitrary units (SD
3.16) on the urea 4% only side, with a mean of the paired differ-
ences of -6.0 arbitrary units (95% CI -7.00 to -5.00), which was
a statistically significant difference in favour of urea 4% only.
Change in health-related quality of life
This outcome was not assessed.
3o Glycerol cream 20% once daily versus urea 4% cream
once daily
These moisturisers constituted the third comparison in the three-
armed study conducted by Lodén 2002 (see Comparisons 2b and
2c). The study lasted 30 days and was assessed as being at an
unclear risk of bias. The participants in all treatment arms were
allowed to continue their use of topical corticosteroids.
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Primary outcomes
Change from baseline in disease severity as assessed by the
participants
In the glycerol cream group, 58/68 participants considered the
dryness of their skin to be improved versus 56/63 in the urea group
with no difference between groups (RR 0.96, 95% CI 0.84 to
1.09; P = 0.54).
Participant satisfaction
This outcome was not assessed.
Adverse events
Smarting was mentioned by 27/68 in the glycerol cream group
and by 41/63 in the urea cream group (RR 0.61, 95% CI 0.43
to 0.86; P = 0.005; NNTH = 4, 95% CI 2 to 11) in favour of
the glycerol cream. However, the investigators stated that there
“were no differences between treatment with the cream containing
glycerol and urea regarding stinging, itching and experience of
dryness/irritation”.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The investigators assessed dryness of skin with the DASI (score
from 0 to 20, higher being worse) (Serup 1995). No exact data
were provided, but the investigators stated “no differences were
observed in disease severity as DASI scores between the glycerol
and urea group (P = 0.787).”
The DASI score improved for 27/68 in the glycerol cream group
and for 56/63 in the urea cream group, which does not agree with
the assessments of the participants (RR 0.45, 95% CI 0.33 to 0.61;
P < 0.00001; NNTB = 2, 95% CI 1 to 3).
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
3p Propyless (containing propylene glycol 20%) twice daily
versus Fenuril (containing urea 4% and sodium chloride 4%)
twice daily
These moisturisers were compared in a two-week within-partici-
pant study with 56 participants, which we assessed as being at a
high risk of bias (Faergemann 2009). No other treatment was al-
lowed. The study was conducted in adult participants with eczema
and with symmetrical areas of dry skin on their lower legs.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
No exact data were provided in the report, and the investigators
merely stated that “Propyless lotion resulted in statistically signif-
icantly less itching (P = 0.046) and irritation (P = 0.014). No sta-
tistical significance was observed for smarting (P = 1.0) or stinging
(P = 0.75). The change in total score was statistically significantly
better for Propyless lotion than for Fenuril cream (P = 0.049).”
Participant satisfaction
This outcome was not assessed.
Adverse events
Two adverse events were reported on the side treated with Propyless
lotion; these were itching in one participant and eczema in another
participant.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
No precise data were reported. Investigators reported improve-
ments for both treated sides and that “there were no statistically
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significant differences between the two treatments with respect to
the DASI [score from 0 to 20, higher being worse] evaluations”
and “In total, 69% of the investigators and patients rated the over-
all treatment effect of Propyless as better (40%) or equal (29%) to
that of Fenuril.”
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This was assessed in only 20/56 participants and as with the pre-
viously reported assessments, no precise data were provided. The
investigators only reported that “no (Fenuril) or almost no (de-
crease of 0.1 g/m2/h for Propyless) effect on TEWL was observed
after treatment.”
Change in health-related quality of life
This outcome was not assessed.
3q Ceramide-containing moisturiser twice daily versus
’control moisturiser’ twice daily
This comparison was evaluated in Noh 2011, a six-week trial in
40 children with mild to moderate eczema. We assessed the study
as being at a high risk of bias. Topical corticosteroids were applied
twice daily to all participants.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed.
Participant satisfaction
This outcome was not assessed.
Adverse events
This outcome was not assessed.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The investigators measured disease severity with EASI (score from
0 to 72, higher being worse). The mean change from baseline
in EASI score was -6.65 (SD 2.79) in the ceramide-containing
moisturiser group (15 participants) and -7.31 (SD 2.64) in the
control moisturiser group (17 participants), which are both clini-
cally relevant reductions as the MID for the EASI is estimated at
6.6 (Schram 2012). However, the MD between groups was 0.66
(95% CI -1.23 to 2.55; P = 0.49), which was not a statistically
significant difference.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
The amount of topical corticosteroids used (to achieve a similar
reduction in eczema severity) over a six-week period had to be esti-
mated from a figure and was approximately 10 g in the ceramide-
containing moisturiser group and according to the figure in the
report was 7.46% higher in the control moisturiser group.
Changes in skin barrier function
The mean change from baseline in TEWL was -14 g/m²/h (SD
12.24) in the 15 participants who were treated with the ceramide-
containing moisturiser versus -12 g/m²/h (SD 9.94) in the 17
participants in the control moisturiser group (MD -2.00 g/m2/h,
95% CI -9.79 to 5.79; P = 0.61).
Assessment with a corneometer showed that the hydration of the
skin had improved by 17 arbitrary units (SD 13.98) in the ce-
ramide-containing moisturiser group (15 participants) versus 10
arbitrary units (SD 13.03) in the control moisturiser group (17
participants) (MD 7.00 arbitrary units, 95% CI -2.40 to 16.40;
P = 0.14).
Change in health-related quality of life
This outcome was not assessed.
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3r Furfuryl palmitate enriched moisturiser twice daily
versus moisturiser twice daily
These treatment options were investigated by a single study in 117
children with eczema; we assessed the study as being at a high risk
of bias (Tripodi 2009). The study duration was two weeks, during
which time no other treatment was allowed.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was assessed through a questionnaire completed
by parents and paediatricians, and, although no exact data were
reported, the investigators stated that “both paediatricians and
parents rated the moisturiser cream without furfuryl palmitate to
be more efficacious than the cream with furfuryl palmitate (P =
0.016).”
Participant satisfaction
This outcome was not assessed.
Adverse events
This outcome was not assessed.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Disease severity was evaluated with SCORAD. In the furfuryl
palmitate enriched moisturiser group (39 participants), the mean
change from baseline in SCORAD was -7.10 (SD 8.42), and in
the in the control group (49 participants) -11.60 (SD 6.13), with
a MD of 4.50 (95% CI 1.35 to 7.65; P = 0.005). The MID for
the SCORAD is estimated to be 8.7 (Schram 2012); therefore,
the decrease in SCORAD in the control group was a clinically
relevant reduction.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
3s PRO-AMP cream (containing rhamsosoft, ceramides, L-
isoleucine) twice daily versus ’hydrating’ cream (containing
glycerol, vaseline, paraffin) twice daily
This comparison was assessed in a study we judged as being at a
high risk of bias (Marseglia 2014). The moisturisers were applied
to the faces (only) of 107 children with mild to moderate eczema
for a period of six weeks, and no other treatments were allowed.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed.
Participant satisfaction
This outcome was not assessed.
Adverse events
This outcome was not assessed.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The EASI facial score was used to assess eczema severity; the mean
change from baseline was -5.10 (SD 1.58) in the PRO-AMP
cream group (72 participants) and -2.70 (SD 1.84) in the control
group (35 participants) (MD -2.40, 95% CI -3.11 to -1.69; P
< 0.00001). Sixty-three of the 72 participants in the PRO-AMP
cream group achieved treatment success (i.e. Investigator Global
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assessment (IGA) score < 1: where 0 = clear, 1 = almost clear, 2 =
mild disease, 3 = moderate disease, 4 = severe) versus 20/35 in the
control arm (RR 1.53, 95% CI 1.13 to 2.07; P = 0.005; NNTB
= 3, 95% CI 2 to 8), this result favours the PRO-AMP cream.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
3t Hippophae rhamnoides 10% cream versus Hippophae
rhamnoides 20% cream
This is the third comparison of the Thumm 2000 three-armed
study with 43 participants (see Comparisons 2e-V and 2e-VI too).
Sea buckthorn oil (Hippophae rhamnoides) 10% and 20% cream
containing beeswax, paraffin, and glycerol was applied for four
weeks. We assessed this study as being at an unclear risk of bias.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Disease severity was not assessed by the participants; however,
itch was assessed on a VAS. No precise data were reported other
than that itch severity improved in both groups, but without a
statistically significant difference between the groups.
Participant satisfaction
This outcome was not assessed.
Adverse events
This outcome was not assessed.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The investigators assessed disease severity with the SCORAD. No
standard deviations were provided, but the SCORAD in the H
rhamnoides 10% cream group (17 participants) decreased by 9.52,
and in the H rhamnoides 20% cream group (17 participants), it
decreased by 10.98. Both results indicate clinically relevant re-
ductions (MID for the SCORAD is estimated to be 8.7 (Schram
2012)), but with no important difference between the groups.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
TEWL showed a decrease of 10.20 g/m²/h in the H rhamnoides
10% cream group (n = 17) and of 10.59 g/m²/h in the H rham-
noides 20% cream group (n = 17). No standard deviations were
provided. Skin hydration improved in both arms by 8 units and
14.84 units, respectively.
Change in health-related quality of life
The DLQI was used for measuring changes in quality of life (score
0 to 30, with a higher score indicating greater impairment of
quality of life). The mean change from baseline was -2.74 for the
H rhamnoides 10% cream group (17 participants) and -3.67 for
the H rhamnoides 20% cream group (17 participants). Previously,
the MID of the DLQI varied between three and five, but a MID
of four is the current recommended value for inflammatory skin
diseases (Basra 2015), therefore, these changes from baseline were
not clinically important, nor was the difference between groups.
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3u Lactobacillus sakei-containing moisturiser twice daily
versus ’control moisturiser’ twice daily
A within-participant study in 30 children evaluated the effect of
a moisturiser that contains a vegetable-derived lactobacillus for
the treatment of eczema (Park 2014). The study duration was
four weeks. We assessed the study as being at an unclear risk of
bias. Continued usage of topical corticosteroids on both sides was
permitted.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Disease severity was not assessed, but itch was assessed on a VAS (0
cm to 10 cm, with higher scores indicating more itch) in 28 partic-
ipants. On the side treated withL sakei-containing moisturiser, the
mean change in itch was -2.03 cm (SD 1.12) versus -1.50 cm (SD
1.11) on the control side, with a mean of the paired differences
of -0.53 cm (95% CI -0.84 to -0.22) in favour of the side treated
with L sakei-containing moisturiser.
Participant satisfaction
This outcome was not assessed.
Adverse events
No precise data were provided, but three participants reported
mild burning and stinging on the L sakei-containing moisturiser
side, which resolved within three days.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The investigators reported no statistically significant difference
between the treatment sides (28 participants). The mean change
from baseline as measured on the IGA scale (0 = clear, 4 = severe)
was -0.85 (SD 0.44) on the L sakei-containing moisturiser side
and -0.71 (SD 0.42) on the control side, with a mean of the paired
differences of -0.14 (95% CI -0.26 to -0.02) in favour of L sakei-
containing moisturiser.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
Skin barrier function was assessed through TEWL and corneom-
etry in the 28 participants. The mean change from baseline in
TEWL was -15.10 (SD 5.88) g/m²/h on the L sakei-containing
moisturiser side and -5.30 (SD 5.31) g/m²/h on the control side,
with a statistically significant mean of the paired differences of -
9.80 g/m²/h (95% CI -11.43 to -8.17), which favours L sakei-
containing moisturiser. Corneometry showed an increase of 17.60
(6.83) arbitrary units versus 9.10 (6.32) arbitrary units, respec-
tively, with a mean of the paired differences of 8.50 (95% CI 6.60
to 10.40), which was also statistically significant in favour of the
L sakei-containing moisturiser.
Change in health-related quality of life
This outcome was not assessed.
3v Virgin coconut oil twice daily versus mineral oil twice
daily
A single eight-week study that we assessed as being at an unclear
risk of bias compared these two oils in 117 children with mild to
moderate eczema (Evangelista 2014). No other treatments were
allowed.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed.
Participant satisfaction
This outcome was not assessed.
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Adverse events
No adverse events were reported in the virgin coconut oil group
(59 participants), but five of the 58 children in the mineral oil
group reported adverse events (increase in erythema, pruritus) ne-
cessitating rescue therapy with topical corticosteroids (Peto OR
0.12, 95% CI 0.02 to 0.74; P = 0.02). The P value of Fisher’s
Exact Test was 0.0273.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Disease severity was measured with the SCORAD (score from 0 to
103, with higher scores being worse). Data were reported as ’mod-
erate improvement’ (30% to 75%) or ’excellent improvement’ (>
75%). In the virgin coconut oil group, 28/59 participants expe-
rienced moderate improvement versus 20/58 in the mineral oil
group (RR 1.38, 95% CI 0.88 to 2.15; P = 0.16). Excellent im-
provement was seen in 27/59 in the virgin coconut oil group and
11/58 in the mineral oil group (RR 2.41, 95% CI 1.32 to 4.40;
P = 0.004; NNTB = 4, 95% CI 2 to 9), which was statistically
significant in favour of virgin coconut oil.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
The change from baseline in TEWL was -19.71 g/m²/h (SD 12.72)
in the virgin coconut oil group and -10.57 g/m²/h (SD 12.72)
in the mineral oil group, with a MD of -9.14 g/m²/h (95% CI -
13.75 to -4.53; P = 0.0001). The skin capacitance increased by
10.30 (SD 4.17) versus 6.18 (SD 4.17), respectively (MD 4.12,
95% CI 2.61, 5.63; P < 0.00001). Both measurements were in
favour of virgin coconut oil.
Change in health-related quality of life
This outcome was not assessed.
3w Virgin coconut oil twice daily versus virgin olive oil twice
daily
These two oils were evaluated in 52 adult participants with newly
diagnosed mild to ’high moderate’ eczema (Verallo-Rowell 2008).
We assessed the study as being at an unclear risk of bias. The
study had a four-week duration in which no other moisturisers or
products were allowed.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed.
Participant satisfaction
This outcome was not assessed.
Adverse events
This outcome was not assessed.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The investigators assessed disease severity with the objective SCO-
RAD (Kunz 1997). The mean change from baseline was -16.60
(SD 4.13) in the group treated with virgin coconut oil (26 partic-
ipants) compared to -9.90 (SD 3.84) in the virgin olive oil group
(26 participants), both of which are clinically important reduc-
tions (the MID objective SCORAD is 8.2 (Schram 2012)); the
MD was -6.70 (95% CI -8.87 to -4.53; P < 0.00001) in favour of
virgin coconut oil.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
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Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
3x Bleach bath with moisturiser versus water bath with
moisturiser once daily
The intervention under investigation for this comparison was the
’bleach bath’ and not the moisturiser (Shi 2015). Reducing Staphy-
lococcus aureus has been shown to have an effect on the disease
severity of eczema (Hon 2016). The Shi 2015 study had a within-
participant design with 20 participants, 10 of whom had eczema.
The study was designed to evaluate skin barrier function follow-
ing bleach bath and water bath, and we assessed it as being at a
high risk of bias. Immersion of the volar surface of the forearm in
the bleach bath or water bath for 10 minutes was followed by the
application of a moisturiser containing glycerol and petrolatum.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed.
Participant satisfaction
This outcome was not assessed.
Adverse events
This outcome was not assessed.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
This outcome was not assessed.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
Both treatments (bleach bath and water bath) had very limited
effect on TEWL values and corneometry.
Immediately after the bath, the TEWL increased for both arms
from 12 g/m²/h to slightly over 30 g/m²/h; however, after 15 min-
utes, TEWL decreased again in both volar surfaces of the fore-
arms and remained stable over 60 minutes. After 60 minutes, the
changes from baseline (from before the bath) were -2.15 g/m²/h
(SD 6.18) on the side treated with bleach bath and moisturiser
versus -2.63 g/m²/h (SD 5.19) on the water bath side, with a mean
of the paired differences of 0.48 g/m²/h (95% CI -2.30 to 3.26).
Assessments with the corneometer showed substantial increases
from around 24 arbitrary units for both forearms at baseline, to
around 60 arbitrary units immediately after the bath. Within 15
minutes, these returned to baseline values and remained stable for
60 minutes. The mean changes from baseline from before the bath
were -1.36 arbitrary units (SD 6.85) on the bleach bath side and -
1.84 arbitrary units (SD 6.30) on the water bath side, with a mean
of the paired differences of 0.48 arbitrary units (95% CI -2.70 to
3.66).
Change in health-related quality of life
This outcome was not assessed.
(4) Moisturisers versus active treatment
4a Licochalcone (containing Glycyrrhiza inflata root
extract, decanediol, menthoxypropanediol and ω-6-fatty
acids) twice daily versus hydrocortisone acetate 1% cream
twice daily
Three within-participant studies (100 participants) evaluated
the efficacy of these treatments (Angelova-Fischer 2014;
Udompataikul 2011; Wanakul 2013). We could only include
data for the first week from Angelova-Fischer 2014, because af-
ter one week, all participants received licochalcone-containing
cream. This study evaluated the interventions on forearms only
and included both children and adults. The Udompataikul 2011
and Wanakul 2013 studies lasted six and four weeks, respec-
tively, and were conducted only in children. We assessed both the
Angelova-Fischer 2014 and Udompataikul 2011 studies as being
at a high risk of bias, and the Wanakul 2013 as being at a unclear
risk of bias. Additional treatment for eczema was not permitted in
any of these studies.
See Summary of findings 7.
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Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Disease severity was not assessed by the participants in any of the
three studies. However, itch was assessed in both Angelova-Fischer
2014 and Wanakul 2013. At one week in the Angelova-Fischer
2014 study (18 participants), itch severity assessed on a VAS (0
cm to 10 cm, with 10 being worst imaginable itch), reduced by
1.75 cm (SD 1.82) in the arm treated with licochalcone-contain-
ing cream and by 2.75 cm (SD 1.36) in the arm treated with hy-
drocortisone acetate 1% cream. The mean of the paired differ-
ences was 1.00 cm (95% CI 0.39 to 1.61). The Wanakul 2013
study (52 participants) also assessed itch with a VAS (0 cm to 10
cm). After four weeks, itch had decreased from baseline by 4.00
cm (SD 2.25) on the licochalcone-treated side of the body and
by 4.00 cm (SD 2.22) on the hydrocortisone acetate-treated side.
Both appeared to be effective in reducing itch with no difference
between treatment arms (mean of the paired differences: 0.0 cm,
95% CI -0.47 to 0.47). Pooled data demonstrated a MD of -0.48
(95% CI -1.46 to 0.50; P = 0.34; I² = 85%; Analysis 8.1).
Participant satisfaction
This outcome was only assessed in Udompataikul 2011, where
it was scored on a 5-point Likert scale. Twenty-two of the 30
participants rated their satisfaction as good to excellent, with no
difference between either side.
Adverse events
Both Udompataikul 2011 and Wanakul 2013 reported no adverse
events on either side during the study, however, Angelova-Fischer
2014 reported detailed side effects based on a standardised ques-
tionnaire. There were nine side effects on the 18 forearms treated
with licochalcone (erythema (1), skin dryness (1), burning (2),
skin tightness (1), and itch (4)) and nine on the contralateral arm
(erythema (1), scaling (1), skin dryness (1), burning (3), skin tight-
ness (1), and itch (2)).
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
All three studies measured disease severity with SCORAD (score
from 0 to 103, higher score being worse). In Angelova-Fischer
2014 the SCORAD decreased by 3.50 (SD 2.34) in one week on
the side treated with licochalcone (18 sides) and by 3.50 (SD 1.85)
on the hydrocortisone acetate-treated side (18 sides), with a mean
of the paired differences of 0.0 (95% CI -0.78 to 0.78).
In Udompataikul 2011 (26 participants), the mean change from
baseline in SCORAD after four weeks was -18.72 (SD 6.96) on
the licochalcone side and -21.29 (SD 6.14) on the hydrocortisone
acetate side (mean of the paired differences of 2.57, 95% CI 0.59
to 4.55). In Wanakul 2013 (52 participants), the mean changes
from baseline after four weeks were -14.00 (SD 6.85) on the lic-
ochalcone side and -12.00 (SD 7.09) on the hydrocortisone ac-
etate side (mean of the paired differences of -2.00 (95% CI -3.47
to -0.53)). In both studies, the reductions in both treatment arms
were clinically important, as the MID was met (MID SCORAD
is 8.7 (Schram 2012)). Pooled data of the mean change from base-
line in SCORAD resulted in a MD of 0.08 (95% CI -1.96 to
2.13; P = 0.94; I² = 85%; Analysis 8.2). We explored reasons for
the heterogeneity (see Table 6), and considered that the most im-
portant factor was that the effect sizes differed between the stud-
ies. Furthermore, we could only include data for the first week of
the Angelova-Fischer 2014 study, as the first week was the only
randomised one, and therefore smaller reductions were reported
in both treatment arms compared to the other two studies, which
had a four-week duration with a correspondingly larger treatment
effect. In addition, in Angelova-Fischer 2014 only the forearms/
arms were treated.
Prevention of flares (lengthening the time to first flare)
This outcome was only assessed in the Udompataikul 2011 study
(30 participants), where 3/30 experienced a flare on the side treated
with licochalcone and 6/30 on the side treated with hydrocortisone
acetate 1%.
Change in use of topical active treatment
This outcome was not assessed in any study.
Changes in skin barrier function
Two studies assessed this outcome (Angelova-Fischer 2014;
Wanakul 2013). In Angelova-Fischer 2014 (18 participants), the
mean change from baseline in TEWL after one week was -9.92 g/
m²/h (SD 9.08) on the licochalcone-treated forearms and -12.43
g/m²/h (SD 11.17) on those treated with hydrocortisone acetate
1% (the mean of the paired differences was 2.51 g/m²/h, 95%
CI -1.21 to 6.23). In Wanakul 2013 (52 participants), the mean
change from baseline in TEWL after four weeks was -4.0 g/m²/h
(SD 7.44) on the licochalcone side and -1.00 g/m²/h (SD 8.59)
on the hydrocortisone acetate 1% side (the mean of the paired
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differences was -3.00 g/m²/h, 95% CI -4.71 to -1.29). Pooled
data of the mean change from baseline in TEWL demonstrated a
MD of -0.50 g/m²/h (95% CI -5.88 to 4.87; P = 0.85; I² = 86%;
Analysis 8.3). The reductions on both treatment sides were clearly
smaller after four weeks than the reductions after only one week
in Angelova-Fischer 2014. Furthermore, the differences in effect
between both sides of the body were small in both studies.
Change in health-related quality of life
This outcome was not assessed in any study.
4b-I Stelatopia (2% sunflower oil, fatty acids, ceramides)
twice daily versus hydrocortisone butyric propionate 0.1%
twice daily
This comparison was evaluated over three weeks in the De
Belilovsky 2011 study. We assessed this study as being at a high
risk of bias. It was conducted on 80 children aged four months to
four years, with mild to moderate eczema.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed.
Participant satisfaction
This outcome was not assessed.
Adverse events
No participants reported adverse events.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
After three weeks, the mean change from baseline in SCORAD
was -27.48 (SD 7.63) in the 40 participants treated with Stelatopia
versus -26.20 (SD 9.80) in the 40 treated with hydrocortisone
butyric propionate 0.1% cream (MD -1.28, 95% CI -5.13 to
2.57; P = 0.51), which was not a statistically significant difference
between the groups. However, the reductions in both treatment
arms were substantial and clinically important, as the MID for
SCORAD is estimated at 8.7 (Schram 2012).
Prevention of flares (lengthening the time to first flare)
The investigators ’agreed’ or ’strongly agreed’ (assessment based
on a 5-point Likert scale) that the frequency of flares was reduced
in 37/40 participants treated with Stelatopia versus 32/40 treated
with hydrocortisone butyric propionate 0.1% cream (RR 1.16,
95% CI 0.97 to 1.38; P = 0.11).
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was evaluated with two instruments for all 80 par-
ticipants: the IDQOL (scores range from 0 (no quality of life im-
pairment) to 30 (highest quality of life impairment)) showed mean
changes from baseline of -8.48 (SD 3.54) in the Stelatopia group
versus -6.50 (SD 3.61) in the hydrocortisone butyric propionate
0.1% cream group, with a MD of -1.98 (95% CI -3.55 to -0.41;
P = 0.01) in favour of Stelatopia. The second instrument used was
the DFI questionnaire; the data reported from this supported the
results of the IDQOL. The mean change from baseline in DFI
was -7.47 (SD 3.64) in the Stelatopia group compared to -4.85
(SD 3.16) in the hydrocortisone butyric propionate 0.1% cream
group, with a MD of -2.62 (95% CI -4.11 to -1.13; P = 0.0006).
4b-II EpiCeram twice daily versus fluticasone 0.05% cream
twice daily
One four-week study of 121 participants aged between six months
and 18 years evaluated these treatments (Sugarman 2009). We
assessed this study as being at a high risk of bias. All participants
had moderate to severe eczema, and no other treatments were
allowed.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
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Participants judged any improvement on a 3-point Likert scale
(no change, improved, worsening), and the mean change from
baseline in 53/59 participants in the EpiCeram group was -0.90
(SD 0.61) compared to -0.87 (SD 0.65) in 59/62 treated with
fluticasone 0.05% cream, with a MD of -0.03 (95% CI -0.26 to
0.20; P = 0.80).
Participants assessed itch on a VAS (0 cm to 10 cm) and reported
that itch was reduced by 3.3 cm in the EpiCeram group (59 par-
ticipants) and by 3.7 cm in the fluticasone 0.05% group (54 par-
ticipants). No SDs were provided.
Participant satisfaction
This outcome was not assessed.
Adverse events
The participants did not report any serious adverse events in either
group, but no further details regarding other possible treatment-
related adverse events were reported.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Investigators used the SCORAD. The mean change from baseline
in SCORAD was -18.7 (SD 7.8) in the 53 participants in the
EpiCeram group versus -22.2 (SD 7.8) in the fluticasone 0.05%
group (59 participants) (MD 3.50, 95% CI 0.61 to 6.39; P = 0.02).
Both reductions were clinically important, as the MID for the
SCORAD is estimated at 8.7 (Schram 2012), but the difference
between the two treatments, although statistically significant, is
not clinically important.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
4b-III 20% petrolatum in cetomacrogol combined with wet
wrap versus diluted mometasone furoate 0.1% combined
with wet wrap
Only one study compared wet wrap in combination with a petrola-
tum-cetomacrogol moisturiser in one group and diluted mometa-
sone furoate 0.1% ointment in the other (Janmohamed 2014).
We assessed this study as being at an unclear risk of bias. The du-
ration of the study was four weeks; it included 39 children aged
between six months and 10 years with severe eczema (objective
SCORAD 40 (± 5)) (Kunz 1997). The reporting of data in this
trial was suboptimal, and our attempts to obtain clarification of
missing and incomplete data were unsuccessful (see Table 2).
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Participants or parents applied the Patient-Oriented Eczema Mea-
sure (POEM) (score: 0 to 28, higher score being worse) to assess
this outcome. However, we had to estimate the data from a figure,
and despite numerous attempts to contact the investigators, we
did not obtain more precise data. Estimated reductions were 11 in
the petrolatum-cetomacrogol moisturiser group (16 participants)
and 15.3 in the mometasone furoate 0.1% ointment group, which
according to the investigators was not a statistically significant dif-
ference. Both reductions were clinically important as the MID for
the POEM is estimated at 3.4 (Schram 2012).
Participant satisfaction
This outcome was not assessed.
Adverse events
In the petrolatum-cetomacrogol moisturiser group, 7/20 chil-
dren reported an adverse event (folliculitis (2), secondary infected
eczema (2), the beginning of decubitus due to the mask (2), decu-
bitus at mask (1)) versus 12/19 in the mometasone furoate 0.1%
ointment group (folliculitis (9), severe folliculitis (1), decubitus at
mask (2)) (RR 0.55, 95% CI 0.28 to 1.10; P = 0.09).
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Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Investigators used the objective SCORAD, and as with the POEM,
we had to estimate the data from a figure as no precise data
were provided. Estimated reductions were 20 in the petrolatum-
cetomacrogol moisturiser group (16 participants) and 29.8 in
the mometasone furoate 0.1% ointment group (20 participants),
which are both substantial reductions (MID for objective SCO-
RAD is 8.2 (Schram 2012)). The investigators reported “a differ-
ence of 9.927 (3.68 SE) and a P value of 0.0028”.
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was assessed with the IDQOL, and again we had to
estimate data from a figure. The IDQOL reduced by 4 in the 16
children on petrolatum-cetomacrogol moisturiser versus a reduc-
tion of 12 in the 19 children on mometasone furoate 0.1% oint-
ment. The authors reported that this difference was statistically
significant (“P = 0.0002”).
4b-IV Water-in-oil emulsion Excipial twice daily versus
hydrocortisone 1% in a water-in-oil emulsion
These treatments were examined in a single one-week study with
69 adult participants (Gehring 1996). We assessed the study as
being at an unclear risk of bias; no other treatments were allowed.
Six participants dropped out overall, but it was unclear from which
groups they came.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
’Roughness’ of the skin was assessed with a VAS scale (1 cm to 10
cm, with higher being better). In the 31 participants in the Excipial
moisturiser group, the mean change from baseline was 2.19 cm
(SD 1.31) versus 2.60 cm (SD 0.98) in the 32 participants treated
with hydrocortisone 1% (MD -0.41 cm, 95% CI -0.98 to 0.16;
P = 0.16).
Participant satisfaction
This outcome was not assessed.
Adverse events
This outcome was not assessed.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The investigators assessed redness on a scale from one to four, with
a lower score being better. The mean change from baseline in the
31 participants in the Excipial moisturiser group was -0.84 (SD
0.66) compared to -1.00 (SD 0.52) in the 32 participants in the
hydrocortisone 1% group (MD 0.16, 95% CI -0.13 to 0.45; P =
0.29). Roughness was assessed with the same scale of one to four,
and this demonstrated a change from baseline of -0.97 (SD 0.59)
versus -1.06 (SD 0.46), respectively, with a MD of 0.09 (95% CI
-0.18 to 0.36; P = 0.52).
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed.
Change in use of topical active treatment
This outcome was not assessed.
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Changes in skin barrier function
The data reporting TEWL had to be estimated from a figure and
showed a reduction of 8.2 g/m²/h in the Excipial moisturiser group
(31 participants) versus 8 g/m²/h in the hydrocortisone group (32
participants), which are similar reductions.
Change in health-related quality of life
This outcome was not assessed.
4b-V Moisturiser containing spent grain, Vitellaria
paradoxa (formerly Butyrospermum parkii) extract plus
Argania spinosa kernel oil twice daily versus
hydrocortisone acetate1% cream twice daily
The four-week Jirabundansuk 2014 study examined these treat-
ments in 31 children between two and 15 years of age, with mild to
moderate eczema, using a within-participant design. We assessed
the study as being at a high risk of bias. No other treatments were
allowed.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Twenty-nine children or their parents reported change in disease
severity on a 4-point Likert scale (excellent, good, fair, unchanged).
After four weeks, 89.7% rated the outcome on the side treated
with the moisturiser as good to excellent compared to 93.1% on
the side treated with hydrocortisone acetate 1% cream.
Participant satisfaction
This outcome was not assessed.
Adverse events
The investigators stated that “no specific adverse events were re-
ported”.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The investigators measured disease severity in 29 participants with
the SCORAD (score 0 to 103, higher score being worse). Both
treatment sides showed clinically important reductions (MID
SCORAD is estimated at 8.7 (Schram 2012)). On the side treated
with the moisturiser, the mean change from baseline was -17.92
(SD 5) and on the side treated with hydrocortisone acetate 1%
cream the change was -18.22 (SD 4.74), with a mean of the paired
differences of 0.30 (95% CI -1.07 to 1.67), which was not a sta-
tistically significant difference between the two treatments.
Prevention of flares (lengthening the time to first flare)
After the four-week treatment period, the moisturiser group con-
tinued for a further four weeks with the moisturiser, whilst the hy-
drocortisone acetate 1% group switched to the cream base for the
following four weeks. No recurrences were seen in either group.
However, the investigators also reported that “as for the relapse
rates, it was 17.2% on the HC [hydrocortisone] cream side, and
10.3% on the S [moisturiser] cream side (P = 0.500).” It was not
clear to us what the difference between recurrence and relapse
might be.
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
This outcome was not assessed.
4b-VI Advabase twice daily versus methylprednisolone
aceponate cream two days a week plus moisturiser for
remaining five days
The Peserico 2008 study commenced with an open-label acute
treatment phase of four weeks in which participants - 12 years and
older with moderate to severe eczema - were treated with once-
daily methylprednisolone aceponate cream (MPA) and once-daily
moisturiser (Advabase). The second part of the study was a ran-
domised phase that included 221 participants and had a duration
of 16 weeks. In this phase, one treatment arm used only mois-
turiser (Advabase) and the other used MPA for two consecutive
days a week and moisturiser for the remaining five days a week.
We assessed the study as being at an unclear risk of bias.
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Primary outcomes
Change from baseline in disease severity as assessed by the
participants
Disease severity was not assessed, but itch was assessed on a VAS (0
mm to 100 mm, higher being worse). The investigators were not
able to provide us with SDs. The VAS scores increased during the
second (maintenance) phase in the Advabase moisturiser group
(109 participants) by 23.3 mm and in the MPA cream group (112
participants) by 5.5 mm. Authors reported “P < 0.001”.
Participant satisfaction
This outcome was not assessed.
Adverse events
In the Advabase moisturiser group, 26/109 participants reported
an adverse event compared to 17/112 in the MPA cream group
(RR 1.57, 95% CI 0.91 to 2.73; P = 0.11). Investigators reported
that “no AEs [adverse events] during the MP [maintenance phase]
were considered [to be] related to the study drug”.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
The mean increase in EASI (score from 0 to 72, higher score is
worse) during the maintenance phase was 2.97 in the Advabase
moisturiser group versus 0.5 in the MPA cream group. The trial au-
thors reported “P < 0.001”. The MID for the EASI is 6.6 (Schram
2012), and therefore the difference between the two treatments
was not clinically important.
Prevention of flares (lengthening the time to first flare)
During the 16-week phase of maintenance therapy, 36/109 par-
ticipants experienced a flare in the moisturiser group compared
to 16/112 in the MPA cream group, a result that favours MPA
cream (RR 2.31, 95% CI 1.37 to 3.91; P = 0.002; NNTH = 5,
95% CI 3 to 13). The rate of flare in the moisturiser group was
3.5 times the rate of flare in the MPA cream group (HR 3.5, 95%
CI 1.91 to 6.43; P < 0.0001; Analysis 9.1). Twice-weekly use of
topical corticosteroid cream on consecutive days combined with
use of moisturiser reduced the rate of flare compared to the use of
moisturiser alone (see Comparison 5 too).
Change in use of topical active treatment
This outcome was not assessed.
Changes in skin barrier function
This outcome was not assessed.
Change in health-related quality of life
No precise data were provided for this outcome, and the investi-
gators were not able to provide missing trial details; however, they
reported that, “The DLQI total score improved under MPA treat-
ment by 0.6 points, mainly due to improvements in the categories
’leisure’ (1.6 points) and ’personal relationships’ (1.2 points) but
worsened in all categories (by 4.4 to 13.8 points) in the moisturiser
group. Similarly, the CDLQI had better results in the MPA group
in all categories assessed (data not shown).”
4c Moisturisers versus topical immunomodulators
Three four-week studies, that we assessed as being at a high risk of
bias, evaluated different moisturisers against topical immunomod-
ulators (Emer 2011; Frankel 2011; Takeuchi 2012). Both children
and adults were included and all participants had mild to moder-
ate eczema. Emer 2011 and Frankel 2011 used a within-partici-
pant design. Emer 2011 included 20 participants and compared
Eletone (high in lipids) three times a day on one side of the body
with pimecrolimus cream three times a day on the other side of
the body. Frankel 2011 included 30 participants and compared
application of Hyalotopic (ceramide foam) to one side of the body
with twice daily application of pimecrolimus cream to the other
side. The Takeuchi 2012 study started with an induction phase in
which the 70 participants received tacrolimus. They were moved
to the maintenance phase only when the VAS score (0 mm to 100
mm, higher score is worse) reduced by more than 20 mm (43 par-
ticipants). The application frequency of the moisturiser and the
tacrolimus was not stated.
Trial details were missing and data were inadequately reported
In all three studies; we made numerous attempts to contact the
investigators to clarify missing study details, but were unsuccessful
(see Table 2).
Primary outcomes
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Change from baseline in disease severity as assessed by the
participants
In Emer 2011 (within-participant design), 20 participants com-
pared moisturiser with pimecrolimus on a 4-point Likert scale (0
to 3, higher scores being worse). The score reduced by 1.45 on the
side treated with moisturiser, and by 1.42 on the side treated with
pimecrolimus. Frankel 2011 (within-participant design) provided
no precise data; the investigators reported only that “subject self-
assessment scores decreased quadratically from week 0 to week 4
for both study treatment groups (P = 0.0001). However, there was
no statistically significant difference between the pimecrolimus
cream and ceramide-hyaluronic acid emollient foam [moisturiser]
group in subject self-assessment scores (P = 0.7093).” Itch (mea-
sured on a VAS) was reduced by 54.6% versus 56.4%, respectively.
In Takeuchi 2012, itch was assessed by means of a VAS (0 mm to
100 mm). The mean change from baseline was -31.40 mm (SD
10.66) in the moisturiser group (21 participants) versus 1.50 mm
(SD 12.61) in the tacrolimus group (23 participants) (MD 29.90
mm, 95% CI 23.02 to 36.78; P < 0.00001), which favours the
moisturiser group.
Participant satisfaction
This outcome was assessed only in Frankel 2011. The investigators
of this within-participant study reported that 68% of the 28 par-
ticipants preferred Hyalotopic, while 32% preferred pimecrolimus
cream.
Adverse events
The Emer 2011 and Frankel 2011 studies did not report any
adverse events on either side of the body. In Takeuchi 2012, adverse
events were not assessed during the maintenance phase. In the
induction phase, a transient burning sensation was reported in 32/
69 participants after application of tacrolimus.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Takeuchi 2012 failed to report data on the SCORAD (see ’Risk
of bias’ table in Characteristics of included studies for this study).
The Emer 2011 study assessed this outcome in 20 participants us-
ing a 6-point Likert scale (0 to 5, higher values indicating worse).
The mean score reduced by 2.11 on the side treated with mois-
turiser and by 2.16 on the side treated with pimecrolimus. Frankel
2011 reported that there was an improvement of 67.9% in the
IGA (score 0 to 5, higher being worse) on the side treated with
Hyalotopic and an improvement of 63.1% on the side treated with
pimecrolimus (28 participants).
Prevention of flares (lengthening the time to first flare)
This outcome was not assessed in these studies.
Change in use of topical active treatment
This outcome was not assessed in these studies.
Changes in skin barrier function
This outcome was not assessed in these studies.
Change in health-related quality of life
This outcome was not assessed in these studies.
5 Vehicle cream/ointment twice weekly combined with daily
moisturiser versus fluticasone propionate cream
(0.05%)/ointment (0.005%) twice weekly combined with daily
moisturiser
Three studies with similar designs evaluated these treatments (
Berth-Jones 2003; Glazenburg 2009; Hanifin 2002). We assessed
the three studies as being at an unclear risk of bias. All three started
with a stabilisation phase of four weeks in which all participants
were treated with fluticasone propionate (FP) 0.005% ointment
(Berth-Jones 2003 FP 0.05% cream in one treatment arm). They
then entered a 16-week (Berth-Jones 2003; Glazenburg 2009),
or 20-week (Hanifin 2002), randomised maintenance phase. The
participants had recurring moderate to severe eczema at entry to
the studies. Berth-Jones 2003 was a four-arm study; we considered
only two of its comparisons to be important for this review, i.e.
1) vehicle cream twice weekly combined with daily moisturiser
versus FP cream combined with daily moisturiser, and 2) vehicle
ointment twice weekly combined with daily moisturiser versus FP
ointment combined with daily moisturiser. This study had 376
participants who were 12 to 65 years of age. The Glazenburg 2009
study included 90 children aged four to 10 years, and Hanifin 2002
included 372 participants aged from three months to 65 years. The
objective of these studies was to establish whether intermittent use
of FP added to a moisturiser could reduce the rate of flare over
time.
See Summary of findings 8.
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Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was assessed only in Hanifin 2002, which used a
6-point Likert scale. Thirty-eight of the 119 participants in the
vehicle group reported a good to excellent result compared to 163/
229 in the FP group, with a significant difference in favour of
intermittent FP (RR 0.45, 95% CI 0.34 to 0.59; P < 0.00001;
NNTB = 3, 95% CI 2 to 3).
Participant satisfaction
This outcome was not assessed in these studies.
Adverse events
All three studies reported adverse events. The number of partici-
pants in the vehicle group reporting adverse events did not demon-
strate a statistically significant difference when compared with the
participants in the FP group (RR 0.51, 95% CI 0.22 to 1.14;
P = 0.61; I² = 67%; Analysis 10.1). No adverse events were re-
ported in Berth-Jones 2003, so we repeated our analysis, adding
one adverse event to all treatment arms, which produced an RR of
0.60 (95% CI 0.41 to 0.90; P = 0.01), which is in favour of vehi-
cle plus moisturiser. The investigators in Berth-Jones 2003 stated
that “during the maintenance phase investigators made no reports
of visual signs of skin changes and of atrophy”. Comparison of
the two other studies showed that there were more adverse events
in the FP group in Glazenburg 2009 than in Hanifin 2002. In
Glazenburg 2009, very few participants reported skin-related ad-
verse events, and skin atrophy was not observed. In both studies,
viral infections were reported mostly as adverse events. We assessed
all three studies as being at an unclear risk of bias overall, therefore,
we did not conduct sensitivity analyses for overall risk of bias. We
conducted further stratified analyses for the individual domains of
risk of bias (see Table 6), but the heterogeneity was not reduced.
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
Only the Glazenburg 2009 study assessed this outcome. There
was inconsistency between the data reported in the text regarding
the objective SCORAD, the corresponding data in the table, and
a comment made by the investigators, “Overall a statistically sig-
nificant difference was observed between treatment groups (P =
0.021).” The increase in SCORAD in the twice weekly FP plus
moisturiser group was reported as 7.1 in the data table and as 3.8
in the text. This would appear to be an unintentional error, but
we were unable to clarify or analyse the data further due to a lack
of response from the corresponding author (see Table 2). The in-
crease for the vehicle plus moisturiser group was 12.2, which was
reported consistently in both table and text.
Prevention of flares (lengthening the time to first flare)
The number of participants who experienced a flare was reported
in all three studies. In the vehicle group (combined with mois-
turiser) 203/312 participants had flared after 16 to 20 weeks,
whilst in the FP plus moisturiser group only 115/406 had flared
(RR 2.17, 95% CI 1.51 to 3.11; P < 0.0001; I² = 74%; NNTB
= 3, 95% CI 2 to 3, Analysis 10.2). We explored reasons for the
high level of heterogeneity using stratified analyses for effect size
as well as for ’Risk of bias’ domain, but all studies had an over-
all unclear risk of bias. One study had a smaller effect size, that
is, the second comparison of Berth-Jones 2003 in which vehicle
ointment was compared with FP ointment. The investigators in
Berth-Jones 2003 stated that “the difference between the two for-
mulations was significant (P = 0.002), with a hazard ratio of 2.9
(1.5 to 5.9), indicating that patients using the cream formulation
were approximately one third as likely to have a flare as those using
the ointment.” The other sensitivity analyses according to ’Risk of
bias’ domain did not lead to further reductions in heterogeneity
(Table 6).
The median time to flare in Berth-Jones 2003 was 6.1 weeks for
both vehicle plus moisturiser groups and more than 16 weeks
for both FP plus moisturiser groups. In Glazenburg 2009, the
median time to flare was 2.6 weeks in the vehicle plus moisturiser
group versus more than 16 weeks in the FP plus moisturiser group,
while in Hanifin 2002 the median times were 4.7 weeks and more
than 20 weeks, respectively. The rate of flare in the vehicle plus
moisturiser group was 3.69 times the rate in the FP plus moisturiser
group (HR 3.69, 95% CI 1.80 to 7.55; P = 0.0004; I² = 85%;
Analysis 10.3).
These results indicate that intermittent use of FP (0.05%) cream
or FP (0.005%) ointment in combination with a moisturiser is
more effective than moisturiser alone to reduce the rate of flare.
Change in use of topical active treatment
This outcome was not assessed in any study.
Changes in skin barrier function
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This outcome was not assessed in any study.
Change in health-related quality of life
This outcome was not assessed in any study.
6 Topical active treatment in combination with a
moisturiser versus topical active treatment only
Six studies (648 participants) evaluated whether combining an
active treatment, such as a topical corticosteroid, with a moisturiser
would be more effective than an active treatment alone (Draelos
2008; Gao 2008; Hanifin 1998; Msika 2008; Simpson 2011; Wu
2014). These studies investigated whether moisturisers have an
add-on effect. We assessed all of the studies as being at a high risk
of bias, with the exception of Draelos 2008, which we assessed as
being at an unclear risk of bias. Study duration varied from two
weeks in Gao 2008, to four weeks in Draelos 2008 and Simpson
2011. The Gao 2008 and Msika 2008 studies were conducted
in children; Wu 2014, in adults; and the other studies included
both children and adults. All participants suffered from mild to
moderate eczema.
Two studies had a within-participant design (Hanifin 1998;
Simpson 2011). Draelos 2008 was a three-arm study, and Msika
2008 was a five-arm study. Only two comparisons from each of
these two studies contributed to the present overarching compar-
ison.
See Summary of findings 9.
Primary outcomes
Change from baseline in disease severity as assessed by the
participants
This outcome was not assessed in any study.
Participant satisfaction
This outcome was assessed in two within-participant studies only
(Hanifin 1998; Simpson 2011). In Hanifin 1998 (78 participants),
96% preferred the combination of desonide 0.05% lotion twice
daily with moisturiser three times a day, and only 4% preferred
desonide 0.05% only. In Simpson 2011, 84.3% to 96.7% of the
123 participants (per-protocol population) were cited as saying
that the addition of the moisturiser, RestoraDerm, to the routine
use of their topical steroids “reduces inflammation, relieves dry and
itchy skin, provides long lasting hydration, leaves skin protected
and maintains healthy skin”.
Adverse events
This outcome was assessed by three studies (Draelos 2008; Hanifin
1998; Wu 2014). Draelos 2008 (60 participants) did not report
any adverse events in any of the three study arms (i.e. fluocinonide
0.05% combined with a multilamellar vesicular emulsion (MVE)
ceramide moisturiser, fluocinonide 0.05% combined with a MVE
ceramide-containing liquid cleanser and fluocinonide 0.05% with
a mild cleansing bar). After one week, In Hanifin 1998 (80 partic-
ipants, within-participant design), 10 participants reported burn-
ing and stinging on the side treated with desonide 0.05% com-
bined with moisturiser versus 11 reports for the side treated with
desonide 0.05% alone. After three weeks, none of the participants
reported burning and stinging in the combined treatment side
versus two on the desonide 0.05% lotion only side. In Wu 2014,
4/63 participants treated with flumethasone ointment combined
with moisturiser reported burning, redness, or greasiness versus
10/62 treated with only flumethasone ointment (RR 0.39, 95%
CI 0.13 to 1.19; P = 0.10).
Secondary outcomes
Change from baseline in disease severity as assessed by the
investigators
We could combine data from two of the studies (Msika 2008; Wu
2014). We included two possible comparisons from the five-arm
Msika 2008 study: desonide 0.05% twice daily combined with
moisturiser containing 2% sunflower oil oleodistillate (17 partic-
ipants) versus desonide 0.05% twice daily (18 participants); and
desonide 0.05% once daily combined with moisturiser containing
2% sunflower oil oleodistillate (17 participants) versus desonide
0.05% once daily (15 participants). Msika 2008 assessed disease
severity with SCORAD. The investigators in Wu 2014 used the
EASI to assess disease severity. The reductions in disease severity
in both treatment arms in all of the three comparisons met the
MID (estimated at 8.7 for SCORAD, and 6.6 for EASI (Schram
2012)), but the combination of active treatment (topical corti-
costeroid) plus a moisturiser was only slightly more effective than
active treatment alone with a SMD -0.87 (95% CI -1.17 to -0.57;
P < 0.00001; I² = 0%; Analysis 11.1), and the difference between
the interventions was not clinically important (i.e. the difference
between treatment arms did not meet the MID for any of the three
comparisons).
In Draelos 2008, the reductions in IGA were 2.7 for the fluo-
cinonide 0.05% plus MVE ceramide moisturiser group (20 par-
ticipants), 2.2 for the fluocinonide 0.05% plus MVE ceramide-
containing liquid cleanser group (20 participants), and 1.4 for the
fluocinonide 0.05% with a mild cleansing bar group (20 partici-
pants).
In Gao 2008, BoPao plus urea 10% ointment (101 participants)
was compared against BoPao alone (95 participants). The investi-
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gators stated that BoPao cream was categorised as an “inflamma-
tory and antifungal cream [exact meaning unclear due to transla-
tion issues] for treatment of eczema”, and we were unable to locate
any more information about this cream. Treatment was reported to
be effective in 89/101 participants on combination therapy com-
pared to 70/95 on BoPao only (RR 1.20, 95% CI 1.04 to 1.38; P
= 0.01; NNTB = 7, 95% CI 4 to 28).
In the within-participant Hanifin 1998 study (78 participants),
70% showed marked improvement to ’clear’ on the side treated
with desonide 0.05% plus moisturiser compared to 55% on
the side treated with desonide only (authors stated “P < 0.01”).
Simpson 2011, the other within-participant study (121 partici-
pants), used the EASI. Reductions in EASI were 1.28 (SD 1.94)
on the combined treatment side versus 1.01 (SD 1.50) on the side
that received active treatment only, with a statistically significant
mean of the paired differences of -0.27 (95% CI -0.52 to -0.02)
favouring combined treatment.
All studies showed that the combination of active treatment with a
moisturiser was more effective (statistically significant) than active
treatment alone.
Prevention of flares (lengthening the time to first flare)
This outcome was only assessed in one study (Wu 2014). In the
combined treatment group, 8/60 participants experienced a flare
versus 14/45 in the group on active treatment only (RR 0.43, 95%
CI 0.20 to 0.93; P = 0.03; NNTB = 6, 95% CI 3 to 57), which
favoured combined treatment.
Change in use of topical active treatment
This outcome was not assessed in any study.
Changes in skin barrier function
This outcome was assessed in Simpson 2011 only, via corneometry.
Skin hydration improved by 5.4 arbitrary units on the side treated
with topical corticosteroids plus RestoraDerm, and by 3 arbitrary
units on the side treated solely with topical corticosteroids, which
were both small improvements.
Change in health-related quality of life
Only Msika 2008 evaluated this outcome, and used the IDQOL.
We combined the results of the two comparisons within this study,
and there was no statistically significant difference in change from
baseline in quality of life between desonide 0.05% treatment plus
a moisturiser versus desonide 0.05% alone (MD -1.31, 95% CI -
2.70 to 0.09; P = 0.07; I² = 0%; Analysis 11.2). These data were
confirmed with assessments of the DFI (MD -1.03, 95% CI -2.47
to 0.42; P = 0.17; I² = 0%; Analysis 11.3).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Atopiclair versus vehicle for eczema
Patient or population: people with eczema
Setting: dermatology departments in hospitals
Intervention: Atopiclair
Comparison: vehicle




Quality of the evidence
(GRADE)
Comments
Risk with vehicle Risk with Atopiclair
Change from baseline
in disease severity ac-
cording to participants
(number of part icipants
who considered their
skin to have improved)
Assessed with: Likert
scale, good improve-
ment to total resolut ion
Follow-up: range 43
days to 50 days







ered Atopiclair more ef -
fect ive than its vehicle.
NNTB = 2, 95% CI 1 to 2











145 (Atopiclair) vs 28/
73 (vehicle) wished to
cont inue (RR 2.14, 95%
CI 1.58 to 2.89; P < 0.
00001; NNTB = 2; 95%
CI 2 to 3)
Belloni 2005: 5/ 15 vs
0/ 15 would use again
(Peto OR 10.18, 95% CI

























































































days to 50 days






The number of part ici-
pants report ing adverse
events was not stat ist i-
cally dif f erent between
the 2 groups
33 per 100 34 per 100
(26 to 44)
Change from baseline
in disease severity ac-
cording to the investi-
gators
Assessed with: EASI
Scale f rom: 0 to 72
(higher = worse)
Follow-up: range 43
days to 50 days
The mean change
f rom baseline in dis-
ease severity accord-
ing to the invest igators
ranged f rom - 1.7 to 0.
84
The mean change f rom
baseline in disease
severity according to
the invest igators in the
intervent ion group was






Although there is a sta-
t ist ically signif icant dif -
ference in favour of
Atopiclair, the dif fer-
ence between the treat-
ment group is not clin-
ically important (MID






days to 50 days






Part icipants in the
Atopiclair group expe-
rienced fewer f lares
than the vehicle group
(NNTB 3, 95% CI 3 to 5)
35 per 100 6 per 100
(4 to 11)
Change in use of top-
ical active treatment -
not measured
- - - - - This outcome was not
assessed in any of the
studies.
Change from baseline
in health- related qual-
ity of life - not mea-
sured
- - - - - This outcome was not
assessed in any of the
studies.
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).



















































































rat io;RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Abramovits 2008, Belloni 2005, Boguniewicz 2008.
2Downgraded one level for serious imprecision (wide conf idence interval).
3Abramovits 2008, Belloni 2005.
4Downgraded one level for serious indirectness, as outcomes did not exact ly match part icipant sat isfact ion.
5Abramovits 2008, Belloni 2005, Boguniewicz 2008, Patrizi 2008.
6Downgraded one level for serious imprecision (small sample size and CI includes no dif ference (1) and appreciable harm
(1.25)).
7Downgraded one level for serious inconsistency (I² = 51%), caused by Boguniewicz 2008, which showed a larger ef fect size.
8Abramovits 2008, Boguniewicz 2008, Patrizi 2008.
9Downgraded one level for risk of bias (Abramovits 2008: high risk for attrit ion bias, Boguniewicz 2008: unclear risk of bias





















































































Urea-containing moisturiser versus vehicle, placebo or no moisturiser for eczema
Patient or population: people with eczema
Setting: dermatology departments in hospitals
Intervention: urea-containing moisturiser
Comparison: vehicle, placebo or no treatment (no moisturiser)








placebo or no mois-
turiser
Risk with urea- con-
taining moisturiser
Change from baseline
in disease severity ac-
cording to the partici-
pants
(number of part icipants
who considered their











P = 0.0009. NNTB =
5 (95% CI 3 to 18)






In Wilhelm 1998 (n
= 77, within-part icipant
design), 61% consid-
ered that the side
treated with urea cream
showed moderate to
very good improve-




































































































penetrat ion into the
skin, and skin feel
were assessed. None
of these features were
assessed as being bet-
ter on the urea-treated
side than on the ve-
hicle-treated side. For
details, see compari-













P = 0.005; NNTH = 4,
95% CI 2 to 11.There
were fewer adverse
events in the group
treated with placebo
cream
39 per 100 65 per 100
(46 to 92)
Change from baseline
in disease severity ac-
cording to the investi-
gators
(number of part icipants
who improved accord-
ing to the invest igators)










The assessments of the
invest igators were in
line with the assess-
ments of the part ici-
pants. P = 0.001; NNTB
= 4, 95% CI 3 to 9
The within-part icipant
study of Wilhelm 1998
demonstrated a mean
of the paired dif fer-
ences of -0.57 (95% CI -
1.14 to 0.0) in favour of
urea moisturiser (lower
score being better), and
is more or less in line
with the parallel-design

































































































P = 0.03; NNTB = 3, 95%
CI 2 to 11
The rate of f lare in the
group that did not use
a moisturiser was 3.2
t imes the rate in the
group treated with urea
cream (HR 3.2, 95% CI
1.3 to 7.8; P < 0.01)
68 per 100 32 per 100
(16 to 63)
Change in use of top-
ical active treatment -
not measured
- - - - - This outcome was not
assessed in any of the
studies.
Change from baseline
in health- related qual-
ity of life - not mea-
sured
- - - - - This outcome was not
assessed in any of the
studies.
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; DASI: dry skin area and severity index; RR: risk rat io; HR: hazard rat io; NNTB: number needed to treat for an addit ional benef icial outcome; NNTH:
number needed to treat for one addit ional harmful outcome
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Lodén 2002.
2Downgraded one level for serious indirectness, the study of Lodén 2002 had a parallel study design and the study of Wilhelm


















































































3Downgraded one level for serious imprecision (small sample size).
4Bohnsack 1997.
5Within-part icipant design.
6Downgraded two levels for very serious imprecision (very small sample size).
7Wirén 2009.





















































































Glycerin/ glycerol-containing moisturiser versus vehicle or placebo for eczema
Patient or population: people with eczema
Setting: dermatology departments in hospitals
Intervention: glycerin/ glycerol-containing moisturiser
Comparison: vehicle or placebo




Quality of the evidence
(GRADE)
Comments





in disease severity as
assessed by the partic-
ipants
(number of part icipants
who considered their















ef fect ive for improving
dry skin than placebo
cream (P = 0.03; NNTB
= 6, 95% CI 3 to 60)
70 per 100 85 per 100
(70 to 100)
Participant satisfac-
tion - not measured
- - - - - This outcome was not














were mild to moderate






















































































35 per 100 32 per 100
(24 to 42)
Change from baseline
in disease severity as








The mean change f rom
baseline in disease
severity as assessed by
the invest igators was -
3.1
The mean change f rom
baseline in disease
severity as assessed by
the invest igators in the
intervent ion group was






P = 0.0005, but does not
meet the MID (which is
8.2 for object ive SCO-
RAD (Schram 2012)).
The study of Breternitz
2008 had a within-par-
t icipant design and con-
f irmed these data. The
mean of the paired dif -
ferences was -1.10, CI
95% -1.63 to -0.57
In Lodén 2002, in the
glycerol group 58/ 68
showed improvement
in ’dryness’ of the skin
versus 42/ 66 in the ve-
hicle group (RR 1.34,
95% CI 1.09 to 1.65; P =




flare - not measured
- - - - - This outcome was not
assessed in any of the
studies.
Change in use of top-
ical active treatment -
not measured
- - - - - This outcome was not
assessed in any of the
studies.
Change from baseline
in health- related qual-
ity of life - not mea-
sured
- - - - - This outcome was not





















































































* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; M ID: minimal important dif f erence; NNTB: number needed to treat for an addit ional benef icial outcome; RR: risk rat io; SCORAD: scoring atopic
dermatit is
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Lodén 2002.
2Downgraded one level for serious imprecision (lower bound of CI approaches 1).
3Lodén 2002 and Boralevi 2014.






















































































Oat-containing moisturiser versus vehicle or no moisturiser
Patient or population: people with eczema
Setting: dermatology departments in hospitals
Intervention: oat-containing moisturiser
Comparison: vehicle or no treatment (no moisturiser)




Quality of the evidence
(GRADE)
Comments





in disease severity as
assessed by the partic-
ipants
(number of part icipants
who considered their











P = 0.45. Part ici-
pants did not consider
that the oat-containing
moisturiser was more
ef fect ive than the con-
trol treatment (occlu-
sive vehicle)





ber of part icipants who










P = 0.76. Part icipants
were not more sat is-
f ied with oat-containing
moisturiser than with
the occlusive vehicle
































































































8/ 91 versus 0/ 82 re-
ported an adverse
event.
Peto OR 7.26 (95% CI 1.
76 to 29.92). 3 adverse
events were reported to
be mild, 3 moderate,








in disease severity as





weeks to 8 weeks
- The mean change f rom
baseline in disease
severity in the interven-
t ion group calculated
as the SM D was 0.23






P = 0.30. There was
no stat ist ically signif i-
cant dif f erence accord-
ing to the invest igators













P = 0.01; NNTB = 2, 95%
CI 1 to 5. The HR for
rate of f lare was 4.74
(95%CI 1.57 to 14.34; P
= 0.006) in favour of the
oat-containing cream
65 per 100 20 per 100
(8 to 50)
Total amount of topical
corticosteroids used
Follow-up: range 6
weeks to 2 months
The mean total amount
of topical cort icos-
teroids used ranged
f rom 22.73 g to 62.1 g
The mean total amount
of topical cort icos-
teroids used in the in-
tervent ion group was 9.
3 g lower (15.3 g less





P = 0.003. There is
a stat ist ically signif i-
cant dif f erence show-
ing that the use of mois-
turisers decreased the
use of topical cort icos-
teroids to achieve sim-





























































































Scale f rom: 0 to 30
(higher = worse)
Follow-up: range 6
weeks to 2 months
- The mean change f rom
baseline in health-re-
lated quality of lif e in
the intervent ion group
calculated as the SM D
was 0.09 lower (0.37





There was no stat ist i-
cally signif icant dif f er-
ence in change f rom
baseline in quality of
lif e between the 2 treat-
ment arms
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; CDLQI: Children’s Dermatology Life Quality Index; DLQI: Dermatoloqy Quality of Life Index; EASI: Eczema Area and Severity Index; HR: hazard rat io;
IDQOL: Infant ’s Dermatit is Quality of Life Index; M ID: minimal important dif f erence;NNTB: number needed to treat for an addit ional benef icial outcome; OR: odds rat io; RR:
risk rat io; SCORAD: scoring atopic dermatit is; SM D: standardised mean dif ference
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aWe had to put a value other than 0 in GRADEproGDT to calculate the risk with no moisturiser in relat ion to the RR, and we
chose 0.5 (af ter discussion with the GRADE working Group). GRADEproGDT then calculates the risk with moisturiser.
1Nebus 2009
2Downgraded two levels level for very serious imprecision (small sample size and CI includes no ef fect (1) and appreciable
benef it (1.25)).
3Downgraded one level for serious indirectness as the outcome was more about soothing and calm ing of the skin and not
really part icipant sat isfact ion.
4Downgraded two levels for very serious imprecision as the CI includes both no ef fect, and benef it of both oat-containing
cream as well as of the vehicle.
5Downgraded one level for risk of bias because of performance and detect ion bias.





















































































8Giordano-Labadie 2006, Grimalt 2007, Nebus 2009.
9Downgraded one level for serious inconsistency (I² = 65%), caused by Giordano-Labadie 2006, which was the study showing
a favourable result for the oat-containing creams whilst the other studies showed no dif ference between the treatment arms.
10Downgraded one level for serious imprecision; the CI creates uncertainty with the ef fect, ranging f rom moderate ef fect to
small harmful ef fect.
11Weber 2015.
12Downgraded one level for serious imprecision (small sample size).
13Giordano-Labadie 2006 and Grimalt 2007.
14Downgraded one level for serious inconsistency (I² = 68%). In the study of Giordano-Labadie 2006, far more topical
cort icosteroids were used and the dif ference between the two arms was much larger.
15Downgraded one level for serious imprecision (wide conf idence interval).
16Downgraded one level for serious risk of bias because of performance, detect ion, and attrit ion bias.





















































































All moisturisers compared to vehicle, placebo or no moisturiser for eczema
Patient or population: people with eczema
Setting: dermatology departments in hospitals
Intervention: all moisturisers
Comparison: vehicle, placebo or no moisturiser








placebo or no mois-
turiser
Risk with all moisturis-
ers
Change from baseline
in disease severity as
assessed by the partic-
ipants (number of par-
t icipants who consid-





weeks to 8 weeks







ered the use of a mois-
turiser to be more ef -
fect ive than vehicle/
placebo or no mois-
turiser. P = 0.02, NNTB
= 2, 95% CI 2 to 3







weeks to 8 weeks






P = 0.29. According to
the part icipants, there
was no dif ference be-
tween the 2 treatment
arms for this outcome.
Results are supported




























































































weeks to 6 months






There was no stat ist i-
cally signif icant dif f er-
ence in number of par-
t icipants experiencing
an adverse event
23 per 100 24 per 100
(19 to 30)
Change from baseline
in disease severity as
assessed by the inves-
tigators
As-
sessed with: EASI, SCO-
RAD, object ive SCORAD
Follow-up: range 4
weeks to 6 months
- The mean change f rom
baseline in disease
severity as assessed by
the invest igators in the
intervent ion group cal-
culated as the SM D was






P < 0.0001 The in-
vest igators considered
the use of moisturis-
ers to be more bene-
f icial than the vehicle,
placebo, or no mois-
turiser. However, clini-





weeks to 6 months






P = 0.006; NNTB = 4,
95% CI 3 to 5. The rate
of f lare in the control
group was 3.74 t imes
the rate in the mois-
turiser group based on
Weber 2015 and Wirén
2009 (HR 3.74, 95% CI
1.86 to 7.50; P = 0.
0002 in favour of mois-
turiser)
41 per 100 13 per 100
(7 to 25)
Total amount of topical
corticosteroids used
Follow-up: range 6
weeks to 2 months
The mean amount
of cort icosteroids used
ranged f rom 22.73 g to
62.1 g
The mean amount of
cort icosteroids used in
the intervent ion group
was 9.30 g less (15.30





P = 0.003. There was
a stat ist ically signif i-
cant dif f erence show-
ing that the use of
moisturisers decreased




















































































t icosteroids to achieve
sim ilar reduct ions in
eczema severity
Change from baseline




Scale f rom: 0 to 30
Follow-up: range 6
weeks to 6 months
- The mean change f rom
baseline in health-re-
lated quality of lif e in
the intervent ion group
calculated as the SM D
was 0.39 lower (0.9





The ef fect on quality of
lif e ranges f rom a mod-
erate ef fect on qual-
ity of lif e in favour
of moisturisers to no
dif ference between the
groups
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CDLQI: Children’s Dermatology Life Quality Index; CI: conf idence interval; DFI: Dermatit is Family Impact; EASI: Eczema area and severity index; HR: hazard rat io; IDQOL:
Infant ’s Dermatit is Quality of Life Index; M ID: minimal important dif f erence;NNTB: number needed to treat for an addit ional benef icial outcome; RR: risk rat io; SCORAD:
scoring atopic dermatit is; SD: standard deviat ion; SM D: standardised mean dif ference
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Abramovits 2008, Belloni 2005, Boguniewicz 2008, Lodén 2002, Nebus 2009.
2Downgraded one level for inconsistency (I² = 95%), which was in part caused studies by studies at risk for attrit ion bias
(Abramovits 2008 and Boguniewicz 2008).
3Downgraded one level for serious imprecision (wide conf idence interval).
4Abramovits 2008, Belloni 2005, Nebus 2009.
5Downgraded one level for serious inconsistency (I² = 83%). All heterogeneity was removed when a study at high risk of bias
was excluded (Abramovits 2008); we did not double count for risk of bias.
6Downgraded one level for serious imprecision (CI interval includes no ef fect (1) and appreciable benef it (1.25)).
7Abramovits 2008, Belloni 2005, Boguniewicz 2008, Boralevi 2014, Gayraud 2015, Grimalt 2007, Kort ing 2010, Lodén 2002,
Patrizi 2008, Tan 2010.



















































































9Abramovits 2008, Belloni 2005, Boguniewicz 2008, Boralevi 2014, Gayraud 2015, Giordano-Labadie 2006, Grimalt 2007,
Kort ing 2010, Nebus 2009, Patrizi 2008, Patrizi 2014, Tan 2010.
10We did not downgrade for inconsistency as all sensit ivity analyses show a clear posit ive ef fect of moisturisers.
11Abramovits 2008, Boguniewicz 2008, Gayraud 2015, Patrizi 2008, Weber 2015, Wirén 2009.
12Downgraded one level for serious inconsistency (I² = 73%), which was caused by the studies at unclear to high risk of bias
showing better results.
13Giordano-Labadie 2006, Grimalt 2007.
14Downgraded one level for serious inconsistency (I² = 68%). In the study of Giordano-Labadie 2006, far more topical
cort icosteroids were used and the dif ference between the two arms was much larger.
15Gayraud 2015, Giordano-Labadie 2006, Grimalt 2007.
16We did not downgrade for risk of bias, as, although there was attrit ion bias in Grimalt 2007, it did not impact the overall
result , and even reduced the direct ion of ef fect.
17Downgraded one level for serious inconsistency (I² = 79%), it m ight have no ef fect at all, signal around 0.





















































































Licochalcone-containing moisturiser versus hydrocortisone acetate1% cream for eczema
Patient or population: people with eczema
Setting: dermatology departments in hospitals
Intervention: l icochalcone-containing moisturiser
Comparison: hydrocort isone acetate 1% cream












in disease severity ac-
cording to participants
- not measured
- - - - - This outcome was not















sides, 22/ 30 part ici-
pants rated their sat is-
fact ion good to excel-






weeks to 4 weeks





2011 and Wanakul 2013
reported no adverse
events on any side
during the study. Side
ef fects in Angelova-
Fischer 2014 (within-
part icipant study) were




















































































scaling on both sides.
9 side ef fects were re-
ported on each forearm
(n = 18)
Change from baseline
in disease severity as




Scale f rom: 0 to 103
(higher = worse)
Follow-up: range 1
weeks to 4 weeks
The mean disease
severity as assessed
by the invest igators
ranged f rom - 3.50 to -
21.29
The mean disease
severity as assessed by
the invest igators in the
intervent ion group was






There was no stat is-
t ically signif icant dif -
ference between the
2 treatments, which is
in accordance with the











3/ 30 experienced a
f lare on the side treated
with licochalcone and
6/ 30 on the contralat-
eral side treated with
hydrocort isone acetate
1%
Change in use of active
topical treatment - not
measured
- - - - - This outcome was not
assessed in any of the
studies.
Change from baseline
in quality of life - not
measured
- - - - - This outcome was not
assessed in any of the
studies.
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).




















































































GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Within-part icipant study Udompataikul 2011.
2We did not downgrade for detect ion bias as the part icipants were not blinded, but they considered treatments equally
sat isfactory.
3Downgraded two levels for serious imprecision (very small sample size).
4Within-part icipant study Angelova-Fischer 2014.
5Not downgraded for risk of bias (part icipants in Angelova-Fischer 2014 and Udompataikul 2011 were not blinded) as there
was no dif ference between the both treatment arms regarding report ing adverse events.
6Downgraded two levels for very serious imprecision (very small sample size).
7We did not downgrade for detect ion bias as invest igators were blinded.
8Downgraded two levels for very serious inconsistency (I² = 85%); it could benef it both treatments. We therefore did not
downgrade further for imprecision. Dif ferences in study durat ion, and, in Angelova-Fischer 2014, only forearms were treated.
9Downgraded one level for serious imprecision (small sample size and as we downgraded for risk of bias, we only downgraded
once for imprecision for this outcome).




















































































Vehicle treatment + daily moisturiser compared to fluticasone propionate twice weekly + daily moisturiser for eczema
Patient or population: people with eczema
Setting: dermatology departments in hospitals
Intervention: vehicle treatment + daily moisturiser
Comparison: f lut icasone propionate twice weekly + daily moisturiser










Risk with vehicle treat-
ment + moisturiser
Change from baseline
in disease severity as
assessed by the par-
ticipants (number of
part icipants report ing










NNTB = 3, 95% CI 2 to
3, in favour of f lut ica-
sone propionate twice
weekly + daily mois-
turiser
71 per 100 32 per 100
(24 to 42)
Participant satisfac-
tion - not measured
- - - - - This outcome was not






weeks to 20 weeks












plied that they might




















































































verse events in either
group)
22 per 100 11 per 100
(5 to 25)
Change from baseline
in disease severity as











There were report ing in-
consistencies in the pa-
per between the data ta-
ble and text regarding
the increase in SCORAD
in the twice-weekly f lu-
t icasone propionate +
daily moisturiser group.
These were reported as
7.1 in the table and as
3.8 in the text
In the vehicle + daily
moisturiser group, the
increase was 12.2 in





weeks to 20 weeks






NNTB = 3, 95% CI 2 to
3. Twice-weekly f lut ica-
sone propionate com-
bined with moisturiser
resulted in fewer f lares
than moisturiser alone.
HR of rate of f lare 3.
69, 95% CI 1.80 to 7.
55 in favour of f lut ica-
sone propionate twice
weekly + daily mois-
turiser
28 per 100 61 per 100
(43 to 88)
Change in use of top-
ical active treatment -
not measured
- - - - - This outcome was not




















































































in quality of life - not
measured
- - - - - This outcome was not
assessed in any of the
studies.
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; HR: hazard rat io; NNTB: number needed to treat for an addit ional benef icial outcome; RR: risk rat io; SCORAD: scoring atopic dermatit is
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Hanif in 2002.
2Berth-Jones 2003 (two comparisons), Glazenburg 2009, Hanif in 2002.
3Downgraded one level for serious inconsistency (I² = 67%); as there were no adverse events in both comparisons in
Berth-Jones 2003 in both treatment arms, they could be equally safe.
4Downgraded one level for serious imprecision (CI includes appreciable benef it and no dif ference).
5Glazenburg 2009 (See ’Comments’).
6Downgraded one level for serious imprecision (small sample size).




















































































Topical active treatment in combination with moisturiser compared to topical active treatment alone for eczema
Patient or population: people with eczema
Setting: dermatology departments in hospitals
Intervention: act ive treatment in combinat ion with moisturiser
Comparison: act ive treatment alone




Quality of the evidence
(GRADE)
Comments
Risk with active treat-
ment alone




in disease severity ac-
cording to participants
- not measured
- - - - - This outcome was not










Hanif in 1998: 96%of 78
preferred the combina-
t ion treatment and just
4% the act ive treatment
’only’. Simpson 2011:
84.3% to 96.7% of 123
felt that the addit ion of
the RestoraDerm to the
rout ine use of their top-
ical steroids ‘‘reduces
inf lammation, relieves
dry and itchy skin, pro-
vides long last ing hy-

































































































Draelos 2008: no ad-
verse events. Hanif in
1998 (within-part ici-
pant): 10 part icipants
reported burning and




on the other side
treated with only des-
onide 0.05%
16 per 100 6 per 100
(2 to 19)
Change from baseline
in disease severity as
assessed by the inves-
tigators
Assessed with: SCO-




- The mean change f rom
baseline in disease
severity as assessed by
the invest igators in the
intervent ion group cal-
culated as the SM D 0.






According to the as-
sessments of the inves-
t igators, adding a mois-
turiser to topical act ive
treatment is more ef -
fect ive than topical ac-













to act ive treatment re-
duced the number of
f lares (NNTB = 6, 95%
CI 3 to 57)
31 per 100 13 per 100
(6 to 29)
Change in amount
of use topical active
treatment - not mea-
sured
- - - - - This outcome was not






















































































in health- related qual-
ity of life
Assessed with: IDQOL
Scale f rom: 0 to 30
follow-up: mean 3
weeks
The mean change f rom
baseline in health-re-
lated quality of lif e
ranged f rom - 2.07 to -
3.17
The mean change f rom
baseline in health-re-
lated quality of lif e in
the intervent ion group
was 1.31 lower (2.7





The study durat ion of 3
weeks was short ; there
was no dif ference in
changes f rom baseline
in quality of lif e be-
tween the 2 treatment
groups. Results of DFI
conf irmed this (MD -1.
03, 95% CI -2.47 to 0.
42)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; DFI: Dermatit is Family Impact; EASI: Eczema Area and Severity Index; IDQOL: Infant ’s Dermatit is Quality of Life Index; RR: risk rat io; SCORAD: scoring
atopic dermatit is; SM D: standardised mean dif ference
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Within-part icipant design.
2Hanif in 1998, Simpson 2011.
3Downgraded one level for serious risk of detect ion bias (no blinding of part icipants).
4Downgraded one level for serious indirectness as in both studies sat isfact ion was not really assessed.
5Wu 2014.
6Downgraded one level for risk of bias. Hanif in 1998 and Wu 2014 were assessed as being at a high risk of bias.
7Downgraded one level for serious indirectness for dif f erent report ing on adverse events including outcome def init ions.
8Downgraded one level for serious imprecision (small sample size, too few adverse events, and wide CI).
9Msika 2008 (2 comparisons), Wu 2014.
10Downgraded one level for risk of bias (no blinding of outcome assessors).
11Downgraded one level for risk of bias (attrit ion bias (17/ 62) in the control group).
12Downgraded one level for serious imprecision (small sample size).









































































































































































D I S C U S S I O N
Summary of main results
We included 77 studies with a total of 6603 participants in this
review. Only seven of these studies compared moisturisers versus
no moisturisers, which is probably the most important and highly
informative comparison to use when assessing the efficacy of mois-
turisers in people with eczema. In the 15 studies that compared
a moisturiser with a placebo or vehicle, the placebos and vehicles
were also moisturisers, but lacked the ingredient that was consid-
ered to be the most effective in the moisturiser. These compar-
isons, although valuable, do not provide us with crucial informa-
tion about how effective the tested moisturiser is by itself, as the
placebo or vehicle might decrease disease severity. Indeed, in some
studies the placebo or vehicle performed better than the mois-
turiser under investigation (e.g. 10% and 20% Hippophae rham-
noides cream versus placebo (Thumm 2000), and furfuryl palmi-
tate-enriched moisturiser versus the moisturiser without furfuryl
palmitate (Tripodi 2009)).
There were 29 single study comparisons that evaluated one mois-
turiser versus another moisturiser; these provide information on
whether one moisturiser is more effective than another, but do not
inform us about the efficacy of a moisturiser by itself. However,
in some instances both treatment arms showed clinically impor-
tant reductions from baseline in disease severity (meeting mini-
mal important differences (MID)) suggesting that both were sim-
ilarly effective. It is worth mentioning the Åkerström 2015 study
(assessed as being at low risk of bias), which compared a barrier-
strengthening moisturiser containing 5% urea against a reference
cream without urea. This study started with a stabilisation phase in
which active treatment (mometasone) was used until the eczema
was (almost) cleared. During the maintenance phase of 180 days
(with no active treatment), fewer participants in the group using
barrier-strengthening moisturiser with 5% urea experienced a flare
compared to those using the reference cream, and the time to flare
was considerably lengthened (15 compared to 22 days). Further-
more, two studies at unclear risk of bias that were conducted in
the Philippines, evaluated oils as a moisturiser (Evangelista 2014;
Verallo-Rowell 2008). In Evangelista 2014 virgin coconut oil was
compared to mineral oil, and in Verallo-Rowell 2008 virgin co-
conut oil to virgin olive oil. In both studies the oils showed clin-
ically important reductions in disease severity in both treatment
arms, but virgin coconut oil appeared to be more effective in both
studies.
The Sugarman 2009 study (at high risk of bias), which fits
under the overarching comparison of moisturisers versus active
treatment, indicated that the ceramide-containing barrier cream
(EpiCeram) showed a large reduction in the SCORing Atopic Der-
matitis Index (SCORAD) (18.7) over a four-week period, which is
a clinically important reduction (MID SCORAD is 8.7 (Schram
2012)). However, several other studies (Comparisons 3b, 3d, 3e,
and 3f ) that evaluated the same ceramide-containing barrier cream
showed inconsistent results in improvements in eczema, which
varied from very small improvements to more important clini-
cal reductions. Another study, Jirabundansuk 2014 (high risk of
bias), which evaluated a moisturiser containing spent grain, Vitel-
laria paradoxa (formerly Butyrospermum parkii) extract and Arga-
nia spinosa kernel oil together with other ingredients also demon-
strated a reduction in SCORAD of 17.92, which is a clinically
important reduction. This appeared to indicate that such a mois-
turiser might have an anti-inflammatory effect, but it is equally
possible that this may be due to the effective moisturising action
of the product.
Three studies were conducted to assess whether twice weekly top-
ical fluticasone propionate in combination with a moisturiser was
more effective than moisturiser alone (plus the vehicle of the flu-
ticasone propionate) in preventing flares, which is important for
people with eczema who experience frequent flares. The seven
studies that compared topical active treatment with a moisturiser
versus active treatment alone provide us with insight into the add-
on efficacy of moisturisers when applying topical active treatment.
In general most of the moisturisers that were evaluated appeared
to show at least some beneficial effect as assessed by our predefined
outcomes, however the extent of the effects varied widely across
the included studies.
Our primary outcome ’participant-assessed disease severity’ was
addressed in only a third (24) of the studies and itch was assessed
in 23 studies. In most instances only small reductions were seen
in the outcome change from baseline in itch (Comparisons 1, 2b,
2c, 2d, and 2e), and these were usually based on assessments with
visual analogue scales (VAS). Noteworthy improvements in itch
occurred with Atopiclair, which showed a statistically significant
difference compared to its vehicle (Comparison 2a). Possibly more
importantly, pooled data for all of the moisturisers versus control
(Comparison 2f ) showed a large effect on reduction of itch in
favour of the use of moisturisers. However, apart from the fact that
there was a high degree of inconsistency in the data, the clinical
relevance of this effect is difficult to interpret. As yet no MID
has been established for itch on VAS scales, and the studies that
contributed data to this outcome used a range of different scales.
Based on a recent publication, the MID of the VAS for itch lies
within a two to three point decrease (Reich 2016).
Only 13 studies assessed ’participant satisfaction with treatment’.
These did not report in detail about specific preferences and did
not elaborate about which moisturisers are preferable for daytime
use and which for night-time use, or whether choices vary depend-
ing on the season (e.g. winter versus summer). The secondary out-
come ’change in health-related quality of life’ was only covered in
10 of the 77 studies. As eczema is a chronic disease with a clear
impact on quality of life (Lewis-Jones 2006; Nutten 2015), the
significance of relevant patient-reported outcomes (PROs) would
appear to have been underestimated in the majority of studies.
The reporting of adverse events, although included in over half
of the studies (41/77), was not informative, and most comments
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about these events were limited and quite generic. Most of the
adverse events that were reported with moisturisers consisted of
smarting, stinging, pruritus and erythema, and sometimes folli-
culitis.
The most assessed outcome, assessed in 65 of the 77 studies,
was our prespecified secondary outcome ’investigator-assessed dis-
ease severity’; 25 studies evaluated this with the SCORAD index
(European Task Force on Atopic Dermatitis 1993), and 14 with
the Eczema Area and Severity Index (EASI) (Hanifin 2001), which
is the core outcome instrument for measuring clinician-reported
signs in eczema studies (Schmitt 2014). The remaining studies
used Likert scales or other instruments. The other secondary out-
comes assessed in studies included prevention of flares (16 stud-
ies); change in use of topical active treatment (eight studies); and
changes in barrier function (29 studies).
Pooling of data for the prespecified outcomes of our review was
limited, mainly because of the wide variety of comparisons, which
were often assessed only by single studies. We have provided ’Sum-
mary of findings’ tables for those comparisons we consider to be
the most important and where data could be pooled.
For the comparison ’moisturisers versus no moisturiser’ (Summary
of findings for the main comparison), there was low quality evi-
dence of a statistically significant difference favouring moisturis-
ers over no moisturiser for the outcome ’change from baseline
in disease severity as assessed by the investigators’ based on the
SCORAD. However, the SCORAD MID of 8.7 was not met
(Schram 2012). There was also low quality evidence that more
adverse events occurred in the moisturiser group than in the no
moisturiser group, which was not totally unexpected. We reported
two important observations (both low quality evidence); firstly,
that there was a clinically relevant and statistically significant dif-
ference in favour of moisturisers for rate of flare which was reduced
to almost a quarter (0.27), with a prolonged time to flare; and sec-
ondly, when moisturisers were used, a smaller quantity of topical
corticosteroids was needed to achieve a greater reduction in SCO-
RAD. However, this difference in SCORAD did not meet the
MID. There were no statistically significant differences between
the groups for changes in quality of life (low quality evidence).
There was moderate quality evidence for the efficacy and safety
of Atopiclair over its vehicle for all the outcomes evaluated by the
studies (Summary of findings 2). Both participants and investi-
gators were in agreement that Atopiclair was the more effective,
but the difference in investigator scores with the EASI did not
meet the MID of 6.6 (Schram 2012). In addition, participants
in the Atopiclair group experienced fewer flares than those in the
vehicle group. Atopiclair contains glycyrrhetinic acid, which, as
summarised in Abramovits 2008, “has anti-inflammatory effects,
possibly mediated through inhibition of 11-β-hydroxysteroid de-
hydrogenase, an enzyme that interconverts active cortisol to and
from inactive cortisone; this inhibition may increase the cortisol
available for binding to local glucocorticoid receptors, including
in the skin”. Atopiclair reduced itch more effectively than its vehi-
cle and the difference might be clinically important (Reich 2016),
on the basis of the MID described above.
There was low to moderate quality evidence for several outcomes
assessed in the comparison of urea-containing moisturisers versus
vehicle, placebo or no moisturiser (Summary of findings 3). Both
participants and investigators considered urea-containing cream
to be more effective than its control, but there were fewer adverse
events in the control group. It is fairly widely acknowledged that
urea can cause transient burning and stinging after application.
The use of urea-containing moisturiser reduced the rate of flare
by one-third (0.31) (low quality evidence).
The effects of glycerol (glycerine) are summarised in Summary of
findings 4. There was moderate to high quality evidence for the
outcomes assessed. Both participants and investigators considered
glycerol-containing moisturiser to be more effective than vehicle
or placebo cream. However, for the investigator-assessed change
in disease severity, the 8.2 SCORAD MID was not met between
the two treatment arms.
When oat-containing creams were compared to vehicle or no mois-
turiser there was no difference between the two treatment arms
for participant- and investigator-assessed change in disease sever-
ity (low to very low quality evidence) (Summary of findings 5). In
contrast there were statistically significantly fewer flares in the oat-
containing moisturiser group, and the rate of flare was reduced
by a factor of almost five (0.21), which was quite remarkable.
Furthermore, smaller amounts of corticosteroids were needed in
the oat-containing moisturiser group than in the control group.
However, more adverse events were reported in the oat-containing
moisturiser group.
Summary of findings 6 compares all moisturisers to vehicle,
placebo or no moisturiser, and the quality of evidence ranges from
low to high. Participants considered the use of a moisturiser to be
more effective than the control (low quality evidence), and this
was confirmed by the judgement of the investigators in 12 studies
(high quality evidence). There was low quality evidence of no dif-
ference in participant satisfaction or in the number of participants
experiencing an adverse event between the two treatment arms.
There was a statistically significant difference in the number of
participants who experienced a flare which was three times lower
in the moisturiser group (moderate quality evidence), and rate of
flare was nearly reduced by a factor of four (0.27). The data showed
that the use of moisturisers decreased use of topical corticosteroids
without compromising reductions in disease severity (low qual-
ity evidence). There was no statistically significant difference in
changes in quality of life between the two treatment groups (low
quality evidence). Pooled data from seven studies showed that the
use of moisturisers had a large effect on itch compared to the con-
trol group. However, due to considerable heterogeneity in the re-
sults, the use of different assessment scales, and the fact that the
clinical relevance of this outcome is difficult to estimate, caution
must be exercised in interpreting these data.
Three within-participant studies compared a licochalcone-con-
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taining moisturiser with topical hydrocortisone acetate 1% cream
(Summary of findings 7). These studies showed that there were
no statistically significant differences between the treatment ef-
fect, satisfaction, adverse events and number of participants who
experienced a flare (all low quality evidence). In Udompataikul
2011 the study investigators stated that “licochalcone A, a major
phenolic constituent of liquorice species Glycyrrhiza inflata, has
lately been reported to possess anti-inflammatory and antimicro-
bial properties”. The investigators in Angelova-Fischer 2014 in-
dicated that “licochalcone A suppress the production of pro-in-
flammatory mediators and cytokines such as PGE2, LTB4, IL-6
and TNF-α in in vitro systems relevant to the skin such as dermal
fibroblasts, granulocytes, dendritic cells and human skin equiva-
lents”. It is interesting to note that moisturisers with non-steroidal
anti-inflammatory properties, such as these licochalcone-contain-
ing moisturisers (as well as Atopiclair), would appear to have sim-
ilar effects to low potency topical corticosteroids.
Four trials that investigated vehicle treatment combined with a
moisturiser compared to fluticasone propionate twice weekly in
combination with a moisturiser mainly addressed the potential
benefits of the twice weekly fluticasone propionate in preventing
flares (Summary of findings 8). There was high quality evidence
that participants considered twice weekly fluticasone propionate
more effective than the control treatment in achieving good to ex-
cellent improvement. Furthermore, twice weekly fluticasone pro-
pionate in combination with a moisturiser was shown to be ef-
fective in reducing flares compared to a moisturiser with vehicle
treatment (moderate quality of evidence), and reduced the rate of
flare to almost a quarter (0.27). There was no statistically signifi-
cant difference between the intervention groups for the number of
participants who reported an adverse event (low quality evidence).
The last comparison for which we were able to pool data was topi-
cal active treatment in combination with a moisturiser versus top-
ical active treatment alone, summarised in Summary of findings
9. There was low quality evidence that participants were more sat-
isfied with the combined therapy, and moderate quality evidence
from the investigators that adding a moisturiser to topical active
treatment was more effective than topical active treatment alone.
There was no difference in the number of adverse events (very
low quality of evidence) and, based on one study, the addition of
a moisturiser to topical active treatment reduced the number of
participants who experienced a flare. There was no difference in
change of quality of life (low quality of evidence), but it is likely
that the three-week study duration was probably too short to de-
tect a difference.
The results of the 29 studies that assessed change from baseline in
skin barrier function showed wide and inconsistent variation of
small to substantial improvements.
The overall conclusion from the various comparisons is that mois-
turisers are effective at reducing rate of flare, can prolong time to
flare, reduce the use of topical corticosteroids, and, when com-
bined with topical active treatment, lead to better results than ac-
tive treatment alone. However, the quality of evidence varied from
low to high, and the MID for the investigators’ assessments based
on (objective) SCORAD and EASI was not met.
Overall completeness and applicability of
evidence
Although we were able to include 77 studies, the majority (70/77)
were at unclear to high risk of bias, and very few studies compared
similar interventions.
The comparison that would be expected to provide the most reli-
able information about the efficacy of moisturisers in eczema was
moisturiser versus no moisturiser, but this was only addressed in
seven studies (six provided usable data). The low quality evidence
from these studies indicated that the use of moisturisers was more
effective, but not clinically important (investigator-reported), than
no moisturiser and resulted in fewer flares, a prolonged time to
flare and a reduced need for topical corticosteroids to reach com-
parable reductions in eczema severity.
The 29 studies that compared one moisturiser with another mois-
turiser (23 provided usable data) were all evaluated in single stud-
ies with different treatment arms, which did not permit pooling
of their data. Although it was clear from some of these studies that
improvements were experienced in one or both treatment arms
(participant-reported, investigator-reported, or both), these stud-
ies mainly indicated that moisturisers might have a similar effect
to each other, or that one moisturiser might be better than an-
other, though evidence for this was based on a single study - often
with a small sample size- and mostly at an unclear to high risk
of bias. It also demonstrated the heterogeneous performance of
moisturisers, which, as was emphasised by Danby and colleagues,
has a notable impact on the treatment of eczema, and its long-
term control (Danby 2016).
There was moderate quality evidence that Atopiclair, urea-contain-
ing moisturisers and glycerol-containing moisturiser (high quality
evidence for investigators’ assessment) were more effective than
their control (no moisturiser, vehicle or placebo), although the
MID for investigator assessments was not met. Both Atopiclair
and urea-containing moisturisers reduced the number of flares
(this outcome was not assessed in the comparisons with glycerol-
containing moisturisers).
The overall conclusion, according to both participants (low qual-
ity evidence) and investigators (high quality evidence), when all
comparisons of moisturiser versus vehicle, placebo or no mois-
turiser were combined, was that moisturisers are effective, can re-
duce flares (moderate quality evidence), and have a corticosteroid-
sparing effect.
Adding moisturisers to an active topical treatment resulted in bet-
ter clinical results than topical active treatment alone, which is
an encouragement for the continued use of moisturisers during
eczema flare-ups (moderate quality evidence). Twice weekly fluti-
casone propionate added to daily use of moisturisers reduced the
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likelihood of flares over time, and has key implications for daily
practice, particularly in people with eczema who experience fre-
quent flare-ups. Furthermore, the use of moisturisers decreased
usage and the need for topical corticosteroids, which is another
important outcome. There was low quality evidence that licochal-
cone was as effective as hydrocortisone acetate 1% cream.
The majority of moisturisers considered in this systematic re-
view included a large array of ingredients (see Notes sections in
Characteristics of included studies), which made it impossible to
distinguish clearly between hydrophilic and hydrophobic mois-
turisers, or, indeed, between humectant, emollient and occlusive
moisturisers. Uncertainty about the exact proportions of these in-
gredients in a moisturiser does not permit a clear distinction to
be made, especially as the proportions are rarely mentioned in the
labelling or packaging. The quantity of certain ingredients can
also affect the way a moisturiser feels on the skin. Some ingredi-
ents in a moisturiser enhance its ability to remain on the skin (e.g.
petrolatum), while others (e.g. oils) transfer quickly to clothes or
bed linen. Temperature can influence the viscosity of moisturis-
ers, which is crucially important for application on the skin, as
the higher the viscosity of the moisturiser, the more difficult it
is to smear and spread on the skin, which can cause friction and
lead to friction-related adverse events. Once all of these aspects
are taken into account, as well as dryness, day or night-time, the
seasons, the weather, and even the clothes that are worn, people
with eczema will express a variety of preferences in different situa-
tions. The ideal moisturiser should be easy to spread on the skin,
have no smell, contain no irritating or sensitising ingredients, be
cosmetically acceptable without excessive sticking to clothes and
bed linen, and be affordable for people with eczema.
This review does not address the importance of educating people
with eczema on how to apply moisturisers, how much to use or
how often to use them. Cork and colleagues demonstrated that
correct and adequate instructions in usage “of the treatments re-
sulted in an 800% increase in the use of emollients, a reduction in
disease severity as assessed with six area, six sign atopic dermatitis
severity score (SASSAD) (89% reduction compared with baseline)
and no overall increase in the use of topical steroids” (Cork 2003a).
The importance of education as part of the management strategy
has also been emphasised by several other investigators (Arkwright
2013; Ersser 2014; Mason 2013; Oakley 2016). Another short-
coming of the studies in this review was the lack of detailed report-
ing of adverse events, which meant that we could not conclude
which moisturiser might be preferable for avoiding adverse events.
None of the studies reported aspects such as the smell, stickiness
or greasiness of the moisturiser, but rather adverse effects such as
pruritus, stinging, smarting or increase in erythema. We are still
unable to confirm how often moisturisers need to be applied, al-
though it is more generally acknowledged that this should be at
least once a day and preferably more frequently. Current recom-
mended quantities of moisturisers range from 250 g to 500 g per
week (Moncrieff 2013; NICE 2007; Wollenberg 2016).
Quality of the evidence
Limitations in study design and implementation
Although we only included randomised controlled trials (RCTs),
we assessed most studies as being at either unclear risk or high risk
of bias (for details see the Risk of bias in included studies). The
method of sequence generation was described in detail in slightly
more than half of the studies and allocation concealment in just
under half, so for the remaining studies we judged these domains
as being at unclear risk of bias. The lack of (adequate) blinding was
the most frequent reason for us giving studies an overall assessment
of a high risk of bias. In addition, in one-third of the studies (25/
77) there was a degree of incomplete data reporting, which did
not permit a full and accurate interpretation of the study results.
In 33 instances investigators or pharmaceutical companies were
helpful in providing us with missing study details (seeTable 2). We
were not successful in obtaining any response from investigators
or industry in 13 cases, despite repeated attempts to clarify missing
study details. We did not seek further clarification for 21 studies,
mainly because publication was more than 10 years ago, or because
we were unable to locate a current email addresses for any of the
investigators.
Inconsistency of the results
Most of the comparisons included in this review were assessed in
single studies, which did not allow us to assess consistency of re-
sults across studies for the various moisturisers. For several com-
parisons where pooling of data was possible, we observed substan-
tial heterogeneity for one or more outcomes. In Comparison 1
(moisturiser versus no moisturiser; Summary of findings for the
main comparison), one study, Giordano-Labadie 2006, was re-
sponsible for substantial heterogeneity for the outcome ’amount
of corticosteroid used’ (I² = 68%), as far more topical corticos-
teroids were used in both treatment arms than in the other study
(Grimalt 2007). This was surprising, especially when considering
that disease severity at baseline was markedly worse in the Grimalt
2007 study. (See Summary of findings 5 and Summary of findings
6).
In Comparison 2a (Atopiclair versus vehicle; Summary of findings
2), we observed substantial heterogeneity (I² = 51%) for the out-
come ’change from baseline in disease severity as assessed by the
investigators’. This was mainly caused by the Boguniewicz 2008
study, which showed a greater effect size and was the only study
in which there was uncertainty regarding the efficacy of the allo-
cation concealment and of the blinding. We observed consider-
able heterogeneity (97%) for the outcome ’change from baseline
in itch’, but the reasons for this remain unexplained.
In Comparison 2d (oat-containing moisturiser versus vehicle or
no moisturiser; Summary of findings 5), there was substantial het-
erogeneity for the outcome ’change from baseline in disease sever-
ity as assessed by the investigators’ (I² = 65%). We explored the
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heterogeneity by conducting further sensitivity analyses based on
individual domains of risk of bias in addition to carrying out a
stratified analysis adjusting for effect size. This heterogeneity ap-
peared to be caused by Giordano-Labadie 2006, which showed a
greater effect than the other two studies, and, although its exclu-
sion from the analysis eliminated the heterogeneity, it did not alter
the conclusions (Table 6).
In Comparison 2f (all moisturisers versus vehicle, placebo or no
moisturiser; Summary of findings 6), five studies contributed to
the outcome ’change from baseline in disease severity as assessed
by the participants’. There was considerable inconsistency (I² =
95%) between the studies, which was in part reduced through
sensitivity analyses based on risk of bias domain, especially with
our sensitivity analysis for risk of attrition bias. For the outcome
’change from baseline in itch’ the same held true (I² = 94%), but
the heterogeneity remained unexplained. For the outcome ’par-
ticipant satisfaction’ (I² = 83%), the repeat sensitivity analysis no
longer showed heterogeneity after we excluded a study at high risk
of bias (Abramovits 2008). Pooled data for the outcome ’number
of participants who experienced a flare’ also demonstrated hetero-
geneity (I² = 73%), with those studies that had been judged to be
at an unclear to high risk of bias showing better results. Consid-
erable heterogeneity was also seen for the outcome ’change from
baseline in quality of life’ (I² = 79%). Gayraud 2015 was the only
study at low risk of bias and demonstrated the largest effect size,
whilst we assessed the other two studies as being at a high risk
of bias (Giordano-Labadie 2006; Grimalt 2007). Furthermore, in
the Grimalt 2007 study, 40% of participants did not complete the
questionnaires, and therefore we assessed this domain as being at
high risk of attrition bias, which might explain some of the het-
erogeneity.
In Comparison 4a (licochalcone-containing moisturiser versus hy-
drocortisone acetate 1% cream) the pooled data from two within-
participant studies for the outcome ’change from baseline in itch’
demonstrated considerable heterogeneity (I² = 85%). There was a
difference in study duration (four weeks for Wanakul 2013 versus
one week for Angelova-Fischer 2014), and a difference in applica-
tion sites, as Wanakul 2013 used the two sides of the body, while
Angelova-Fischer 2014 used a straight comparison between the
two forearms, which could explain the inconsistency. These ex-
planations are also applicable for the outcome ’change from base-
line in transepidermal water loss’ (I² = 86%). In addition, there
was a similar degree of inconsistency (I² = 85%) for ’change from
baseline in disease severity as assessed by the investigators’, which
was addressed in three studies (see Summary of findings 7). We
explored possible explanations for the heterogeneity (see Table 6),
and considered that the most important explanation was that the
effect sizes differed between the three studies. We could only in-
clude data for the first week of the Angelova-Fischer 2014 study, as
only the first week was randomised, and therefore smaller reduc-
tions were reported in both treatment arms than in the other two
studies that had four-week durations and correspondingly larger
treatment effects (Udompataikul 2011; Wanakul 2013).
In Comparison 5 (vehicle twice weekly combined with daily mois-
turiser versus fluticasone propionate twice weekly combined with
daily moisturiser; Summary of findings 8), there was substantial
heterogeneity for the number of participants reporting an adverse
event (I² = 67%). No adverse events were reported in either of
the two comparisons included in Berth-Jones 2003, while in the
other two studies adverse events were reported in both arms, with a
predominance in the fluticasone propionate treatment arm. There
was also substantial heterogeneity for the number of participants
experiencing a flare (I² = 72%). One study had a smaller effect size
(i.e. the second comparison of Berth-Jones 2003 in which vehicle
ointment was compared with fluticasone propionate ointment),
removal of the study from the analysis reduced some, but not all,
of the heterogeneity. The investigators in Berth-Jones 2003 stated
that “the difference between the two formulations was significant
(P = 0.002), with a hazard ratio of 2.9 (1.5 to 5.9), indicating
that patients using the cream formulation were approximately one
third as likely to have a flare as those using the ointment.” We
also observed considerable heterogeneity in the pooled data of the
three studies for this comparison in the hazard ratio for rate of flare
(I² = 85%), which remained unexplained (see sensitivity analyses
in Table 5 and Table 6).
Indirectness of the evidence
The participants in the included studies had mostly mild to
moderate eczema according to prespecified criteria (see Types of
participants) and, therefore, were a reasonably representative group
that matched our inclusion criteria. However, only a limited num-
ber of studies evaluated the most informative outcome for this
review, which was whether moisturisers are effective (and safe) in
people with eczema; i.e. by comparing moisturiser versus no mois-
turiser, though many of the comparisons provided us with indirect
evidence (e.g. moisturiser versus another moisturiser).
Patient-reported outcomes (PROs) have been a target of increasing
interest for the last 30 years. Data derived from PROs have demon-
strated improvements in communication and decision-making be-
tween physicians and patients, and can lead to greater satisfaction
with a chosen treatment regimen (Nelson 2015). However, PROs
for this clinical topic appear not to have been adequately appre-
ciated, especially with regard to participant satisfaction with the
use of moisturisers - which can be sticky, greasy, smelly, and time-
consuming to apply. Frequently the included studies based infer-
ences on simple questions (“Which one do you prefer?” or “Do
you want to continue?”) instead of addressing satisfaction with
treatment, and this provided us with a reason to downgrade the
quality of the evidence for indirectness in Summary of findings 2,
Summary of findings 5 and Summary of findings 9.
Imprecision of the results
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Together with inconsistency, imprecision was the most frequent
reason for downgrading the quality of evidence for predefined
outcomes in the ’Summary of findings’ tables. Small sample sizes
and low occurrence of events leading to wide confidence intervals
caused us to downgrade for imprecision for one or more outcomes
in all of the ’Summary of findings’ tables.
Publication bias
We included a number of abstracts from conference proceedings,
most of which subsequently appeared as full text publications.
However, among the ongoing trials, which were often industry-
sponsored, there were a number of studies that had completed a
few years ago, but have not been published, which tends to suggest
that these trials showed no, or marginal, benefit for the moisturiser
under investigation. Furthermore, we identified 47 duplicate pub-
lications for the same study data (Figure 1). Comparison 2f (all
moisturisers versus control) was the single comparison for which
we had more than 10 studies addressing an outcome; 12 studies
contributed to the outcome ’change in disease severity as assessed
by the investigators’; the funnel plot showed no asymmetry (Figure
4).
Potential biases in the review process
Although we took numerous steps to reduce publication bias
through systematic searching and inclusion of studies published
in languages other English, it is possible that the analyses in this
review are based on an incomplete set of the data collected and
analysed in the original trials. We made every attempt to contact
investigators for missing trial data, sometimes six times over a six-
month period. However, despite our numerous attempts, we re-
ceived no response for 13 studies and so were unable to obtain
clarification of some of the missing trial details and study data
(see Table 2). Data from studies that had a within-participant de-
sign could not be adjusted accurately. The absence of a correlation
coefficient for these studies meant that we could not analyse the
data in a way that took account of the within-participant nature
of the design. For a limited number of dichotomous outcomes the
results have been presented narratively, and for continuous data
our decision to apply a pragmatic correlation coefficient to adjust
continuous data from within-participant studies may not reflect
the true nature of the within-person correlation.
Agreements and disagreements with other
studies or reviews
Our extensive searches identified several reviews and guidelines,
a practice statement and a dissertation that addressed the effi-
cacy and usefulness of moisturisers in the treatment of eczema
(Eichenfield 2014b; Hoare 2000; Katayama 2014; Lindh 2015;
Mack Correa 2012; Moncrieff 2013; Nankervis 2016; NICE
2007; Oakley 2016; Penzer 2012; Ring 2012a; SIGN 2011;
Silverberg 2014; Sirikudta 2013; Wollenberg 2016).
A general conclusion that can be drawn from the reviews and
guidelines is that consistent, frequent, and generous use of mois-
turisers is necessary to restore or maintain the skin barrier. Their
recommendations indicate that physicians should advise their pa-
tients to use moisturisers in large amounts (250 g to 500 g per
week), preferably after bathing or showering. Educational pro-
grammes, supportive information and guidance were considered
to be essential for moisturisers to achieve an optimal benefit. There
was general agreement that people with eczema should have the
opportunity to choose between different moisturisers and, more
specifically, those that are most suitable for their own skin. Sev-
eral of these reviews and guidelines referred to the studies of Cork
2003b and Danby 2011b, which stated that aqueous cream BP
(or other leave-on moisturisers containing sodium lauryl sulphate)
should not be used as a leave-on moisturiser in eczema, as this has
been shown to have a negative impact on the skin barrier. Furthe-
more, some recent studies have questioned or discouraged the use
of oils as they can damage the skin barrier, or impair skin barrier
maturation in neonates (Cooke 2016; Danby 2013; Kanti 2014).
A comprehensive systematic review of treatments for atopic eczema
was conducted in 2000 as a part of the NHS Health Technology
Assessment (HTA) Programme (Hoare 2000). Only five RCTs
were retrieved at that time and the authors of that review con-
cluded that although moisturiser “may have beneficial actions,
there is an urgent need to answer several basic questions about
their use, preferably through industry-independent RCTs”. They
also provided a summary of the research gaps in addition to the
top 10 questions that required addressing in future RCTs. Re-
cently, a systematic scoping review that provides an update to this
review has been published; this has a search date of August 2013
(Nankervis 2016). The reviewers acknowledged that the number
of RCTs evaluating moisturisers had increased considerably, with
the addition of 15 studies since 2000, but that still these studies
were poorly designed, with small sample sizes and short follow-
up periods, and reporting of results was frequently inadequate.
The ’Risk of bias’ assessment of the included studies in this HTA
update was somewhat limited compared to our review, and did
not include an evaluation of reporting bias and attrition bias. The
authors discussed the studies in detail with respect to benefits,
harms and overall implications for research and practice, but did
not perform meta-analysis or provide a rating of the quality of
the evidence. The conclusions were “that the trial evidence was
not clear enough to make recommendations with regard to using
emollients to reduce the severity of eczema and prevent flares or to
reduce the need for other eczema treatments”. Our current review
builds on the scoping review by reporting moderate to low quality
evidence for the efficacy of moisturisers to prevent flares, as well as
low quality evidence that moisturisers reduce the need for topical
corticosteroids to attain similar reductions in eczema severity.
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Another more recent systematic review, which had a broader scope
than our review, summarised the clinical effectiveness of moisturis-
ers in atopic dermatitis and related disorders, and also included
participants with irritant hand dermatitis and ichthyosis vulgaris
(Lindh 2015). Our search retrieved 45 more studies that addressed
eczema, which might be because we conducted more extensive
searches for studies in additional databases. Although a ’Risk of
bias’ assessment was conducted in the Lindh 2015 review, sup-
portive judgements and justifications for those judgements were
often lacking. However in our review we were quite successful at
contacting principal investigators, and consequently our judge-
ments for the various ’Risk of bias’ domains differed in a number
of instances. The authors of the Lindh 2015 review considered
that the efficacy for urea-based preparation was most well-docu-
mented and concluded that they had “found convincing evidence
that moisturizer treatment is beneficial for AD [atopic dermatitis]
and related disorders”. Although we are in general in concordance
with the conclusion of the review - that moisturiser treatment is
beneficial - a rating of the quality of evidence by the reviewers was
lacking.
An evidence-based treatment update for atopic dermatitis was pub-
lished in 2014 (Silverberg 2014). This systematic review included
randomised controlled trials as well as systematic reviews, com-
plied with the PRISMA statement, and covered the period from
2011 until August 2013.However, the searches were restricted to
MEDLINE only. There were clear inclusion and exclusion criteria
and GRADE was used to assess the quality of evidence, but only
for the systematic reviews retrieved by the search, which did not
include any for moisturisers. The time span was quite limited (2.5
years) and only one RCT was included and a full critical appraisal
was not carried out. The review reached no clear conclusions on
the efficacy of moisturisers.
We identified and evaluated several narrative reviews, such as the
Mack Correa 2012 review, which described the role of moisturisers
in eczema management and summarised studies conducted with
moisturisers, but did not appraise the studies that were selected
critically. The narrative Sirikudta 2013 review provided a general
overview of active ingredients in moisturisers, including those in
popular over-the-counter moisturisers, and those that are supposed
to have an anti-inflammatory effect such as Vitellaria paradoxa
(shea butter; formerly Butyrospermum parkii), glycyrrhetinic acid
and licochalcone A (from Glycyrrhiza inflata), as well as a list of
moisturising properties of the active ingredients. Our Cochrane
Review included studies that evaluated moisturisers containing
these ingredients.
Moncrieff 2013 is a consensus statement on the use of emollients
in dry-skin conditions that summarised current data and practice,
and emphasised that there is evidence that urea-containing creams
enhance efficacy, prolong time to flare, and are topical corticos-
teroid-sparing when compared to not using a moisturiser. The
statement covers seven key topics, and concludes with consensus-
based conclusions and recommendations that are consistent with
the findings of our review. An additional important conclusion
was that the efficacy of a moisturiser is dependent on the adherence
to treatment of people suffering from eczema, and that informed,
shared decision making based on a spectrum of moisturisers, is
key to optimising moisturiser treatment.
Preparation of the eczema treatment guideline of the American
Academy of Dermatology included an extensive search across var-
ious databases (Eichenfield 2014a). Its authors based the evidence
on the ’Strength of Recommendations Taxonomy’ (SORT), where
levels of evidence for individual studies are graded on a 3-point
scale and recommendations are formulated according to the best
available evidence (graded A, B, C). This guideline reported that
there is strong evidence that the use of moisturisers can reduce
disease severity and the need for pharmacological treatment, and
that, therefore, their use should be an integral part of eczema treat-
ment. The number of studies included to evaluate the efficacy of
moisturisers was much smaller than in our review, but the results
and conclusions of the guideline are in broad agreement with our
findings.
Katayama 2014, a Japanese guideline, was not very informative re-
garding moisturisers for eczema; it contained no evidentiary sup-
port from clinical trials, ratings of the quality of evidence or grad-
ings of strengths of recommendations, but mainly reported that
moisturisers are recommended and useful to prevent flares. The
guideline, however, did provide a warning that “urea preparations
should be used with caution, as they can stimulate an eroded sur-
face or strongly inflammatory skin”.
Similarly, the Canadian Practical Guide for treatment and man-
agement of eczema did not involve a robust methodological ap-
proach, but mainly indicated that moisturising of the skin is a
fundamental part of treatment for eczema (Lynde 2005).
The National Institute for Health and Clinical Excellence (NICE)
guideline only addressed eczema in children from birth to 12 years
old (NICE 2007). The recommendations support the daily use of
moisturisers for all eczema severities based on children’s need and
preferences. Data from a limited number of RCTs that investigated
the efficacy of moisturisers were summarised in evidence tables.
Follow-up searches (surveillance review) were conducted up to
2013 and concluded there was no new evidence that might have
an impact on the clinical recommendations. In July 2016 it was
decided not to update this guideline further (www.nice.org.uk/
Guidance/CG57).
The guideline from the European Dermatology Forum, Euro-
pean and the European Academy of Dermatology and Venereol-
ogy (EADV), the European Task Force on Atopic Dermatitis (ET-
FAD), European Federation of Allergy (EFA), the European Soci-
ety of Pediatric Dermatology (ESPD), and the Global Allergy and
Asthma European Network (GA2LEN) (Ring 2012a), reported
that there was “limited evidence-based proof” for using moisturis-
ers. Different ingredients in moisturisers were described, together
with their benefits and harms, but these guidelines did not under-
take any ’Risk of bias’ assessments or any appraisal of the method-
99Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ological quality of the included studies.
The Scottish Intercollegiate Guidelines Network (SIGN) guide-
line presented conclusions based on the Hoare 2000 systematic re-
view, and provided levels of evidence, graded recommendations (A
to D), and identified good practice points for the various eczema
treatments (SIGN 2011). Its authors concluded that people with
eczema should have continuous treatment with moisturisers, and
should continue moisturiser treatment during treatment with top-
ical corticosteroids. Furthermore, twice weekly maintenance treat-
ment with topical corticosteroids should be considered in people
with moderate to severe eczema with frequent flares (based on the
Berth-Jones 2003 study).
An overview of how moisturisers should be used in practice, how
they work, and what type of moisturisers are available, was sum-
marised in a best practice statement produced by the British Der-
matology Nursing Group (BDNG) in association with Dermato-
logical Nursing (Penzer 2012). The statements made in this pub-
lication were supported by studies or guidelines, and are in con-
cordance with the conclusions we draw in this Cochrane Review.
A recent paper entitled ’Views on unwanted effects of leave-on
emollients and experiences surrounding their incidence’ addressed
the results of a survey amongst 210 people with eczema and their
carers (Oakley 2016). This study aimed to gain a greater under-
standing of unwanted events associated with moisturisers, and
whether these might influence adherence. The findings of this sur-
vey are consistent with the results our review, as we found that par-
ticipants’ satisfaction with moisturisers was only assessed in 13/77
studies and that reporting of adverse events was inconsistent, with-
out clear distinction between adverse events and unwanted events.
In the Oakley 2016 survey 126/185 responders reported that they
had experienced unwanted effects with the use of moisturisers
(stinging was most reported), and 90/126 stopped using the mois-
turiser because of this unwanted effect. Oakley 2016 stated that
these results confirm that poor adherence is related to unwanted
effects, which underlines the importance of patient satisfaction
with moisturisers in both clinical practice and future research.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Treatment for eczema encompasses active treatments to address
active inflammatory lesions, management strategies to minimise
triggers, life style measures and education about eczema, but also
adjunctive therapies to optimise skin barrier function and to pre-
vent flare-ups. The use of moisturisers has always been an inte-
gral part of eczema treatment and there was an unmet need for
summarising the overall evidence about their effects. This review
included 77 studies from which, although we assessed most as be-
ing at unclear to high risk of bias, we have been able to draw the
following conclusions:
• There is low quality evidence that applying moisturisers is
effective in reducing disease severity compared to not using
moisturisers (investigator-assessed outcome), although not to a
clinically important extent, as the minimal important difference
(MID) was not met. However, use of moisturisers reduced the
number of participants who experienced a flare, prolonged the
time to flare, reduced the rate of flare by a factor of almost four
and reduced the total amount of topical corticosteroids that
would have been needed to achieve similar reductions in the
SCORing Atopic Dermatitis Index (SCORAD), all of which are
clinically important.
• There is moderate quality evidence that Atopiclair is more
effective than vehicle (investigator and participant assessments),
but the MID was not met. It had an important effect on itch and
on reduction of flares.
• There is low to moderate quality evidence that urea-
containing creams are more effective than no moisturiser,
placebo or vehicle (based on both investigator and participant
assessments), and reduced rate of flare by a third, but with more
adverse events. Efficacy was confirmed by one study, at low risk
of bias, conducted over 180 days, that showed that barrier-
strengthening moisturiser with 5% urea reduced the number of
participants who experienced a flare, and increased time to flare
in comparison to the reference cream.
• There is moderate to high quality evidence that glycerol-
containing moisturisers are more effective than ’vehicle’ or
placebo (investigator and participant assessments), but the MID
was not met.
• There is low to very low quality evidence that there is no
difference in efficacy between oat-containing cream and vehicle
or no moisturiser (investigator and participant assessments), and
more adverse events were seen. However, the use of oat-
containing creams reduced flares by a third, rate of flare to a fifth,
and reduced the need to apply topical corticosteroids.
• There is high quality evidence that the use of moisturisers is
more effective (investigator assessments) than the use of no
moisturiser, vehicle or placebo (controls). Use of moisturisers had
a large beneficial effect on itch compared to controls. However,
due to considerable heterogeneity in the results, the use of
different assessment scales and because the clinical relevance of
this outcome is difficult to estimate, caution must be exercised in
interpreting these data. Use of moisturiser reduced flares by a
third, and rate of flare to almost a quarter. Reduced amounts of
topical corticosteroids were needed when moisturisers were used.
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• There is low quality evidence that licochalcone-containing
cream is as effective as hydrocortisone acetate 1% cream
(investigator assessments).
• There is high quality evidence that twice weekly fluticasone
propionate plus a moisturiser provides more effective eczema
control than a moisturiser alone (participant assessments), and
moderate quality evidence that it reduces the number of flares by
a factor of two, and reduces the rate of flare to almost a quarter.
• There is moderate quality evidence that combining topical
active treatment with a moisturiser is more effective than
treatment with active treatment alone (investigator assessments).
There is also low quality evidence that participants were more
satisfied with the combined treatment.
• There were no differences between treatments for the
number of participants experiencing an adverse event (except for
urea- and oat-containing creams), or in self-assessed quality of
life.
• Reductions in itch were generally small, except with
Atopiclair, where the effect seemed larger and clinically
important.
• Improvements in skin barrier function varied from small to
more substantial improvements, but these were inconsistent
across studies.
• Overall, considering the various included studies and
comparisons in this review we can conclude that the efficacy of
moisturisers varied from minimal to substantial.
Moisturisers appeared to have a beneficial effect, but the extent of
the effect varied widely, and in only a few studies did moisturisers
produce a reduction in disease severity that met the MID. There
is no convincing evidence that moisturisers improve eczema when
used alone. However, the overall conclusion is that moisturisers
are safe, prevent flares, prolong time to flare, reduce the amount of
topical corticosteroids needed, and that topical active treatment is
more effective when used in combination with moisturisers.
This review does not inform us about the importance of educa-
tion in how to apply moisturisers, in particular how often they
need to be applied and how much to use. However, since mois-
turisers reduce flares, prolong the time to flare, decrease the neces-
sity for topical corticosteroids and increase the efficacy of active
treatment, it makes clinical sense to encourage adherence to mois-
turiser therapy. This is especially important as moisturiser therapy
is time consuming and often required throughout life, as eczema
is a chronic condition.
This review provides no information about which moisturisers
might be preferred for different parts of the body, or preferred dur-
ing different seasons or personal circumstances, or which mois-
turisers best fit the actual disease status (acute or chronic) or sever-
ity (mild, moderate or severe). There is no evidence to support
a ’one size fits all’ approach. Therefore, clinical decisions about
choices of moisturiser should be based on the available evidence,
and take into account the experiences and preferences of the per-
son with eczema.
Implications for research
There was substantial variation in the way the included studies
were conducted, and in their quality of reporting. Standardisation
of outcome reporting, as suggested by the Core Outcome Mea-
sures in Effectiveness Trials (COMET) Initiative, would improve
the assessment and comparison of relevant outcomes significantly (
www.comet-initiative.org). The Harmonising Outcome Measures
in Eczema (HOME) initiative has defined and agreed a core set of
domains, i.e. symptoms, signs, quality of life and long term con-
trol (www.nottingham.ac.uk/homeforeczema/index.aspx), while
the Eczema Area and Severity Index (EASI) and the Patient Ori-
ented Eczema Measure (POEM) have been agreed on as the best
outcome measures for signs and symptoms, respectively. EASI,
the objective SCORAD and POEM are scales recommended for
studies (Schmitt 2007; Schmitt 2014). Of the 77 studies in this
Cochrane Review, 14 used EASI, 25 used SCORAD (with objec-
tive SCORAD used in just four), and two used POEM, so there
are clear opportunities for improved uniformity in future studies.
The MIDs of SCORAD, objective SCORAD, EASI and POEM
that were used in this review were based on the Schram 2012 study.
Only the MID of POEM has been investigated in another study
(Gaunt 2016), which determined a value of around 3, while we
used 3.4 (Schram 2012). The MIDs of (objective) SCORAD and
EASI have not been confirmed in other studies yet. As MIDs may
vary by population and context (Schram 2012), further research is
needed to confirm or adjust MIDs for relevant outcome measures.
In this review we were unable to conclude specifically that some
of the moisturisers, or some ingredients in moisturisers, are better
than others, as most head to head comparisons had been evaluated
in single studies, which generally had small sample sizes. Since
moisturisers can contain many different ingredients, more research
is needed about their effects, and also about their safety on lesional
and non-lesional skin of people with eczema, including their po-
tential for sensitisation and absorption (Halling-Overgaard 2016).
We were not able to conclude that the use of moisturisers is suffi-
cient to treat (very) mild eczema, which therefore needs future re-
search. In addition, more research is needed on the benefit of mois-
turisers in the different phases of the disease (i.e. acute, chronic
and between flares), including the amounts and frequency of ap-
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plication that give the best results. This should yield information
about adequate use of moisturisers and active treatment, and en-
able prevention of under- and over-treatment with moisturisers or
topical active treatments (such as corticosteroids), or both. The
paediatric population is of especial importance, since the preva-
lence of eczema in this group is much higher than in adults, as
are the negative consequences of under- and over-treatment. An-
other area of consideration for further research is the possibility
of increasing the efficacy of moisturisers by ensuring adherence
through proper and timely information and education, and in-
creasing self-management skills.
Reporting of adverse events in future research needs to be more
complete, with clear explanations of what is considered to be an
adverse or unwanted event. Since in (acute) eczema almost every-
thing applied to lesional skin causes transient stinging and ery-
thema (Ring 2012a), thought needs to be given to whether this
should be judged as an adverse event, or whether it should be
classed as an adverse event only when the stinging and erythema
persist over a longer period of time. The reporting of unwanted
effects such as smell and stickiness, and difficulty in smearing and
spreading, as adverse events hampers proper data collection about
adverse events, although this information can be very useful for
evaluating the suitability of a moisturiser. Almost half of the stud-
ies in this Cochrane Review did not report on adverse events, most
probably because moisturisers are not always seen by investigators
as treatment, but as more basic ’innocent’ maintenance. Clinicians
may fail to consider that this ’maintenance’ is life long. The ac-
ceptability of a substance that smells, is sticky, ruins clothes, leaves
traces on furniture and bed linen, and is expensive for people with
eczema to purchase in the large quantities required, is an important
area to consider. The distinction between these unwanted effects
and treatment-related adverse events is frequently blurred in the
published research. Therefore reporting on such unwanted effects
in addition to ’real’ adverse events is to be recommended. Ideally,
both patient satisfaction with the moisturisers and the acceptabil-
ity of them in daily use should be included in patient-assessed
outcomes of studies.
Future randomised controlled trials should be rigorously designed
and conducted, with adequate reporting on methodological as-
pects as well as complete and transparent reporting according to the
Consolidated Standards of Reporting Trials (CONSORT) state-
ment. This will improve critical appraisal and interpretation as
well as assessment of the validity of the results.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abramovits 2008
Methods Randomised, double-blind, vehicle-controlled study
Setting
Multicentre (10) in USA
Date of study
Unspecified. Duration of intervention: 50 days
Participants N = 218 (127 female, 91 male)
Mean age = 44.5 years (18 to 84 years)
Inclusion criteria of the trial
• Mild-to-moderate atopic dermatitis based on Hanifin and Rajka criteria (Hanifin
1980) and Rajka and Langeland criteria (Rajka 1989)
Exclusion criteria of the trial
• Severe atopic dermatitis
• Active skin infection requiring antimicrobial treatment
• History of allergy to study cream components
• Previous treatment with MAS063DP
• Skin or systemic condition that could interfere with study participation.
Randomised
N = 218 (MAS063DP group = 145, vehicle group = 73)
Withdrawals/losses to follow-up
32 overall (14.6%); MAS063DP group = 16/145 (11%), vehicle group = 16/73 (21.9%)
• Use of prohibited medication; MAS063DP group (6), vehicle group (1)
• Consent withdrawal; MAS063DP group (4), vehicle group (7)
• Need for additional topical or systemic medication for atopic dermatitis;
MAS063DP group (0), vehicle group (6)
• Suicide; MAS063DP group (1), vehicle group (0)
• Severe excoriation; MAS063DP group (1), vehicle group (0)
• Side effects; MAS063DP group (2), vehicle group (0)
• Lost to follow-up; MAS063DP group (2), vehicle group (2)
Baseline data
Duration of the current episode of atopic dermatitis ranging from 5 days to 58 years. The
most common atopic dermatitis pattern was constant or frequent (80% of participants)
and with no seasonal course (66%)
Mean EASI: MAS063DP group 5.76 (SD 4.68), vehicle group 6.03 (SD 6.62)
Mean itch (VAS): MAS063DP group 7.51 (SD 1.6), vehicle group 7.05 (SD 1.62)
Interventions Intervention
• MAS063DP (Atopiclair) 3 times daily for up to 50 days (N = 145)
Comparator
• Vehicle cream 3 times daily for up to 50 days (N = 73)
Topical corticosteroids, immunomodulators, antihistamines, non-steroidal anti-inflam-
matory drugs and phototherapy were excluded during a washout period prior to treat-
ment initiation and during the study
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Abramovits 2008 (Continued)
Outcomes Assessments (5): at baseline, days 8, 22, 36, and 50
Outcomes of the trial (as reported)
• EASI (Hanifin 2001) at day 22
• Percentage of affected BSA
• IGA: 5-point Likert scale (worse, no change, slight improvement, good
improvement, total resolution)
• Need for rescue medication
• Patient global assessment of clinical improvement from baseline and itch over
total body improvement from baseline (both using an individual assessment score
ranging from -1 = worse to 3 = total resolution)
• Pruritus score: VAS
• Patient acceptability of the study cream formulation (willingness to continue on
study substance, effectiveness compared with prior treatments, ease of use/spreading;
cosmetic acceptability, odour and staining of clothing): 4-point Likert scale
• Adverse events
Denotes outcomes prespecified for this review
Funding source None declared. However, the product under research is produced by Sinclair Pharma
Ltd, Godalming, UK
Declaration of interest Almost all investigators were investigators or consultants (or both) of Sinclair Pharma
Ltd, as well as of Graceway Pharmaceuticals, LCC and received compensations
Notes MAS063DP (Atopiclair, Sinclair Pharma Ltd, Godalming, UK) contains glycyrrhetinic
acid, which is believed to contribute to the cream’s antipruritic and anti-inflammatory
properties. It inhibits the enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD), re-
sponsible for the metabolism of cortisol into cortisone. Glycyrrhetinic acid, has a chem-
ical structure related to cortisone and has been shown to potentiate the action of hy-
drocortisone on skin. Further ingredients include: aqua, ethylhexyl palmitate, Vitellaria
paradoxa (formerly called Butyrospermum parkii), pentylene glycol, arachidyl alcohol,
behenyl alcohol, arachidyl glucoside, glyceryl stearate, PEG-100 stearate, butylene gly-
col, glycyrrhetinic acid, capryloyl glycine, bisabolol, tocopher acetate, carbomer, ethyl-
hexylglycerin, piroctone olamine, sodium hydroxide, allantoin, DMDM hydantoin, Vi-
tis vinifera, sodium hyaluronate, disodium EDTA, ascorbyl tetraisopalmitate, propyl gal-
late, telmesteine
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
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Abramovits 2008 (Continued)
Random sequence generation (selection
bias)
Low risk Quote (page 328) and (page 237 of 2006
publication): “Patients were randomized
(2:1)” “Patients were assigned a study num-
ber according to their entry into the study
and following a computer generated ran-
domization code”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: central alloca-
tion via pharmaceutical company, sequen-
tially numbered tubes of identical appear-
ance
Comment: central allocation, de-identified
tubes. Allocation appears to have been ad-
equately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 327): “double-blind...”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
After email communication: “tubes of drug
or placebo/vehicle looking identical”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 327): “double-blind...”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty with regard to the
effectiveness of blinding of outcomes as-
sessors (participants/healthcare providers)
during the study
Insufficient information to permit a clear
judgement.
After email communication: “tubes of drug
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Abramovits 2008 (Continued)
or placebo/vehicle looking identical”
Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
High risk 32 (14.6%) overall, MAS063DP (Atopi-
clair) group = 16/145 (11%), vehicle group
= 16/73 (21.9%). Per-protocol analysis
Comment: the total number of drop-
outs was unbalanced between the groups,
which, combined with a per-protocol anal-
ysis represents a high risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appears to be free
from other forms of bias
Andersson 1999
Methods Randomised, double-blind, ’other moisturiser’-controlled study
Setting
Department of Medical Sciences, University Hospital, Uppsala, and ACO Hud AB,
Stockholm, Sweden
Date of study
February to April, not clear which year. Duration of intervention: 30 days
Participants N = 50 (38 female, 12 male)
Age = 18 to 55 years
Inclusion criteria of the trial
• Atopic dermatitis criteria of Hanifin and Rajka (Hanifin 1980)
Exclusion criteria of the trial
• No other significant concurrent illness
• Known allergy to test cream ingredients
Randomised
N = 50 (5% urea (Canoderm) group = 25, 4% urea (Fenuril) group = 25)
Withdrawals/losses to follow-up
2/50 (4%)
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Andersson 1999 (Continued)
Interventions Intervention
• 5% urea as active substance (Canoderm) at least once daily for 30 days (N = 25)
Comparator
• 4% urea and 4% NaCl (Fenuril) at least once daily for 30 days (N = 25)
Allowed to continue use of topical corticosteroids
Outcomes Assessments (3): baseline, days 15 and 31
Outcomes of the trial (as reported)
• Clinician assessed: DASI score evaluating xerosis, erythema, scaling and skin
fissuration using a 5-point scale (1 = no sign of symptoms to 5 = severe) with a range of
minimum and maximum score values of 4 to 20 in 4 body regions (Serup 1995)
• Participant-rated skin dryness: 14 cm VAS: ’extremely dry skin, worst ever’ 0 cm
to ’no dry skin at all’ at 14 cm
• TEWL and skin capacitance
• Adverse events: degree of smarting, stinging, itching and dryness on 5-point
Likert scale (0 to 4)
Denotes outcomes prespecified for this review
Funding source None declared, however, 1 of the products under research is produced by ACO Hud
AB, Sweden
Declaration of interest None declared. Dr Lodén was an employee of ACO Hud AB, the manufacturer of the
principal intervention
Notes Fenuril (Pharmacia AB, Sweden) contained 4% urea and 4% NaCl as water-binding sub-
stances in an oil-in-water emulsion, pH about 5. Other ingredients were liquid paraffin,
PEG- 5-glyceryl stearate, cetyl alcohol, stearyl alcohol, stearic acid, trometamol, methyl
para-hydroxybenzoate, propyl para-hydroxybenzoate, hydrochloric acid and water
Canoderm (ACO Hud AB, Sweden) contained 5% urea in an oil-in-water emulsion,
pH about 5. Other ingredients were fractionated coconut oil, cetearyl alcohol, PEG-20
stearate, hydrogenated canola oil, propylene glycol, carbomer, methicone, hard paraffin,
glyceryl poly-methacrylate, propylparaben, methylparaben, sodium lactate, lactic acid,
glyceryl stearate, polyoxyethylene stearate, cetyl acetate, oleyl acetate, acetylated lanolin
alcohols and water
As the study was 17 years old we did not contact the investigators for data. The data all
needed to be estimated from box-and whisker plots, which made them difficult to use
(Table 4).
The adverse events were addressed in a separate publication (Lodén 1999 added in
’References to studies’ under the primary publication Andersson 1999)
Risk of bias
Bias Authors’ judgement Support for judgement
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Andersson 1999 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote (page 165): “randomized double-
blind study”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 165): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 165): “double-blind”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty with the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study. Insufficient information to permit a
clear judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/50 (4%) withdrew for “reasons not re-
lated to treatment” in Fenuril group. Per-
protocol analysis
Comment: low number of losses to follow-
up, and despite use of per-protocol analysis,
considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
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Angelova-Fischer 2014
Methods Randomised, investigator-blinded, active-controlled, within-participant study
Setting
Department of Dermatology, University of Lübeck, Lübeck, Germany
Date of study
Unspecified. Duration of intervention: 1 week, followed by 3 weeks’ treatment with
’moisturiser only’
Participants N = 20 (16 female, 4 male)
Age = 12 to 65 years, median age = 26.2 years
Inclusion criteria of the trial
• Presence of at least 2 inflammatory lesions of comparable clinical severity
symmetrically on the forearms/arms
• SCORAD intensity parameters (local SCORAD) in the test area > 4 and <= 8
Exclusion criteria of the trial
• SCORAD intensity parameters in the test area < 4 and > 8 or with severe forms of
atopic dermatitis
• History for other skin or systemic diseases
• Treatment with topical or systemic corticosteroids, immunosuppressive agents,
UV-light as well as topical or systemic antimicrobial agents in the 2 weeks preceding
the study
• Previously known or suspected delayed-type sensitisation
• Pregnancy or lactation
• Participation in another study within the preceding 4 weeks
Randomised
N = 20, to either forearm (within-participant)
Withdrawals/losses to follow-up
2/20 (10%)
• 2 excluded in the second and fourth study weeks because of worsening of skin
condition outside the test area that required topical treatment
Baseline data
Mean local SCORAD: O/W formulation group 7.0, hydrocortisone group 6.5
Mean itch severity (VAS): O/W formulation group 3.5, hydrocortisone group 3.75
Mean TEWL (g/m²/h): O/W formulation group 16.47, hydrocortisone group 16.28
Interventions Intervention
• O/W formulation containing licochalcone A (Glycyrrhiza inflata root extract),
decane diol (decylene glycol), menthoxypropanediol and ω-6-fatty acids twice daily for
1 week on 1 forearm
Comparator
• Hydrocortisone cream twice daily for 1 week on contralateral forearm
After 1 week both arms were treated with the O/W (oil in water) formulation and no
other treatment
Outcomes Assessments (3): baseline, days 7 and 28
Outcomes of the trial (as reported)
• SCORAD intensity parameters in the test area (local SCORAD) (0 to3),
European Task Force on Atopic Dermatitis 1993)
• Itch intensity: VAS from 0 (no perceptible itch in the test area) to 10 (worst
imaginable itch)
125Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Angelova-Fischer 2014 (Continued)
• Improvement of the skin barrier function: TEWL
• Stratum corneum hydration: capacitance assessed with Corneometer CM825,
Courage and Khazaka Electronics, Cologne, Germany
• Reduction in the lesional skin colonisation with Staphylococcus aureus
• Skin tolerability: standardised questionnaire (erythema, scaling, skin dryness,
burning, skin tightness, itch, other)
Denotes outcomes prespecified for this review
Funding source Quote (page 9): “The study was funded by Beiersdorf AG”
Declaration of interest Quote (page 9): “I, Angelova-Fischer has been investigator for and received honoraria as
a speaker from Beiersdorf AG” [sic]
Notes Licochalcone A is an extract from Glycyrrhiza inflata that has anti-inflammatory prop-
erties. After 1 week both arms were treated with a moisturiser, therefore we have only
included data from the first week
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 10): “were randomized to re-
ceive”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “random
number table”
Comment: probably done.
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: this remains
unclear.
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Angelova-Fischer 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 10): “investigator-blinded”
Comment: the report did not provide suffi-
cient detail about the specific measures used
to blind study personnel from knowledge of
which intervention a participant received
on each forearm, to permit a clear judge-
ment, and participants were not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 10): “investigator-blinded”.
Outcomes were investigator-assessed as
well as participant-assessed
Comment: there was uncertainty about the
effectiveness of blinding of outcomes as-
sessors (healthcare providers) during the
study, and participants were not blinded
The outcome measurement was likely to be
influenced by the lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/20 (10%), 2 excluded in the second and
fourth study weeks because of worsening of
the skin condition outside the test area that
required topical treatment
Comment: as we only included data from
the first week we judged this as being at a
low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free
from other forms of bias
Belloni 2005
Methods Randomised, double-blind, vehicle-controlled study
Setting
European Institute of Dermatology, Milan, Italy
Date of study
Unspecified. Duration of intervention: 22 days, with follow-up of 2 weeks
Participants N = 30 (14 female, 16 male)
Age = 13 to 43 years, median age = 22.5 years
Inclusion criteria of the trial
• Fair/light skin without sun tan, > 16 years, mild to moderate eczema (according to
Rajka and Langeland’s criteria of 3.0 to 7.5 (Rajka 1989)) < 20% surface involvement
• Written consent
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Belloni 2005 (Continued)
• Negative pregnancy test for sexually active women and willingness to use active
birth control
Exclusion criteria of the trial
• Cutaneous or systemic viral (including HIV or AIDS), mycotic or bacterial
disease requiring topical or systemic therapy
• Systemic disease
• Insulin-dependent diabetes mellitus uncontrolled by diet
• Pregnant or breastfeeding women
• Another skin condition
• History of allergy to ingredients of MAS063D
• Previous treatment with MAS063D
• History of substance or alcohol abuse
• Psychological condition that could affect co-operation
• Having friends or relative in the study centre
Randomised
N = 30 (MAS063D group = 15, vehicle group = 15)
Withdrawals/losses to follow-up
All participants finished the study protocol
Baseline data
Eczema severity and location of the lesions, disease duration and current episode were
comparable
Interventions Intervention
• MAS063D hydrolipidic cream (Atopiclair) containing hyaluronic acid,
telmesteine, Vitis vinifera and glycyrrhetinic acid 3 times daily for up to 21 days (N =
15)
Comparator
• Vehicle 3 times daily for up to 21 days (N = 15)
Participants receiving systemic medication (antihistamines, corticosteroids, NSAIDs, or
other topical and systemic investigational drugs) were maintained on their medications
at a constant dose throughout the study. Participants receiving topical medications (e.
g. topical antihistamines, corticosteroids, NSAIDs) were taken off the medication in a
washout period of 7 days, so that no participants were using these medications 7 days
before the study or during it. Washout period for phototherapy and tranquillisers was 4
weeks and 5 days respectively
Outcomes Assessments (5): baseline, days 8, 15, 22 and 36
Outcomes of the trial (as reported)
• Clinical symptoms and signs: Rajka and Langeland criteria (Rajka 1989)
• Percentage of body area affected
• EASI score (Hanifin 2001)
• Itch score: VAS
• Hours of sleep
• Patient’s view on how much cream helped the pain and itch: 4-point Likert scale
(0 to 3)
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Belloni 2005 (Continued)
• Willingness to use again
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 35): “The study was supported by a grant from Sinclair Pharmaceuticals,
Godalming, Surrey, UK”
Declaration of interest None declared
Notes Participants receiving topical medications (e.g. topical antihistamines, corticosteroids,
NSAIDs) were taken off the medication in a washout period. See in Notes section of
Characteristics of included studies of Abramovits 2008 for details on Atopiclair
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 32): “Randomisation was car-
ried out in blocks of six patients using a ran-
dom number generator in Microsoft Excel”
Comment: probably done.
Allocation concealment (selection bias) Low risk Quote (page 32): “Patients were ran-
domised to receive MAS063D or vehicle-
only control, according to their order of en-
try into the study. MAS063D and control
were presented in identical, blindly, pre-la-
belled containers. Each container was la-
belled with patient’s study number and pa-
tients, observers and all trial personnel were
blinded to study code”
Comment: central allocation, de-identified
drug containers. Allocation appears to have
been adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 32): “The jars contain-
ing MAS063D or control were presented
blindly, labelled with identical directions
for use...”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
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Belloni 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 32): “The jars contain-
ing MAS063D or control were presented
blindly, labelled with identical directions
for use...”
Outcomes were investigator-assessed as
well as participant-assessed
Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Berents 2015
Methods Randomised, investigator-blinded, controlled, within-participant study
Setting
Multicentre (3), baby clinics in Oslo, Norway
Date of study
2008 to 2011; duration of intervention: 4 weeks
Participants N = 9 (6 female, 3 male)
Mean age = 18.5 months
Inclusion criteria of the trial
• Children with atopic dermatitis according to Hanifin and Rajkas criteria (Hanifin
1980), with a mother breastfeeding the child or a sibling
• The eczema spots in the treatment and control areas were to be similar in features
and extent as well as being localised on contralateral parts of the body
Exclusion criteria of the trial
• The severity of the eczema spots indicated need for treatment with antibiotics or
steroids, or both
Randomised




• Remission (1), hospitalisation (1), lost to follow-up (1)
Baseline data
Mean SCORAD: 35 (range 22-45)
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Berents 2015 (Continued)
Interventions Intervention
• Moisturiser (Apobase creme, Actavis Norway AS) plus fresh expressed milk 3
times daily for 4 weeks on 1 site of the body
Comparator
• Moisturiser only (Apobase creme, Actavis Norway AS) 3 times daily for 4 weeks
on contralateral site of the body
Outcomes Assessments (5): baseline, weeks 1, 2, 3 and 4
Outcomes of the trial (as reported)
• Proportional change in the area of the eczema spot from baseline, as measured by
Visitrak
• Transmission of bacteria from mother’s milk to eczema spots in the child
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest Quote (page 6): “The authors declare that they have no competing interests”
Notes None of our outcomes were addressed (Table 4). Apobase creme contains: aqua, paraf-
finum liquidum, petrolatum, cetearyl alcohol, ceteareth-20, ceteareth-12, sodium glu-
conate, caprylyl glycol, phenoxyethanol, and has a total lipid content of 30%
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (pages 2-3): “Another physician,
who did not see the child, was responsible
for the randomization”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “ Physician
1 prepared 12 letters, 6 right and 6 left,
with treatment information. These were
then folded, so the information was hid-
den. Thereafter one and one was ran-
domly drawn and included into envelopes
numbered 1-12. Finally these envelopes
were sealed. This procedure was performed
physically outside the clinical department
where physician 2 works. Physician 1 was
the only one with access to the randomiza-
tion code.”
Comment: probably done.
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Berents 2015 (Continued)
Allocation concealment (selection bias) Low risk Quote (page 3): “The child was given a
randomization number and the mothers
were then informed on which side to apply
the fresh expressed human milk and emol-
lient, and on which side to apply emollient
alone”.
The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “Physician 2
received one sealed, numbered envelope,
for each new included patient, from physi-
cian 1”
Comment: allocation appears to have been
adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 2): “physician-blinded”
Comment: The report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived, to permit a clear judgement
After email communication: “Physician 2
delivered the sealed envelope with the cor-
rect patient number, to the mother. The
mother opened the sealed envelope outside
the sight of physician 2. If she had any ques-
tions she could talk to physician 1 by tele-
phone, without physician 2 listening. This
happened once”
Comment: the report provided sufficient
detail about the measures used to blind
study personnel from knowledge of which
intervention a participant received. How-
ever, participants were not blinded and so
we judged this study as being at an unclear
risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were investigator-assessed.
Blinding of the outcomes assessors was en-
sured, and it was unlikely that the blinding
could have been broken
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Berents 2015 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 3/9 (33.3%). Per-protocol analysis.
Comment: high number of losses to fol-
low-up, combined with per-protocol anal-
ysis meant we considered this study to be
at a high risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was avail-
able (NCT02381028), and the prespeci-
fied outcomes and those mentioned in the
methods section appear to have been re-
ported
Other bias Low risk Comment: the study appears to be free
from other forms of bias
Berth-Jones 2003
Methods Randomised, double-blind, active-controlled study
Setting
Multicentre (39), 6 countries in Europe
Date of study
Recruitment January 1998 to July 1999. Duration of intervention: 4 weeks for stabil-
isation phase, and 16 weeks maintenance phase. We only included the data from the
maintenance phase
Participants N = 376 (205 female, 171 male)
Mean age = 28.8 years
Inclusion criteria of the trial
• Participants with recurrent moderate to severe atopic dermatitis (12 to 65 years)
(Williams 1994), with a flare
Exclusion criteria of the trial
• Any medical condition for which topical corticosteroids were contraindicated
• Other dermatological conditions that may have prevented accurate assessment of
atopic dermatitis
• Those receiving any concomitant medications that might have affected the study’s
outcome
Randomised
N = 376 (fluticasone cream once daily group = 95, fluticasone cream twice daily group =
91, fluticasone ointment once daily group = 100, fluticasone ointment twice daily group
= 90)
Withdrawals/losses to follow-up
Stabilisation phase: 83/376 overall (22%); fluticasone cream once daily group = 19/95,
fluticasone cream twice daily group = 15/91, fluticasone ointment once daily group = 23/
100, fluticasone ointment twice daily group = 26/90, reasons reported (2/83, however,
entered into the maintenance phase)
Maintenance phase:
• Discontinued 27/295 (9.2%): fluticasone cream twice weekly plus moisturiser =
5/70, vehicle cream twice weekly plus moisturiser = 7/84, fluticasone ointment twice
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Berth-Jones 2003 (Continued)
weekly plus moisturiser = 6/68, vehicle ointment twice weekly plus moisturiser 9/73.
Reasons: lost to follow-up (11), withdrew consent (3), protocol violation (7), adverse
events (4), other (2)
• Relapse 135/295 (45.7%): fluticasone cream twice weekly plus moisturiser = 13/
70, vehicle cream twice weekly plus moisturiser = 54/84, fluticasone ointment twice
weekly plus moisturiser = 27/68, vehicle ointment twice weekly plus moisturiser 41/73
Baseline data
Mean extent of atopic dermatitis (%): fluticasone cream once daily group 28.8% (SD
19), fluticasone cream twice daily group 17.7% (SD 16.2), fluticasone ointment once
daily group 17.5% (SD 14.6), fluticasone ointment twice daily group 18.4% (SD 16.1)
Median TIS score: fluticasone cream once daily group 5.0 (range 4-6), fluticasone cream
twice daily group 5.0 (range 4-9), fluticasone ointment once daily group 5.0 (range 4-
7), fluticasone ointment twice daily group 5.0 (range 4-7)
Interventions Initially the flare was stabilised with fluticasone propionate cream 0.05% or fluticasone
propionate ointment 0.005%, once or twice daily, for 4 weeks. After that the maintenance
phase continued as follows:
Intervention
• fluticasone propionate 0.05% cream twice weekly plus daily moisturiser for 16
weeks (N = 70)
Comparator 1
• Vehicle cream twice weekly plus daily moisturiser for 16 weeks (N = 73)
Intervention 2
• fluticasone propionate 0.005% ointment twice weekly plus daily moisturiser for
16 weeks (N = 68)
Comparator 2
• Vehicle ointment twice weekly plus daily moisturiser for 16 weeks (N = 84)
Outcomes Assessments (7): baseline, weeks 2 and 4 (end of stabilisation phase), weeks 2, 6, 10 and
16 (end maintenance phase)
Outcomes of the trial (as reported)
• Flare or relapse: TIS, the sum of 3 signs: erythema, oedema or papulations, and
excoriations (each scored 0 = absent, 1 = mild, 2 = moderate, or 3 = severe (total of ≥ 4
= relapse or flare) (Wolkerstorfer 1999)
• Adverse events
• Skin atrophy
Denotes outcomes prespecified for this review
Funding source Quote (page 6): “Funding: Glaxo Wellcome (now GlaxoSmithKline) R & D, United
Kingdom”
Declaration of interest Quote (page 6): “Competing interests: CP is employed full time by GlaxoSmith-Kline”
Notes The moisturiser was a cetomacrogol-based cream
We received responses to our request for study details (Table 2).
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 2): “Investigators at each cen-
tre allocated patients to treatment groups
in equal numbers according to a computer
generated randomisation code. The block
size for the study was eight, and each re-
cruiting centre received 16 treatment allo-
cation numbers”
Comment: probably done.
Allocation concealment (selection bias) Low risk Quote (page 2): “Investigators at each cen-
tre allocated patients to treatment groups
in equal numbers according to a computer
generated randomisation code. The block
size for the study was eight, and each re-
cruiting centre received 16 treatment allo-
cation numbers”
Comment: form of central allocation,
probably done.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 1 and 2): “double-blind” and
“Patients who achieved remission (see as-
sessments) then entered a maintenance
phase and, using the same formulation as
in the stabilisation phase, applied fluticas-
one propionate or its placebo base on two
successive evenings per week for up to 16
weeks”
Comment: the report did not provide suf-
ficient detail about the specific measures,
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
After email communication: “blinding was
achieved using matching tubes containing
either active medication or vehicle alone”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 1 and 2): “double-blind” and
“Patients who achieved remission (see as-
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Berth-Jones 2003 (Continued)
sessments) then entered a maintenance
phase and, using the same formulation as
in the stabilisation phase, applied fluticas-
one propionate or its placebo base on two
successive evenings per week for up to 16
weeks”
Outcomes were investigator-assessed as
well as participant-assessed
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study, insufficient information to permit a
clear judgement
After email communication: “blinding was
achieved using matching tubes containing
either active medication or vehicle alone”
Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up in stabilisation phase 83/
376 (22%), reasons reported, balanced be-
tween groups, intention-to-treat and per-
protocol analysis
Discontinued in maintenance phase 27/
295 (9.2%); fluticasone cream twice weekly
plus moisturiser = 5/70, vehicle cream twice
weekly plus moisturiser = 7/84, fluticasone
ointment twice weekly plus moisturiser =
6/68, vehicle ointment twice weekly plus
moisturiser 9/73); Reasons: lost to follow-
up (11), withdrew consent (3), protocol vi-
olation (7), adverse events (4), other (2).
Intention-to treat analysis. “We conducted
all analyses on an intention to treat basis
(all subjects were included in the analysis
if they were randomised and applied the
study medication at least once).” Without
further information regarding the main-
tenance phase (the number initially ran-
domised, does not match the number in
the maintenance phase)
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
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Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Bissonnette 2010
Methods Randomised, double-blind, ’other moisturiser’-controlled study
Setting
Multicentre, Montreal Quebec, Canada
Date of study
March 2007 to October 2007. Duration of intervention: 42 days
Participants N = 100 (71 female, 29 male)
Mean age = 36.1 years
Inclusion criteria of the trial
• Male or female
• Aged > 18 years
• Diagnosed with atopic dermatitis, SCORAD < 30
Exclusion criteria of the trial
• Pregnancy and lactation
• Known allergy to 1 of the components of the study products
• Dermatological conditions that could interfere with study evaluations
Randomised
N = 100 (urea 5% moisturiser group = 50, urea 10% lotion group = 50)
Withdrawals/losses to follow-up
12/100 overall (12%); 6 in each group discontinued treatment
• Urea 5% moisturiser (6/50): lost to follow-up (5), early termination (1). Non
compliance - missed 30% of applications (2/44)
• Urea 10% lotion (6/50): lost to follow-up (4), early termination (2). Non
compliance - missed 30% of applications (1/44); “out of window” visit - delayed 35
days after study completion (1/44)
Baseline data
Mean SCORAD: 5% moisturiser group 20.35 (SD 5.81), 10% lotion group 21.4 (SD
4.96)
Interventions Intervention
• Urea 5% moisturiser (Iso-Urea) applied twice daily for 42 days (N = 50)
Comparator
• Urea 10% lotion applied twice daily for 42 days (N = 50)
Washout period: topical immuno modulators and phototherapy (2 weeks), PUVA and
systemic treatment (4 weeks)
Use of topical corticosteroids permissible if frequency of application constant for 2 weeks
prior to start of study and throughout
Outcomes Assessments (3): day 3; day 21 phone call to verify compliance and tolerability; day 42
follow-up visit, efficacy and safety
Outcomes of the trial (as reported)
• SCORAD (European Task Force on Atopic Dermatitis 1993)
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Bissonnette 2010 (Continued)
• Tolerability: 5-point Likert scale (1 = very good, 2 = good, 3 = average, 4 = poor, 5
= very poor)
• Adverse events
• Cosmetic acceptability questionnaire: 21 questions with answer values of 0-3 and
no comments (0 = totally agree, 1 = agree, 2 = disagree, 3 = totally disagree)
• Quality of life questionnaire (not validated): 22 questions with answer values of 0-
3 and no comments (0 = totally agree, 1 = agree, 2 = disagree, 3 = totally disagree)
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared, but 2 investigators are employed by La Roche-Posay Laboratoire Phar-
maceutique, Asnières Cedex, France
Notes Iso-Urea, La Roche-Posay Laboratoire Pharmaceutique, Asnières Cedex, France. Ingre-
dients: aqua /water, Vitellaria paradoxa (formerly called Butyrospermum parkii; shea but-
ter), glycerol, cyclohexasiloxane, urea, paraffinum liquidum mineral oil, sodium lac-
tate, cetearyl alcohol, PEG-100 stearate, glyceryl stearate, propylene glycol, glycine, to-
copherol, stearic acid, myristic acid, palmitic acid, bisabolol, triethanolamine, dime-
thicone, dimethiconol, disodium EDTA, hydroxyethyl piperazine ethane sulfonic acid,
xanthan gum, acrylates C10-30 alkyl acrylate crosspolymer, citric acid, chlorhexidine
digluconate, phenoxyethanol, methylparaben, propylparaben, fragrance
10% urea lotion contains: aqua, urea, sodium lactate, paraffinum liquidum, octyldode-
canol, caprylic capric triglyceride, isopropyl palmitate, glycerol, PEG-7 hydrogenated
castor oil, benzyl alcohol, methoxy PEG-22 docecyl glycol copolymer, PEG-45 do-
decyl glycol copolymer, dimethicone, magnesium sulfate, lactic acid, ozokerite, PEG-2
hydrogenated castor oil, sorbitan isostearate, hydrogenated castor oil
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 17): “Subjects were random-
ized (1:1)”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “The alloca-
tion sequence was generated by an in-
dependent statistician” “Individuals were
randomised by a computer-generated list,
which was maintained centrally ”
Comment: probably done.
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Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “Individuals
were randomised by a computer-generated
list, which was maintained centrally. Treat-
ments were assigned to consecutive patients
in a sequential order”
Comment: form of central allocation,
probably done.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 17 ): “double-blind...”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
After email communication: “Two copies
of the randomisation list were prepared:
one was used by for the labeling of the tubes
performed by the sponsor (tubes were des-
ignated for each patient - All tubes were
equal in weight, and similar in appearance)
and the other one was kept by the sponsor
until the end of the study”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 17 ): “double-blind...”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement.
After email communication: blinding of
the outcomes assessors, key personnel, and
participants was ensured, and it was un-
139Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bissonnette 2010 (Continued)
likely that the blinding could have been
broken
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 12/100 (12%); 6 in each group discontin-
ued treatment. Reasons reported. Per-pro-
tocol analysis (88/100) Missing data for 4
participants on: SCORAD, cosmetic ac-
ceptability and quality of life questionnaire
Comment: balanced and moderate number
of dropouts at follow-up, combined with
the per-protocol analysis, poses an unclear
risk of bias for this domain
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appear to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Boguniewicz 2008
Methods Randomised, double-blind, vehicle-controlled study
Setting
Multicentre (7), Dermatology and Pediatric departments, children’s hospitals in USA
Date of study
November 2005 to May 2006. Duration of intervention: 43 days
Participants N = 142 (74 female, 68 male)
Mean age = 5 years
Inclusion criteria of the trial
• 6 months to 12 years of age with atopic dermatitis according to Hanifin and
Rajka criteria (Hanifin 1980)
• IGA score of mild (IGA 2) or moderate (IGA 3) atopic dermatis with at least 5%
BSA affected by atopic dermatitis at study entry
• Participants needed to score at least 40 mm on a VAS for itch out of a total 100
mm, where 0 correlated to no itch and 100 to the worst possible itch
Exclusion criteria of the trial
• Severe atopic dermatitis
• Active skin infection
• Another skin condition that could interfere with evaluation of atopic dermatitis
• Intolerance to extract of Vitellaria paradoxa (formerly called Butyrospermum
parkii, shea nut), insulin-dependent diabetes, or other systemic disease that could
interfere with participation
• People who previously had used MAS063DP
• Women who had reached menarche
Randomised
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N = 142 (MAS063DP group = 72, vehicle group = 70)
Withdrawals/losses to follow-up
36/142 overall (25.4%); MAS063DP group = 19/72 (26.3%), vehicle group = 17/70
(24.2%)
• Poor control of atopic dermatitis: MAS063DP group (5), vehicle group (10)
• Withdrawal of consent: MAS063DP group (5), vehicle group (3)
• Side effects: MAS063DP group (3), vehicle group (3)
• Failure to follow up: MAS063DP group (3), vehicle group (0)
• Adverse event: MAS063DP group (1), vehicle group (1)
• Protocol violation: MAS063DP group (1), vehicle group (0)
• Moving out of state: MAS063DP group (1), vehicle group (0)
Baseline data
IGA of atopic dermatitis mild: MAS063DP group (37/72), vehicle group (37/70)
IGA of atopic dermatitis moderate: MAS063DP group (35/72), vehicle group (33/70)
Itch (VAS score) mean: MAS063DP group 6.2 (SD 11.7), vehicle group 6.7 (SD 1.7)
Interventions Intervention
• MAS063DP (Atopiclair) 3 times daily for 43 days (N = 72)
Comparator
• Vehicle 3 times daily for 43 days (N = 70)
If clinically indicated, a low potency rescue topical steroid was prescribed for participants
by the study investigator
Outcomes Assessments (6): baseline, days 3, 8, 22, 29, 43
Outcomes of the trial (as reported)
• IGA at day 22: 6-point Likert scale (0 to 5, where 0 correlated to clear and 5 to
severe disease), success of treatment was defined as reaching an IGA score of 0 or 1
• IGA scores at other time points
• Participants’/caregivers’ assessment of pruritus: 100 mm VAS scale and 0 to 3
ordinal scale
• Onset and duration of itch relief
• EASI at study visits (Hanifin 2001)
• Participants’/caregivers’ assessment of global response
• Need for rescue medication in the event of an atopic dermatitis flare
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 854): “This work was sponsored by Sinclair Pharmaceuticals Ltd (Surrey,
UK)”
Declaration of interest None declared
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Notes Quote (page 855): “Patients and caregivers agreed to refrain from using other topical and
systemic medications (including phototherapy) during the wash-out and study periods. A
washout period of 7 or 14 days was used for patients on topical and systemic medications,
respectively, including topical and systemic corticosteroids, topical calcineurin inhibitors,
antihistamines,and phototherapy”
See Notes of Characteristics of included studies of Abramovits 2008 for details of Atopi-
clair
We mailed investigators numerous times to clarify study details, but received no response
(Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 855): “Eligible subjects were
randomized to receive either MAS063DP
or vehicle in a 1:1 ratio according to a com-
puter generated code”
Comment: probably done.
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 855): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 17 ): “double-blind...”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 36/142 (25.4%); MAS063DP group = 19/
72 (26.3%), vehicle group 17/70 (24.2%)
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, reasons reported. Both per-protocol and
intention-to-treat analysis
Comment: the percentage of drop-outs
exceeded 20%, however, the investigators
provided both a per-protocol and an inten-
tion-to-treat analysis (last observation car-
ried forward). We judged this as being at
an unclear risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Bohnsack 1997
Methods Randomised, double-blind, placebo-controlled, within-participant study
Setting
BioSkin Institut für dermatologische Forschung und Enwicklung, Hamburg, Germany
Date of study
Unspecified. Duration of intervention: 4 weeks, followed by a 5-month open phase for
dermal tolerance
Participants N = 41 (31 female, 10 male)
Mean age = 31 years
Inclusion criteria of the trial
• At least 2 major and 3 minor criteria of atopic eczema according to Hanifin and
Rajka (Hanifin 1980)
• Xerosis and corneometry < 50 units of the forearms
Exclusion criteria of the trial
• Not reported
Randomised
N = 41, to either forearm (within-participant)
Withdrawals/losses to follow-up
3/41 (7.3%), worsening eczema (1), other reasons unrelated to the study (2)
Baseline data
Corneometry mean units: urea 10% lotion side 40.4 (SD 6.6), vehicle side 40.0 (SD 8.
0)
Combined total eczema score for all participants: urea 10% lotion side 91, vehicle side
88
Interventions Intervention
• Urea 10% lotion (Laceran) applied twice daily for 4 weeks on one forearm
Comparator
• Vehicle applied twice daily for 4 weeks on contralateral forearm
No other treatments and moisturising shower and bath products were allowed
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Outcomes Assessments (6): baseline, days 8, 15, 22, 29 and 32
Outcomes of the trial (as reported)
• Skin capacitance: Corneometer CM 820, Courage & Khazaka
• Investigators’ assessment of dryness of the skin: 4-point Likert scale (0 to3) (0 =
fine shiny skin surface, 1 = dry mat skin surface, 2 = mild scaling, 3 = obvious mild to
moderate scaling)
• Participant assessment: questionnaire (skin feeling, spreadability, ability to
penetrate, smell, all separately scored on a 4-point Likert scale 1 = not satisfactory, 2 =
satisfactory, 3 = good, 4 = very good)
Denotes outcomes prespecified for this review
Funding source None declared, however, 1 of the products under research is from Beiersdorf AG, Ham-
burg, Germany
Declaration of interest None declared, however 2 of the investigators are employees of Beiersdorf AG, Hamburg,
Germany, the manufacturer of the principal intervention
Notes As the study was 19 years old we did not contact the investigators for data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 35): “randomisiert zugeord-
net” (translation: assigned randomly)
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 34): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received on each forearm,
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to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 34): “double-blind”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/41 (7.3%) withdrew for worsening of the
skin condition (1) and reasons not related
to treatment (2). Per-protocol analysis
Comment: low number of losses to fol-
low-up, and although per-protocol analy-
sis, considered as being at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Boralevi 2014
Methods Randomised, double-blind, vehicle-controlled study
Setting
Multicentre in France (4 centres), Estonia (5 centres), Lithuania (5 centres), Poland (9
centres), and Romania (7)
Date of study
November 2011 to May 2012. Duration of the intervention 28 days with a follow-up
(open-label) period of 46 days
Participants N = 251 (122 female, 127 male and 2 gender unknown)
Mean age = 4 years
Inclusion criteria of the trial
• Children 2 to 6 years of age with atopic dermatitis according to the diagnostic
criteria of the UK Working Party (Williams 1994), and with an objective SCORAD
index < 15.0
• Xerosis, including moderate or severe dryness on the anterior part of lower limbs
as indicated by a SCORAD xerosis score (XS) ≥ 2 associated with palmar
hyperlinearity, scales on the lower limbs, or both
Exclusion criteria of the trial
• Acute atopic dermatitis with moderate to severe erythema and any excoriation,
crust, oozing, or exudation
• Recent treatment using systemic corticosteroids, antibiotics, antivirals, or
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hospitalisation
• Primary skin infection, ulcerated lesions, acne, or rosacea
• Dermatological disease that could interfere with the assessment of xerosis
• History of allergy or intolerance to 1 of the components of the tested or associated
products or to cosmetics
• Immune suppression
• History of serious disease considered incompatible with the study
Randomised
N = 251 (V0034CR01B moisturiser group = 125, vehicle group= 126)
Withdrawals/losses to follow-up
10/251 overall (4%); V0034CR01B group = 5/125, vehicle group = 5/126
• Safety; V0034CR01B group (1), vehicle group (3)
• Efficacy; V0034CR01B group (1), vehicle (1)
• Other; V0034CR01B group (3), vehicle group (1)
Baseline data
Mean objective SCORAD: V0034CR01B group 11.7 (SD 2.1), vehicle group 11.2 (SD
2.1)
Mean itch (VAS): V0034CR01B group 2.8 (SD 2.2), vehicle group 2.5 (SD 1.9)
Mean corneometry units: V0034CR01B group 29.1 (SD 10.3), vehicle group 29.4 (SD
11.3)
Interventions Intervention
• V0034CR01B moisturiser (Dexeryl) twice daily for 28 days (then open-label
period of 56 days) (N = 125)
Comparator
• Vehicle moisturiser twice daily for 28 days (then open-label period of 56 days) (N
= 126)
In case of atopic dermatitis flares, the test treatment had to be applied in the morning
and a moderately potent corticosteroid 0.1% desonide in the evening until complete
resolution of inflammatory skin lesions
Outcomes Assessments (5): days 1, 7, 14, 21 and 28
Outcomes of the trial (as reported)
• Dryness severity assessment of the SCORAD index: (0 = absent; 1 = mild; 2 =
moderate; 3 = severe) (European Task Force on Atopic Dermatitis 1993)
• Objective SCORAD index (Kunz 1997)
• Xerosis: VAS; linear 100 mm scale where 0 = ’no dry skin at all’ and 100 =
’extremely dry skin’
• Pruritus: VAS
• HI: a portable Corneometer, Courage-Khazaka Electronic GmbH, Cologne,
Germany
• Compliance: tubes of used and unused products were returned to investigators
and weighed
• Adverse events
Denotes outcomes prespecified for this review
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Funding source Quote (page 1456): “This study was funded by Pierre Fabre”
Declaration of interest Quote (page 1456): “F.B. received consulting fees and fees for participation in review
activities from Pierre Fabre. M.S.A. and A.D. are employees of Pierre Fabre. G.T. received
consulting fees from Pierre Fabre. H.R., A.K. and M.B. declare no conflicts of interest
related to this article”
Notes We only included the double-blind period of 28 days. Ingredients of V0034CR01B
moisturiser: glycerol 15%, liquid and soft paraffin 10%, glycerol monostearate, stearic
acid, polydimethylcyclosiloxane, silicone oil, macrogol 600, trolamine, propyl parahy-
droxybenzoate and purified water
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1457): “During the double-
blind period, patients were randomized 1:1
using a computer-generated and -validated
list to be treated for 28 days...”
Comment: probably done.
Allocation concealment (selection bias) Low risk Quote (page 1457): “The randomization
list was generated by the Clinical Phar-
macology Department using proprietary
software and with parallel groups and a
block size of four, and the list was vali-
dated by the Biometry Department. Treat-
ments were provided in identical, sequen-
tially numbered containers and were as-
signed to patients by investigators on the
basis of the sequence number”
Comment: central allocation, de-identified
drug containers. Allocation appears to have
been adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 1457): “Treatments were pro-
vided in identical, sequentially numbered
containers and were assigned to patients by
investigators on the basis of the sequence
number. Thus, patients, investigators and
pharmacists were blinded to which treat-
ment (emollient or vehicle) was supplied”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
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pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were investigator-assessed as
well as participant-assessed
Comment: blinding of the outcomes asses-
sors, key personnel, and participants was
ensured, and it was unlikely that the blind-
ing could have been broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10/251 (4%): V0034CR01B group = 5, ve-
hicle group = 5. Intention-to-treat analysis
Comment: the low total number of drop-
outs, balanced between the groups com-
bined with a intention-to-treat analysis,
meant we considered this study to be at a
low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was available
(EudraCT number 2011-003295-37), and
the prespecified outcomes and those men-
tioned in the methods section did not all
appear to have been reported. VAS data on
pruritus are missing and very limited data
on SCORAD and objective SCORAD are
available
Comment: initially we judged this as being
at a high risk of bias
After email communication: we received all
necessary data.
Comment: subsequently, we judged this as
being at a low risk of bias
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Breternitz 2008
Methods Randomised, double-blind, placebo-controlled, within-participant study
Setting
Department of Dermatology, Friedrich Schiller University, Jena, Germany
Date of study
November 2004 to March 2006. Duration of intervention: 4 weeks
Participants N = 24 (8 female, 16 male)
Mean age = 23 years (range 15-49 years)
Inclusion criteria of the trial
• Atopic dermatis (Erlangen atopy score > 10) and mild to moderate local severity
of eczema of both forearms (Diepgen 1996)
Exclusion criteria of the trial
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• Other significant concurrent illness
• Known allergy to ingredients of the test creams
• No topical or systemic treatment in the prior 2 weeks and in washout phase
Randomised
N = 24, to either forearm (within-participant)
Withdrawals/losses to follow-up
No losses to follow-up reported
Baseline data
The eczema on both forearms was of comparable severity
Mean adaptation of SCORAD: glycerol 20% side 2.9 (SD 1.3), vehicle side 3.2 (SD 1.
3)
Mean TEWL (g/m²/h): glycerol 20% side 18.4 (SD 8.2), vehicle side 26.6 (SD 17.3)
Interventions Intervention
• Glycerol 20% cream on volar forearm twice daily for 4 weeks
Comparator
• Glycerol-free vehicle on contralateral volar forearm twice daily for 4 weeks
Outcomes Assessments (7): baseline, weeks 1, 2, 3, 4, 5 and 6
Outcomes of the trial (as reported)
• Stratum corneum hydration: Corneometer CM 825, Courage & Khazaka
• TEWL: Tewameter TM 300, Courage & Khazaka, Cologne, Germany
• Skin surface pH: Skin pH-meter PH 900, Courage & Khazaka
• Erythema: Mexameter MX 16, Courage & Khazaka
• SCORAD (European Task Force on Atopic Dermatitis 1993)
Denotes outcomes prespecified for this review
Funding source Quote (page 44): “This study was supported by Spirig AG, Egerkingen, Switzerland”
Declaration of interest None declared, but 1 of the investigators was an employee of Spirig AG
Notes Assessment were performed 12 hours after last application and after a washout period of
2 weeks. It remains unclear if this is a product being developed by this company
The glycerol cream contained 20% glycerol (200 mg/g) and the following ingredients :
aqua, cetearyl alcohol, isopropyl myristate, paraffinum liquidum, PEG-40 hydrogenated
castor oil, glyceryl behenate, glyceryl dibehenate, tribehenin, citric acid, sodium citrate,
methylparaben, propylparaben. The composition of the placebo was identical but with-
out glycerol
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote (page 40): “According to a random-
ization list, the right or left forearm was se-
lected...”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “The ran-
domization list was generated from the
sponsor of the study not being part of the
study during the trial”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: initially there was insufficient
information to permit a clear judgement
After email communication: “we received
just A and B labelled tubes and allocated
them according to the randomization list
to each of the arms”
Comment: central allocation, de-identified
drug containers. Allocation appears to have
been adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 39): “...double-blind...” ..
“The composition of the placebo was iden-
tical without glycerol”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
After email communication: “The study
was fully double-blinded until the statisti-
cal analysis was finalized. Both creams had
the identical consistence and filled in iden-
tical tubes by the sponsor of the study”
Comment: the email communication pro-
vided sufficient detail about the measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 39): “...double-blind...”
Outcomes were investigator-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement.
After email communication: “The study
was fully double-blinded until the statisti-
cal analysis was finalized. Both creams had
the identical consistence and filled in iden-
tical tubes by the sponsor of the study”
Blinding of the outcomes assessors, key per-
sonnel, was ensured, and it was unlikely
that the blinding could have been broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
Selective reporting (reporting bias) Low risk Quote (page 41): trial registered on Eu-
ropean Clinical Trials Database (EudraCT
(2004-004443-22)), protocol not accessi-
ble. The prespecified outcomes and those
mentioned in the methods section appear
to have been reported
Other bias Unclear risk Baseline differences in TEWL and ery-
thema in favour of active treatment group
Danby 2011
Methods Randomised, controlled, within-participant study
Setting
The University of Sheffield, South Yorkshire, UK
Date of study
Unspecified. Duration of intervention: 2 weeks
Participants N = 38 (29 female, 9 male)
Mean age = 32 years
Inclusion criteria of the trial
• Previous history of atopic dermatitis
Exclusion criteria of the trial
• Not reported
Randomised
N = 50, to either forearm (within-participant)
Withdrawals/losses to follow-up
7/38, reasons unrelated to the trial
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Baseline data
Mean TEWL (g/m²/h): Aqueous cream BP 12.868 (SD 3.253), Oilatum Junior Bath
additive 12.819 (SD 3.446)
Interventions Intervention
• Aqueous cream BP twice daily for 2 weeks on 1 volar forearm
Comparator
• Oilatum Junior Bath additive twice daily for 2 weeks on the contralateral forearm
Outcomes Assessments (2): baseline and week 2
Outcomes of the trial (as reported)
• Skin barrier function: TEWL in conjunction with tape stripping
• Skin surface pH
• Protease activity
Denotes outcomes prespecified for this review
Funding source Quote (page 45): “This study was funded by a research grant from Stiefel, a GSK
company”
Declaration of interest None declared
Notes Poster abstract. Little information was provided. We received responses to our request
for study details (Table 2; Table 4).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 44): “randomized compari-
son”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “with a ran-
domization list”
Comment: probably done.
Allocation concealment (selection bias) High risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: initially, there was insufficient
information to permit a clear judgement
After email communication: “no conceal-
ment”
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Comment: subsequently, we judged this as
at a high risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Nothing reported regarding blinding.
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received on each forearm,
to permit a clear judgement
After email communication: “no blinding”
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes were investigator-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement.
After email communication: “no blinding”
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Nothing reported, little information pro-
vided.
Comment: there was insufficient informa-
tion to permit a clear judgement
Selective reporting (reporting bias) Unclear risk Comment: there was insufficient informa-
tion to permit a clear judgement
Other bias Unclear risk Comment: there was insufficient informa-
tion to permit a clear judgement
De Belilovsky 2011
Methods Randomised, investigator-blinded, active-controlled study
Setting
Multicentre in Spain, 12 dermatologists in private practices
Date of study
August to October 2007. Duration of intervention: 3 weeks
Participants N = 80 (44 female, 36 male)
Mean age = 2.3 years
Inclusion criteria of the trial
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• Children of 4 months to 4 years of age, with mild to moderate atopic dermatitis
• Clinical definition of atopic dermatitis was based on the presence of acute lesions
in the folds of the elbows, and/or knees, and/or on the surfaces of the limbs and/or on
cheeks. Severity was quantified by an initial SCORAD index of 15 to60 (European
Task Force on Atopic Dermatitis 1993)
Exclusion criteria of the trial
• Infected atopic dermatitis
• Application of topical steroids during the previous 8 days
• Use of systemic steroids
• Antibiotic or immunosuppressive treatment
• Antihistamine treatments with the exception of children undergoing long-term
antihistamine treatment for asthma or allergic rhinitis
• Other cosmetic treatments with the same aim as the product being tested
• State of health not compatible with this type of study
Randomised
N = 80 (STELATOPIA moisturiser = 40, hydrocortisone butyric-propionate cream group
= 40)
Withdrawals/losses to follow-up
No losses to follow-up reported
Baseline data
Mean SCORAD: STELATOPIA moisturiser 36.86 (SD 12.01), hydrocortisone butyric-
propionate cream group 37.19 (SD 15.28)
Interventions Intervention
• STELATOPIA moisturiser twice daily for 3 weeks (N = 40)
Comparator
• Hydrocortisone butyric-propionate cream 1 mg/g twice daily for 3 weeks (N = 40)
All children also received a body hygiene product in its marketed form (STELATOPIA
milky bath oil, Mustela; Laboratoires Expanscience), to be used at least once every other
day
Outcomes Assessments (3): baseline, weeks 1 and 3
Outcomes of the trial (as reported)
• SCORAD (European Task Force on Atopic Dermatitis 1993)
• Specific items of SCORAD (extent of atopic dermatitis lesions, erythema,
oedema/papulation, oozing/crusting, excoriation, lichenification, dry skin in healthy
areas, pruritus and sleep loss) were examined separately to assess different clinical
impacts of the moisturiser and topical steroid
• IGA: 5 answer levels (strongly agree, agree, disagree, strongly disagree, neither
agree nor disagree) to 5 questions: the treatment has a soothing effect on atopic lesions;
is appropriate in the treatment of atopic skin conditions; reduces the frequency of acute
attacks; lessens the severity of acute attacks; is satisfactory overall. A favourable answer
was the sum of the frequency of ’strongly agree’ and ’agree’
• Quality of life: IDQOL (Lewis-Jones 2001) and DFI (Lawson 1998)
• Tolerance and safety
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Denotes outcomes prespecified for this review
Funding source Quote (page 364): “This study was supported by Laboratoires Expanscience, R&D
Center, France. Dr C. de Belilovsky was supported and paid by Laboratoires Expanscience
for managing the project”
Declaration of interest Quote (page 364): “The authors report no conflicts of interest. The authors alone are
responsible for the content and writing of the paper”. Several authors were employees of
Laboratoires Expanscience, the manufacturer of the primary intervention
Notes STELATOPIA moisturiser, Mustela; Laboratoires Expanscience, France contains: 2%
sunflower oleodistillate, essential fatty acids, bio-ceramides, β-sitosterol and a complex
of emulsifying sugars
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (360): “were randomly assigned
by the dermatologists” and “following a
chronologic order of inclusion on a ran-
domized attribution list”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: initially, there was insufficient
information to permit a clear judgement
After email communication: allocation was
controlled by the Clinical Reseach Organ-
isation
Comment: form of central allocation. Al-
location appears to have been adequately
concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (360): “single-blind” and “observa-
tion blinded”
Comment: the report alone did not provide
sufficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived, to permit a clear judgement
After email communication: “Anonymous
sealed identical packaging provided by the
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Clinical Reseach Organisation”
Comment: the report provided sufficient
detail about the measures used to blind
study personnel from knowledge of which
intervention a participant received, how-
ever, participants were not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (360): “single-blind” and “observa-
tion blinded”
Outcomes were investigator-assessed as
well as participant-assessed
Comment: blinding of the outcomes asses-
sors, was ensured, but participants and par-
ents were not blinded
The outcome measurement was likely to be
influenced by the lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Draelos 2008
Methods Randomised, investigator-blinded, active-controlled study
Setting
Dermatology Clinic, High Point, North Carolina, USA
Date of study
Unspecified. Duration of intervention: 4 weeks
Participants N = 60 (gender not reported)
Age range = 5 to 80 years
Inclusion criteria of the trial
• 5 to 80 years of age with mild to moderate eczema defined as the severity of
eczema expected to exhibit reasonable clearing with a high-potency topical
corticosteroid in 4 weeks
Exclusion criteria of the trial
• Not reported
Randomised
N = 60 (fluocinonide cream 0.05% + cleansing bar group = 20, fluocinonide cream
0.05% + MVE liquid cleanser group = 20, fluocinonide cream 0.05% + MVE liquid
cleanser + MVE moisturising cream = 20)
Withdrawals/losses to follow-up
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No losses to follow-up reported
Baseline data
Mean Global Disease Severity: fluocinonide cream 0.05% + cleansing bar group = 3.0,
fluocinonide cream 0.05% + MVE liquid cleanser group = 3.1, fluocinonide cream 0.
05% + MVE liquid cleanser + MVE moisturising cream = 3.0
Interventions Intervention
• Fluocinonide cream 0.05% twice daily plus a mild bar cleanser as needed for 4
weeks (N = 20)
Comparator 1
• Fluocinonide cream 0.05% twice daily plus a MVE ceramide-containing liquid
cleanser as needed for 4 weeks (N = 20)
Comparator 2
• Fluocinonide cream 0.05% twice daily plus MVE ceramide-containing liquid
cleanser plus MVE moisturising cream as needed for 4 weeks (N = 20)
Participants underwent a 4-week oral and topical eczema treatment washout period
before study entry
Outcomes Assessments (4): baseline, weeks 1, 2, and 4
Outcomes of the trial (as reported)
• Global disease severity and signs and symptoms of eczema: 5-point Likert scale (0
= none, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe), incidence and time to disease
clearance
• Incidence and time to disease clearance
• Photography of target site
• Tolerability
Denotes outcomes prespecified for this review
Funding source Quote (page 87): “This study was supported by an unrestricted educational grant from
Coria Laboratories, Ltd”
Declaration of interest Quote (page 87): “The author reports no conflict of interest”
Notes MVE = multilamellar vesicular emulsion. Quote (page 87): “In MVE, there are concen-
tric layers of oil-in-water emulsions, which are referred to as vesicles. The vesicles are un-
folded when placed in contact with the skin surface to release ceramides; cholesterol; free
fatty acids; phytosphingosine; and other moisturising ingredients, such as dimethicone,
glycerol, and hyaluronic acid, onto the skin surface”
We mailed investigators numerous times to clarify study details, but received no response
(Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote (page 88): “Subjects were random-
ized to 1 of 3 balanced treatment groups of
20 subjects each”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants were not blinded, unclear if
physicians were blinded
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 89): “Blinded investigator as-
sessments”
Outcomes were (mainly) investigator-as-
sessed as well as participant-assessed
Comment: uncertainty about the effective-
ness of blinding of healthcare providers
during the study, and participants and par-
ents were not blinded
Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
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Methods Randomised, investigated-blinded, ’other moisturiser’-controlled, within-participant
study
Setting
Dermatology Clinic, High Point, North Carolina, USA
Date of study
Unspecified. Duration of intervention: 4 weeks
Participants N = 60 (gender not reported)
Age > 18 years
Inclusion criteria of the trial
• > 18 years with symmetrical mild to moderate eczema of the arms or legs
Exclusion criteria of the trial
• Not reported
Randomised
N = 60 to either forearm or leg (within-participant)
Withdrawals/losses to follow-up
1/60 (1.7%)
• 1 participant was unable to complete the study due to relocation
Baseline data
The groups were properly balanced at baseline between arm and leg target sites and
eczema severity, as no statistically significant differences between groups were present at
baseline.
Mean participant-assessed disease severity (6-point Likert scale): Albolene side 2.8,
MimyX side 2.8
Mean investigator-assessed disease severity (6-point Likert scale): Albolene side 2.6,
MimyX side 2.6
Interventions Intervention
• OTC moisturiser (Albolene) twice daily for 4 weeks to forearm or leg
Comparator
• Rx device (MimyX) twice daily for 4 weeks to contralateral forearm or leg
In people with moderate eczema, treatment was combined with 0.1% triamcinolone
acetonide
Outcomes Assessments (4): baseline, weeks 1, 2, and 4
Outcomes of the trial (as reported)
• Erythema, desquamation, lichenification, excoriation, stinging/burning, itching,
and overall eczema severity: 6-point Likert scale (0 = none, 1 = minimal, 2 = mild, 3 =
moderate, 4 = moderately severe, 5 = severe)
• Participant assessments of target site skin appearance for redness, peeling, dryness,
stinging/burning, and overall eczema appearance: 6-point Likert scale (0 = none, 1 =
minimal, 2 = mild, 3 = moderate, 4 = moderately severe, 5 = severe)
• Adverse events
Denotes outcomes prespecified for this review
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Funding source Quote (page 40): “This study was funded through an unrestricted grant from DSE
Healthcare Solutions, which manufactures Albolene, one of the products evaluated in
this research”
Declaration of interest None declared
Notes Albolene, Clarion Brands Inc contains mineral oils, petrolatum, paraffin, ceresin and
betacarotene
Mimyx, Stiefel, Coral Gables, FL, contains lipids (triglycerides, phospholipids), squalene,
phytosterole, and N-palmitoylethanolamide (has anti-inflammatory effect)
We mailed the investigator numerous times to clarify study details, but received no
response (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 41): “were asked to use the
OTC moisturizer twice daily to the ran-
domized right or left target limb and an Rx
device to the other randomized target limb”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 41): “The study could only be
investigator blinded, as it was not possible
to make the two study moisturizers appear
identical, since the products were studied as
currently marketed”. Participants were not
blinded
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived on each body part, to permit a clear
judgement
160Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Draelos 2009 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 41): “The study could only be
investigator blinded”
Outcomes were investigator-assessed as
well as participant-assessed
Comment: uncertainty about the effective-
ness of blinding of healthcare providers
during the study, and participants and par-
ents were not blinded
The outcome measurement was likely to be
influenced by the lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1/60 (1.7%), reason reported. Per-protocol
analysis.
Comment: low number of losses to fol-
low-up, and although per-protocol analy-
sis, considered as at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Draelos 2011
Methods Randomised, double-blind, ’other moisturiser’-controlled, within-participant study
Setting
Dermatology Clinic, High Point, North Carolina, USA
Date of study
Unspecified. Duration of intervention: 4 weeks
Participants N = 20 (all female)
Mean age was not reported
Inclusion criteria of the trial
• Women > 18 years with mild-to-moderate atopic dermatitis (IGA, with
symmetrically distributed target lesions on the arms or legs. Each target lesion required
a minimum score of 3, on a 6-point target lesion severity scale (0 = none, 1 = minimal,
2 = mild, 3 = moderate, 4 = moderately severe, 5 = severe), at baseline)
• Minimum total BSA involvement, including the investigator-evaluated target
lesions, of 10% to ensure an appropriate level of experience with the aesthetics of each
product
• Agreed to avoid all other topical medications and moisturisers during the study
period and for 2 weeks prior to study enrolment
Exclusion criteria of the trial
• Not reported
Randomised
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N = 20 to either body site (within-participant)
Withdrawals/losses to follow-up
2/20 (10%)
• Worsening atopic dermatitis at all sites (1), lost to follow-up (1)
Baseline data
Mean overall severity score 2 = mild, 3 = moderate: hyaluronic acid-based emollient
foam 2.9, ceramide-containing emulsion cream 2.9
Interventions Intervention
• Hyaluronic acid-based emollient foam (Hylatopic) twice daily for 4 weeks on 1
body site
Comparator
• Ceramide-containing emulsion cream (EpiCeram) twice daily for 4 weeks to
contralateral body site
Outcomes Assessments (3): baseline, weeks 2 and 4
Outcomes of the trial (as reported)
• Overall eczema severity, erythema, desquamation, lichenification, excoriation,
stinging and burning: 6-point Likert scale (0 = none, 1 = minimal, 2 = mild, 3 =
moderate, 4 = moderately severe, 5 = severe)
• Participant assessments of target site skin appearance for redness, peeling, dryness,
stinging/burning and overall skin irritation: 6-point Likert scale (0 = none, 1 =
minimal, 2 = mild, 3 = moderate, 4 = moderately severe, 5 = severe)
• Preference (spreadability, moisturisation, soothing, skin absorption, and lack of
odour): survey
• Patient-assessments regarding which worked best, which product they were
willing to pay more for and which they preferred
• Adverse events
• Compliance: diaries
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared
Notes EpiCeram contains a blend of ceramides, cholesterol and free fatty acids. Hyalotopic con-
tains water, glycerol, ethylhexyl palmitate, cetearyl alcohol, Theobroma grandiflorum seed
butter, petrolatum, dimethicone, parabens, tocopherol acetate and sodium hyalorunate
We mailed the investigator numerous times to clarify study details, but received no
response (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote (page 186): “This single-centered,
double-blinded, randomized, split body
study”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 186): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived on each part of the body, to permit
a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 186): “Blinded investigator
ratings” and “double-blind”
Outcomes were investigator-assessed as
well as participant-assessed
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/20 (10%), worsening atopic dermatitis
at all sites (1), lost to follow-up (1). Per-
protocol analysis
Comment: low number of losses to fol-
low-up, and although per-protocol analy-
sis, considered as at a low risk of bias
Selective reporting (reporting bias) High risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared not to be all reported. Results on
participant assessments of target site skin
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appearance for redness, peeling, dryness,
stinging/burning, and overall skin irrita-
tion were missing
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Emer 2011
Methods Randomised, investigator-blinded, active-controlled, within-participant study
Setting
Outpatient clinic of Dermatology Clinical Trials Center, Mount Sinai School of
Medicine, New York, USA
Date of study
September 2009 to March 2010. Duration of intervention: 4 weeks
Participants N = 20 (gender not reported)
Age range = 14 to 50 years
Inclusion criteria of the trial
• Male and female ≥ 2 years of age with clear diagnosis of mild to moderate atopic
dermatitis for at least 1 year
• Symmetrical target eczematous areas on opposite sides of the body with a PGA of
at least mild (2) severity
• Females of child-bearing potential needed to have negative urine pregnancy test
and agree to adequate birth control
Exclusion criteria of the trial
• Pregnant and nursing females, or willing to conceive
• Hypersensitivity to the study medications or its excipients
• Active skin infection in selected target areas
• Use of medication known to alter course of atopic dermatitis
• Systemic antibiotics < 14 days prior to study
• Systemic corticosteroids or immunosuppressants < 28 days prior to study
• Topical corticosteroids, or other topical modalities (tar, topical calcineurin
inhibitors) for atopic dermatitis < 7 days prior to study
• Phototherapy (UVA and UVB) < 28 days prior to study
Randomised
N = 20 to either body site (within-participant)
Withdrawals/losses to follow-up
No losses to follow-up reported.
Baseline data
PGA mild: Eletone N = 2, pimecrolimus N = 2
PGA moderate: Eletone N = 15, pimecrolimus N = 15
PGA severe: Eletone N = 3, pimecrolimus N = 3
Mean PGA (0-5): Eletone side 3.08, pimecrolimus side 3.03
Mean participants’ self-assessment (0-3): Eletone side 2.32, pimecrolimus side 2.33
Interventions Intervention
• Topical medical device cream (Eletone) 3 times a day for 4 weeks to 1 body site
Comparator
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• Pimecrolimus 1% cream twice daily for 4 weeks to contralateral body site
Outcomes Assessments (3): baseline, weeks 2 and 4
Outcomes of the trial (as reported)
• PGA: 6-point Likert scale (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 =
severe, 5 = very severe)
• Target lesion severity score: assessment on erythema, papulation/infiltration,
excoriation and lichenification on a 4-point Likert scale (0 = clear, 1 to 3 increasing
severity)
• Participants’ self-assessments: 4-point Likert scale (0 to 3)
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 741): “Funding Sources: Fernadale Laboratories”
Declaration of interest Quote (page 471): “The authors have no relevant conflict of interest to disclose”
Notes Eletone contains a high lipid content that utilizes a specialized hydrolipid technology, a
reverse-phase formulation of 70% lipids dispersed in 30% outer phase of water
We mailed investigators numerous times to clarify study details, but received no response
(Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 737): “medication was ran-
domized in a 1:1 ratio”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 737): “investigator blinded”
and “subsequently dispensed by an un-
blinded study coordinator to ensure inves-
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tigator blindness”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived on each part of the body, to permit
a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 737): “investigator-blinded”.
Outcomes were investigator-assessed as
well as participant-assessed
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study, and
participants were not blinded
The outcome measurement was likely to be
influenced by the lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Evangelista 2014
Methods Randomised, double-blind, ’other moisturiser’-controlled study
Setting
Dermatology Outpatient Department of the Jose R Reyes Memorial Medical Center,
Manila, Philippines
Date of study
March 2011 to June 2012. Duration of intervention: 8 weeks
Participants N = 117 (50 female, 47 male and 20 gender unknown)
Mean age = 4.5 years
Inclusion criteria of the trial
• Children aged 1 to 13 years with mild to moderate paediatric atopic dermatitis
(Williams 1994)
Exclusion criteria of the trial
• Topical or systemic antibiotic or steroid treatments 2 weeks prior to study
• Non-responders to standard treatments (including moderate-potency topical
corticosteroids)
• Persistent disease or frequent flares, or both
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• Previous hospitalisation as a direct consequence of atopic dermatitis
• Requiring systemic therapies for flares or maintenance, or both
• Grossly infected lesions that required oral or intravenous antibiotics and ancillary
therapy
• Dermatologic diagnoses other than atopic dermatitis
• Hypersensitivity to virgin coconut oil or mineral oil
• Any genetic skin disorder or compromised immune state
• Any other major medical problem that the investigator deemed likely to increase
the risk for adverse events associated with the intervention
Randomised
N = 117 (virgin coconut oil group = 59, mineral oil group = 58)
Withdrawals/losses to follow-up
16/117 overall (13.7%); virgin coconut oil group = 5/59 (8.5%), mineral oil group =
11/58 (19.0%)
• Dropout: virgin coconut oil group (2), mineral oil group (2)
• Withdrawn: virgin coconut oil group (3), mineral oil group (9)
Reasons for withdrawal
• Poor compliance: virgin coconut oil group (2), mineral oil group (4)
• Adverse events: virgin coconut oil group (0), mineral oil group (5)
• Apllied other moisturiser: virgin coconut oil group (1), mineral oil group (0)
Baseline data
Mean SCORAD index: virgin coconut oil group 13.28, mineral oil group 12.29
Mean TEWL (g/m²/h): virgin coconut oil group 26.68, mineral oil group 24.12
Mean skin capacitance (corneometry units): virgin coconut oil group 32.00, mineral oil
group 31.31
Interventions Intervention
• Virgin coconut oil (VCO) twice daily for 8 weeks (N = 59)
Comparator
• Mineral oil twice daily for 8 weeks (N = 58)
All parents were asked to give the participating children a bath once daily with warm
water for 5-10 minutes and to apply the assigned oil immediately after bathing and at
night
Outcomes Assessments (4): baseline, weeks 2, 4 and 8
Outcomes of the trial (as reported)
• SCORAD (European Task Force on Atopic Dermatitis 1993); moderate
improvement was considered if the decrease from the baseline SCORAD index was ≥
30% but < 75% and excellent improvement was considered if the decrease was ≥ 75%
• TEWL: TEWA meter TM210
• Skin capacitance: Corneometer CM825, Courage & Khazaka Electronic GmbH,
Cologne, Germany
• Adverse events
Denotes outcomes prespecified for this review
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Funding source None declared
Declaration of interest Quote (page 100): “Conflicts of interest: None”
Notes Parents were advised not to give or apply any other medication (excluding multivitamins)
or moisturiser during the study period
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 102): “The study statistician
generated a list of random numbers using
the table of random numbers”
Comment: probably done.
Allocation concealment (selection bias) Low risk Quote (page 102): “uniform opaque plas-
tic bottles” and “The bottles were coded (A
or B) by the pharmacist” and “An assigned
resident, who was blinded to the codes, al-
located the treatments randomly using the
list and dispensed the packaged bottles ac-
cordingly. The codes were not disclosed to
the investigators until the end of the study”
Comment: central allocation, de-identified
uniform bottles. Allocation appears to have
been adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 102): “Both VCO and min-
eral oil were obtained from local compa-
nies. They were repackaged into uniform
opaque plastic bottles with a small opening
to mask the color and scent of both oils.
There are no other apparent differences be-
tween the oils as both are clear, colorless,
and of similar viscosity. The bottles were
coded (A or B) by the pharmacist”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 102): “Both VCO and min-
eral oil were obtained from local compa-
nies. They were repackaged into uniform
opaque plastic bottles with a small opening
to mask the color and scent of both oils.
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There are no other apparent differences be-
tween the oils as both are clear, colorless,
and of similar viscosity. The bottles were
coded (A or B) by the pharmacist”
Outcomes were investigator-assessed as
well as participant-assessed
Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 16/117 (13.7%), virgin coconut oil group
= 5/59 (8.5%), mineral oil group = 11/
58 (19.0%), reasons reported. Intention-
to-treat analysis
Comment: the total number of dropouts
were unbalanced between the groups and
although combined with a intention-to-
treat analysis, represents an unclear risk of
bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free
from other forms of bias
Faergemann 2009
Methods Randomised, investigator-blinded, ’other moisturiser’-controlled within-participant
study
Setting
2 Dermatology departments Sahlgrenska University Hospital, Göteborg and University
Hospital MAS, Malmö, Sweden
Date of study
October to March unclear which years. Duration of intervention: 2 weeks
Participants N = 56 (39 female, 17 male)
Mean age = 46 years
Inclusion criteria of the trial
• Adults 18 to 70 years of age, with a diagnosis of atopic dermatitis (Williams
1994), and with symmetrical dry skin on their lower legs
Exclusion criteria of the trial
• Active skin disease on the test areas
• Acute or chronic systemic illness of clinical significance
• Allergy or idiosyncrasy reaction to any of the 2 test formulations
• Use of oral corticosteroids, immunosuppressive drugs or other topical
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formulations in the test area
Randomised
N = 56 to either leg (within-participant)
Withdrawals/losses to follow-up




• Propyless lotion (containing 20% propylene glycol, Schering-Plough, Brussels,
Belgium) twice daily for 2 weeks to 1 leg
Comparator
• Fenuril cream (containing 4% urea and 4% NaCl, ACO, Upplands Väsby,
Sweden) twice daily for 2 weeks to contralateral leg
Outcomes Assessments (2): baseline and week 2
Outcomes of the trial (as reported)
• Patient-assessed symptom severity of smarting, stinging, itching and irritation: 5-
point Likert scale (0 = none, 1 = very weak, 2 = weak, 3 = moderate or 4 = severe)
• DASI (Serup 1995): 4 signs (scaling, roughness, redness and cracks/fissures)
normally scored at 4 different body regions (head and neck, upper extremities, trunk
and lower extremities) according to a 0-4 categorical scale (0 = absent, 1 = slight, 2 =
moderate, 3 = severe, 4 = extreme). DASI is the sum of the 4 body regions. In this
study, only the lower extremities were included, and therefore the DASI score in this
area only was assessed
• Patient cosmetic acceptability
• TEWL measured in a sub-group of 20 participants: evaporimeter
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 307): “This study was supported by Schering-Plough AB, Sweden and
writing of the article was supported by TFS Trial Form Support, Sweden”
Declaration of interest Quote (page 307): “Conflict of interest: Petter Olsson is an employee of Schering-Plough
AB, Sweden”
Notes The investigator was not able to provide us with more information on study details
(Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote (page 305-6): “according to ran-
domization 1:1 ratio” and “The subjects
were randomized into two groups (1:1)”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 305): “Single-blind” and “The
allocation of treatment was known to the
patients but not to the investigator”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived on each leg, to permit a clear judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 305): “Single-blind”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study.
Participants were not blinded
The outcome measurement was likely to be
influenced by the lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1/56 (1.8%) before start of treatment. In-
tention-to-treat analyses
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
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Ferreira 1998
Methods Randomised, ’other moisturiser’-controlled study
Setting
Dermatology Department, Hospital do Desterro, Lisbon, Portugal
Date of study
Unspecified. Duration of intervention: 12 weeks
Participants N = 23 (7 female, 16 male)
Mean age = 9.7 years
Inclusion criteria of the trial
• Atopic dermatitis in clinical remission
Exclusion criteria of the trial
• Topical or systemic therapies
Randomised




Mean xerosis scores: Nioleol group 26.6 (SD 22.5), Atopic group 23.3 (SD 17.5), Uriage
group 30.0 (SD 28.2), Atoderm group 33.3 (SD 27.3)
Mean pruritus scores: Nioleol group 14 (SD 11.4), Atopic group 13.5 (SD 12.1), Uriage
group 11.7 (SD 9.8), Atoderm group 14.6 (SD 10.5)
Mean cutaneous hydration units: Nioleol group 109 (SD 15.6), Atopic group 107 (SD
12.8), Uriage group 108 (SD 21.3), Atoderm group 99 (SD 16.8)
Mean TEWL (g/m²/h): Nioleol group 9.25 (SD 3.5), Atopic group 9.05 (SD 4.3),
Uriage group 9.05 (SD 2.4), Atoderm group 8.15 (SD 3.0)
Interventions Intervention
• Nioleol (10% primrose oil, 8%-9% γ -linolenic acid) once daily for 12 weeks
Comparator 1
• Uriage (borage oil (24% γ -linolenic acid)) once daily for 12 weeks
Comparator 2
• Atopic (35%-40% γ -linolenic acid) once daily for 12 weeks
Comparator 3
• Atoderm control moisturiser once daily for 12 weeks
Outcomes Assessments (8): baseline, weeks 1, 2, 3 4, 6, 8 and 12
Outcomes of the trial (as reported)
• Xerosis (DASI score) (Serup 1995): 4 signs (scaling, roughness, redness and
cracks/fissures) normally scored at 4 different body regions (head and neck, upper
extremities, trunk and lower extremities) according to a 0 to 4 categorical scale (0 =
absent, 1 = slight, 2 = moderate, 3 = severe, 4 = extreme). DASI is the sum of the 4
body regions
• Pruritus: 5-point Likert scale (0 = absent, 1 = slight, 2 = moderately, 3 = intense, 4
= very intense)
• Skin hydration: Nova DPM 9003, Nova Technology Corporation, Gloucester,
MA, USA
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• TEWL: Tewameter TM 2010, Courage & Khazaka, Köln, Germany
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared
Notes Atoderm, Bioderma, Laboratoire Dermatologique contains: aqua, mineral oil (paraf-
finum liquidum), glycerol, cetearyl isonanoate, glyceryl stearate, PEG-100 stearate,
myreth-3 myristate, steareth-21, tocopheryl acetate, mannitol, xylitol, rhamnose, fructo-
oligosaccharides, laminaria ochroleuca extract, cyclopentasiloxane, cyclohexasiloxane,
triethanolamine, cetyl alcohol, palmitic acid, stearic acid, acrylates/C10-30 alkyl acry-
late crosspolymer, caprylic/capric trygliceride, disoidum EDTA, phenoxyethanol, chlor-
phenesin, sodium hydroxide
As the study was 18 years old we have not contacted the investigators for missing trial
data. As it is unclear how many were randomised to each group, this study is included
in Table 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 139): “They were randomised
into four groups”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No reporting of measures used to blind
study participants and personnel from
knowledge of which intervention a partic-
ipant received
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported. Outcomes were in-
vestigator-assessed as well as participant-as-
sessed
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Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Nothing reported, unclear how many were
randomised to each group
Comment: there was insufficient informa-
tion to permit a clear judgement
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Frankel 2011
Methods Randomised, investigator-blinded, active-controlled, within-participant study
Setting
Outpatient clinic of Dermatology Clinical Trials Center, Mount Sinai School of
Medicine, New York, USA
Date of study
March 2010 to October 2010. Duration of intervention: 4 weeks
Participants N = 30 (gender not reported)
Age range = 4 to 69 years
Inclusion criteria of the trial
• Males and females ≥ 2 years of age with clear diagnosis of mild-to moderate
atopic dermatitis for at least 1 year
• Symmetrical target eczematous areas on opposite sides of the body with a PGA of
at least mild (2) severity
• Females of child-bearing potential needed to have negative urine pregnancy test
and agree to adequate birth control
Exclusion criteria of the trial
• Pregnant and nursing females, or wishing to conceive
• Hypersensitivity to the study medications or its excipients
• BSA > 30% involvement of atopic dermatitis
• Active skin malignancy or infection in selected target areas
• Use of medication known to alter course of atopic dermatitis
• Systemic antibiotics < 14 days prior to study
• Systemic corticosteroids or immunosuppressants < 28 days prior to study
• Topical corticosteroids, or other topical modalities (tar, topical calcineurin
inhibitors) for atopic dermatitis < 7 days prior to study
• Phototherapy (UVA and UVB) < 28 days prior to study
Randomised
N = 30 to either body site (within-participant)
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Withdrawals/losses to follow-up
2/30 (6.7%) reasons unreported
Baseline data
Mean IGA: Hylatopic side 2.62 (SE 0.14), pimecrolimus side 2.62 (SE 0.14)
Interventions Intervention
• Ceramide hyaluronic-acid-based emollient foam (Hylatopic) 3 times per day for 4
weeks on 1 body site
Comparator
• Pimecrolimus 1% cream twice daily for 4 weeks on contralateral body site
Outcomes Assessments (3): baseline, weeks 2 and 4
Outcomes of the trial (as reported)
• IGA: 6-point Likert scale (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 =
severe, 5 = very severe)
• Target lesion severity score: assessment on erythema, papulation/infiltration,
excoriation and lichenification on a 4-point Likert scale (0 = clear, 1 to 3 increasing
severity)
• Participants’ self-assessments of disease control: 4-point Likert scale (0 to 3, 0 =
complete disease control, 3 = uncontrolled)
• Itching Severity Scale: VAS
• Product preference
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 671): “Study support was provided by Onset Dermatologics”
Declaration of interest Quote (page 671): “The authors have no relevant financial conflicts of interest to disclose”
Notes Hyalotopic contains water, glycerol, ethyl-hexyl palmitate, cetearyl alcohol, Theobroma
grandiflorum seed butter, petrolatum, dimethicone, parabens, tocopherol acetate and
sodium hyaluronate
We mailed investigators numerous times to clarify study details, but received no response
(Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 669): “were screened and ran-
domized in a 1:1 ratio”
Quote (page 668): “A randomized list was
created to determine which side the subject
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Allocation concealment (selection bias) Unclear risk Quote (page 668): “The list was only avail-
able to the un-blinded study coordinator”
The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 668): “investigator-blinded”
“subsequently dispensed by an unblinded
study coordinator to ensure investigator
blindness”. Participants were not blinded
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived on each part of the body, to permit
a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 668): “investigator-blinded”.
Outcomes were investigator-assessed as
well as participant-assessed
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study, and
participants were not blinded
The outcome measurement was likely to be
influenced by the lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/30 (6.7%); reasons unreported. Per-pro-
tocol analysis.
Comment: low number of losses to follow-
up, and although per-protocol analysis con-
sidered as at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was avail-
able (NCT01202149), and the prespeci-
fied outcomes and those mentioned in the
methods section appeared to have been re-
ported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
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Methods Two randomised, double-blind, ’other moisturiser’-controlled, within-participant stud-
ies
Setting
Two Dermatology clinics of the Central Hospitals Västerás and Sundsvall, Sweden
Date of study
During winter 1972-73. Duration of interventions: 4 weeks
Participants N = 2 studies of 30 (gender not reported)
Mean age not reported
Inclusion criteria of the trials
• Study 1: bilateral dry scaling skin of equal severity associated with present or
earlier atopic dermatitis
• Study 2: bilateral eczematous dermatitis of the hands in atopic skin
Exclusion criteria of the trials
• Not reported
Randomised
N = 2 studies of 30, to either side of the body (within-participant)
Withdrawals/losses to follow-up




• Aquacare twice daily for 4 weeks to 1 body site
Comparator
• Calmurid twice daily for 4 weeks to contralateral body site
No other treatments were permitted
Outcomes Assessments (3): baseline, weeks 2 and 4
Outcomes of the trial (as reported)
• Adverse events
• Treatment preference (physician and participants): disease severity on a 6-point
Likert scale (0 = no objective symptoms, 1 = slight signs, 2 = mild condition, 3 =
moderate condition, 4 = severe condition, 5 = severest possible condition)
• Cosmetic acceptability
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared
Notes Quote (page 442): “Aquacare® is a moisturising emulsion containing 10% urea, multi
sterols, phospholipids and fatty diols. Calmurid® contains 10% urea, betaine, and a
high content lactic acid”
As the study was 41 years old we have not contacted the investigators for data
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 443): “after being randomly
marked left and right”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk Quote (page 443): “Tubes containing 90
gm of Aquacare HP Cream and Calmurid
Cream were packed into identical car-
tons after being randomly marked left and
right”. Unclear who packed the tubes and
if allocation was indeed concealed to the
investigators
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 443): “These were dispensed
in a double-blind fashion” and “Tubes con-
taining 90 gm of Aquacare HP Cream and
Calmurid Cream were packed into iden-
tical cartons after being randomly marked
left and right”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partic-
ipant received on each part of the body, to
permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 443): “These were dispensed
in a double-blind fashion” and “Tubes con-
taining 90 gm of Aquacare HP Cream and
Calmurid Cream were packed into iden-
tical cartons after being randomly marked
left and right”
Outcomes were investigator-assessed as
well as participant-assessed
Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported. Data pre-
sented on all randomised participants
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Gao 2008




Unspecified. Duration of intervention: 2 weeks
Participants N = 196 (108 female, 88 male)
Mean age = 4 months
Inclusion criteria of the trial
• Atopic eczema
Exclusion criteria of the trial
• Not reported
Randomised




Disease duration 14 days in BoPao + 10% urea cream and 10 days in Bopao only group
Interventions Intervention
• Anti-inflammatory antifungal ’BoPao cream’ + urea 10% ointment, once to twice
daily for 2 weeks (N = 101)
Comparator
• Anti-inflammatory antifungal ’BoPao cream’, once to twice daily for 2 weeks (N =
95)
Outcomes Assessments (2): baseline and week 2
Outcomes of the trial (as reported)
• Clinical assessment of erythema, papules, rash, scaling: 4-point Likert scale (0 =
no, 1 = mild, 2 = moderate, 3 = severe)
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared
Notes We were unable to retrieve the correct email address for Dr Gao
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 294): translation: “randomly
divided”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No reporting of measures used to blind
study participants and personnel from
knowledge of which intervention a partic-
ipant received
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported. Outcomes were in-
vestigator-assessed as well as participant-as-
sessed
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nothing reported, there seems to have been
an intention-to-treat analysis
Comment: we judged this as at a low risk
of bias.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Unclear risk Comment: there was insufficient informa-
tion to permit a clear judgement
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Methods Randomised, double-blind, placebo-controlled study
Setting
Investigational site in Poland
Date of study
March 2012 to June 2013. Duration of intervention: 6 months
Participants N = 130 (56 female, 67 male and 7 gender unknown)
Mean age = 5 years
Inclusion criteria of the trial
• Children aged 6 months to 15 years with an atopic dermatitis severity score of 15
to 40 on the SCORAD scale at selection visit.
• Suffered 3 to 6 eczema flare-ups during the 6 months prior to the study and
presenting at least 1 flare-up at selection visit
Exclusion criteria of the trial
• History of allergy
Randomised
N = 130 (65 to either group)
Withdrawals/losses to follow-up
7/165 overall (4.2%); SBT complex = 3/65 (4.6%), moisturiser base 4/65 (6.2%)
• Reasons: wrongful inclusion as initial treatment duration with corticoids or
tacrolimus/pimecrolimus was longer or shorter than that mentioned in the inclusion
criteria
Baseline data
Mean SCORAD: SBT complex 26.5 (SE 0.9), moisturiser base 26.4 (SE 1.0)
Mean PO SCORAD: SBT complex 32.1 (SE 1.9), moisturiser base 32.4 (SE 1.7)
Interventions Intervention
• SBT complex for Skin Barrier Therapy (Atoderm Intensive cream) twice daily for
6 months (N = 65)
Comparator
• Moisturiser base (containing glycerol 2% and stearic acid) twice daily for 6
months (N = 65)
Quote (page 108): “Alternately or adjunctively to their conventional topical AD
treatment (topical corticosteroids or calcineurin inhibitors such as pimecrolimus or
tacrolimus). AD treatments were prescribed at selection visit, prior to entering the study.
Subjects were not allowed to alter their prescribed AD medication regimen and to con-
tinue concomitantly their current moisturiser or moisturising products”
Outcomes Assessments (4): baseline, days 56, 112 and 168
Outcomes of the trial (as reported)
• SCORAD (European Task Force on Atopic Dermatitis 1993)
• PO-SCORAD (Stalder 2011)
• Relapse (flare-up) rate, severity, and time-to-first relapse as well as treatment
duration
• Quality of life: IDQOL (Lewis-Jones 2001), CDLQI (Lewis-Jones 1995), DFI
(Lawson 1998) on the following scale (0 to 1 = no effect at all on patient’s life, 2 to 5 =
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small effect on patient’s life, 6 to 10 = moderate effect on patient’s life, 11 to 20 = very
large effect on patient’s life to 21 to 30 = extremely large effect on patient’s life)
• Participants’ assessment of efficacy and cosmetic perception
• Safety and local tolerance
• Mean number of treatment days for both groups: the number of days during
which topical corticosteroids, calcineurin inhibitors, or antihistamines were applied
Denotes outcomes prespecified for this review
Funding source Quote (page 112): “The study was granted by Laboratoire Bioderma, France”
Declaration of interest Quote (page 112): “All authors are employees of Laboratoire Bioderma, Lyon, France”
Notes Quote (page 108): “SBT complex contains vitamin B3 palmitoyl ethanolamide (PEA)
an anti-pruritus agent, sucro-esters, β-sitosterol an anti-inflammatory agent and zinc
known for its antibacterial action against Staphylococcus aureus”
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 108): “Subjects were random-
ized at the investigational site in a 1:1 way”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “The alloca-
tion sequence was generated under SAS v9.
2 statistical software”
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “The alloca-
tion sequence was provided to the study
center before the beginning of the study.
This list assigned each of the product code
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to a subject number. The complete list
was available for the investigator from the
beginning of the study. The participants
didn’t see the allocation sequence. It was
impossible for them to guess which prod-
uct they or the following subjects received”
Comment: central allocation. Allocation
appears to have been adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 165): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
After email communication: “The tested
products were packaged identically in white
plastic bottle with pomp dispenser [SIC],
with the exact same labeling. The color
and texture of both topical products were
the same: white emulsion. The only differ-
ence between both product were the iden-
tification code BIXXXVX. Neither the in-
vestigator nor the caregivers knew the na-
ture of the products used (tested product or
placebo). The investigator and CRO staff
was just following the randomization list to
allocate the product without knowing if it
was the tested product or the placebo. The
nature of the products was only known by
the Sponsor”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
After email communication: blinding of
the outcomes assessors, key personnel, and
participants was ensured, and it was un-
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likely that the blinding could have been
broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7/165 (4.2%); SBT complex = 3/65 (4.6%)
, moisturiser base 4/65 (6.2%). Per-proto-
col analysis
Comment: low number of losses to follow-
up, and although per-protocol analysis con-
sidered as at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Gehring 1996
Methods Randomised, double-blind, active-controlled study
Setting
Dermatology clinic, Karlsruhe, Germany
Date of study
Unspecified. Duration of intervention: 2 weeks
Participants N = 69 (39 female, 24 male and 6 gender unknown)
Mean age = 27 years
Inclusion criteria of the trial
• Participants with atopic eczema
Exclusion criteria of the trial
• Not reported
Randomised
N = 69 (water-in-oil emulsion group = 31, water-in-oil emulsion plus hydrocortisone
group = 32)
Withdrawals/losses to follow-up
6/69 (8.7%) unclear from which group
• Loss to follow-up, protocol violation, adverse event
Baseline data
Mean roughness according to participants: 3.97 (SD 2.12) water-in-oil emulsion group,
4.31 (SD 1.57) hydrocortisone group
Mean itch according to participants: 4.65 (SD 2.51) water-in-oil emulsion group, 4.72
(SD 2.46) hydrocortisone group
Mean redness according to physicians: 2.23 (SD 0.80) water-in-oil emulsion group, 1,
97 (SD 0.82) hydrocortisone group
Mean roughness according to physicians: 3.42 (SD 0.62) water-in-oil emulsion group,
3.13 (SD 0.71) hydrocortisone group
Mean TEWL (g/m²/h): 24 water-in-oil emulsion group, 20 hydrocortisone group
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Interventions Intervention
• Water-in-oil emulsion (Excipial U lipo lotion) twice daily for 2 weeks (N = 31)
Comparator
• Hydrocortisone 1% in water-in-oil emulsion (Excipial U lipo lotion) twice daily
for 1 week followed by water-in-oil emulsion (Excipial U lipo lotion) only twice daily
for 1 week (N = 32)
Outcomes Assessments (3): baseline, weeks 1 and 2
Outcomes of the trial (as reported)
• Physician’s evaluation: erythema and roughness of the skin on a 4-point Likert
scale (1 = very good, 4 = very bad)
• Participants’ self-assessment; roughness of skin and itch on a VAS scale from 1 to
10 (higher score = better)
• Measurement of skin colour: Chromameter CR-200, Minolta
• Laser doppler-flowmetry: Periflux PF 2, Perimed, Sweden
• TEWL: evaporimeter, Courage & Khazaka, Cologne, Germany
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared
Notes Excipial U lipo lotion, Spirig Pharma, Erkingen, Germany contains: urea 4%, lipids
36%
We have only included the first week of the trial.
As the study was 20 years old we have not contacted the investigators for data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 554): “randomized double-
blind study design”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
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tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 165): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6/69 (8.7%) unclear from which group.
Per-protocol analysis.
Comment: low number of losses to follow-
up, and although per-protocol analysis con-
sidered as at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Gehring 1999
Methods Two randomised, double-blind, vehicle-controlled, within-participant studies
Setting
Dermatology Clinc, Karlsruhe, Germany
Date of study
Unspecified. Duration of intervention: 4 weeks with 1 week follow up
Participants Study 1: N = 20 (14 female, 6 male); Study 2: N = 20 (18 female, 2 male)
Mean age study 1 = 25.1 years, mean age study 2 = 22.9 years
Inclusion criteria of the trials
• Atopic dermatitis (Diepgen 1989)
• > 18 years, history of eczema but no active eczema in test areas
Exclusion criteria of the trial
• Sensitivity to ingredients of test substances
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• Systemic medication (apart from oral contraceptives)
Randomised
Study 1: N = 20 to either forearm (within-participant); Study 2: N = 20 to either forearm
(within-participant)
Withdrawals/losses to follow-up
No losses to follow-up in study 1
1/20 lost to follow-up in Study 2 due to acute exacerbation of eczema
Baseline data
Study 1 mean TEWL (g/m²/h): 1.38, corneometry 4.8
Study 2 mean TEWL (g/m²/h): 1.50, corneometry 1.9
Interventions Study 1
Intervention
• Evening primrose oil (20%) amphiphilic oil-in-water emulsion twice daily on the
flexor side of the forearm for 4 weeks
Comparator
• Miglyol (20%) substitute oil twice daily on the flexor side of the contralateral
forearm for 4 weeks
Study 2
Intervention
• Evening primrose oil (20%) water-in-oil emulsion twice daily on the flexor side of
the forearm for 4 weeks
Comparator
• Liquid paraffin substitute oil twice daily on the flexor side of the contralateral
forearm for 4 weeks
Outcomes Assessments (6): baseline, weeks 1, 2, 3, 4 and 5
Outcomes of the trial (as reported)
• TEWL: Tewameter TM 210, Courage and Khazaka, Cologne, Germany
• Stratum corneum hydration: Corneometer CM 820, Courage and Khazaka
• Nicotinic acid-induced erythema: Chroma meter and by Laser Doppler
flowmetry (LDF), Perimed, Stockholm, Sweden
• Barrier function test with sodium lauryl sulphate after 4 weeks of treatment
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared
Notes Ingredients Study 1: evening primrose oil 30.0 ml, glycerol monostearate 4.0 ml, cetyl
alcohol 6.0 ml, polyoxyethylene glycerol monostearate 7.0 ml, glycerol 15.0 ml, propy-
lene glycol 10.0 ml, purified water to 150.0 ml
Ingredients Study 2: evening primrose oil 20%, aqua, paraffinum liquidum, caprylic/
capric triglyceride, urea, myristyl lactate, dimethicone, methoxy PEG-22/dodecyl, glycol
copolymer, sodium lactate, PEG-7 hydrogenated castor oil, sorbitan isostearate, PEG-
2 hydrogenated castor oil, ozokerite, hydrogenated castor oil, chlorhexidine, triclosan,
lactic acid, perfume
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As the study was 17 years old, we have not contacted the investigators for data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 636): ”a vehicle-controlled,
randomised, double-blind trial“
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 165): ”double-blind“ and
”taken from containers labelled “RIGHT”
and “LEFT”. The vehicle was similar in
both active treatment and placebo arms
Comment: the report provided sufficient
detail about the specific measures used
to blind study participants and personnel
from knowledge of which intervention a
participant received on each forearm, to
permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were investigator-assessed.
Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up in Study 1, but 1/
20 lost to follow-up in Study 2 due to acute
exacerbation of eczema. Per-protocol anal-
ysis
Comment: low number of losses to follow-
up, and although per-protocol analysis con-
sidered as at a low risk of bias
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Giordano-Labadie 2006
Methods Randomised, controlled (inactive) study
Setting
Department of Dermatology Hôpital Purpan Toulouse, France
Date of study
Unspecified. Duration of intervention: 2 months
Participants 76 children (gender not reported)
Mean age = 4 years
Inclusion criteria of the trial
• Children aged 6 months to 12 years
• Atopic dermatitis mild to moderate; SCORAD index < 35
Exclusion criteria of the trial
• Not reported
Randomised
N = 76 (active treatment group = 37, non-treated group = 39)
Withdrawals/losses to follow-up
No losses to follow-up reported, after email contact it appeared that there were 2 losses
in Exomega group
Baseline data
Mean SCORAD: active treatment group 25.96 (SD 7.67), non-treated group 23.3 (SD
7.63)
Mean CLQI: active treatment group 2.24 (SD 0.25), non-treated group 1.59 (SD 0.7)
Interventions Both groups received a cleansing bar (A-Derma, Pierre Fabre Laboratories)
Intervention
• Exomega moisturiser milk applied twice daily and cleansing bar (A-Derma, Pierre
Fabre Laboratories) for 2 months (N = 37)
Comparator
• No treatment for 2 months (N = 39)
Use of strong/moderate topical corticosteroids allowed. No other moisturiser permitted
Outcomes Assessments (3): baseline, days 28 and 56
Outcomes of the trial (as reported)
• SCORAD (European Task Force on Atopic Dermatitis 1993)
• Tolerance: 4-point Likert scale
• Measurement of topical steroid use
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• Quality of life questionnaire: CDLQI (Lewis-Jones 1995)
Denotes outcomes prespecified for this review
Funding source None declared. However, the product under research comes from the Pierre Fabre Re-
search Institute, the manufacturer of the drug under investigation
Declaration of interest None declared, but 1 of the investigators was an employee of Pierre Fabre Research
Institute, the manufacturer of the drug under investigation
Notes Washout period of 1 week before study started
Exomega milk contains: evening primrose oil, Rhealba oat extract, chlorphenizine, phe-
noxyethanol, butyl hydroxy toluene, glycols, paraffin jelly, paraffin oil, shea butter
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 79): “randomized...”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “The ran-
domization was generated by the means of
a program created with SAS® software”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “Sequence
generation, has been done centrally by the
pharmaceutical company”
Comment: probably done.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 79 ): “It was packaged in
unidentifiable 200 ml bottles”
After email communication: “The investi-
gators were not blind because they could
see the products when they were handed
over to the patients”
Comment: no similar placebo intervention
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in control group. The outcome was likely
to be influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 79): “It was packaged in
unidentifiable 200 ml bottles”
Outcomes were investigator-assessed as
well as participant-assessed
Comment: no similar placebo intervention
in control group. The outcome measure-
ment was likely to be influenced by the lack
of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
After email communication: “2 subjects
were losses in Exomega group between D0
and D28”
Comment: we judged this to be at a low
risk of bias.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Glazenburg 2009
Methods Two-phase study, the maintenance phase of which was randomised, double-blind, and
placebo-controlled
Setting
Multicentre (N = 13) in the Netherlands (N = 12) and Belgium (N = 1)
Date of study
Unspecified. Duration of first phase 4 weeks (not randomised), then a 16-week ran-
domised phase
Participants N = 90 (52 female, 38 male)
Mean age = 5.7 years
Inclusion criteria of the trial
• Non-hospitalised children (aged 4 to 10 years) with a documented history of
moderate to severe recurring atopic dermatitis of whom atopic dermatitis exacerbated
(Williams 1994)
• TIS score ≥ 3 and < 6
• Only restricted medication (moisturiser, hydrocortisone acetate 1% and/or
antihistamines when needed)
Exclusion criteria of the trial
• Systemic treatment beyond 1 month prior to study entry
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Randomised
N = 90, in maintenance phase N = 75 (fluticasone group = 39, placebo group = 36)
Withdrawals/losses to follow-up
3/90 in first phase; serious adverse event (1), withdrawal of consent (1), lost to follow-
up (1)
12/87 (13.8%) in maintenance phase; target TIS > 1 (9), consent withdrawn (1), target
TIS ≤ 1 at the original lesion but target TIS > 1 at another lesion (1) and exacerbation of
atopic dermatitis (1) between the end of the acute phase and the start of the maintenance
phase
Baseline data at maintenance phase
Mean TIS score: for both groups 0
Mean objective SCORAD: fluticasone group 3.6, placebo group 7.0
Interventions Acute phase; all children received twice daily fluticasone propionate 0.005% ointment
over 4 weeks on all originally affected sites, even if no visible signs of atopic dermatitis
were detectable, and on all newly occurring lesions. Standard moisturiser was supplied
for use as required.
We only included the maintenance phase of this study.
Intervention
• Fluticasone propionate 0.005% ointment twice weekly on 2 consecutive evenings
for up to 16 weeks (N = 39)
Comparator
• Placebo ointment twice weekly on 2 consecutive evenings for up to 16 weeks (N =
36)
During maintenance phase a moisturiser was applied twice daily. On days when study
medication was applied, moisturiser was applied only in the morning
Outcomes Assessments (7): baseline, weeks 4, 6, 8, 12, 16 and 20
Outcomes of the trial (as reported)
• Objective SCORAD (Kunz 1997)
• TIS score (Wolkerstorfer 1999)
• The proportion of children experiencing a relapse and the time to relapse
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 66): “This study was conducted with financial support from GlaxoSmithK-
line, London, UK”
Declaration of interest None declared, but the lead author is an employee of GlaxoSmithKline, Zeist, The
Netherlands, the manufacturer of fluticasone propionate 0.005% ointment
Notes We included only the randomised maintenance phase
We mailed investigators numerous times to clarify study details, as there was inconsistency
in the data reported regarding objective SCORAD, in the text and the corresponding data
in the table, which was also not in agreement with a comment made by the investigators
“overall a statistically significant difference was observed between treatment groups (P =
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0.021)”. However, we received no response (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 60): “Randomization was
achieved by a computer-generated scheme
and performed by the statistician”
Comment: probably done.
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 60): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 60): “double-blind”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 12/87 (13.8%) in maintenance phase, rea-
sons reported. Per-protocol analysis
Comment: balanced and moderate num-
ber of drop-outs combined with the per-
protocol analysis poses an unclear risk of
bias for this domain
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
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Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Grimalt 2007
Methods Randomised, controlled (inactive) study
Setting
Multicentre, 41 dermatologists in France
Date of study
January 2004 to end July 2004. Duration of intervention: 6 weeks
Participants N = 173 (69 female, 93 male and 11 gender unknown)
Mean age = 6 years
Inclusion criteria of the trial
• Male and female infants < 12 months old
• Moderate to severe atopic dermatitis; SCORAD between 20 and 70
Exclusion criteria of the trial
• SCORAD below 20 or over 70
• Used moisturisers or topical corticosteroids within previous week
• History of allergy to a constituent of the study product
• Any medical problem that could interfere with evaluation of atopic dermatitis
Randomised
173 (moisturiser group = 91, no moisturiser group = 82)
Withdrawals/losses to follow-up
25/173 overall (14.5%); moisturiser group (13), no moisturiser group (12)
• Moisturiser group (13); not meeting inclusion criteria (2), no follow-up value (5),
another treatment taken (3), adverse events (2), personal reason (1)
• No moisturiser group (12); no follow-up value (4), another treatment taken (8)
Baseline data
Mean SCORAD index: moisturiser group 35.63 (SE 1.25); no moisturiser group 35.96
(SE 1.16)
Interventions Both groups received a “hygiene product - pain dermatologique”
Intervention
• Exomega lotion containing oat extracts, RV2478B (Laboratoires Pierre Fabre)
twice daily for 6 weeks (N = 91)
Comparator
• No emollient for 6 weeks (N = 82)
Inflammatory lesions in both groups were treated with topical corticosteroids of high
[micronized desonide 0.1% cream (Locatop, Laboratoires P. Fabre)] or moderate po-
tency [desonide 0.1% cream (Locapred,Laboratoires P. Fabre)], or both, according to
the investigators’ regular practice
Outcomes Assessments (3): baseline, days 21 and 42
Outcomes of the trial (as reported)
• Steroid-sparing effect of the moisturiser
• Severity of atopic dermatitis: SCORAD index (European Task Force on Atopic
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Dermatitis 1993)
• Quality of life: IDQOL (Lewis-Jones 2001), DFI (Lawson 1998)
• Global Tolerance: 4-point Likert scale
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 66): “This work was supported by the Institut de Recherche Pierre Fabre,
France”
Declaration of interest None declared, but 1 of the investigators was an employee of Pierre Fabre Research
Institute, the manufacturer of the drug under investigation
Notes Outcomes assessment parent proxy reports
Exomega lotion, Laboratoires Pierre Fabre, France, mainly contains water, petrolatum,
shea butter, evening primrose oil, glycerol, paraffin oil, niacinamide, butylene glycol,
benzoic acid, carbomer and also specific active Rhealba oat extracts that had previously
demonstrated potential beneficial effects on skin inflammation
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 62): “randomly allocated...”
“according to a randomization list on the
basis of their order of inclusion”
After email communication: “the list was
provided from the promotors of the study.
” “A randomisation list was established by
Pierre Fabre Biometric Department. The
randomization was generated by the means
of a program created with SAS® software”
“randomization was perform in blocks of
4”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
After email communication: “The study
products were labelled with the subject
number according the randomization, and
each center have to follow and attribute
the subject number in the chronological
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order of arrival at the randomization visit.
The entry order of the subjects in the study
and the following of the randomization
has been checked and validated during the
blind review of the study.”
Comment: central allocation, judged as at
a low risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 62 ): “This emollient was
packed in unidentifiable 400-ml bottles”
After email communication: “We prepared
the study product RV2478B and the hy-
giene product as the following; emol-
lient group received hygiene product and
RV2478B milk...non-treated group hy-
giene product alone”
Comment: no corresponding intervention
or placebo in control group, uncertainty
that knowledge of the allocated interven-
tion was adequately prevented during the
study. The outcome was likely to be influ-
enced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No corresponding intervention or placebo
in control group.
Outcomes investigator-assessed as well as
by participants’ carers
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 7/91 in moisturiser group and 4/82 in the
no moisturiser group, were excluded from
the analysis reasons reported (9/173 no fol-
low-up data, 2/173 late exclusions)
Incomplete outcome data: 103/173
IDQOL and 102/173 DFI questionnaires
completed
Comment: we judged this as being at a high
risk of bias.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appear to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
196Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hagströmer 2001
Methods Randomised, double-blind, ’other moisturiser’-controlled, within-participant study
Setting
Section of Dermatology and Venereology, Department of Medicine, Karolinska Institutet
at Huddinge University Hospital, Stockholm, Sweden
Date of study
January to May 1998. Duration of intervention: 2 weeks
Participants N = 22 (16 female, 6 male)
Mean age = 32 years
Inclusion criteria of the trial
• Atopic dermatitis according to the Hanifin and Rajka criteria (Hanifin 1980)
Exclusion criteria of the trial
• Concurrent illness
Randomised
N = 22 to either forearm (within-participant)
Withdrawals/losses to follow-up
No losses to follow-up reported
Baseline data
Mean TEWL (mg/m²/h): NaCl 40 mg/g and urea 40 mg/g in an oil-in-water emulsion
side 7.5 (SD 3), urea side 6 (SD 2.5)
Mean corneometry units: NaCl 40 mg/g and urea 40 mg/g in an oil-in-water emulsion
side 54 (SD 4), urea side 51 (SD 5)
Interventions Intervention
• NaCl 40 mg/g and urea 40 mg/g in an oil-in-water emulsion twice daily for 2
weeks on forearm
Comparator
• Urea 40 mg/g in an oil-in-water emulsion twice daily for 2 weeks on contralateral
forearm
Outcomes Assessments (3): baseline, weeks 1 and 2
Outcomes of the trial (as reported)
• TEWL: Evaporimeter EPI, Servomed AB, Kinna, Sweden
• Electrical capacitance measurements: Corneometer CM 820, Courage-Khasaka,
Cologne, Germany
• Electrical impedance of the skin: selective depth-controlled instrument designed
by Stig Ollmar, SciBase, Novum, Huddinge, Sweden
Denotes outcomes prespecified for this review
Funding source Quote (page 33): “This study was supported by grants from the Swedish Council for
Work Life Research, the Swedish Society of Medicine, Karolinska Institutet, Edvard We-
lander Foundation, Finsen Foundation, Åke Wiberg Foundation, Tore Nilson Founda-
tion for Medical Research and Pharmacia Upjohn Sweden AB”
Declaration of interest None declared
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Notes With the exception of the NaCl and urea, the other ingredients in the emulsions were
identical, namely liquid paraffin, PEG-5 glyceryl stearate, cetyl alcohol, stearyl alcohol,
stearic acid, trometamol, methylparaben, propylparaben, hydrochloric acid and water.
Both creams were prepared by Pharmacia & Upjohn Sweden AB, Stockholm, Sweden
As the study was 15 years old we have not contacted the investigators for data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 28): “The study was compar-
ative, double-blind and randomised”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 28): “The study was compar-
ative, double-blind and randomised”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received on each forearm,
to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appear to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Hagströmer 2006
Methods Randomised, controlled (no treatment), within-participant study
Setting
Department of Medicine, Section of Dermatology and Venereology, Karolinska Institutet
at Huddinge University Hospital, Stockholm, Sweden
Date of study
Unspecified. Duration of the intervention 3 weeks
Participants N = 24 (20 female, 4 male)
Mean age = 35 years
Inclusion criteria of the trial
• Atopic dermatitis according to the Hanifin and Rajka criteria (Hanifin 1980),
with rough skin that appeared normal clinically, or was non eczematous
Exclusion criteria of the trial
• Concurrent illness
• Known allergy to parabens
Randomised
N = 24 to either forearm (within-participant)
Withdrawals/losses to follow-up




• Proderm (a foam) twice daily or 3 times daily in an area of about 10 cm² on the
volar aspect of the forearm for 3 weeks
Comparator
• No treatment for 3 weeks on contralateral forearm
During the study, the participants were allowed to wash in the usual manner, but not to
use any other skin care products on their arms
Outcomes Assessments (3): baseline, days 10 and 21
Outcomes of the trial (as reported)
• TEWL: Evaporimeter EPI, Servomed AB, Kinna, Sweden
• Electrical capacitance measurements: Corneometer CM 820, Courage-Khasaka,
Cologne, Germany
• Electrical impedance of the skin: selective depth-controlled instrument designed
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Hagströmer 2006 (Continued)
by Stig Ollmar, SciBase, Novum, Huddinge, Sweden
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest Quote (page 272): “None declared”
Notes The study also included 20 healthy participants
Proderm, Ponsus Pharma AB, Stockholm, Sweden contains: dimethicone (< 1%), glyc-
erol (1% to 5%), stearic acid (5% to10%), propylene glycol (5% to 10%), polyvinyl py-
rolidone (1% to 5%), polysorbate 20 (1% to 5%), triethanolamine (1% to 5%), methyl-
, butyl-, ethyl- and propylparabens, and purified water (approximately 80%)
We failed to contact any of the investigators of this study. No baseline data nor end
value data were reported. The data were reported in box-and-whisker plots, and were
not interpretable (Table 4).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 273): “a randomized forearm”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported.
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported. Outcomes were in-
vestigator-assessed.
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
200Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hagströmer 2006 (Continued)
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appear to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Hamada 2008
Methods Randomised, double-blind, placebo-controlled, cross-over study
Setting
Multicentre (5), Dermatological clinics in Fukuoka Prefecture of Japan
Date of study
March to June 2006. Duration of intervention: 4 weeks (cross-over after 2 weeks)
Participants N = 42 (26 female, 13 male and 3 gender unknown)
Mean age = 17.9 years
Inclusion criteria of the trial
• Participants with mild or moderate atopic dermatitis as diagnosed by a
dermatologist using the standardised diagnostic criteria of the Japanese Dermatological
Association (Saeki 2009)
Exclusion criteria of the trial
• Not clearly defined (translated “The patient who an investigator thought was not
suitable for the trial”)
Randomised
N = 42 (camellia oil first group = 30, purified water first group = 9, 3 unknown)
Withdrawals/losses to follow-up
3/42 (7.1%), reasons not reported
Baseline data
Mild eczema: camellia oil first group 17 participants, purified water group 4 participants
Moderate eczema: camellia oil first group 13 participants, purified water group 5 partic-
ipants
Interventions Intervention
• Camellia oil spray (Atopico skin health care oil) for 2 weeks then cross-over (N =
30)
Comparator
• Purified water spray for 2 weeks then cross-over (N = 9)
Any treatments including topical ointments (e.g. corticosteroids) and oral medications
(e.g. antihistamine, corticosteroids) were allowed without changing during the trial
Outcomes Assessments (2): baseline and week 4
Outcomes of the trial (as reported)
• Disease severity: 5-point Likert scale (much effective, effective, slightly effective,
not effective, not preferable)
• Adverse events
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• Feeling of the spray regarding hydration, dryness, irritation
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared
Notes We only included the first 2 weeks, before cross-over. Except for disease severity, no
separate data were provided at the end of 2 weeks, only after 4 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 218): “randomized controlled
study”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 214): “double-blind” (trans-
lated)
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 214): “double-blind” (trans-
lated)
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information provided to per-
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mit a clear judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/42 (7.1%), reasons not reported. Per-
protocol analysis.
Comment: low number of losses to follow-
up, and although a per-protocol analysis we
considered this to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appear to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Hanifin 1998
Methods Randomised, investigator-blinded, active-controlled, within-participant study
Setting
Multicentre (unclear how many centres) in US
Date of study
Unspecified. Duration of intervention: 3 weeks
Participants N = 80 (51 female, 29 males)
Mean age = 24.4 years
Inclusion criteria of the trial
• > 6 years of age with confirmed diagnosis of mild to moderate atopic dermatitis
• Erythema, dryness or scaling, and pruritus on both sides of the body
Exclusion criteria of the trial
• < 7 days prior to study entry use of any treatments that could interfere with study
drug
Randomised
N = 80 to either body side (within-participant)
Withdrawals/losses to follow-up
2/80 (2.5%)
• No pruritus at baseline (1), protocol violation (1)
Baseline data
“The overall severity (mean total sign and symptom) scores were similar for both sides”
Interventions Intervention
• Desonide 0.05% lotion twice daily for 3 weeks on 1 side of the body
Comparator
• Desonide 0.05% lotion twice daily plus moisturising cream 3 times daily for 3
weeks on contralateral side of the body
In order to standardise the cleansing regimen, all participants were provided with a non-
medicated cleansing bar (Cetaphil Gentle Cleansing bar, Galderma Laboratories, Inc)
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Outcomes Assessments (3): baseline, weeks 1 and 3
Outcomes of the trial (as reported)
• Signs and symptoms of erythema, dryness or scaling, pruritus, excoriations,
lichenification, oozing or crusting, induration or papules: scale 0-9 (0 = none, 1 to 3 =
mild, 4 to 6 = moderate, 7 to 9 = severe). Total sign and symptom scores were the sum
of the 7 individual efficacy variables (range 0 to 63)
• PGA; clear = 100% clearance; marked improvement = 75% to 99%; definite
improvement = 50% to 74%; minimal improvement = 25% to 49%; no change or
exacerbation = 0 to 24%
• Tolerability; stinging and burning after application
• Preference of participant
Denotes outcomes prespecified for this review
Funding source Quote (page 232): “This study was financially supported by Galderma Laboratories Inc,
Fort Worth, Texas”
Declaration of interest None declared, but 1 of the investigators was an employee at Galderma Laboratories the
manufacturer of the desonide lotion (DesOwen), the moisturiser and the cleansing bar
Notes The moisturiser (Cetaphil Moisturising cream, Galderma Laboratories, Inc, Forth
Worth, Texas) possesses humectant, emollient and occlusive properties and contains:
aqua, glycerol, petrolatum, dicaprylyl ether, dimethicone, glyceryl stearate, cetyl alco-
hol, Prunus amygdalus (synonym: Prunus dulcis) (sweet almond) oil, PEG-30 stearate,
tocopheryl acetate, acrylates/C10-30 alkyl acrylate crosspolymer, dimethiconol, benzyl
alcohol, phenoxyethanol, glyceryl acrylate/acrylic acid copolymer, propylene glycol, dis-
odium EDTA, sodium hydroxide
As the study was 18 years old we did not contact the investigators for data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 228): “Treatments were ran-
domly assigned by a third party”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
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was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 227): “investigator-blinded”,
however, participants were not blinded
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived on each part of the body, to permit
a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 227): “investigator-blinded”.
Outcomes were investigator-assessed as
well as participant-assessed
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study, and
participants were not blinded
The outcome measurement was likely to be
influenced by the lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/80 (2.5%), reasons reported. Per-proto-
col analysis.
Comment: low number of losses to follow-
up, and although per-protocol analysis, we
considered this to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appear to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Hanifin 2002
Methods Three-phase study in which the maintenance phase was randomised, double-blind, and
had an active control
Setting
Multicentre (16) in USA and Canada
Date of study
Unspecified. Duration of intervention: Stabilisation phase was up to 4 weeks and main-
tenance phase was 20 weeks
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Participants N = 372 entered the stabilisation phase (216 female, 156 male), and 348 entered the
maintenance phase (more than half the population was female)
Mean age = 16.8 years (7.1 years for children and 35.9 years for adults)
Inclusion criteria of the trial
• 3 months to 65 years of age with moderate to severe atopic dermatitis on the
head/neck, trunk, upper limbs or lower limbs as defined by Rajka Langeland Severity
Grading (sum scores > 4) (Rajka 1989)
For entrance in maintenance phase
• Participants who achieved an IGA score of ≤ 2 (i.e. cleared, almost cleared or
marked clearing), and a score of ≤ 1 (i.e. none or mild) for each of 3 signs symptoms
(erythema, pruritus and papulation induration oedema) at any time during this phase
were deemed to be a treatment success. IGA score: healing was assessed and scored
using the following 6-point scale: 0, cleared; 1, almost cleared; 2, marked clearing; 3,
modest clearing; 4, no change; 5, exacerbation or worsening. In addition, each of 3
signs symptoms (erythema, pruritus and papulation induration oedema) were scored
on a 4-point scale (0, absent; 1, mild; 2, moderate; 3, severe)
Exclusion criteria of the trial
• Dermatitis on the face, feet or hands only
• Erythroderma or toxicoderma
• Psoriasis
• Diagnosed contact dermatitis at predilection sites of atopic dermatitis
• Atrophy, or telangiectasia
• Systemic treatment for atopic dermatitis (including psoralen-ultraviolet A
(PUVA) or ultraviolet B (UVB)) in the month preceding the prestudy visit
• Topical treatment with tar or corticosteroids in the week preceding the prestudy
visit
• History of metabolic disease, immunodeficiency syndromes or ongoing
malignancies (treated or untreated)
• Concomitant systemic or topical treatment with antibiotics or corticosteroids
• Hypersensitivity to any component of the study drugs
• Pregnancy or breast-feeding
Randomised
N = 348 (maintenance phase; fluticasone propionate group = 229, vehicle group = 119)
Withdrawals/losses to follow-up
Lost to follow-up: 44/348 overall (12.6%); fluticasone propionate group = 32/229 (14%)
, vehicle group = 12/119 (10%)
Relapse: 110/348 overall (31.6%); fluticasone propionate group = 27/229 (11.8%),
vehicle group = 83/119 (69.7%)
Baseline data
Moderate eczema 63%, mean Rajka and Langeland Severity Grading score was 7 for
all participants, approximately 3/4 of the population suffered continuously from atopic
dermatitis without remission
Interventions All participants entered an open-label stabilisation phase of up to 4 weeks’ duration on




• Fluticasone propionate 0.05% cream once daily 4 days a week for 4 weeks and
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then once daily for 2 days a week for 16 weeks in combination with a moisturiser (N =
229)
Comparator
• Vehicle twice a week for 20 weeks in combination with a moisturiser (N = 119)
It is unclear which moisturiser was used
Outcomes Assessments Maintenance phase (7): ’baseline’, weeks 2, 4, 8, 12, 16 and 20, then ’follow-
up phase’
Outcomes of the trial (as reported)
• Relapse: IGAS of ≥ 3 and a score of 2 to 3 for any 2 of the following 3 signs/
symptoms: erythema, pruritus and papulation/induration/oedema
• Time to relapse
• Percentage BSA affected
• PGA score: 4-point Likert scale (excellent, good, fair or poor)
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 536): “This study (FPC40002) was conducted with a grant from Glaxo
Wellcome Inc., Research Triangle Park, NC, U.S.A.”
Declaration of interest None declared, but 1 of the investigators was an employee of Glaxo Wellcome Inc, the
manufacturer of the fluticasone propionate cream
Notes For participants who completed the maintenance phase on intermittent fluticasone pro-
pionate 0.05% cream without a relapse, the intermittent fluticasone propionate 0.05%
cream dosing/moisturiser regimen was extended for a further 24 weeks in a subsequent
follow-up phase
As the study was 14 years old we have not contacted the investigators for data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 147): “Subjects who entered
the second part of the study were random-
ized (2 : 1 within each age stratum)”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
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seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 147): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information provided to per-
mit a clear judgement
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 44/348 (12.6%) were lost to follow-up; flu-
ticasone propionate group = 32/229 (14%)
, vehicle group = 12/119 (10%). Intention-
to-treat analysis
Comment: balanced but moderate num-
ber of drop-outs (although an intention-to-
treat analysis), poses an unclear risk of bias
for this domain
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appear to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
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Methods Randomised, double-blind, controlled, cross-over study
Setting
Out-patient Dermatology Clinic at Queen Elizabeth Hospital for Children, London,
UK
Date of study
Unspecified. Duration of intervention: two 4-week periods (cross-over study) with 2-
week separation
Participants N = 30 (17 female, 9 male and 4 gender unknown)
Mean age = 4.5 years
Inclusion criteria of the trial
• > 6 months of age with atopic eczema, displaying features of recurrent infection
and or frequent exacerbations
Exclusion criteria of the trial
• Use of systemic or topical antibiotics or oral corticosteroids concurrently, or
within 2 weeks prior to study entry
Randomised
N = 30 (unclear how many to each arm)
Withdrawals/losses to follow-up
4/30 (13.3%)
• Withdrawn for reasons unrelated to study therapy (2), severe pruritus (1),
deterioration (1)
Baseline data
Therapeutic control was adequate for 10 patients and ’marginal with exacerbations in
16’
Interventions Intervention
• 15 mL Oilatum Plus was mixed in an 8-inch bath of water and the participant
was instructed to soak for 10 to 15 min
Comparator
• 15 mL Oilatum Emollient was mixed in an 8-inch bath of water and the
participant was instructed to soak for 10 to 15 min
Use of other bath additives was not allowed. Emulsifying ointment or aqueous cream
were used as a soap substitute in all cases throughout the study period. Pre-study topical
therapy was continued unaltered during the study
Outcomes Assessments (3): baseline, weeks 2 and 4 (then cross-over phase)
Outcomes of the trial (as reported)
• Sign and symptoms of eczema (Costa 1989): scaling, erythema, oedema, vesicles,
crusts, excoriations, lichenification, pigmentation, scratching and loss of sleep) and area
of body affected
• Global Impression (GIS) and Global Change (GCS) Scale: GIS (not ill at all,
borderline ill, mildly ill, moderately ill, severely ill or extremely ill); GCS (much worse,
minimally worse, no change, minimally improved, much improved and very much
improved)
• Parent- or patient-assessed skin condition: 0 to 3 scale (0 = clear, 1 = mild, 2 =
moderate and 3 = severe)
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• Recording corticosteroid use
• Adverse events
Denotes outcomes prespecified for this review
Funding source None declared, but under acknowledgements “Also Dennis Joseph from Stiefel for his
contribution”
Declaration of interest None declared
Notes Oilatum Plus includes triclosan and benzalkonium chloride. We have only included the
first 4 weeks before the cross-over part
As the study was 21 years old we have not contacted the investigators for data
Inconsistency of reporting of number of participants; stated on 2nd page that 32 patients
(88%) experienced at least 3 exacerbations. Number randomised to each arm was unclear
and there are inconsistencies in data reporting (Table 4).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 42): “The order in which the
two preparations were used was determined
by a computer generated random code”
Comment: probably done.
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 42): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcome assessors (par-
ticipants/healthcare providers) during the
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study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 4/30, reasons reported, unclear how many
participants randomised to each arm, and
inconsistent reporting of number of par-
ticipants throughout study. Intention-to
treat-analysis
Comment: we judged this as being at an
unclear risk of bias.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appear to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Hlela 2015
Methods Two randomised, investigator-blinded, ’other moisturiser’-controlled, studies
Setting
Red Cross Children’s War Memorial Hospital, Cape Town, South Africa
Date of study
February 2013 to July 2013. Duration of intervention: 3 months
Participants N = 120: Study 1 N = 40 (17 female, 20 male and 3 gender unknown); Study 2 N = 80
(37 female, 36 male and 7 gender unknown)
Mean age = 5.6 years
Inclusion criteria of the trial
• 1 to 12 years of age with mild to moderate atopic eczema (Williams 1994)
Exclusion criteria of the trial
• Severe atopic eczema
• Secondary infections
• Medically unwell
• Using systemic therapy
Randomised
N = 120: Study 1 N = 40 (aqueous cream group = 20, baby oil group = 20), Study 2 N
= 80 (cetomacrogol group = 20, emulsifying ointment group = 20, glycerol/petroleum
group = 20, petroleum group = 20)
Withdrawals/losses to follow-up
Study 1: 3/40 (7.5%); 3 lost to follow-up in baby oil group
Study 2: 7/80 (8.8%); cetomacrogol group (3), emulsifying ointment group (0), glycerol/
petroleum group (1), petroleum group (3)
Baseline data
Study 1: mean SCORAD: aqueous cream group 33.11 (SD 16.82), baby oil group 23.
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02 (SD 11.79)
Study 1: mean POEM: aqueous cream group 11.50 (SD 7.97), baby oil group 9.00 (SD
5.06)
Study 1: mean NESS: aqueous cream group 9.50 (SD 3.25), baby oil group 10.20 (SD
1.96)
Study 1: mean IDQOL aqueous cream group 7.00 (SD 4.86), baby oil group 6.45 (SD
4.78)
Study 2: mean SCORAD: cetomacrogol group 24.78 (SD 16.90), emulsifying ointment
group 28.40 (SD 16.16), glycerol/petroleum group 21.52 (SD 15.24), petroleum group
26.77 (SD 12.09)
Study 2 mean POEM: cetomacrogol group 9.47 (SD 6.02), emulsifying ointment group
9.10 (SD 4.56), glycerol/petroleum group 9.75 (SD 7.23), petroleum group 11.29 (SD
7.06)
Study 2 mean NESS: cetomacrogol group 9.35 (SD 2.40), emulsifying ointment group
9.85 (SD 2.83), glycerin/petroleum group 9.25 (SD 3.64), petroleum group 10.00 (SD
3.35)
Study 2 mean IDQOL: cetomacrogol group 7.23 (SD 4.48), emulsifying ointment group




• Aqueous cream for 3 months (N = 20)
Comparator
• Baby oil for 3 months (N = 20)
All the participants in study 1 used emulsifying ointment as a moisturiser
Study 2
Intervention
• Cetomacrogrol for 3 months (N = 20)
Comparator 1
• Emulsifying ointment for 3 months (N = 20)
Comparator 2
• Glycerol/petroleum (1:2) for 3 months (N = 20)
Comparator 3
• Petroleum jelly for 3 months (N = 20)
All participants in Study 2 washed with baby oil and applied this as soap instead of
aqueous cream
All the participants in both studies continued to use clinic-prescribed topical steroids
during the study period, and brought back all tubes so that the amount used during the
previous month could be recorded at every visit
Outcomes Assessments (4): baseline, months 1, 2 and 3
Outcomes of the trial (as reported)
1. Disease severity: SCORAD (European Task Force on Atopic Dermatitis 1993),
the Nottingham Atopic Eczema Severity Score (NESS) (Emerson 2000), POEM
(Charman 2004)
2. Quality of life: IDQOL) (Lewis-Jones 2001)
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3. Amount of topical steroids used in the preceding month
4. Adverse events
laura.prescott@nottingham.ac.uk
Denotes outcomes prespecified for this review
Funding source Quote (page 738): “The study was investigator initiated, and all emollients were requested
from and donated by Sekpharma (SA), a generic medicine supply company”
Declaration of interest None declared
Notes Frequency of use during day or week were not reported. There were some inconsistencies
between text and figures. No end data were reported for Study 2, just stated that all scores
tended to decline. We mailed investigators numerous times to clarify study details, but
received no response (Table 2; Table 4).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 781): “Patients were ran-
domised using an automatic online enrol-
ment system in a 1:1 ratio for study 1 or a
1:1:1:1 ratio for study 2”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 781): “single (assessor)-blind
trial”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 781): “single (assessor)-blind
trial”
Outcomes were investigator-assessed as
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well as participant-assessed
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study, and
participants were not blinded
The outcome measurement was likely to be
influenced by the lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study 1: 3/40 (7.5%): 3 lost to follow-
up in baby oil group. Study 2: 7/80 (8.
8%): cetomacrogol group (3), emulsifying
ointment group (0), glycerol/petroleum
group (1), petroleum group (3). Per-proto-
col analysis
Selective reporting (reporting bias) Unclear risk The protocol for the study was available
(NCT02084472) and the prespecified out-
comes and those mentioned in the Meth-
ods section appear to have been reported.
However, for Study 2 very few data were
provided (“all mean scores tended to de-
cline over time”, without providing the
data)
Other bias Unclear risk There was baseline imbalance in SCORAD
for study 1, but not for the other disease
severity scores
Comment: we judged this as at an unclear
risk of bias.
Janmohamed 2014
Methods Randomised, double-blind, active-controlled study
Setting
Multicentre (4), dermatology outpatient clinics in Rotterdam, the Netherlands
Date of study
February 2009 to February 2012. Duration of intervention: 4 weeks
Participants N = 39 (14 female, 25 male)
Mean age = 3.4 years
Inclusion criteria of the trial
• Between 6 months and 10 years of age with severe atopic dermatitis (Hanifin
1980)
Exclusion criteria of the trial
• Underlying severe illness
• (Secondary) infected eczema or signs of systemic infection
• Abnormalities of the hypothalamic-pituitary-adrenal (HPA) axis
• Use of systemic therapy with corticosteroids
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Janmohamed 2014 (Continued)
• Children with severe growth retardation
Randomised
N = 39 (corticosteroid group = 19, placebo group = 20)
Withdrawals/losses to follow-up
4/39 (9.8%); all in placebo group
• SCORAD had not decreased by 10% after 1 week (2)
• Declined further participation (1)
• Child refused wet wrap therapy (1)
Baseline data
Mean objective SCORAD was 35 to 40 or higher (indicating severe eczema) on 2
measuring points before start of treatment
Mean objective SCORAD: corticosteroid group 43.8, vehicle group 43.0
Mean POEM: corticosteroid group 23, placebo group 22 (estimated from figure)
Mean IDQOL: corticosteroid group 17, placebo group 14 (estimated from figure)
Interventions Intervention
• Diluted mometasone furoate 0.1% ointment in combination with wet-wrap for 4
weeks (N = 19)
Comparator
• Petrolatum 20% in cetomacrogol cream in combination with wet-wrap for 4
weeks (N = 20)
For the face, mometasone furoate 0.1% ointment was diluted 1:19, although pime-
crolimus 1% cream was used in some participants. For the body, a 1:3 dilution was used
Participants were not allowed to use other moisturisers or topical agents
Outcomes Assessments (5): baseline, days 1, 4, 7, 14 and 28
Outcomes of the trial (as reported)
• Objective SCORAD (Kunz 1997)
• POEM (Charman 2004)
• Quality of life (parent-reported): IDQUOL (Lewis-Jones 2001)
• Adverse events
• Medication consumption
Denotes outcomes prespecified for this review
Funding source Quote (page 1076): “Nonrestricted funds were received from Schering-Plough BV, Fa-
gron, Astellas, Molnlycke, Aardbeesie Project (www.aardbeesie.nl), and Foundation for
Pediatric Dermatology Rotterdam (www.pediatric-dermatology.com)”
Declaration of interest Quote (page 1076): “Conflicts of interest: None declared”
Notes We mailed investigators numerous times to clarify study details, but received no response
(Table 2).
Risk of bias
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Janmohamed 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1077): “Computerized ran-
domization was performed by our statisti-
cian”
Comment: probably done.
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 1076): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 1076): “double-blind”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4/39 (9.8%); all in placebo group, reasons
reported. Per-protocol analysis
Comment: low number of losses to follow-
up, and although per-protocol analysis, we
considered this study to be at a low risk of
bias
Selective reporting (reporting bias) Low risk The protocol for the study was avail-
able (EudraCT Number: 2007-005232-
81) and the prespecified outcomes and
those mentioned in the Methods section
appear to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
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Jirabundansuk 2014
Methods Randomised, investigator-blinded, active-controlled, within-participant study
Setting
Skin Center, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand
Date of study
Unspecified. Duration of intervention: 4 weeks
Participants N = 31 (11 female, 18 male and 2 gender unknown)
Mean age = 4.3 years
Inclusion criteria of the trial
• 2 to 15 years of age with the diagnosis of mild or moderate atopic dermatitis
based on the Hanifin and Rajka criteria (Hanifin 1980)
• Skin lesions on both sides of the body
Exclusion criteria of the trial
• Oral medications (e.g. corticosteroids and antihistamines) within 4 weeks prior to
study entry
• Topical treatments (corticosteroids, calcineurin inhibitors and moisturisers)
within 2 weeks prior to study entry
• Skin lesion other than atopic dermatitis in the area to be treated
Randomised
N = 31 to either body site (within-participant)
Withdrawals/losses to follow-up
2/31 (6.5%) lost to follow-up
Baseline data
Mean SCORAD: spinosa kernel oil cream side 25.6 (SD 7.9), hydrocortisone cream side
25.7 (SD 7.5)
Interventions Intervention
• Moisturiser containing spent grain wax, Vitellaria paradoxa (formerly called
Butyrospermum parkii) extract, Argania spinosa kernel oil twice daily on 1 side of the
body for 4 weeks
Comparator
• Hydrocortisone 1% cream followed by cream base on the contralateral side of the
body for 4 weeks
Outcomes Assessments (4): baseline, weeks 2, 4 and 8
Outcomes of the trial (as reported)
• SCORAD index (European Task Force on Atopic Dermatitis 1993)
• Global self-evaluation: 4-point Likert scale (excellent, good, fair, and unchanged)
• Relapse at 8 weeks
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 824): “The authors wish to thank Hoe Pharmaceutical Sdn Bhd for their
support of the experimental S [spinosa kernel oil] cream for this research”
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Jirabundansuk 2014 (Continued)
Declaration of interest Quote (page 824): “Potential conflicts of interest: None”
Notes The spinosa kernel oil cream consisted of linoleic acid (omega-6), oleic acid, palmitic
acid, stearic acid, polyphenols, tocopherols, phenolic acid, and squalene. Cream base
was comprised of butylene glycol, mineral oil, ethylhexyl stearate, tocopheryl acetate,
sodium polyacrylate
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 821): “All patients who met
eligible criteria were randomized. The ran-
domization schedule was prepared by a
third party”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 821): “randomized assessment
blind controlled trial” and “The cassettes
of both agents were similar in shape and
color, however they were labeled as ’left’ or
’right’.”
On the hydrocortisone side two different
tubes or cassettes were used compared to
one tube or cassette on the S [spinosa ker-
nel oil] cream side. The trialists state “as-
sessment blind”, but did not report on the
blinding of participants
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received on each side of
the body, to permit a clear judgement
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Jirabundansuk 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 821): “randomized assessment
blind controlled trial”
Outcomes were investigator-assessed as
well as participant-assessed
Comment: uncertainty about the effective-
ness of blinding of healthcare providers
during the study and participants and par-
ents seem not to be blinded
The outcome measurement was likely to be
influenced by the lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/31 (6.5%) lost to follow-up. Per-protocol
analysis.
Comment: low number of losses to follow-
up, and although per-protocol analysis, we
considered this trial to be at a low risk of
bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appear to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Kircik 2009
Methods Randomised, investigator-blinded, active-controlled, within-participant pilot study
Setting
Indiana University Medical Center, Indianapolis, USA
Date of study
Unspecified. Duration of intervention: 4 weeks
Participants N = 6 (gender not reported)
Mean age not reported
Inclusion criteria of the trial
• Mild to moderate atopic dermatitis
Exclusion criteria of the trial
• Not reported
Randomised
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Kircik 2009 (Continued)
Interventions Intervention
• Midpotency corticosteroid cream on 1 side of the body for 4 weeks
Comparator
• Midpotency corticosteroid cream combined with a hydrolipid cream on
contralateral side of the body for 4 weeks
Outcomes Assessments (2): baseline and week 4
Outcomes of the trial (as reported)
• IGA
• TEWL
• Skin hydration: corneometry
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page AB67): “Commercial support: Poster production sponsored by Ferndale
Laboratories, Inc”
Declaration of interest None declared
Notes Poster abstract. Little information was provided, PI was not able to provide more study
data (Table 2), therefore the study is moved to Table 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page AB67): “were randomized”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 1482): “investigator-blinded
study”
Comment: the report did not provide suf-
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Kircik 2009 (Continued)
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received on each side of
the body, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes were investigator-assessed and
participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants and healthcare providers) during
the study
Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Nothing reported, little information pro-
vided.
Comment: there was insufficient informa-
tion to permit a clear judgement
Selective reporting (reporting bias) Unclear risk Comment: there was insufficient informa-
tion to permit a clear judgement
Other bias Unclear risk Comment: there was insufficient informa-
tion to permit a clear judgement
Kircik 2014
Methods Randomised, investigator-blinded, ’other moisturiser’-controlled, within-participant
study
Setting
Icahn School of Medicine at Mount Sinai, New York, USA
Date of study
Unspecified. Duration of intervention: 4 weeks
Participants N = 10 (6 female, 4 male)
Mean age = 31 years
Inclusion criteria of the trial
• Definitive diagnosis of atopic dermatitis as per Rajka-Hanifin criteria (Hanifin
1980), rated as mild to moderate in disease severity (score of 2 or 3) based on the IGA
score at baseline
• > 7 years old
Exclusion criteria of the trial
• Not reported
Randomised
N = 10 to either body side (within-participant)
Withdrawals/losses to follow-up
None reported
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Kircik 2014 (Continued)
Baseline data
Mean IGA scores: 2 (5 participants), 3 (5 participants)
Interventions Intervention
• Barrier repair emulsion cream (EpiCeram) for 4 weeks on 1 side of the body
Comparator
• Petrolatum-based moisturising lotion (Eucerin) for 4 weeks on contralateral side
of the body
Frequency of application not reported
Outcomes Assessments (2): baseline and week 4
Outcomes of the trial (as reported)
• TEWL: a Tewameter300 meter, Courage + Khazaka [C + K] GmbH Electronic,
Koln, Germany
• Corneometry: Corneometer 825 meter, C + K Electronic GmbH, Koln, Germany
Denotes outcomes prespecified for this review
Funding source Quote (page 1484): “This study is funded by Puracap Pharmaceutical, LLC. ”
Declaration of interest Quote (page 1484): “Dr. Kircik has served as an advisor, investigator, and consultant for
Puracap Pharmaceutical, LLC”
Notes EpiCeram contains a blend of ceramides, cholesterol and free fatty acids
Most data had to be estimated from graphs, principal investigator was not able to provide
us with more exact study data (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1482): “Subjects were ran-
domized at a 1:1 ratio”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “pre sched-
uled list by the CRO” [Clinical research or-
ganisation]
Comment: probably done.
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
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Kircik 2014 (Continued)
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 1482): “investigator-blind
study”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 1482): “investigator-blind
study”
Outcomes were investigator-assessed.
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study
Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appear to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Korting 2010
Methods Randomised, vehicle-controlled study
Setting
Multicentre (3), outpatient centres in Cologne, Kiel and Heilbronn, Germany
Date of study
October 2003 and January 2005. Duration of intervention: 4 weeks
Participants N = 99 (39 female, 58 male and 2 gender unknown)
Mean age = 3.5 years
Inclusion criteria of the trial
• 0 to 12 years of age with Caucasian background suffering from mild to moderate
atopic eczema (total EASI score at time of admission ≤ 21(Hanifin 2001))
Exclusion criteria of the trial
• Severe manifestations of atopic eczema (total score > 21)
• Other inflammatory skin or systemic diseases
• Severe accompanying diseases
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• Oral therapy with corticosteroids, antibiotics,
-linolenic acid, antihistamines or centrally dampening pharmaceuticals shortly before
or during the study
• Topical therapy with corticosteroids, bufexamac, antibiotics, retinoids or
antihistamines shortly before or during the study
• Application of other medical or cosmetic preparations
Randomised
N = 99 (pale sulfonated shale oil (PSSO) = 51, vehicle = 48)
Withdrawals/losses to follow-up
2/99 (2%), 1 participant in each group did not appear for any follow-up visits
7/99 (11.7%) “were excluded from per-protocol analysis”
• Adverse events: PSSO group (2), vehicle group (3)
• Personal reasons: PSSO group (0), vehicle group (1)
• Severe accompanying disease: PSSO group (1), vehicle group (0)
Baseline data
Mild eczema: PSSO group 35 participants, vehicle group 37 participants
Moderate eczema: PSSO group 15 participants, vehicle group 10 participants
Mean EASI: PSSO group 13.4 (SD 3.7), vehicle group 13.0 (SD 3.1)
Interventions Intervention
• Pale sulfonated shale oil (PSSO) 4% cream 3 times per day for 4 weeks (N = 51)
Comparator
• Vehicle cream 3 times per day for 4 weeks (N = 48)
Accompanying medications of any kind (systemic or topical) were not permitted. The
use of skin care products on areas of unaffected skin was allowed as usual
Outcomes Assessments (4): baseline, weeks 1, 2 and 4
Outcomes of the trial (as reported)
• Reduction in EASI score (Hanifin 2001)
• The reduction of the total score after 1 and 2 weeks of treatment
• The reduction of individual symptoms/signs after 1, 2 and 4 weeks of treatment
• The reduction of the topographical distribution of the disease addressing face +
neck, head, torso front, torso back, arms, hands + wrists, legs and feet after 1, 2 and 4
weeks of treatment
• Tolerability: 4-point Likert scale (good, medium, moderate and bad)
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 1176): “The preparation of this article was supported by an educational
grant to Dr Schöllmann.”
Declaration of interest Quote (page 1176): “Prof. Korting collaborates with Ichthyol-Gesellschaft, Hamburg,
in the development of topical drugs for skin diseases. Dr Cholcha and Dr Wolff are
employed by the company that supported this multicentre study but do not have any
personal financial interest in the research described in the manuscript”
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Korting 2010 (Continued)
Notes Quote (page 1177): “The verum product was an oil-in-water cream with sodium bitumi-
nosulfonate 4%, pale (trade name: Ichthosin cream; manufacturer: Ichthyol-Gesellschaft,
Hamburg, Germany). The vehicle was a correspondingly coloured cream without an
active ingredient, containing propylene glycol, glycerol monostearate, cetyl alcohol,
medium chain triglycerides, macrogol-1000-glycerol monostearate, white vaseline, pu-
rified water, and - for adjustment to the verum regarding colour - additionally spirit
caramel and quinoline yellow.”
The lead author died in 2012 and the other authors could not be contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1177- 8): “The randomiza-
tion occurred in blocks of 2 with a ran-
domizing ratio of 1:1” and “Block random-
ization was chosen and calculated with the
validated program RanCode (version 3.6,
IDV Gauting, Germany)”
Comment: probably done.
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No reporting of measures used to blind
study participants and personnel from
knowledge of which intervention a partic-
ipant received
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported. Outcomes were in-
vestigator-assessed as well as participant as-
sessed
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/99 (2%), 1 from each group did not ap-
pear for any follow-up visit and were ex-
cluded from intention-to treat analysis. Al-
though 7 others appeared to have violated
the protocol, these seem to have been in-
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Korting 2010 (Continued)
cluded in the analyses
Comment: low number of losses to follow-
up, and although per-protocol analysis, we
considered this to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appear to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Larregue 1996
Methods Randomised, double-blind, vehicle-controlled, within-participant study
Setting
Multicentre (4) in France and Italy
Date of study
Unspecified. Duration of intervention: 4 weeks
Participants N = 46 (21 female, 25 male)
Age range 6 to 12 years
Inclusion criteria of the trial
• 6 to 12 years of age with moderate atopic dermatitis (not oozing)
Exclusion criteria of the trial
• Topical or systemic treatment < 15 days before study entry
Randomised
N = 46 to either body side (within-participant)
Withdrawals/losses to follow-up




• Ammonium lactate 6% in water-in oil emulsion twice a day for 4 weeks on 1 side
of the body
Comparator
• Vehicle emulsion twice as day for 4 weeks on contralateral side of the body
Outcomes Assessments (3): baseline, weeks 2 and 4
Outcomes of the trial (as reported)
• Pruritus
• Signs of eczema (erythema, xerosis, desquamation, lichenification, hyperkeratosis,
presence of papules and excoriations): 4-point Likert scale (0 = normal, 1 = mild, 2 =
moderate, 3 = severe)
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Larregue 1996 (Continued)
• Tolerance: questionnaire
• Efficacy according to parents: questionnaire
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared
Notes The emulsion contained almond oil, olive oil, gamma oryzanol and alpha tocopherol
As the study was 20 years old we did not contact the investigators for data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 720): “une etude clinique ran-
domisée” (translation: randomised clinical
study)
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 720): “double-aveugle” (trans-
lation: double-blind): pre-coded tubes and
the investigator was not aware of content.
Products were identical except for the lactic
acid
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received on each body side, to permit
a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 720): “double-aveugle” (trans-
lation: double-blind): pre-coded tubes and
the investigator was not aware of content.
Products were identical except for the lactic
acid
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Larregue 1996 (Continued)
Outcomes were investigator-assessed as
well as participant-assessed
Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/46 (4.3%), exacerbation (1), personal
reasons (1). Per-protocol analysis
Comment: low number of losses to follow-
up, and although per-protocol analysis, we
considered this to be at a low risk of bias
Selective reporting (reporting bias) High risk The following predefined outcomes were
not addressed; pruritus, and efficacy ac-
cording to the parents and only P value
provided for erythema,papules and excori-
ations
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Laumann 2006




Unspecified. Duration of intervention: 12 weeks
Participants N = 74 (42 female, 32 male)
Mean age = 26 years
Inclusion criteria of the trial
• 7 to 65 years of age
• Atopic dermatitis in remission with history of frequent flares based on Hanifin
and Rajka criteria (Hanifin 1980)
• History of 2% to 10% total BSA affected with atopic dermatitis
• Willing to limit bathing to no more than twice a day using a non-soap cleanser
• Use of an effective method of birth control for females of childbearing potential
Exclusion criteria of the trial
• History of atopic dermatitis of the face, feet, neck, or hands only or atopic
dermatitis covering < 2% or > 10% total BSA
• Concurrent use of any topical medicated moisturisers or treatments including
tars, retinoids, or corticosteroids (no washout period required)
• Concurrent use of any phototherapy or systemic treatments including
immunomodulators, immunosuppressants, and corticosteroids (no washout period
required)
• Use of a systemic antihistamine 24 hours prior to the baseline visit
• Pregnant or nursing women or women trying to become pregnant
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Laumann 2006 (Continued)
Randomised
N = 74 to either body side (within-participant)
Withdrawals/losses to follow-up
8/74 (10.8%)
• No longer being able to participate (3)
• Adverse event not related to study medication (1)
• Lost to follow-up (1)
• Major protocol deviation (1)
• Major entry criteria deviation (1)




• MimyX cream in combination with a moisturiser (Eucerin cream) twice daily for
12 weeks on 1 side of the body
Comparator
• Moisturiser (Eucerin cream) twice daily for 12 weeks on the contralateral side of
the body
Rescue medication (triamcinolone cream 0.1%) was provided in the event of flare
Outcomes Assessments (7): baseline, weeks 2, 4, 6, 8, 10 and 12
Outcomes of the trial (as reported)
• Relapse
• Erythema, pruritus, and papulation/induration/oedema assessed bilaterally: 4-
point Likert scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe)
• BSA affected (excluding the head, neck, and hands) assessed bilaterally
• Participants completed a questionnaire about MimyX Cream
Denotes outcomes prespecified for this review
Funding source None declared but product under investigation was from Stiefel Labs Inc
Declaration of interest None declared
Notes MimyX cream contains purified water, olive oil, glycerol, pentylene glycol, palm glyc-
erides, vegetable oil, hydrogenated lecithin, squalane, betaine, palmitamide MEA, hy-
droxyethyl cellulose, sodium carbomer, carbomer, xanthan gum
Poster abstract. Little information was provided. We received responses to our request
for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
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Laumann 2006 (Continued)
Random sequence generation (selection
bias)
Low risk Quote (page 45): “Subjects were random-
ized” and “randomly assigned to one of two
groups”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “each subject
was assigned a number in numerical se-
quence of entry. This number was used to
enter a computer-generated assignment to
each of the two groups”
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: Central allo-
cation by sponsor and “The study products
were dispensed in opaque bags”
Comment: central allocation, de-identified
study products. Allocation appears to have
been adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 45): “investigator blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived on each side of the body, to permit
a clear judgement
After email communication: “investigators
were blinded and the containers were not
labeled with what it contained” and “The
study products were dispensed in opaque
bags”
Comment: blinding of investigators was
ensured, but participants were not blinded.
We judged this as an unclear risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 45): “investigator blind”
Outcomes were investigator-assessed.
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
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(healthcare providers) during the study
Insufficient information to permit a clear
judgement.
After email communication: “investigators
were blinded and the containers were not
labeled with what it contained” and “The
study products were dispensed in opaque
bags”
Blinding of the outcomes assessors was en-
sured, and it was unlikely that the blinding
could have been broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk 8/74 (10.8%), reasons reported. Intention-
to-treat analysis.
Selective reporting (reporting bias) High risk Erythema, pruritus, and papulation/in-
duration/oedema assessment and BSA as-
sessment were predefined outcomes that
were not addressed in the Results
Other bias Unclear risk Comment: there was insufficient informa-
tion to permit a clear judgement
Lodén 2001
Methods Randomised, double-blind, ’other moisturiser’-controlled study
Setting
Multicentre (4) in Stockholm (2), Uppsala, Linköping, Sweden
Date of study
Specified February to April but unclear which year. Duration of intervention: 30 days
Participants N = 110 (93 female, 16 male and 1 gender unknown)
Mean age = 34 years
Inclusion criteria of the trial
• Atopic dermatitis (Hanifin 1980)
Exclusion criteria of the trial
• Significant concurrent illness
• Known allergy to ingredients of test creams
Randomised
N = 110 (unclear how many randomised to each arm)
Withdrawals/losses to follow-up




• Glycerol cream 20% for 30 days, application frequency unclear
Comparator
• Urea cream (urea 4% and 4% NaCl) for 30 days, application frequency unclear
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Outcomes Assessments (2): baseline and day 31
Outcomes of the trial (as reported)
• TEWL: evaporimeter, Servomed, Kinna, Sweden
• Skin hydration: corneometer CM-820 and CM 825, Courage and Khazaka
GmbH, Cologne, Germany
• Scaling, roughness, redness and cracks: 5-point Likert scale (0-4)
Denotes outcomes prespecified for this review
Funding source None declared, however, study was probably sponsored by ACO Hud AB, Sweden (see
Andersson 1999; Lodén 2002).
Declaration of interest None declared. Dr Lodén was an employee of ACO Hud AB.
Notes Unclear how many participants were randomised to each arm, and also how frequently
the treatments were applied. The data were estimated from box and whisker plots, which
made them difficult to use (Table 4).
As the study was 15 years old, we did not contact the investigators for data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 201): “randomized, double-
blind”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 201): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes were investigator-assessed.
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study
Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1/110 (< 1 %) dropped out, unclear from
which group. Per-protocol analysis
Comment: low number of losses to follow-
up, and although per-protocol analysis, we
considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Lodén 2002
Methods Randomised, double-blind, ’other moisturiser’- and placebo-controlled study
Setting
Multicentre in Stockholm, Uppsala, Linköping, Göteborg, Umeå and Malmö, Sweden
Date of study
February-April, unclear which year. Duration of intervention: 30 days
Participants N = 197 (151 female, 46 male)
Mean age = 33 years
Inclusion criteria of the trial
• Atopic dermatitis
Exclusion criteria of the trial
• Known allergy to ingredients of test products
Randomised






• Glycerol 20% cream at least once daily for 30 days (N = 68)
Comparator 1
• Urea cream (urea 4% and 4% NaCl) at least once daily for 30 days (N = 63)
Comparator 2
• Placebo cream at least once daily for 30 days (N = 66)
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The participants were allowed to continue use of topical corticosteroids
Outcomes Assessments (3): baseline, weeks 2 and 4
Outcomes of the trial (as reported)
• Local tolerance as degree of smarting on skin sensation (a sharp, local, superficial
effect which can be experienced during contact with for example acidic solutions),
stinging, itching and dryness/irritation on a scale of 5 levels (0 to 4) after 2 weeks of
treatment
• Dryness on a VAS scale (14 cm)
• Dermatologist assessed dryness of skin via DASI (Serup 1995)
Denotes outcomes prespecified for this review
Funding source Quote (page 47): “The study was sponsored by Aco Hud AB, Stockholm, Sweden”
Declaration of interest None declared. Dr Lodén was an employee of ACO Hud AB.
Notes The glycerol cream contained 20% glycerol, aqua, petrolatum, cream, canola, mineral
oil, cetearyl alcohol, glyceryl stearate, dimethicone, PEG-100 stearate, glyceryl poly-
methacrylate, cholesterol, propylene glycol, methylparaben and propylparaben. In the
placebo cream, glycerol was replaced with water. The urea cream contained 4% urea
and 4% NaCl as water-binding substances in an oil-in-water emulsion, pH about 5.
Other ingredients were paraffin liquidum, PEG-5-glyceryl-stearate, cetyl alcohol, stearyl
alcohol, stearic acid, trometamol, methylparaben, propylparaben, hydrochloric acid and
water
As the study was 14 years old we did not contact the investigators for data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 45): “were randomized into
three groups”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
234Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 45): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 45): “double-blind”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Marseglia 2014
Methods Randomised, investigator-blinded, ’other moisturiser’-controlled study
Setting
Multicentre (5), dermatology departments in Pavia, Bargamo, Bari, Sassudo and Milan,
Italy
Date of study
January to May 2013. Duration of intervention: 6 weeks
Participants N = 107 (48 female, 59 male)
Mean age = 6 years
Inclusion criteria of the trial
• 6 months to 14 years of age with mild-to-moderate, chronic, atopic facial eczema
(Hanifin 1980)
Exclusion criteria of the trial
• Severe atopic eczema
• Treatment with systemic or topical steroids or calcineurin inhibitors < 4 weeks
prior to study entry
• Presence of active cutaneous bacterial, viral, or fungal infections in target areas
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Randomised
N = 107 (pro-AMP group = 72, placebo group = 35)
Withdrawals/losses to follow-up
No losses to follow-up reported
Baseline data
Mean eczema severity score: pro-AMP group 6.1 (SD 2.5), placebo group 5.3 (SD 3)
Interventions Intervention
• Pro-AMP cream twice daily on the face for 4 weeks (N = 72)
Comparator
• Hydrating cream (15% glycerol-based cream also containing vaseline 8% and
liquid paraffin 2%) twice daily on the face for 4 weeks (N = 35)
Outcomes Assessments (3): baseline, weeks 3 and 6
Outcomes of the trial (as reported)
• Facial Eczema Severity Score (ESS): 4-point Likert scale (0 = no sign, to 3 =
severe); facial EASI (Hanifin 2001)
• IGA score: 5-point Likert scale of 0-4 (0 = clear, 1 = almost clear, 2 = mild disease,
3 = moderate disease, 4 = severe)
• Tolerability: 4-point Likert scale (0 = low tolerability to 3 = very good tolerability)
Denotes outcomes prespecified for this review
Funding source Quote (page 274): “This was a non-profit study” and “Isdin Srl has kindly provided the
products used in the trial”
Declaration of interest Quote (page 274): “MM is an employee of Isdin Srl. He was involved in the study design
and in the manuscript preparation” and “The other authors have declared no conflict of
interest”
Notes Nutratopic Pro-AMP cream contains 2.5% rhamnosoft (Biosaccharide GUM-2), ce-
ramides (ceramide 3), and 2% ILE (Isdin Barcelona, Spain)
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 272): “Computer-generated
number randomization list was used” “with
imbalanced treatment allocation 2:1”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
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Marseglia 2014 (Continued)
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “Conceal-
ment was obtained using sealed envelopes”
Comment: allocation appears to have been
adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 272): “assessor blinded”
Comment: the report did not provide suffi-
cient detail about the specific measures used
to blind study personnel from knowledge of
which intervention a participant received,
to permit a clear judgement and parents
and participants seem not to be blinded
After email communication: “Physicians
performing the first visit with treatment al-
location were not the physicians perform-
ing the follow up visits. The latter were not
aware of the type of treatment”
Comment: the report provided sufficient
detail about the measures used to blind
study personnel from knowledge of which
intervention a participant received. How-
ever, participants were not blinded and so
we judged this as being at an unclear risk
of bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 272): “assessor blinded”
Outcomes were investigator-assessed as
well as participant assessed
Comment: blinding of the outcomes asses-
sors, was ensured, and it was unlikely that
the blinding could have been broken, how-
ever, participants and parents seem not to
have been blinded
The outcome measurement was likely to be
influenced by the lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
Selective reporting (reporting bias) Low risk The protocol for the study was available
(NTR4084) and the prespecified outcomes
and those mentioned in the methods sec-
tion appear to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
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Methods Randomised, double-blind, ’other moisturiser’-controlled study
Setting
Wake Forest University Health Sciences Clinical Studies Center, North Carolina, USA
Date of study
Not reported. Duration of intervention: 3 weeks
Participants N = 39 (22 female, 17 male)
Mean age = 7.9 years
Inclusion criteria of the trial
• Mild to moderate atopic dermatitis
• Rating 2-3 on IGA 5-point scale
• ≥ 1% overall BSA
• Including facial and intertriginous skin
Exclusion criteria of the trial
• Systemic corticosteroids in previous 4 weeks
• Topical corticosteroids or topical anti-inflammatory in previous 2 weeks
• Concurrent medication with impact on study outcomes or assessments
• Introduction of other topical or systemic agents for atopic dermatitis
• Extent of disease requiring > 60 g of cream/week
• Allergy to Barrier Repair Cream including glycyrrhetinic acid (BRC-Gly), Barrier
Repair Cream including ceramides (BRC-Cer) or Over-the-Counter petrolatum based
moisturiser (OTC-Pet)
Randomised
N = 39 (BRC-Gly group = 13, BRC-Cer group = 13, OTC-Pet group = 13)
Withdrawals/losses to follow-up
1/39 (2.5%) of OTC-Pet group due to disease flaring
Baseline data
Disease severity was comparable in the 3 groups
Mean itch (VAS): BRC-Gly group 51.68 (SD 23.42), BRC-Cer group 50.77 (SD 24.
34), OTC-Pet group 58.27 (SD 18.05)
Mean EASI: BRC-Gly group 4.05 (SD 3.68), BRC-Cer group 4.23 (SD 2.34), OTC-
Pet group 5.30 (SD 3.70)
Interventions Intervention
• BRC-Gly (Atopiclair) 3 times a day for 3 weeks, using smallest amount needed to
cover the area (N = 13)
Comparator 1
• BRC-Cer (EpiCeram) 3 times a day for 3 weeks, using smallest amount needed to
cover the area (N = 13)
Comparator 2
• OTC-Pet (Aquaphor Healing Ointment) 3 times a day for 3 weeks, using smallest
amount needed to cover the area (N = 13)
Outcomes Assessments (3): baseline, days 7 and 21
Outcomes of the trial (as reported)
• IGA (0 to 4)
• BSA involvement (0 to 100)
• IGA of Improvement (IGAI) (0 to 6)
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• EASI (0 to 72) (Hanifin 2001)
• VAS (100 mm) for itch intensity
Denotes outcomes prespecified for this review
Funding source Text in the submitted version that was deleted in the published version read: “This study
was supported by Beiersdorf, Inc”
Declaration of interest Text in the submitted version that was deleted in the published version read: “Dr Fleis-
cher has received research, speaking and/or consulting support from Astellas, Centocor,
Amgen, Galderma, Stiefel, Medicis and Intendis. Dr Weber is an employee of Beiersdorf
Inc”
Notes Oral antihistamines were allowed if not initiated or discontinued during study. Com-
pliance was monitored with a diary. See Notes of Characteristics of included studies of
Abramovits 2008 for details on Atopiclair and of Draelos 2011 for details on EpiCe-
ram. Aquaphor Healing Ointment contains petrolatum, cera microcristallina, panthenol,
glycerol, bisabolol
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 531 ): “were randomized 1:1:
1...”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “This was an
investigator-initiated protocol. The clini-
cal studies coordinator, who did no assess-
ments, followed a randomization chart ob-
tained online for trichotomization into 3
groups. On this chart the coordinator fol-
lowed the next randomization”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “No person
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involved in any clinical assessment had ac-
cess to the randomization scheme. There
were no sealed envelopes”
Comment: reasonable to assume allocation
adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 535): “Each of the mois-
turizers was distributed in a plain white
jar so that subjects and investigators were
blinded...”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 535): “Each of the mois-
turizers was distributed in a plain white
jar so that subjects and investigators were
blinded...”
After email communication: “No person
involved in any clinical assessment had ac-
cess to the randomization scheme”
Comment: Outcomes were investigator-as-
sessed as well as participant assessed. Blind-
ing of participants and key study person-
nel was ensured, and it is unlikely that the
blinding could have been broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1/39 (2.5%) of OTC-Pet group, reason re-
ported. Per-protocol analysis
Comment: low number of losses to follow-
up, and although per-protocol analysis, we
considered this to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was avail-
able (NCT01093469), and the prespeci-
fied outcomes and those mentioned in the
Methods section appeared to have been re-
ported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
240Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Msika 2008
Methods Randomised, active-controlled study
Setting
Multi-centre (20 paediatricians) in France
Date of study
March to June 2003. Duration of intervention: 3 weeks
Participants N = 90 children (41 female, 45 male and 4 gender unknown)
Mean age = 16 months (range: 4 to 48 months)
Inclusion criteria of the trial
• Mild to moderate atopic dermatitis
• No topical corticosteroid application for previous 8 days
Exclusion criteria of the trial
• Not reported
Randomised
N = 90 (Group A = 18, Group B = 17, Group C = 15, Group D = 17, Group E = 19,
unclear = 4)
Withdrawals/losses to follow-up
4/90 (4.4%): unclear from which groups, lost to follow-up (1), prematurely stopped the
study for their own convenience (not for side effects) (2), forms incorrectly filled out or
incomplete (1)
Baseline data
Mean SCORAD index: Group A 33.28, Group B 34.60, Group C 34.50, Group D 35.
18, Group E 35.91
Interventions Intervention (Group A)
• Desonide 0.05% twice daily for 21 days (N = 18)
Comparator 1 (Group B)
• Desonide 0.05% twice daily plus a moisturiser containing 2% sunflower oil
oleodistillate twice daily for 21 days (N = 17)
Comparator 2 (Group C)
• Desonide 0.05% once daily for 21 days (N = 15)
Comparator 3 (Group D)
• Desonide 0.05% once daily plus a moisturiser containing 2% sunflower oil
oleodistillate twice daily for 21 days (N = 17)
Comparator 4 (Group E)
• Desonide 0.05% once a day every other day plus a moisturiser containing 2%
sunflower oil oleodistillate twice daily for 21 days (N = 19)
Outcomes Assessments (3): baseline, days 7 and 21
Outcomes of the trial (as reported)
• SCORAD (European Task Force on Atopic Dermatitis 1993)
• IGA: 5-point Likert scale (completely agree, quite agree, not very agree, not agree,
no opinion)
• Infants Dermatitis Quality of Life Index (IDQOL)(10 item; score 0to 3)
(Lewis-Jones 2001)
• Dermatitis Family Impact (DFI) (10 item; score 0-3)(Lawson 1998)
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Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared, but 3 investigators were employees of Laboratoires Expanscience, Eper-
non, France, manufacturer of the product under research
Notes STELATOPIA moisturiser, Mustela; Laboratoires Expanscience, France contains: 2%
sunflower oleodistillate, essential fatty acids, bio-ceramides, β-sitosterol and a complex
of emulsifying sugars
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 607): “randomly assigned...
”. “Each study center received one test kit
containing five treatments. The five treat-
ment options studies were successively allo-
cated to patients according to chronologi-
cal order of entry in the study. Patients were
randomized based on chronological order
of entry in the study”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “there was
randomized attribution list, the order of at-
tribution to different subjects was pre-de-
termined in a balanced fashion, following
the attribution list”
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: Central allo-
cation, identical packages “On this pack,
was only printed the number of chronolog-
ical attribution to follow. The doctor did
not know what was inserted in this pack
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(what protocol of emollient and steroid)”
Comment: reasonable to assume allocation
adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No reporting of measures used to blind
study participants and personnel from
knowledge of which intervention a partic-
ipant received
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported. Outcomes were in-
vestigator-assessed as well as participant as-
sessed
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
After email communication: “One was lost
to follow-up. Two stopped prematurely the
study for their own convenience (not for
side effect). One file was not correctly filled
and incomplete and was excluded from the
analysis. So, we studied 86 children.” Per-
protocol analysis
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Namazova-Baranova 2012
Methods Open randomised, ’other moisturiser’-controlled study
Setting
Institute of Preventive Pediatrics and Rehabilitation Scientific Center of Children’s
Health RAMS, Moscow, Russia
Date of study
Unspecified. Duration of intervention: 1 year
Participants N = 44 (24 female, 20 male)
Age range: 6 months to 12 years
Inclusion criteria of the trial
• 6 months to 12 years of age with moderate severity atopic dermatitis (SCORAD
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between 20 and 60 points)
Exclusion criteria of the trial
• Children with a primary episode of atopic dermatitis with exudation in the foci of
inflammation not allowing them to use ointment formulations
• Hypersensitivity to any components of the studied drugs in the presence of
secondary infection of the skin
• Treatment with phototherapy, immunosuppressive, cytotoxic agents, systemic
corticosteroids, inhibitors of calcineurin, and moisturisers with ceramides, in the
previous month
• Topical corticosteroid therapy in the previous 7 days
• Children with severe somatic diseases, infectious and oncological diseases
Randomised
N = 44 (Locobase Repair group = 22, Atoderm group = 22)
Withdrawals/losses to follow-up
4/44 (9%); Locobase Repair group due to respiratory infection (1), Atoderm group due
to protocol violation (1), worsening skin (2)
Baseline data
Median SCORAD: Locobase Repair group 38.3, Atoderm group 36.6
Mean daily consumption of topical corticosteroid: Locobase Repair group 2.8 g, Atoderm
group 3.0 g
Mean CDLQI: Locobase Repair group 15.83, Atoderm group 15.35
Interventions Intervention
• Locobase Repair twice daily for 1 year (N = 22)
Comparator
• Atoderm twice daily for 1 year (N = 22)
As a basic therapy the participants received 0.1% hydrocortisone 17-butyrate cream (Lo-
coid) 1 to 3 times a day as needed. Systemic therapy in both groups was of antihistamines
(cetirizine, levocetirizine) in dosages for age
Outcomes Assessments (4): baseline, months 1, 6 and 12
Outcomes of the trial (as reported)
• Disease severity: SCORAD (European Task Force on Atopic Dermatitis 1993)
• Quality of life: CDLQI (Lewis-Jones 1995)
• Objective measuring of skin by ultrasound: e.g. echogenicity, skin thickness,
intradermal arterial/venous blood flow, swelling and infiltration
• Flares
• Use of topical corticosteroids
• Adverse events
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared
244Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Notes Locobase Repair contains petrolatum, water, paraffin, liquid paraffin, glycerol, sorbi-
tan oleate, carnauba wax, cholesterol, ceramides 3, oleic acid, palmitic acid, carbomer,
tromethamine. Atoderm contains vaseline-glycerol complex in dispersed state, sodium
salt of EDTA, vitamin E, phenoxyethanol, parabens
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (translated from Russian): “All the
children were randomly assigned into 2
groups of 22 people each”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “a computer
generated randomisation list was used”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “sealed en-
velops for allocation, provided by research
department”
Comment: reasonable to assume allocation
adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No reporting of measures used to blind
study participants and personnel from
knowledge of which intervention a partic-
ipant received
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported. Outcomes were in-
vestigator-assessed as well as participant as-
sessed
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
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Namazova-Baranova 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4/44 (9%), reasons reported, per-protocol
analysis.
Comment: low number of losses to follow-
up, and although per-protocol analysis, we
considered this to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Nebus 2009
Methods Randomised, double-blind, ’other moisturiser’-controlled study
Setting
Multicentre (2) in USA
Date of study
Unspecified. Duration of intervention: 8 weeks
Participants N = 50 (gender not reported)
Mean age = 29.8 years
Inclusion criteria of the trial
• 12 to 60 years of age with mild to moderate atopic dermatitis (Hanifin 1980)
Exclusion criteria of the trial
• Not reported
Randomised
N = 50 (oatmeal group = 25, occlusive vehicle group = 25)
Withdrawals/losses to follow-up
3/50 (6%): all in occlusive vehicle group
Baseline data
IGA score: oatmeal group 2.58, occlusive vehicle group 2.58
Mean EASI: oatmeal group 6.55 (SD 5.10), occlusive vehicle 8.87 (SD 6.10)
Mean DLQI: oatmeal group 5.96 (SD 5.80), occlusive vehicle 7.46 (SD 4.29)
Interventions Intervention
• Oatmeal-based occlusive cream (with vitamins and ceramides) twice daily and an
oatmeal glycerol cleanser for all moisturising and body cleansing for 8 weeks (N = 25)
Comparator
• Occlusive vehicle twice daily and an oatmeal glycerol cleanser for all moisturising
and body cleansing for 8 weeks (N = 25)
Participants were allowed to use their normal topical medications for their atopic der-
matitis
Outcomes Assessments (3): baseline weeks 2, 4 and 8
Outcomes of the trial (as reported)
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• EASI (Hanifin 2001)
• IGA
• Quality of Life: DLQI (Finlay 1994)
• Moisturisation of involved skin
• Patient safety assessments: 5-point Likert scale (0 to 4): itching, burning and
stinging
• Final participant assessments based on the efficacy and acceptability of the
regimen
Denotes outcomes prespecified for this review
Funding source Quote (page AB67) “Commercial support: 100% sponsored by Johnson and Johnson
Consumer Products Worldwide”
Declaration of interest None declared, but several investigators were employees of Johnson and Johnson Con-
sumer Products Worldwide, the manufacturer of the drug under investigation
Notes Poster abstract with limited details provided. We received responses to our request for
study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page AB67): “multicenter, double-
blinded, randomized clinical study”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “The ran-
domization was generated by SAS by a
statistician. The method used to assign pa-
tients to treatment was a block design. Sub-
jects were assigned in a 1:1 ratio to the two
treatments, with a block size of 4.”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
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Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “The treat-
ment codes (M and C) were kept in a sealed
envelope by our clinical supplies depart-
ment. The tubes were randomized labeled
prior to sending to the investigator - so sub-
jects were dispensed treatment according
to enrollment/randomization order. Both
treatment creams were in the same 6 oz.
beige tube, same cap color. Both creams
were basically the same color and unfra-
granced”
Comment: central allocation, de-identified
tubes. Allocation appears to have been ad-
equately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page AB67): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
After email communication: “Both treat-
ment creams were in the same 6 oz. beige
tube, same cap color. Both creams were ba-
sically the same color and unfragranced”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page AB67): “double-blind”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement.
After email communication: “Both treat-
ment creams were in the same 6 oz. beige
tube, same cap color. Both creams were ba-
sically the same color and unfragranced”
Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
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it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/50 (6%), all in the occlusive vehi-
cle group. Intention-to-treat analysis per-
formed
Comment: we considered this trial to be at
a low risk of bias because the total number
of dropouts was low, and intention-to-treat
analysis was performed
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported. We re-
ceived additional information from the
principal investigator
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Nho 2014





Participants N = 31, 5 participants had atopic dermatitis (gender not reported)
Mean age not reported
Inclusion criteria of the trial
• People with red face caused by atopic dermatitis, seborrhoeic dermatitis, irritant
contact dermatitis, allergic contact dermatitis, rosacea, or acne
Exclusion criteria of the trial
• Not reported
Randomised






• Moisturiser with PPARα (peroxisome proliferator-activated receptor alpha)
activator and ceramide twice daily for 2 weeks to 1 side of the face
Comparator
• Moisturiser without PPARα activator and ceramide twice daily for 2 weeks to
contralateral side of the face
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Outcomes Assessments (2): baseline and week 2
Outcomes of the trial (as reported)
• Erythema level: erythema index measured by DermaVision-PRO
• Improvement of erythema as shown on photographs (investigator-assessed)
Funding source None declared
Declaration of interest None declared, but 3 authors were employees of R&I Center, Cosmax Co. Ltd, the
manufacturer of the drug under investigation
Notes Three PPARα activators used (Euryale ferox, Euphorbia lathyris, Rosa multiflora)
Only 5 participants met our inclusion criteria. No individual patient data (Table 4)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page S95): “were randomly applied
on half of the face”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Nothing reported regarding blinding.
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Nothing reported regarding blinding.
Outcomes were investigator-assessed.
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Little information provided.
Comment: there was insufficient informa-
tion to permit a clear judgement
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Selective reporting (reporting bias) Unclear risk Comment: there was insufficient informa-
tion to permit a clear judgement
Other bias Unclear risk Comment: there was insufficient informa-
tion to permit a clear judgement
Noh 2011
Methods Randomised, double-blind, ’other moisturiser’-controlled study
Setting
Department of Dermatology and Cutaneous Biology Research Institute, Yonsei Univer-
sity College of Medicine, Seoul, Korea
Date of study
Unspecified. Duration of intervention: 6 weeks
Participants N = 40 (17 female, 23 male)
Mean age = 12.95 years
Inclusion criteria of the trial
• Mild to moderate atopic dermatitis according to criteria Hanifin and Rajka
(Hanifin 1980)
• > 3 years of age
• EASI score of 5 to 20
Exclusion criteria of the trial
• Oral immunosuppressive drugs, immunomodulatory, topical steroid within 2
weeks prior to study entry
• Antihistamines within 1 week prior to study entry
Randomised
N = 40 (ceramide containing moisturiser group = 20, control moisturiser group = 20)
Withdrawals/losses to follow-up
8/40 overall (20%): ceramide containing moisturiser group (5), control moisturiser group
(3)
• Dropped out (5), protocol violation (3)
Baseline data
Mean EASI: ceramide containing moisturiser group 10.45 (SE 1.17), control moisturiser
group 9.51 (SE 1.02)
Mean TEWL (g/m²/h): ceramide containing moisturiser group 45 (SE 5), control mois-
turiser group 42 (SE 4)
Mean corneometry units: ceramide containing moisturiser group 18 (SE 2), control
moisturiser group 24 (SE 3)
Interventions Intervention
• Ceramide-containing moisturiser, APDDR-0801 twice daily for 6 weeks (N = 20)
Comparator
• Control moisturiser twice daily for 6 weeks (N = 20)
Corticosteroid cream also applied (Zemaderm) twice daily for 6 weeks
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Outcomes Assessments (3): baseline, weeks 3 and 6
Outcomes of the trial (as reported)
• EASI (0 to 72) (Hanifin 2001)
• IGA: 7-point Likert scale (worsened greatly to improved greatly)
• TEWL: evaporimeter, Tewameter TM 210, Courage-Khazaha, Koln, Germany
• Skin hydration: corneometer CM 820, Courage & Khazaka, Cologne, Germany
• Amount of corticosteroid cream used
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared
Notes Atobarrier cream, ceramide-containing moisturiser, APDDR-0801. APDDR-0801 is
the research name of in the Atobarrier cream
We received responses to our request for study details (Table 2)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 227): “randomized, con-
trolled, double-blinded”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “block ran-
domization method”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “central ran-
domization independent of researcher
who’s doing enrollment and also used
coded container”
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Comment: central allocation, de-identified
drug containers. Allocation appears to have
been adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 227): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 227): “double-blind”
Outcomes were investigator-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
High risk 8/40 (20%); ceramide containing mois-
turiser group (5), control moisturiser group
(3). Per-protocol analysis
Comment: the total number of dropouts,
combined with a per-protocol analysis rep-
resented a high risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Nuñez 2013




Unspecified. Duration of intervention: 3 weeks
Participants N = 49 (gender not reported)
Age = 2 to 15 years
Inclusion criteria of the trial
• African American children with mild to moderate atopic dermatitis
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Exclusion criteria of the trial
• Not reported
Randomised
N = 49 (colloidal oatmeal group = 25, prescription barrier repair cream group = 24)
Withdrawals/losses to follow-up
7/49 (14.3%), unclear from which group(s)
Baseline data
Mean EASI: colloidal oatmeal group 3.56 (SD 1.8), prescription barrier repair cream
group 3.15 (SD 2.5)
Mean VAS itch: colloidal oatmeal group 1.4 (SD 2.3), prescription barrier repair cream
group 1.4 (SD 3.3)
Interventions Intervention
• Colloidal oatmeal cream twice daily for 3 weeks (N = 25)
Comparator
• Prescription barrier repair cream (EpiCeram) twice daily for 3 weeks (N = 24)
Outcomes Assessments (4): baseline, weeks 1, 2 and 3
Outcomes of the trial (as reported)
• Disease severity of atopic dermatitis: EASI (Hanifin 2001)
• Subjective assessment of itch: questionnaires using a 10-point scale (1 = very itchy,
10 = not itchy at all)
Denotes outcomes prespecified for this review
Funding source Quote (page AB73): ”This study was sponsored by Johnson & Johnson Consumer
Companies, Inc.“
Declaration of interest None declared, but 4 investigators were employees of Johnson & Johnson Consumer
Companies, Inc, the manufacturer of the drug under investigation
Notes See Notes section of Characteristics of included studies of Draelos 2011 for details on
EpiCeram.
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page AB73): ”randomly assigned“
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: ”Eligible sub-
jects were randomly assigned to one of the
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two investigational products in a 1:1 ratio.
The randomization scheme was generated
by the Sponsor using the random num-
ber generating procedure in SAS (Statisti-
cal Analysis System) package“
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: ”Eligible sub-
jects were randomized in a sequential or-
der. That is, the smallest random code
in the randomization list was picked up
and assigned to the next eligible sub-
ject. Thus, both subjects and investiga-
tor couldn’t foresee the upcoming treat-
ment assignment. J&J Clinical supply team
completely overwrapped the products with
plain white labels with study information
printed on the white label. That would in-
clude randomization number, study site, PI
phone number and instructions for use. We
did not repackage the products from their
original container“
Comment: central allocation, de-identified
tubes. Allocation appears to have been ad-
equately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Nothing reported regarding blinding.
Comment: the outcome was likely to be
influenced by the lack of blinding
After email communication: ”double-
blind, products were overwrapped and ran-
domization number and instructions for
use were included on the overwrapped la-
bel“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Nothing reported regarding blinding.
Outcomes were investigator-assessed and
participant-assessed
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
After email communication: ”double-
blind, products were overwrapped and ran-
domization number and instructions for
use were included on the overwrapped la-
bel“
Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Little information provided.
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: 7/49 (14.3%)
, unclear from which group. Intention-to
treat analysis
Comment: we judged this as being at an
unclear risk of bias.
Selective reporting (reporting bias) Unclear risk Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: ”The study
was part of protocol (NCT01326910)
, there was an additional outcome pro-
vided in the protocol “Investigator’s Global
Atopic Dermatitis Assessment”
Comment: as this was a poster presenta-
tion, and the sub-study has not yet been
published in full, we judged this as being
at an unclear risk of bias
Other bias Unclear risk Comment: there was insufficient informa-
tion to permit a clear judgement
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Methods Randomised, double-blind, ’other moisturiser’-controlled, within-participant study
Setting
Department of Dermatology, Chungnam National University School of Medicine, Dae-
jeon, Korea
Date of study
June to November 2011. Duration of intervention: 4 weeks
Participants N = 30 (20 female, 10 male)
Mean age = 14.2 years
Inclusion criteria of the trial
• At least 6 months of bilateral atopic dermatitis (Hanifin 1980)
Exclusion criteria of the trial
• Cyclosporine or systemic corticosteroids used within 4 weeks prior to study entry
Randomised
N = 30 to either side of the body (within-participant)
Withdrawals/losses to follow-up
2/30 (6.7%) lost to follow-up
Baseline data
Mean IGA: treatment side 2.75 (SD 0.70), control side 2.71 (SD 0.66)
Mean VAS: treatment side 6.53 (SD 1.77), control side 6.50 (SD 1.75)
Mean TEWL (g/m²/h): treatment side 37.10 (SD 9.30), control side 34.30 (SD 8.40)
Mean skin capacitance: treatment side 27.40 (SD 10.80), control side 28.90 (SD 10.00)
Interventions Intervention
• Lactobacillus sakei Probio 65-containing moisturiser twice daily for 4 weeks on 1
side of the body
Comparator
• Control moisturiser twice daily for 4 weeks on contralateral side of the body
Continued use of antihistamines and topical steroids was permitted
Outcomes Assessments (4): baseline, weeks 1, 2 and 4
Outcomes of the trial (as reported)
• IGA: 5-point Likert scale (0 = clear; 1 = nearly clear, 2 = mild, 3 = moderate, 4 =
severe)
• Pruritus: VAS
• TEWL: Tewameter TM210, CK electronic, Cologne, Germany
• Skin capacitance: Corneometer CM825, CK electronic, Cologne, Germany
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 155): “This study was supported by a grant from the Korea Ministry of
Health and Welfare (A091121)”
Declaration of interest None declared
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Notes We mailed investigators numerous times for more precise study details, but received no
response (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 151): “was randomly as-
signed”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 150): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received on each part of
the body, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/30 (6.7%) lost to follow-up. Per-protocol
analysis.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
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Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Patrizi 2008
Methods Randomised, double-blind, ’other moisturiser’- and vehicle-controlled study
Setting
Two dermatological sites, Department of Specialistic and Experimental Clinical
Medicine, Division of Dermatology, University of Bologna, Bologna, San Gallicano Der-
matological Institute, Rome, Italy
Date of study
February 2005 to April 2006. Duration of intervention: 43 days
Participants N = 60 (30 female, 30 male)
Mean age = 5.5 years
Inclusion criteria of the trial
• Children and adolescents aged between 2 and 17 years, with diagnosis of atopic
dermatitis according to Hanifin and Rajka’s criteria (Hanifin 1980), and a grading of 2
(mild) or 3 (moderate) on the IGA scale
• The area affected by atopic dermatitis had to be ≥ 5% of the total BSA
Exclusion criteria of the trial
• Another skin disease other than atopic dermatitis, that could interfere with the
study results
• Severe excoriations
• History of allergy to an extract of the nut Vitellaria paradoxa (formerly
Butyrospermum parkii; shea butter)
• Had previously been treated with MAS063DP or had participated in other
Sinclair-sponsored studies
• Patients with insulin-dependent diabetes mellitus or another systemic disease that
could interfere with their participation in the study
Randomised
N = 60 (MAS063DP (Atopiclair) group = 20, MAS060 (Atopiclair light) group = 20,
vehicle group = 20)
Withdrawals/losses to follow-up
14/60 overall (23.3%): MAS063DP group = 1/20 (5%), MAS060 group = 7/20 (35%)
, vehicle group = 6/20 (30%)
• No information after baseline: MAS063DP group (1), MAS060 group (1),
vehicle group (0)
• Withdrew consent: MAS063DP group (0), MAS060 group (4), vehicle group (2)
• Atopic dermatitis poorly controlled: MAS063DP group (0), MAS060 group (1),
vehicle group (3)
• Side effects: MAS063DP group (0), MAS060 group (1), vehicle group (1)
Baseline data
Number of participants with:
• Pruritus: MAS063DP group (20), MAS060 group (18), vehicle group (20)
• Lichenification: MAS063DP group (6), MAS060 group (10), vehicle group (5)
• Chronic relapsing course: MAS063DP group (20), MAS060 group (16), vehicle
group (18)
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• Personal/family history of atopy: MAS063DP group (16), MAS060 group (16),
vehicle group (18)
Interventions Intervention 1
• MAS063DP 3 times daily for up to 43 days (N = 20)
Comparator 1
• MAS060 3 times daily for up to 43 days (N = 20)
Comparator 2
• Vehicle 3 times daily for up to 43 days (N = 20)
Participants had to observe a 7- or 14-day washout period if appropriate, and had to
refrain from using other medications for the treatment of atopic dermatitis during the
study. The use of other topical or systemic medications for the treatment of atopic
dermatitis, and phototherapy were not permitted during the washout and study period.
If atopic dermatitis was poorly controlled to the degree that additional therapy/rescue
regimen was needed, then either hydrocortisone butyrate 0.1% or desonide 0.5% cream
were allowed twice daily for 1 week. The use for rescue medication was an end-point of
the study
Outcomes Assessments (7): baseline, days 1, 8, 15, 22, 29 and 43
Outcomes of the trial (as reported)
• IGA; 6-point Likert scale (0 = clear, 5 = severe disease)
• Participants or caregivers assessment of pruritus (itch); VAS 0 to 100 mm
• EASI score; (0 to 72) for erythema, induration/papulation, excoriations and
lichenification (Hanifin 2001)
• Need for rescue medication in the event of a flare
• Participants or caregivers appraisal of acceptability of study substance
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 625): “This study was supported by Sinclair Pharmaceuticals Ltd, Godalm-
ing Business Centre, Woolsack way, Godalming, GU7 1XW Surrey, UK”
Declaration of interest None declared
Notes MAS063DP = Atopiclair. See Notes section of Characteristics of included studies of
Abramovits 2008 for details on Atopiclair. MAS060 = Atopiclair light, a water-in-oil
formulation containing the same key ingredients of MAS063DP, but at lower concen-
tration and with no preservatives
Participants were also provided with a specific non medicated, fragrance-free cleanser
(Cetaphil; Galderma, Alby-Sur-Cheran, France) for the entire study duration
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote (page 620): “The randomization list
was generated by computer”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: sponsor pro-
vided numbered identical boxes containing
the different products
Comment: central allocation, de-identified
boxes. Allocation appears to have been ad-
equately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 620): “the tubes were la-
belled in a double-blind manner” and
“MAS063DP, MAS060 and vehicle were
similar in consistency and in colour”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 620): “Investigators, patients
and caregivers remained blinded” and
“MAS063DP, MAS060 and vehicle were
similar in consistency and in colour”.
Outcomes were investigator-assessed as
well as participant-assessed
Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 14/60 (23.3%): MAS063DP group = 1/
20 (5%), MAS060 group = 7/20 (35%),
vehicle group = 6/20 (30%). Intention-to-
treat analysis based on 57/60
Comment: although ’modified’ intention-
to-treat analysis, the high number of losses
to follow-up posed an unclear risk of bias
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Patrizi 2014
Methods Randomised, open, controlled study
Setting
Multicentre (3) in Italy and Romania
Date of study
Unspecified. Duration of intervention: 28 days
Participants N = 55 (gender not reported)
Mean age = 2.5 years
Inclusion criteria of the trial
• Children aged 1 to 4 years with mild atopic dermatitis (SCORAD 5-20) and mild
to moderate xerosis on the selected measurement areas (SCORAD xerosis score of 1 or
2) not exhibiting atopic dermatitis flares at inclusion (European Task Force on Atopic
Dermatitis 1993)
Exclusion criteria of the trial
• Use of topical corticosteroids within 7 days or systemic corticosteroids within 15
days prior to inclusion
• History of allergy to study product components
• Immunodeficiency or chronic or acute diseases
• Treatment with a reintroduction diet or immunosuppressants in the month before
inclusion
• Systemic antibiotics
• Topical or systemic anti-inflammatory treatment or probiotics within 2 weeks
before inclusion
• Topical immunosuppressants, antibiotics, antiseptics or antihistamines in the
week before inclusion
• Use of any moisturiser within 48 hours before inclusion
• Breastfed children of mothers receiving immunosuppressants in the month before
inclusion
• Systemic corticosteroids, antibiotics, or antiinflammatory agents or probiotics in
the 2 weeks before inclusion
• Antihistamines in the week before inclusion
Randomised
N = 55 (emollient balm group = 28, control group = 27)
Withdrawals/losses to follow-up
1/55 (1.8%), from control group
Baseline data
Mean SCORAD: emollient balm group 11.7 (SD 3.1), control group 10.2 (SD 3.3)
Mean pruritus intensity: emollient balm group 1.67 (SD 1.20), control group 1.77 (SD
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1.52)
Mean TEWL (g/m²/h): emollient balm group 35.46 (SD 20.90), control group 21.55
(SD 9.43)
Interventions Intervention
• Emollient balm in combination with a hygiene product used for bathing twice
daily for 28 days (N = 28)
Comparator
• Hygiene product used for bathing twice daily for 28 days (N = 27)
Outcomes Assessments (3): baseline, days 15 and 28
Outcomes of the trial (as reported)
• SCORAD index (European Task Force on Atopic Dermatitis 1993)
• Intensity of xerosis and pruritus over the whole body: SCORAD-derived scales (0
= absence, 3 = severe)
• Barrier function tests: TEWL, Aquaflux AF200, Biox Systems, London, UK
• RNA expression of involucrin, loricrin, filaggrin, and corneodesmosin; real-time
reverse transcription polymerase chain reaction (RTPCR) analysis
• Skin microbiological diversity and quantification of S aureus and S epidermidis
Denotes outcomes prespecified for this review
Funding source Quote (page 170 of co-publication Bianchi 2016, under primary reference): “The study
was funded and conducted by Pierre Fabre Dermo-Cosmetique”
Declaration of interest Quote (page 170 of co-publication Bianchi 2016, under primary reference): “P. Bianchi,
J. Theunis, C. Casas, C. Villeneuve, C. Phulpin, A. Bacquey, D. Redoules, V. Mengeaud,
and A-M Schmitt are employees of Pierre Fabre Dermo- Cosmetique. The principal
investigator, Dr. Patrizi, signed a contract with Pierre Fabre Dermo-Cosmetique for this
study”
Notes The study product (Avene Xeracalm balm; Pierre Fabre Dermo Cosmetique, Boulogne,
France) was an oil-in-water emulsion. The associated hygiene product (emollient cleans-
ing gel; Trixera; Pierre Fabre Dermo, Boulogne, France) was indicated for dry and atopic
skin and was used for bathing and then rinsed off once a day
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 170 of co-publication Bianchi
2016): “were randomized to receive”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
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groups
After email communication: “The ran-
domization list was generated by the Pierre
Fabre Biometrie Department. Our statisti-
cal department used a specific software to
generate the randomization list”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “The ran-
domization list was not given to the inves-
tigator. Only sponsor had access to this list
and could see it”
Comment: central allocation, allocation
appears to have been adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page AB62): “open, randomized”
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page AB62): “open, randomized”
Outcomes were investigator-assessed and
participant-assessed
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1/55 (1.8%), from control group. Per-pro-
tocol analysis.
Comment: low number of losses to follow-
up, and although per-protocol analysis con-
sidered as at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
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Methods Three randomised, double-blind, vehicle-controlled, within-participant studies, only 1
of which was in atopic dermatitis
Setting
Department of Physiology, Institute of Biomedicine, University of Turku, Turku, Finland
Date of study
October 2008 to May 2009. Duration of intervention: 28 days
Participants N = 14 (9 female, 5 male)
Mean age = 28 years
Inclusion criteria of the trial
• Adults with chronic, mild to moderate atopic dermatitis with representative
symmetrically affected volar forearms
• History within previous 12 months of itching dermatitis in 1 or several of
localisations typical of atopic dermatitis (antecubital/cubital fossae; face/neck/upper
trunk; volar aspects upper extremities/thighs)
• Objective signs of mild or moderate eczema or dry skin in 1 or several of above-
mentioned locations
• Good general health ascertained by medical history, physical examination, ECG
recording and laboratory determinations, showing no signs of clinically significant
findings, except chronic atopic dermatitis
Exclusion criteria of the trial
• History of significant skin disease (e.g. any skin disease requiring hospitalisation),
or skin manifestations of allergic illness or other dermatologic condition that would
interfere with the trial assessments or compromise the participant’s safety according to
the opinion of the investigator
• Use of any active systemic medication (i.e. oral, subcutaneous, intravenous) for
chronic atopic dermatitis within 1 month (30 days)
• Use of active topical medication in the investigational area for chronic atopic
dermatitis within 1 month (30 days)
• Asymmetric presentation or only single lesion of atopic dermatitis on volar
forearms
• History of sunny holiday or solarium use within 1 month (30 days) before
beginning of study treatments,or planning such during the study or within 30 days
after the study
• Tattoos on the volar side of either forearm
• Earlier participation in a clinical study performed with cis-urocanic acid (cis-
UCA)
• Use of prescription drugs within 14 days prior to dosing or over-the-counter
medication within 7 days prior to dosing. Paracetamol was allowed for occasional pain
• Donation of blood or participation in another drug study within 60 days (males)
or 90 days (females) before the first product administration in this study
• Excessive use of alcohol (on average > 24 units per week for males, and more than
16 units per weeks for females; unit = 4 cL spirits or equivalent)
• Damaged skin at the test site (e.g. uneven skin pigmentation, numerous freckles,
scars or other disfigurations) or clinical signs or symptoms of skin irritation (e.g.
pruritus, burning, erythema)
• Allergy to cis-UCA, or ingredients of the base cream
• History of any cancer or current cancer
Randomised
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N = 14 to either forearm (within-participant)
Withdrawals/losses to follow-up
2/14 (14.3%): withdrew consent (1), and worsening eczema (1)
Baseline data
Mild atopic dermatitis: 10/13
Moderate atopic dermatitis: 3/13
Interventions Intervention
• Cis-urocanic acid (cis-UCA) 5% emulsion cream (0.7 mg cis-UCA per kg per
day) on 1 of the forearms between the antecubital fossa and the wrist twice daily for 10
days, and then 0.35 mg cis-UCA per kg per day for the following 18 days
Comparator
• Control vehicle on the contralateral forearm twice daily for 28 days
Outcomes Assessments (3): baseline, weeks 2 and 4
Outcomes of the trial (as reported)
• Pharmacokinetic blood samples; liquid chromatography-tandem mass
spectrometry (LC-MS/MS method)
• Pharmacokinetic urine fractions
• Tolerability; visual skin reaction severity (VSS) scoring for erythema, skin swelling,
formation of papules, formation of vesicles or bullae, and scaling (each graded as 0 to 3)
• TEWL
• PGA
• Total-body EASI (Hanifin 2001)
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 420): ”The 3 studies were funded by BioCis Pharma Ltd“
Declaration of interest Quote (page 420): ”The authors LP, LL, and JKL were employees of BioCis Pharma Ltd
at the time the studies were conducted. LL and JKL are also shareholders and patent
inventors for BioCis Pharma Ltd“
Notes 5% (w/w) cis-UCA emulsion cream (BioCis Pharma, Turku, Finland) and the same
vehicle emulsion cream base (Orion, Espoo, Finland). The cream base contained aqua,
decyl oleate, cetearyl alcohol, glycerol, sodium cetearyl sulphate, and methyl paraben.
Both products were pH 6.5
Data needed to be estimated from figures (TEWL), otherwise no precise data were
provided other than the statement that ”there were no significant differences.“ We mailed
investigators numerous times for more precise study details, but received no response
(Table 2; Table 4).
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 415): Randomisation was per-
formed by computer-generated (SAS Sys-
tem, Cary, NC, USA) lists by a randomi-
sation expert with no clinical involvement
in the trials”
Comment: probably done.
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 415): “the investigators, and
the study site personnel were blinded for
the identity of the treatments” and “The
products were packed in identical tubes la-
belled for either arm for each subject num-
ber”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 415) “The products were
packed in identical tubes labelled for either
arm for each subject number”
Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2/14 (14.3%): withdrew consent (1), and
worsening eczema (1). Per-protocol analy-
sis
Comment: moderate number of dropouts
at follow-up combined with the per-proto-
col analysis posed an unclear risk of bias for
this domain
Selective reporting (reporting bias) Unclear risk The protocol for the study was available
(Eudra-2008-005075-10). Not all the pre-
specified outcomes and those mentioned in
the Methods section appeared to have been
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reported. Data on skin swelling, formation
of papules, formation of vesicles or bullae,
and scaling were missing
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Peserico 2008
Methods Two-phase randomised, double-blind, active-controlled study
Setting
Multicentre (20) in Germany, Italy and Spain
Date of study
August 2005 to January 2006. Duration of intervention: acute treatment phase of up to
4 weeks and a 16-week maintenance phase
Participants N = 249 in acute treatment phase, and 221 in maintenance phase (142 female, 79 male)
Mean age = 30.9 years
Inclusion criteria of the trial
• Participants ≥ 12 years of age with a history of moderate to severe atopic
dermatitis for ≥ 2 years were eligible if they had an acute flare of atopic dermatitis
according to an IGA score of ’severe’ or ’very severe’ (IGA score ≥ 4) at baseline
Exclusion criteria of the trial
• Systemic atopic dermatitis therapy, vaccination, local therapy with tacrolimus,
and pimecrolimus within 4 weeks prior to study entry
• Glucorticosteroids within 1 week prior to study entry
• Antihistamines within 2 weeks prior to study entry
• Pregnancy and lactation
• Known sensitivity to methylprednisolone aceponate (MPA), moisturiser and/or to
any content of the respective formulations
• Known immune, hepatic, or renal insufficiency, and acute infections and
infestations
Randomised
N = 221 (moisturiser group = 109, MPA group = 112)
Withdrawals/losses to follow-up
8/221 overall (3.6%): moisturiser group = 3, MPA group = 5
• Lost to follow-up; moisturiser group (2), MPA group (3)
• Protocol deviation; moisturiser group (0), MPA group (2)
• Adverse event; moisturiser group (1), MPA group (0)
Baseline data at start maintenance phase
Mean EASI: moisturiser group 1.4, MPA group 1.6
Mean itching: moisturiser group 8.7, MPA group 10.1
Interventions First phase open-label methylprednisolone aceponate (MPA) cream once a day as well
as open-label moisturiser once a day for a maximum of 4 weeks
Second, maintenance phase:
Intervention
• Moisturiser (Advabase) twice daily for 16 weeks (N = 109)
Comparator
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• MPA cream once daily for 2 consecutive days a week (weekends) and moisturiser
twice daily for 5 days a week for 16 weeks (N = 112)
Outcomes Assessments (5): baseline, weeks 2, 6, 10 and 16
Outcomes of the trial (as reported)
• Time to relapse
• EASI (Hanifin 2001)
• Assessment of target lesions, and intensity of itching: 100-mm VAS
• IGA score
• Affected BSA
• DLQI (Finlay 1994) and CDLQI (Lewis-Jones 1995)
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 806): “This study was sponsored by Intendis GmbH, Berlin”
Declaration of interest None declared, but 1 of the authors was an employee at Intendis GmbH, Berlin, man-
ufacturer of Advabase
Notes Advabase, Intendis GmbH, Berlin, Germany contains aqua, decyl oleate, glyceryl
stearate, caprylic/capric/stearic triglyceride, glycerol, cetearyl alcohol, hydrogenated
coco-glycerides, benzyl alcohol, disodium EDTA, BHT
We had email communication with the corresponding author, but he could not help us
with missing trial details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 802): “Randomization at the
end of the AP [acute treatment phase] was
carried out in blocks according to the pa-
tients’ arrival at the study centre and aimed
to achieve a 1:1 randomization ratio overall
and within each centre”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
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Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 801): “double-blind” and
“MP medication was packed in identical
tubes to ensure blinding”
In view of the difference in number of tubes
(1 or 2) in the interventions groups it re-
mains unclear if blinding was effective
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 801): “double-blind” and
“MP medication was packed in identical
tubes to ensure blinding”. In view of the
difference in number of tubes (1 or 2) in
the interventions groups it remains unclear
if blinding was effective
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 8/221 (3.6%); moisturiser group = 3, MPA
group = 5. Both intention-to-treat analysis
and per-protocol analysis
Comment: low number of losses to follow-
up, and combined with both intention-to-
treat as well as per-protocol analysis meant
we considered this trial as being at a low
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
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Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Pigatto 1996
Methods Randomised, double-blind, ’other moisturiser’-controlled study
Setting
Department of Dermatology, University and Ospedale Maggiore IRCCS of Milan, Mi-
lan, and S Gallicano Dermatological Institute, Rome, Italy
Date of study
Unspecified. Duration of intervention: 1 month
Participants N = 70 (30 healthy adults: 8 female, 22 male, and 40 adults with atopic dermatitis: 10
female, 30 male)
Age range = 27 to 45 years
Inclusion criteria of the trial
• Healthy adults and adults with atopic dermatitis according to criteria of Hanifin
and Rajka (Hanifin 1980)
Exclusion criteria of the trial
• Not reported
Randomised






• Cream containing 10% urea twice daily for a month
Comparator
• Commercially available base cream twice daily for a month
Outcomes Assessments (2): baseline, week 4
Outcomes of the trial (as reported)
• Eczema severity according to Rajka 1989
• Clinical modifications of the dryness of the skin, of the erythema and of the
itching
• Subjective opinion in terms of a rating of the cosmetic acceptance (participant-
assessed)
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared
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Notes Cream containing urea (Laceran, Beiersdorf AG) and Essex Base Cream containing white
petrolatum, paraffin, cresol chloride and polyethylene glycol (Schering-Plough)
Unclear how many were randomised to each treatment arm, no separate data for healthy
and atopic adults (Table 4)
As the study was 20 years old we did not contact the investigators for data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 171): “The patients and con-
trols were assigned randomly to one or the
other treatment”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 171): “Patients, normal con-
trols and the physicians (AB and CC) who
examined them were blind to the treat-
ments”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 171): “Patients, normal con-
trols and the physicians (AB and CC) who
examined them were blind to the treat-
ments”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
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Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Nothing reported, little information pro-
vided.
Comment: there was insufficient informa-
tion to permit a clear judgement
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Unclear risk Comment: there was insufficient informa-
tion to permit a clear judgement
Puschmann 2003
Methods Randomised, double-blind, ’other moisturiser’-controlled study
Setting
Klinik für Dermatologie und Venereologie der Universität Lubeck, Germany
Date of study
Unspecified. Duration of intervention: 2 weeks
Participants N = 54 (20 healthy participants, 34 participants with atopic dermatitis, gender not
reported)
Mean age not reported
Inclusion criteria of the trial
• Healthy participants and participants with atopic dermatitis
Exclusion criteria of the trial
• Not reported
Randomised
N = 54 unclear how many to each treatment arm
Withdrawals/losses to follow-up




• Commercial cream containing polidocanol and urea twice daily for 14 days
Comparator
• New formulation also containing polidocanol and urea twice daily for 14 days
Outcomes Assessments (3): baseline, weeks 1 and 2
Outcomes of the trial (as reported)
• Tolerability
• Itch: VAS 0 to 10
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• Moisturising effect: corneometry (corneometer: Courage and Khazaka, Cologne,
Germany)
• Effect on skin lipids: sebumetry (sebumeter: Courage and Khazaka, Cologne,
Germany)
Denotes outcomes prespecified for this review
Funding source None declared, but Dr Puschmann was employed by HERMAL, the manufacturer of
the moisturiser under investigation, therefore the trial was likely to have been funded by
HERMAL Kurt Herrmann GmbH & Co, Reinbek
Declaration of interest None declared, but Dr Puschmann was employed by HERMAL Kurt Herrmann GmbH
& Co, Reinbek, the manufacturer of the moisturiser under investigation
Notes Commercial cream contains polidocanol 3% and urea 5%, water, octyl dodecanol, poly-
methylphenylsiloxane, stearin palm, dimethicone, glycerol, paraffin, hexadecyl palmi-
tate, polysorbate 40, carbomer, benzyl alcohol, and trometamol. The products differ
chiefly in the number of carbomers the molecules contain
Unclear how many were randomised to each treatment arm, no separate data for healthy
participants and atopic participants (Table 4)
As the study was 13 years old we did not contact the investigators for data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 78): “einer doppelblin-
den, randomisierten” (translation: double-
blind, randomised)
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 78): “doppelblinden” (trans-
lation: double-blind)
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
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tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 78): “doppelblinden”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5/54 dropouts (9.3%): reasons unreported,
unclear from which treatment arm(s) they
came, little information provided. Per-pro-
tocol analysis
Comment: there was insufficient informa-
tion to permit a clear judgement
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Shi 2015
Methods Randomised, participant-blinded, controlled, within-participant study
Setting
Multicentre, Sacramento, California, USA
Date of study
January 2014 to May 2015. Duration of the intervention 10 minutes
Participants N = 20 of which 10 had atopic dermatitis and 10 were healthy subjects (9 female, 11
male)
Mean age = 26.3 years
Inclusion criteria of the trial
• Age 8 years to 65 years
• Diagnosed with atopic dermatitis by a board-certified dermatologist at UC Davis
Exclusion criteria of the trial
• Those who were pregnant, prisoners, or cognitively impaired
Randomised
N = 20 to either forearm (within-participant)
Withdrawals/losses to follow-up
No losses to follow-up reported
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Baseline data of 10 participants with atopic dermatitis
Severity of eczema: mild (n = 5), moderate (n = 3), severe (n = 2)
Mean TEWL (g/m²/h): bleach side 12.58 (SD 8.74), water side 11.89 (SD 8.64)
Mean corneometry units: bleach side 23.66 (SD 11.38), water side 24.47 (SD 10.44)
Interventions Intervention
• Bleach bath immersion for 10 minutes followed by moisturiser (petrolatum and
glycerol at 2 different sites) or followed by no treatment (third different site) on 1
forearm
Comparator
• Water bath immersion for 10 minutes followed by moisturiser (petrolatum and
glycerol at 2 different sites) or followed by no treatment (third different site) on 1
forearm
Outcomes Assessments (4): baseline, 15 minutes, 30 and 60 minutes
Outcomes of the trial (as reported)
• Change in TEWL post immersion in the bath
• Change in TEWL after moisturiser application
• Change in skin pH after moisturiser application
• Change in skin hydration post immersion in the bath: measured by corneometry
• Change in skin pH post immersion in the bath
Denotes outcomes prespecified for this review
Funding source Quote (page AB76): “Commercial support: None identified”
Declaration of interest None declared
Notes Poster abstract. We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page AB76): “randomized con-
trolled study”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “The alloca-
tion sequence was generated a priori with
binary randomization generator.”
Comment: probably done.
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Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication (and in Shi
2016): “The randomization was performed
prior to recruitment by the study coordi-
nator, and stored in sealed envelopes that
were not opened until the subject was re-
cruited by the investigators.”
Comment: allocation appears to have been
adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk According to protocol (NCT02594969
available at clinicaltrials.gov): “partici-
pant-blinded” and “Participants remained
blinded to the water or dilute hypochlorite
immersion”. Investigators were not blinded
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes were investigator-assessed.
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up.
Selective reporting (reporting bias) Low risk The protocol
was available (NCT02594969 available at
clinicaltrials.gov), and the prespecified out-
comes and those mentioned in the Meth-
ods section appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
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Methods Randomised, double-blind, active- and vehicle-controlled, within-participant study
Setting
Multicentre (25) in Japan
Date of study
Unspecified. Duration of intervention: 4 weeks with 2 months of follow-up
Participants N = 552 (gender not reported)
Mean age not reported
Inclusion criteria of the trial
• Bilateral lesions of ichthyosis vulgaris, senile xerosis or atopic skin (inclusive of dry
form of infantile eczema)
Exclusion criteria of the trial
• Systemic treatment with any form of therapy
Randomised
N = 552 to either side of the body (within-participant)
Withdrawals/losses to follow-up
61/552 (11%), unclear from which groups, due to:
• no lesions left to treat
• neither drug was effective
• adverse events at both sides
• other reasons
Baseline data of per-protocol population
Ichtyosis vulgaris (137), senile xerosis (170), atopic skin (184)
Interventions Intervention
• Urea 10% ointment twice daily for 4 weeks on 1 side of the body
Comparator
• Cream base or urea 20% ointment twice daily for 4 weeks on contralateral side of
the body
Outcomes Assessments (5): baseline, weeks 1, 2, 3 and 4
Outcomes of the trial (as reported)
• Global improvement: 6-point Likert scale (cure, marked improvement, moderate
improvement, slight improvement, no change, exacerbation)
• Time to relapse of lesions
• Drug preference
• Adverse events
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared
Notes The data were confusingly reported in this study and did not lend themselves to further
analysis (Table 4).
As the study was 39 years old we did not contact the investigators for data
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Shiratori 1977 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 104): “doubleblind ran-
domised control trial”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 104): “doubleblind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received on each side of
the body, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 104): “doubleblind”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 61/552 (11%), unclear from which groups.
Per-protocol analysis
Comment: we judged this to be at an un-
clear risk of bias.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
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Simpson 2011
Methods Randomised, investigator-blinded, controlled, within-participant study (study D)
Setting
Multi-centre (3) in USA
Date of study
Unspecified. Duration of intervention: 4 weeks
Participants N = 127 (gender not reported)
Mean age not reported
Inclusion criteria of the trial
• > 3 years old
• Mild to moderate atopic dermatitis as rated by IGA
Exclusion criteria of the trial
• Not reported
Randomised
N = 127 to either side of the body (within-participant)
Withdrawals/losses to follow-up
4/127 (3%), reasons unreported
Baseline data
Mean corneometry units: Cetaphil RestoraDerm moisturiser side 42.5, control 41.8
Interventions Intervention
• Cetaphil RestoraDerm moisturiser twice a day on one half of the body plus
routine use of topical corticosteroids for 4 weeks
Comparator
• Routine use of topical corticosteroids plus no moisturiser on other half of the
body for 4 weeks
Outcomes Assessments (5): days 0, 7, 14, 21 and 28
Outcomes of the trial (as reported)
• Stratum corneum hydration: corneometry, Corneometer CM 825
• Modified EASI (adapted to split body design)
• Satisfaction questionnaire
Denotes outcomes prespecified for this review
Funding source Quote (page 748): “The studies were supported by Galderma R & D”
Declaration of interest Quote (page 748): “Dr Simpson is a consultant for Galderma. Dr Dutronc is an employee
of Galderma”
Notes This reference includes data on 4 studies, of which only study D matched our inclusion
criteria
Cetaphil RestoraDerm contains aqua, glycerol, caprylic/capric triglyceride, Helianthus
annus (sunflower) seed oil, pentylene glycol, Vitellaria paradoxa (formerly called Butyros-
permum parkii; shea butter), sorbitol, cyclopentasiloxane, cetearyl alcohol, behenyl alco-
hol, glyceryl stearate, tocopheryl acetate, hydroxypalmitoyl sphinganine, niacinamide,
allantoin, panthenol, arginine, disodium ethylene dicocamide PEG-15 disulfate, glyceryl
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stearate citrate, sodium PCA, ceteareth-20, sodium polyacrylate, caprylyl glycol, citric
acid, dimethiconol, disodium EDTA, sodium hyaluronate, cetyl alcohol
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 745): “...randomized...”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “This was
a left/right comparison study, comparing
treatment with Cetaphil cream on one side
of the body versus no treatment on the con-
tralateral side. The allocation of treatments
(Cetaphil cream or no treatment) was ran-
domized and the allocation sequence was
generated by an independent statistician”
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “The study
medications were dispensed by someone
other than the investigator designated as
Study Drug Dispenser. The randomization
list was secured in a locked cabinet and in an
electronic file with restricted access to only
the designated personnel directly respon-
sible for labelling and handling the study
medications, until the study database was
locked and ready to be unblinded.”
Comment: reasonable to assume allocation
adequately concealed. We judged this as at
a low risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 745): “evaluator-blinded”
Comment: participants were not blinded.
The report provided insufficient detail
about the measures used to blind study per-
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Simpson 2011 (Continued)
sonnel from knowledge of which interven-
tion a participant received on each side of
the body, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 745): “evaluator-blinded”
Outcomes were investigator-assessed and
participant-assessed
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study, and
participants were not blinded
The outcome measurement was likely to be
influenced by the lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4/127 (3%), reasons unreported. Per-pro-
tocol analysis.
Comment: low number of losses to follow-
up, and although per-protocol analysis, we
considered this to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Simpson 2013
Methods Randomised, investigator-blinded, controlled (inactive), within-participant study
Setting
Pro-DERM Institute in Germany
Date of study
December 2010 to February 2011. Duration of intervention: 27 days
Participants N = 20 (16 female, 4 male)
Mean age = 40.9 years
Inclusion criteria of the trial
• Male or female volunteers from 18 to 65 years old with controlled atopic
dermatitis (without active lesions in the target area)
• Clinically xerotic skin, corresponding to a score of at least 1 on a dryness scale at
inclusion (mild dryness), and a corneometer value < 30 (very dry skin) at inclusion
Exclusion criteria of the trial1
• Other topical products on the target areas for the duration of the study
• Women who were pregnant or breastfeeding
Randomised
N = 20 to either leg (within-participant)
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Withdrawals/losses to follow-up
No losses to follow-up reported
Baseline data
Mean dryness: CRM-treated area 2.05 (SD 0.63), untreated area 2.07 (SD 0.63)
Mean skin hydration (corneometry units): CRM-treated area 17.77 (SD 5.24), untreated
area 18.25 (SD 5.91)
Mean TEWL (g/m²/h): CRM-treated area 5.15 (SD 1.53), untreated area 15.32 (SD 1.
73)
Interventions Intervention
• Cetaphil Restoraderm Body Moisturiser (CRM) twice daily on 1 leg for 27 days
Comparator
• No treatment on contralateral leg for 27 days
Outcomes Assessments (2): baseline and day 28
Outcomes of the trial (as reported)
• Dryness: 5-point Likert scale (0 to 4, 0 = no dryness, 4 = very dry)
• TEWL: evaporimeter, Dermalab, Cortex
• Skin hydration: corneometry (IU), Corneometer CM825 Courage & Khazaka,
Cologne, Germany
• Changes in the stratum corneum after the treatment with CRM: Raman
spectroscopy
• Adverse events
Denotes outcomes prespecified for this review
Funding source None declared but the manufacturer of the drug under investigation is Galderma, R&
D, Sophia Antipolis, France
Declaration of interest Quote (page 125): “Dr. Simpson is a consultant for Galderma, and Dr. Böhling and Mr.
Bielfeldt received investigator fees for this research study. Ms. Bosc and Mr. Kerrouche
are employees of Galderma”
Notes Cetaphil Restoraderm Body Moisturiser (CRM - Galderma S.A.) contains filaggrin
breakdown products (components of NMF), ceramide precursor, and niacinamide, fatty
acids, humectants, filmogenic substances, emollients, and shea butter. CRM contains no
fragrances and has a pH of approximately 5.5
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 122): “statistician generated
a randomization list” and “randomly as-
signed to the right or left lower leg (for each
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subject, one 4x4 cm area treated with CRM
and one symmetric untreated control area)
with a block size of four subjects”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 122): “a statistician gener-
ated a randomization list and each bottle
of product was identified by a randomiza-
tion number and was labeled with the side
to be treated...The randomization list was
kept under restricted access until the study
database was locked and ready to be un-
blinded for statistical analyses”
Comment: central allocation, de-identified
bottles. Allocation appears to have been ad-
equately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 122): “investigator-blinded”;
participants were not blinded
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived on each leg, to permit a clear judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 122): “investigator-blinded”;
participants were not blinded
Outcomes were (mainly) investigator-as-
sessed as well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
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Sugarman 2009
Methods Randomised, investigator-blinded, active-controlled study
Setting
Multicentre (5) in USA
Date of study
December 2006 to February 2007. Duration of intervention: 4 weeks
Participants N = 121 (73 female, 48 male)
Mean age = 7.1 years
Inclusion criteria of the trial
• 6 months to 18 years with moderate to severe atopic dermatitis diagnosed by
dermatologist and quantitated by SCORAD (European Task Force on Atopic
Dermatitis 1993)
Exclusion criteria of the trial
• Systemic treatments (except antihistamines and antibiotics) < 1 month prior to
study entry
• Topical medication < 3 days prior to study entry
Randomised
N = 121 (barrier repair group = 59, fluticasone group = 62)
Withdrawals/losses to follow-up
12/121 overall (9.9%); barrier repair group = 6/59, fluticasone group 3/62
• Needed rescue medication: barrier repair group (1), fluticasone group (0)
• Discontinued (loss to follow-up, protocol deviations): barrier repair group (5),
fluticasone group (3)
Baseline data
Mean SCORAD: barrier repair group 37.2, fluticasone group 33.8
Mean self-assessment: barrier repair group 0.1 (SD 0.40), fluticasone group 0.11 (SD 0.
46)
Interventions Intervention
• Barrier repair cream (EpiCeram Skin Barrier Emulsion) twice daily on lesions for
4 weeks (N = 59)
Comparator
• Fluticasone 0.05% cream twice daily on lesions for 4 weeks (N = 62)
Cetaphil lotion was applied to clinically uninvolved areas twice daily
Outcomes Assessments (3): baseline, days 14 and 28
Outcomes of the trial (as reported)
• SCORAD (European Task Force on Atopic Dermatitis 1993): score 0 to 72 (0 =
none, 72 = severe)
• Pruritus score: VAS (0 = none, 10 = severe)
• Sleep habit: VAS (0 = no sleep problems, 10 = severe sleep problems)
• Patient/family self-assessments of improvement: 3-point Likert scale (no change,
improved, worsening)
• IGA: 5-point Likert scale (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 =
severe)
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• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 1110): ”company-sponsored study (Ceragenix Corporation, Dever, CO)
Declaration of interest Quote (page 1110): “Neither of the authors is a consultant or shareholder at Ceragenix”
Notes See Notes section of Characteristics of included studies of Draelos 2011 for details on
EpiCeram.
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1107): “were assigned ran-
domly at entry”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “A central
randomization schedule was produced pro-
viding random allocation to the two treat-
ment groups. A block size of 4 will be
used in the generation of the randomiza-
tion code”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “central allo-
cation by sponsor”
Comment: allocation appears to have been
adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page
1106): “investigator-blinded”. Participants
were not blinded, quote (page 1107) “the
subjects could not be blinded”
Comment: the report did not provide suf-
ficient detail about the specific measures
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used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived, to permit a clear judgement
After email communication: “The per-
son dispensing the study medication and
performing ongoing study medication ac-
countability will NOT perform any of the
efficacy assessments required by the proto-
col”
Comment: the report provided sufficient
detail about the measures used to blind
study personnel from knowledge of which
intervention a participant received, how-
ever, participants were not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 1106): “investigator-blinded”
Outcomes were investigator-assessed as
well as participant-assessed
Comment: blinding of the outcomes asses-
sors, was ensured but participants and par-
ents were not blinded
The outcome measurement was likely to be
influenced by the lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12/121 (9.9%), reasons reported. Inten-
tion-to-treat analysis
Comment: low number of losses to follow-
up, combined with intention-to-treat anal-
ysis, meant we considered this domain to
be at a low risk of bias
Selective reporting (reporting bias) Unclear risk The protocol for the study was available
(NCT00616538) and the prespecified out-
come “Patient/family self assessments of
improvement” and “IGA” mentioned in
the methods section was inadequately re-
ported (“demonstrated highly significant
improvement”)
Comment: we judged this as being at an
unclear risk of bias.
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
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Takeuchi 2012
Methods Two-phase, randomised, open-label, active-controlled study
Setting
Multicentre (8) in Japan
Date of study
Unspecified. Induction phase 1-4 weeks, maintenance phase > 4 weeks
Participants N = 70 (37 female, 33 male)
Mean age = 31 years
Inclusion criteria of the trial
• > 10 years of age with atopic dermatitis and VAS-itch scores between 30 to 80 on
a scale from 0 to 100
Exclusion criteria of the trial
• VAS score < 30 or > 80
• Corticosteroids, cyclosporine, or antihistamines < 2 weeks prior to study entry
Randomised
N = 70 (induction phase: moisturiser group = 35, tacrolimus group = 35; maintenance
phase moisturiser group = 21, tacrolimus group = 23)
Withdrawals/losses to follow-up
Induction phase 2/70 (2.9%): 1 in each group and in 24 the VAS-itch score did not
reduce by more than 20 and did not make it to maintenance phase, 1 refused to continue
Maintenance phase 1/43 (2.3%): in moisturiser group
Baseline data
Mean itch (VAS): moisturiser group 19.3 (SD 16.7), tacrolimus group 28.1 (SD 15.4)
Interventions Phase 1: induction phase, all participants received topical tacrolimus (0.03% < 16 years
old and 0.1% otherwise). Moisturisers twice daily in addition to usual topical corticos-
teroid treatment (maximum use, 10 g/week). Participants who showed a reduced VAS-
itch score by > 20 points were considered to show relief from pruritus, and only these
induction therapy responders proceeded into maintenance treatment
Phase 2: maintenance phase
Intervention
• Moisturiser therapy for at least 4 weeks (N = 21)
Comparator
• Tacrolimus for at least 4 weeks (N = 23)
Outcomes Assessments (2): baseline and day 28
Outcomes of the trial (as reported)
• Recurrent pruritus
• Mean change in VAS itch score: 0 to 100 mm
• Percentage of participants with pruritus recurrence
• SCORAD (European Task Force on Atopic Dermatitis 1993)
Denotes outcomes prespecified for this review
Funding source Quote (page 150): “This work was supported by research grants from the Ministry of
Health, Labour and Welfare, Japan”
288Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Takeuchi 2012 (Continued)
Declaration of interest None declared
Notes We only include data on phase 2, the maintenance phase of the study
We mailed investigators numerous times for more precise study details, but received no
response (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 146): “random allocated”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 144): “open-label”
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 144): “open-label”
Outcomes were investigator-assessed as
well as participant assessed
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk We only include data on maintenance
phase, 1/43 dropped out in the moisturiser
group
Without further information regarding the
maintenance phase (the number initially
randomised, do not match the number in
the maintenance phase)
Selective reporting (reporting bias) High risk Atopic dermatitis severity score (SCO-
RAD), was a predefined outcome in the
Methods section, but was not reported for
the maintenance phase
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Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Tan 2010
Methods Randomised, double-blind, vehicle-controlled study
Setting
National Skin Centre, Singapore
Date of study
Unspecified. Duration of intervention: 41 days
Participants N = 60 (21 female, 39 male)
Mean age = 18 years
Inclusion criteria of the trial
• 12-40 years of age with mild to moderate atopic dermatitis (Hanifin 1980)
Exclusion criteria of the trial
• Severe atopic dermatitis
• Recent hospitalisation
• Recent or current use of systemic antibiotics, systemic corticosteroids, potent or
very potent topical steroids or phototherapy in the past 1 month
• Known contact allergy to any of the ingredients in the moisturiser
• Unco-operative patients; and pregnant women
Randomised
N = 60 (study cream group = 30, vehicle group = 30)
Withdrawals/losses to follow-up
No losses to follow-up
Baseline data
Mild atopic dermatitis (number of participants): study cream group (7), vehicle group
(7)
Moderate atopic dermatitis (number of participants): study cream group (23), vehicle
group (23)
Mean SCORAD: study cream group 28.85, vehicle group 29.51
Interventions For ethical reasons and recruitment effectiveness, all participants were provided with 0.
025% betamethasone valerate cream, for the first 27 days. Following this, participants
who still had persistent eczema were allowed to continue use of the steroid if necessary,
which most did
Intervention
• Study cream (triclosan 1% containing moisturiser) twice daily for 41 days (N =
30)
Comparator
• Vehicle cream twice daily for 41 days (N = 30)
Participants were provided with emulsifying ointment as cleansers throughout the study
period and were instructed not to use any systemic or topical antibiotics, antibacterial
soap or antibacterial shampoo until the end of study
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Outcomes Assessments (4): baseline, days 14, 27 and 41
Outcomes of the trial (as reported)
• SCORAD index (European Task Force on Atopic Dermatitis 1993)
• Adverse events
• Amount of topical corticosteroid use and study cream used
Denotes outcomes prespecified for this review
Funding source Quote (page e109): “This study was sponsored by Hygieia Healthcare Ltd”
Declaration of interest None declared
Notes All participants underwent a washout period of 1 week during which no topical corti-
costeroid was allowed
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page e110): “Patients were assigned
to one of two treatment groups according to
a computer-generated randomization list,
stratified according to disease severity”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “Pharmaceu-
tical company prepared identical labelled
bottles”
Comment: central allocation, de-identified
bottles. Allocation appears to have been ad-
equately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page e109 and e110): “double-
blind” and “All study personnel and physi-
cians remained blinded to allocation of
treatment until completion of data analy-
sis. Both the study cream and vehicle were
odourless, of the same appearance and con-
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sistency, and provided in identical bottles”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page e109 and e110): “double-
blind” and “All study personnel and physi-
cians remained blinded to allocation of
treatment until completion of data analy-
sis. Both the study cream and vehicle were
odourless, of the same appearance and con-
sistency, and provided in identical bottles”
Outcomes were investigator-assessed as
well as participant-assessed
Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Thumm 2000
Methods Randomised, double-blind, active- and placebo-controlled study
Setting
Klinikum Mannheim gGmbH, Universitätsklinikum, Fakultät für Klinische Medizin
Mannheim der Universität Heidelberg, Germany
Date of study
Unspecified. Duration of intervention: 4 weeks
Participants N = 58 (40 female, 18 male)
Mean age = 31.1 years
Inclusion criteria of the trial
• 18- 55 years of age with mild to moderate atopic dermatitis according to criteria
Hanifin and Rajka (Hanifin 1980)
Exclusion criteria of the trial
• Not reported
Randomised
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N = 58 (sea buckthorn oil (Hippophae rhamnoides oil) 10 % group = 17, sea buckthorn
oil 20% group = 17, placebo group = 19, 5 unclear)
Withdrawals/losses to follow-up




• Sea buckthorn oil (Hippophae rhamnoides)10% in a cream containing beeswax,
paraffin and glycerol for 4 weeks (N = 17)
Comparator 1
• Sea buckthorn oil (Hippophae rhamnoides) 20% in a cream containing beeswax,
paraffin and glycerol or 4 weeks (N = 17)
Comparator 2
• Placebo (cream containing beeswax, paraffin and glycerol) for 4 weeks (N = 19)
Application frequency unclear
Outcomes Assessments (5): baseline, weeks 1, 2, 3 and 4
Outcomes of the trial (as reported)
• SCORAD index (European Task Force on Atopic Dermatitis 1993)
• Pruritus and sleeping problems as assessed by participants: VAS (0 to 10)
• TEWL: evaporimeter, Tewameter TM 120, Courage & Khazaka, Cologne,
Germany
• Skin hydration: corneometer, Corneometer CM 820, Courage & Khazaka,
Cologne, Germany
• Quality of life: DLQI (Finlay 1994)
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared, but 1 of the authors was an employee of Weleda AG, Schwabisch Gmund,
the manufacturer of the product under investigation
Notes As the study was 16 years old we have not contacted the investigators for data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 285): “randomized” and on
page 287 “nach dem Zufallsprinzip” (trans-
lation: at random)
Comment: insufficient detail was reported
about the method used to generate the allo-
293Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Thumm 2000 (Continued)
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 285): “double blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5/58 (8.6%) lost to follow-up, reasons un-
reported and unclear from which groups.
Per-protocol analysis
Comment: low number of losses to follow-
up, and although per-protocol analysis, we
considered this domain to be at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
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Unspecified. Duration of intervention: 2 weeks
Participants N = 117 (46 female, 71 male)
Mean age = 4.3 years
Inclusion criteria of the trial
• Children between 3 months and 14 years with atopic dermatitis based on the UK
Working Party’s diagnostic criteria (Williams 1994)
• No changes to their usual lifestyle (diet, allergen avoidance, etc)
Exclusion criteria of the trial
• Topical and systemic treatment < 1 week before the start of treatment
Randomised
N = 117 (furfuryl palmitate enriched moisturiser group = 57, moisturiser group = 60)
Withdrawals/losses to follow-up
29/117 overall (24.8%); furfuryl palmitate enriched moisturiser group 18/57, mois-
turiser group 11/60
• Lost to follow-up: furfuryl palmitate enriched moisturiser group 4/57, moisturiser
group 4/60
• Protocol violation: furfuryl palmitate enriched moisturiser group 14/57,
moisturiser group 7/60
Baseline data
Mean SCORAD: furfuryl palmitate enriched moisturiser group 28.1 (SD 10.6), mois-
turiser group 25.6 (SD 10.1)
Interventions Intervention
• Furfuryl palmitate-enriched moisturiser twice daily for 2 weeks (N = 57)
Comparator
• Moisturiser twice daily for 2 weeks (N = 60)
Treatment with systemic or topical corticosteroids, topical immunomodulators, and
topical or oral antihistamines was not allowed
Outcomes Assessments (3): baseline, weeks 1 and 2
Outcomes of the trial (as reported)
1. SCORAD index (European Task Force on Atopic Dermatitis 1993)
2. Efficacy and tolerability according to paediatricians and parents: questionnaire
(worsening, in-existent, poor, good, or very good, and tolerability was rated as poor,
good, or very good)
Denotes outcomes prespecified for this review
Funding source None declared, however, quote (page 207): “Both products were provided by the same
manufacturer (ICIM International Srl, Milan, Italy)”
Declaration of interest None declared
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Notes Moisturiser containing various antioxidant molecules (superoxide dismutase, 18-ß-gly-
cyrrhetinic acid, vitamin E, and α-bisabolol). Furfuryl palmitate enriched formulation
was same moisturiser with addition of furfuryl palmitate
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 206): “Randomization was
performed using a computer-generated
list”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “Each tube
had a letter ”A“ or ”B“, and we assigned the
cream preparation to the patients on the
basis of computer randomization list made
directly by the Producer and sent to the
each center before starting the trial. Obvi-
ously the investigators did not know if ”A“
or ”B“ was the active or not”
Comment: central allocation, de-identified
tubes; allocation appears to have been ade-
quately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 207): “The study was double
blind, with the key code disclosed only after
statistical evaluations. The 2 topical prod-
ucts had an identical color, smell, and con-
sistency and were indistinguishable to both
parents and examining pediatricians”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 207): “The study was double
blind, with the key code disclosed only after
statistical evaluations. The 2 topical prod-
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ucts had an identical color, smell, and con-
sistency and were indistinguishable to both
parents and examining pediatricians”
Outcomes were investigator-assessed as
well as participant-assessed
Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
High risk 29/117 (24.8%) lost to follow-up; furfuryl
palmitate-enriched moisturiser group 18/
57, moisturiser group 11/60, reasons re-
ported. Per-protocol analysis
Comment: the total number of dropouts,
combined with a per-protocol analysis rep-
resents a high risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Udompataikul 2011
Methods Randomised, investigator-blinded, active-controlled, within-participant study
Setting
Skin Center, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand
Date of study
Unspecified. Study duration 6 weeks
Participants N = 30 (12 female, 14 male and 4 gender unknown)
Mean age = 5.8 years (2 months to 10 years)
Inclusion criteria of the trial
• Children 2 to 15 years with mild to moderate atopic dermatitis (Hanifin 1980)
• Skin lesions on both flexural areas of the body
Exclusion criteria of the trial
• Oral medications (e.g. corticosteroids and antihistamines) in previous 4 weeks
• Topical medications (corticosteroids, calcineurin inhibitors and moisturisers) in
previous 2 weeks
• Other skin infections
Randomised
N = 30 to either body side (within-participant)
Withdrawals/losses to follow-up
4/30 (13%): bacterial folliculitis (1) incomplete follow-up (3)
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Baseline data
Mean SCORAD: licochalcone A side 28.28, hydrocortisone acetate 1% side 28.52
Interventions Intervention
• Licochalcone A lotion twice daily on one side for 6 weeks
Comparator
• Hydrocortisone acetate 1% lotion twice daily on contralateral side for 4 weeks
followed by cream base twice a day for 2 weeks
Outcomes Assessments (6): efficacy for the first 4 weeks; 2 weeks of relapse-rate
Outcomes of the trial (as reported)
• SCORAD (European Task Force on Atopic Dermatitis 1993)
• Global self-evaluation of satisfaction: 5-point Likert scale (excellent to no change)
• Adverse events
• Relapse
Denotes outcomes prespecified for this review
Funding source None declared. However, the study design is identical - with a similar comparison with
licochalcone - to Angelova-Fischer 2014 and Wanakul 2013, which were sponsored by
Beiersdorf.
Declaration of interest Quote (page 660): ”No conflict of interest“
Notes Licochalcone in ceramide and linoleic acid lipid base formulation (Eucerin Soothing
lotion 12% omega, Beiersdorf, Germany). Licochalcone A is an extract from Glycyrrhiza
inflata (Chinese liquorice) that has anti-inflammatory property
We received several responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 661): ”Treatment was ran-
domly assigned by a third party“
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk Quote (page 661): ”The trial codes were
broken only after data were analyzed“
The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
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seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 660-661): ”investigator-
blinded and “The tubes were similar in
shape and colour”
Comment: the report provided sufficient
detail about the measures used to blind
study personnel from knowledge of which
intervention a participant received on each
side of the body, however, participants were
not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 660): “investigator-blinded”
Outcomes were investigator and partici-
pant-assessed.
Blinding of key study personnel was en-
sured, and it is unlikely that the blinding
could have been broken, however partici-
pants were not blinded
Comment: we judged this domain to be at
a high risk of bias.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 4/30 (13%) lost to follow-up; bacterial fol-
liculitis (1) incomplete follow-up (3) low
number, and per-protocol analysis
Comment: moderate number of losses
to follow-up, combined with per-protocol
analysis, so we considered domain to be at
an unclear risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk The study appears to be free of other forms
of bias.
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Methods Randomised, double-blind, ’other moisturiser’-controlled study
Setting
Two outpatient dermatology clinics Makati City, Philippines
Date of study
Unspecified. Study duration 4 weeks
Participants N = 52 (25 female, 27 male)
Mean age = 32 years
Inclusion criteria of the trial
• 18 to 40 years
• Newly diagnosed with atopic dermatitis (modified Hanifin major criteria)
• Low to high moderate objective SCORAD index (European Task Force on Atopic
Dermatitis 1993)
Exclusion criteria of the trial
• Topical steroids or topical or oral antibiotics in the previous 2 weeks
• Grossly infected lesions needing oral or intravenous antibiotics and ancillary
therapy
• Dermatologic diagnoses other than atopic dermatitis
• Previous hypersensitivity to coconut or olive oil
• Diabetes mellitus or compromised immune status.
Randomised
N = 52 (virgin coconut oil group = 26, virgin olive oil group = 26)
Withdrawals/losses to follow-up
No dropouts or protocol violators
Baseline data
Mean objective SCORAD: virgin coconut oil group 39.2 (SD 6.4), virgin olive oil group
36.6 (SD 6.3)
Colonisation with Stapylococcus aureus: virgin coconut oil group 20/26, virgin olive oil
group 12/26
Interventions Intervention
• Virgin coconut oil (VCO) massaged twice daily into skin for several seconds for 4
weeks (N = 26)
Comparator
• Virgin olive oil (VOO) massaged twice daily into skin for several seconds for 4
weeks (N = 26)
No other moisturisers, creams, or oil-based products were allowed
Outcomes Assessments (2): baseline and week 4
Outcomes of the trial (as reported)
• Staphylococcus aureus colony growth and growth effectiveness
• Objective SCORAD Severity Index (O-SSI) (Kunz 1997)
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 309): “the randomization key,
and the codes were carried out by the phar-
macist of Skin Sciences Laboratory, Inc.,
and was disclosed to the investigators only
at the end of the study” and “underwent
simple concealed random allocation (by
drawing rolled pieces of paper labeled ”A“
or ”B“) to control or treatment arms by the
two dermatology residents, both of whom
were blind to the codes”
Comment: probably done.
Allocation concealment (selection bias) Low risk Quote (page 309): “the randomization key,
and the codes were carried out by the phar-
macist of Skin Sciences Laboratory, Inc.,
and was disclosed to the investigators only
at the end of the study” and “repackaged
in uniform medicinal opaque plastic bot-
tles with a small opening to mask the color
and scent of both oils”
Comment: central allocation, de-identified
bottles; allocation appears to have been ad-
equately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 208-209): “double-blind” and
“repackaged in uniform medicinal opaque
plastic bottles with a small opening to mask
the color and scent of both oils”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
of low risk
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 208-209): “double-blind” and
“repackaged in uniform medicinal opaque
plastic bottles with a small opening to mask
the color and scent of both oils”
Outcomes were investigator-assessed.
Comment: the report provided sufficient
detail about the measures used to blind out-
comes assessors from knowledge of which
301Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Verallo-Rowell 2008 (Continued)
intervention a participant received, to per-
mit a clear judgement of low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote (page 311 ): “There were no drop-
outs or protocol violators”
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the outcomes mentioned in the
Methods section appeared to have been re-
ported
Other bias Unclear risk There was baseline imbalance regarding
colonisation with S aureus in favour of the
virgin oil group (77% versus 46%).
Wanakul 2013
Methods Randomised, double-blind, active-controlled, within-participant study
Setting
Multicentre (4) in Bangkok, Thailand
Date of study
March 2010 to December 2011. Duration of intervention: 4 weeks followed by 4 weeks
open label licochalcone A
Participants N = 55 (28 female, 27 male)
Mean age = 3.1 years
Inclusion criteria of the trial
• 3 months to 14 years old
• Atopic dermatitis of mild to moderate severity (SCORAD < 40), and had an
active flare
Exclusion criteria of the trial
• Skin infection
• Topical corticosteroid and/or topical calcineurin inhibitor < 2 weeks prior to
study entry
Randomised
N = 55 to either side of the body (within-participant)
Withdrawals/losses to follow-up
3/55 (5.5%), reasons unreported
Baseline data
Mean SCORAD: licochalcone side 26 (SD 8.8), hydrocortisone 1% side 26 (SD 9.8)
Mean TEWL (g/m²/h): licochalcone side 29 (SD 12.1), hydrocortisone 1% side 27 (SD
14.0)
Interventions Intervention
• Licochalcone A lotion twice daily on one side for 4 weeks
Comparator
• Hydrocortisone acetate 1% lotion twice daily on contralateral side for 4 weeks
After 4 weeks both sides were treated with licochalcone A lotion. We only include the
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first 4 randomised weeks
Outcomes Assessments (3): baseline, weeks 2 and 4
Outcomes of the trial (as reported)
• SCORAD (European Task Force on Atopic Dermatitis 1993)
• TEWL: evaporimeter Cutometer MPA580 of Courage & Khazaka, Cologne,
Germany
• Adverse events
Denotes outcomes prespecified for this review
Funding source Quote (page 1140): “The present study was supported by Beiersdorf (Thailand) Co.
Ltd. The sponsor had no influence on study design, data collection, and data analyses”
Declaration of interest None declared
Notes Licochalcone in ceramide and linoleic acid lipid base formulation (Eucerin Soothing
lotion 12% omega, Beiersdorf, Germany). Licochalcone A is an extract of Glycyrrhiza
inflata (Chinese liquorice) that has anti-inflammatory property
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1136): “The assignment of ap-
plying the test substance was performed by
block randomization by the principal in-
vestigator to all four sites before the present
study was started”
Comment: probably done.
Allocation concealment (selection bias) Unclear risk Quote (page 1136): “These code numbers
were assigned sequentially so that the pa-
tients were enrolled in each site” and “sup-
plied in similar containers”
Comment: although this suggests cen-
tral allocation with delivering de-identi-
fied containers to the 4 study sites, the
principal investigator generated the ran-
domisation sequence and it remains un-
clear whether the allocation sequence was
adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 1136): “During the present
study, investigators and patients were
blinded regarding the use of either mois-
turizer containing Lic A lotion or 1% hy-
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drocortisone lotion, which were supplied
in similar containers”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partic-
ipant received on each side of the body, to
permit a clear judgement of low risk
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 1136): “During the present
study, investigators and patients were
blinded regarding the use of either mois-
turizer containing Lic A lotion or 1% hy-
drocortisone lotion, which were supplied
in similar containers”
Outcomes were investigator-assessed as
well as participant-assessed
Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/55 (5.5%) lost to follow-up, reasons un-
reported. Per-protocol analysis
Comment: low number of losses to follow-
up, and although per-protocol analysis, we
considered this domain to be at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the outcomes mentioned in the
Methods section appeared to have been re-
ported
Other bias Low risk The study appears to be free of other forms
of bias.
Weber 2015
Methods Randomised, controlled (inactive), study
Setting
Single dermatology centre, Colorado Springs, CO, USA
Date of study
Unspecified. Duration of intervention: 6 months (study consisted of 3 phases, we only
included the second, i.e. the maintenance phase)
Participants N = 45 (21 female, 24 male)
Mean age = 3.5 years (7 months to 11 years 5 months)
Inclusion criteria of the trial
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• Infants and children aged 3 months to 12 years
• History of atopic dermatitis meeting the Hanifin and Rajka criteria (Hanifin
1980)
Exclusion criteria of the trial
• Active lesions or eczema flares
• Topical moisturising products < 2 days prior to study enrolment
• Eczema treatment products < 5 days prior to study enrolment
Randomised
N = 45 (moisturiser group = 21, control group = 24)
Withdrawals/losses to follow-up
2/45 overall (4.4%); moisturiser group 1/21, control group 1/24
• Withdrew consent: moisturiser group 1/21, control group 0/24
• Adverse event: moisturiser group 0/21, control group 1/24
Baseline data
“The eczema history questionnaire completed at baseline showed that 78% of subjects
had flared 3 to 4 times in the previous 12 months, while 18% had flared 1 to 2 times
during this time period”
Interventions Washout phase of 2 weeks, then maintenance phase
Intervention
• Moisturiser (Eucerin Eczema Relief Body Creme) once daily and a cleanser for 6
months (N = 21)
Comparator
• Cleanser only, once daily for 6 months (N = 24)
In case of acute therapy for active atopic dermatitis lesions Eucerin Eczema Relief Instant
Therapy was provided and participants entered the Treatment phase for 4 weeks
Outcomes Assessments (4): baseline, weeks 2, 6 and until flare
Outcomes of the trial (as reported)
• Number of participants who flared: clinical grading of eczema symptoms of
lesions, including erythema, pruritus, exudation, excoriation, and lichenification (0 =
none, 1 = mild, 2 = moderate, 3 = severe), and by the ADSI, 0-15 scale (Holm 2007)
Denotes outcomes prespecified for this review
Funding source None declared but 3 of the authors were employees of Beiersdorf, therefore it is most
likely that the study was funded by Beiersdorf
Declaration of interest Quote (page 485): “Teresa M. Weber PhD is an employee of Beiersdorf Inc, the manu-
facturer of Eucerin Eczema Relief Body Creme and Eucerin Eczema Relief Flare Treat-
ment. Alexander Filbry PhD and Frank Rippke MD are employees of BeiersdorfAG.
Frank Samaria MD and Michael J. Babcock MD have no conflicts of interest to declare”
Notes Eucerin Eczema Relief Body Creme, Seiersdorf, Wilton, CT contains 1% colloidal
oatmeal, licochalcone A (anti-inflammatory property), ceramide 3, an epidermal bar-
rier Iipid, aqua, glycerol, castor-oil-plant (Ricinus communis) seed oil, mineral oil, cetyl
alcohol, glyceryl sterate, caprylic/capric triglyceride, octyldodecanol, cetyl palmitate,
PEG-40 stearate, Chinese liquorice (Glycyrrhiza inflata) root extract, 2-hexanediol, phe-
noxyethanol, piroctone olamine, caprylyl glycol, ethylhexylglycerin, benzyl alcohol, cit-
305Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Weber 2015 (Continued)
ric acid
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 479): “randomly assigned”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “In order to
enroll subjects across the inclusion age
range and to assure approximately equal
age distribution in the two treatment cells
(moisturizer vs. no moisturizer), subjects
were randomized into 3 age groups, 3
months up to 12 months, >12 months to
24 months, and >24 months to 12 years.
Therefore the study coordinator created 3
randomization lists (1 per age group) with
subject number codes”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “treatment
cell allocation and product distribution was
handled separately, in a different part of the
clinical site from the examination rooms,
away from the investigator. The investiga-
tor was not involved in cell allocation, nor
dispensing the treatment supplies”
Comment: form of central allocation. Al-
location appears to have been adequately
concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No reporting of measures used to blind
study participants and personnel from
knowledge of which intervention a partic-
ipant received
Comment: the outcome was likely to be
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influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported. Outcomes were in-
vestigator-assessed.
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/45 (4.4%): moisturiser group 1/21, con-
trol group 1/24. Per-protocol analysis
Comment: low number of losses to follow-
up, and although per-protocol analysis con-
sidered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the outcomes mentioned in the
Methods section appeared to have been re-
ported
Other bias Low risk The study appears to be free of other forms
of bias.
Wilhelm 1998
Methods Randomised, double-blind, vehicle-controlled, within-participant study
Setting
ProDERM Institut für Angewandte Dermatologische Forschung, Schenefeld, Germany
Date of study
Unspecified. Duration of the intervention 4 weeks
Participants N = 80 (58 female, 22 male)
Mean age not reported
Inclusion criteria of the trial
• 18-55 years of age with mild to moderate atopic dermatitis according to the
criteria of the UK Working party (Williams 1994)
• Xerosis cutis (dry skin)
Exclusion criteria of the trial
• Severe atopic dermatitis
• Topical corticosteroids or urea-containing creams < 2 weeks prior to study entry
• Systemic corticosteroids or antihistamines < 4 weeks prior to study entry
Randomised
N = 80 to either body side (within-participant)
Withdrawals/losses to follow-up
3/80 (3.8%), reasons unreported
Baseline data
65% experience acute episode of atopic dermatitis within last year, 72.5% suffered from
moderate to severe itch
Mean sum score of erythema, dryness, induration/papules: urea cream side 4.05, vehicle
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side 4.11
Mean corneometry: urea cream side 48.6 (SD 9.1), vehicle side 48.2 (SD 10.0)
Interventions Intervention
• Urea 10% cream (Laceran) twice daily for 4 weeks on one side of the body
Comparator
• Vehicle cream twice daily for 4 weeks on contralateral side of the body
During the study no systemic treatments with corticosteroids, antihistamines, NSAIDs,
cytostatic drugs or immunotherapy, nor topical treatments were permitted
Outcomes Assessments (4): baseline, weeks 1, 2 and 4
Outcomes of the trial (as reported)
• Skin hydration: corneometry, Corneometer CM 820, Courage & Khazaka,
Cologne, Germany
• Erythema, dryness, induration/papules: sum score of 5-point Likert scale per sign
(0 = no, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe)
• Itch and feeling of skin tension: 5-point Likert scale (0 = no, 1 = mild, 2 =
moderate, 3 = severe, 4 = very severe)
• Efficacy according to participants
• Tolerance
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared, but 1 of the investigators was an employee of Beiersdorf, Hamburg,
Germany, the manufacturer of the drug under investigation
Notes Vehicle contains: benzyl alcohol, paraffin, sodium lactate, magnesium stearate, ceresin,
glyceryl diisostearate, isopropyl palmitate, wool alcohols, magnesium sulphate, purified
water
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 26): “randomised”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
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seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 165): “double-blind”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received on each side of
the body, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 165): “double-blind”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/80 (3.4%), reasons unreported. Per-pro-
tocol analysis.
Comment: low number of losses to follow-
up, and although per-protocol analysis con-
sidered as at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the Methods section
appeared to have been reported
Other bias Low risk Comment: the study appeared to be free of
other forms of bias
Wirén 2009
Methods Randomised, controlled (inactive) study
Setting
Multicentre (5), dermatology outpatient clinics in Sweden
Date of study
Unspecified. Duration of intervention: 3 weeks for treatment phase, and 6 months
maintenance phase. We only include the data from the maintenance phase
Participants N = 44 (32 female, 12 male)
Mean age = 33.5 years
Inclusion criteria of the trial
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• Known to the clinic for chronic atopic disease, or consecutively diagnosed with
atopic dermatitis according to Hanifin and Rajka (Hanifin 1980)
• Typical lesion on an easily inspected body area, such as arms, legs, chest, abdomen
or back, in addition to possible eczema elsewhere
• The degree of eczema on the identified area had to have an initial score of at least
6 according to the ADSI (Holm 2007)
Exclusion criteria of the trial
• Any concomitant medications that might have affected the study’s outcome
Randomised for maintenance phase
N = 44 (moisturiser group = 22, no moisturiser = 22)
Withdrawals/losses to follow-up
No losses to follow-up reported
Baseline data
Mean TEWL (g/m²/h): moisturiser group 11.9, no moisturiser 14.1




• Moisturiser (Canoderm cream 5%) twice daily for 6 months (N = 22)
Comparator
• No treatment for 6 months (N = 22)
Concomitant treatment of other body areas with other topical preparations (e.g. cos-
metics and corticosteroids) was allowed throughout the study
Outcomes Assessments (2): baseline and week 3
Outcomes of the trial (as reported)
• Relapse (Langan 2006)
• TEWL at 3 weeks: DermaLab, Cortex Technology, Hadsund, Denmark; open
chamber
Denotes outcomes prespecified for this review
Funding source None declared, but the drug under investigation is manufactured by ACO HUD
NORDIC AB, Upplands Väsby, Sweden
Declaration of interest Quote (page 1267): “None declared”, but the first author was an employee of ACO
HUD NORDIC AB, Upplands Väsby, Sweden, the manufacturer of the drug under
investigation
Notes Betnoderm ACO HUD AB, Upplands Väsby, Sweden or Betnovat GlaxoSmithKline,
Solna, Sweden
Canoderm cream 5%, ACO HUD NORDIC AB, Upplands Väsby, Sweden; oil-in-water
emulsion containing fractionated coconut oil, emulsifying wax, hydrogenated canola
oil, propylene glycol, carbomer, dimethicone, hard paraffin, glycerol polymetacrylate,
propyl- and methyl parahydroxybenzoate, sodium lactate solution, lactic acid, glyceryl
stearate, polyoxyethylene stearate, purified water
The co-publication, Hjalte 2010, under the primary reference, contains economic out-
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comes
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1268): “randomized”
Comment: insufficient detail was reported
about the method used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After email communication: “Randomisa-
tion was performed by the Sponsor and
there was one randomisation list for each
part of the study. The randomization was
computer aided (Excel). The investigator
kept the randomisation lists in a sealed
envelope only to be opened in case of a
SAE. When patients were included in the
first part of the study, patients received a
chronological identification number and
received one of the interventional drugs la-
belled with the chronological identification
number. If patients were eligible for the part
two of the study, then they were to receive
either Canoderm or no treatment, also ac-
cording to the predetermined randomiza-
tion list. In this part of the study, blocked
randomization (balanced within blocks of
20) were used to ensure equal number of
Canoderm treatment and no treatment”
Comment: probably done.
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After email communication: “The inves-
tigator kept the randomisation lists in a
sealed envelope only to be opened in case of
a SAE...” (see above) and “The Sponsor dis-
pensed the intervention labelled with ap-
propriate identification number”
Comment: central allocation; allocation
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appears to have been adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No reporting of measures used to blind
study participants and personnel from
knowledge of which intervention a partic-
ipant received
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported. Outcomes were in-
vestigator-assessed.
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the outcomes mentioned in the
Methods section appeared to have been re-
ported
Other bias Low risk The study appears to be free of other forms
of bias.
Wu 2014
Methods Randomised, active-controlled study
Setting
Department of Dermatology, Guangxi Minzu Hospital, Nanning, China
Date of study
February 2012 to July 2013. Duration of intervention: 3 weeks with 2 weeks of follow-
up
Participants N = 125 (62 female, 63 male)
Mean age = 47 years
Inclusion criteria of the trial
• 25 to 70 years of age with eczema.
• The total area of skin lesion < 40% body surface area
• Persistent skin lesions lasting > 16 weeks
Exclusion criteria of the trial
• Severe bacterial, viral or fungal infection
• Skin lesion located on face or in skin folds
• Allergy to the medication or drugs with similar structure
• Severe liver or kidney disease, haematological disease, diabetes mellitus, psychosis,
drug abuse or alcoholism
• Pregnancy or breastfeeding
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• Steroid or NSAID use locally 2 weeks prior to study entry
• Systemic steroid or immunosuppressive drug use 4 weeks prior to study entry
• Enrollment in other clinical trials 4 weeks prior to study entry
Randomised
N = 125 (pilot group = 63, control group = 62)
Withdrawals/losses to follow-up
20/125 overall (16%): pilot group 3/63, control group 17/62; reasons unreported
Baseline data
Mean disease duration: pilot group 18.5 months (SD 35.7), control group 20.3 months
(SD 34.6)
Mean EASI: pilot group 18.9 (SD 0.86), control group 17.94 (SD 0.71)
Interventions Intervention
• Moisture and softening cream combined with flumethasone ointment twice daily
for 3 weeks (N = 63)
Comparator
• Flumethasone ointment twice daily for 3 weeks (N = 62)
Outcomes Assessments (6): baseline, weeks 1, 2, 3, 5 and 8
Outcomes of the trial (as reported)
• EASI (Hanifin 2001)
• Flare-up
• Adverse events
Denotes outcomes prespecified for this review
Funding source None declared
Declaration of interest None declared
Notes We mailed investigators numerous times to clarify study details, but received no response
(Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Translated “Allocated by using a random
number table”
Comment: probably done.
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
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tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No reporting of measures used to blind
study participants and personnel from
knowledge of which intervention a partic-
ipant received
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported. Outcomes were in-
vestigator-assessed as well as participant-as-
sessed
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 20/125 (16%): pilot group 3/63, control
group 17/62, reasons unreported. Per-pro-
tocol analysis
Comment: moderate dropout rate, but
very unbalanced, which, combined with
per-protocol analyses, poses a high risk of
bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the outcomes mentioned in the
Methods section appeared to have been re-
ported
Other bias Low risk The study appears to be free of other forms
of bias.
Åkerström 2015
Methods Randomised, double-blind, ’other moisturiser’-controlled study
Setting
Multicentre (15) in Finland, Noway and Sweden
Date of study
September 2011 to September 2012. After the stabilisation phase, participants entered
the randomised maintenance phase of 180 days. We only include the data from the
maintenance phase
Participants N = 172 (101 female, 71 male)
Mean age = 28 years
Inclusion criteria of the trial
• ≥ 18 years old, diagnosed with atopic dermatitis according to UK working party’s
criteria 1994 (Williams 1994)
• visible atopic eczema of the body surface area, corresponding to a total area of at
314Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Åkerström 2015 (Continued)
least the size of the palm of a hand
Exclusion criteria of the trial
• Eczema exclusively on the hands
• Any concomitant medications that might affect the study’s outcome
• Known hypersensitivity or allergy to any of the study products
• Any serious current medical condition that could interfere with the evaluation of
the study results
• People assessed by the investigator to have poor compliance
• Enrolled in any investigational study or using an investigational drug within 3
months prior to the screening visit
• Pregnant, breastfeeding, or planning to become pregnant during the study time
Randomised
N = 172 (barrier-strengthening moisturiser = 87, reference cream = 85)
Withdrawals/losses to follow-up
7/172 overall (4.1%): barrier-strengthening moisturiser 3/87 (3.4%), reference cream 4/
85 (4.7%)
• Lost to follow-up: barrier-strengthening moisturiser 3/87, reference cream 3/85
• Adverse events: barrier-strengthening moisturiser 0/87, reference cream 1/85
Baseline data stabilisation phase
Mean SCORAD: barrier-strengthening moisturiser 35.62 (SD 12.24), reference cream
37.68 (SD 13.56)
Baseline data maintenance phase:
Mean SCORAD: barrier-strengthening moisturiser 6.14 (SD 6.38), reference cream 5.
97 (SD 5.84)
Interventions Stabilisation phase: once-daily topical mometasone furoate cream 0.1% (Elocon, Merck
Sharp & Dohme B.V, Netherlands) on the trunk and extremities and/or hydrocortisone
acetate cream 1% (Hyderm ACO Hud Nordic, Upplands Väsby, Sweden) on the face,
groin and armpits. In addition, participants used a medicinal moisturiser containing
20% glycerol (Miniderm, ACO Hud Nordic, Upplands Väsby, Sweden)
Maintenance phase
Intervention
• Barrier-strengthening moisturiser (Canoderm cream 5%) twice daily for 180 days
(N = 87)
Comparator
• Reference cream (Miniderm) without urea twice daily for 180 days (N = 85)
Outcomes Assessments (4): baseline, end of stabilisation phase (visit 2), relapse visit (visit 3), day
180 (visit 4)
Outcomes of the trial (as reported)
• Relapse: an episode that, from the patient’s perspective, required escalation of
treatment of the study areas
• SCORAD (European Task Force on Atopic Dermatitis 1993)
• Quality of life: EQ-5D
• IGA
• Adverse events
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Denotes outcomes prespecified for this review
Funding source Quote (page 591): “This study was sponsored by ACO Hud Nordic AB, an Omega
Pharma Company and partly funded by the Knowledge Foundation, Sweden. The spon-
sor was responsible for the study design, co-ordination and collection of data provided by
the investigators. The authors were responsible for data analysis, manuscript preparation
and the decision to submit the manuscript for publication”
Declaration of interest Quote (page 591):“U.Å., K.W. and P.S. are employees of ACO Hud Nordic AB. M.G.
was an employee at ACO Hud Nordic AB at the time when the study was conducted. Å.
S. participated as principal investigator, but did not receive any personal compensation.
S.R. has acted as an expert and/or given lectures for ACO Hud Nordic AB, Dignity
Sciences, and Astellas Pharma Europe. M.B. has acted as an expert and/or given lectures
for ACO Hud Nordic AB. M.L. has acted as a paid consultant to ACO Hud Nordic AB
and has received funding for research carried out in this work.”L.K., none declared. L.
R., none declared. T.L., none declared”
Notes Canoderm (ACO Hud Nordic, Sweden), an oil-in-water emulsion containing 5% urea,
fractionated coconut oil, polysorbate 60, hydrogenated canola oil, propylene glycol,
carbomer, dimethicone, hard paraffin, glyceryl polymethacrylate, propyl- and methyl
parahydroxybenzoate, sodium lactate, lactic acid, glyceryl stearate, polyoxyethylene
stearate, cetostearyl alcohol and purified water
The reference cream was Miniderm without glycerol (ACO Hud Nordic, Upplands
Väsby, Sweden) and contains white soft paraffin, hydrogenated canola oil, light liquid
paraffin, glyceryl stearate, polyoxyethylene stearate, cetostearyl alcohol, hard paraffin,
dimethicone, cholesterol, propyl- and methyl parahydroxybenzoate and purified water
We received responses to our request for study details (Table 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 588): “Randomization to test
cream and reference cream groups in 1:1,
was performed according to a randomiza-
tion list, with a block size of 4, and strat-
ified for country with one randomization
list for each country” and “The randomiza-
tion was prepared by an independent statis-
tician using a validated SAS® program”
Comment: probably done.
Allocation concealment (selection bias) Low risk Quote (page 558): “The patients were pro-
vided with a randomization number” and
“All study personnel at the clinics and the
sponsor staff remained blinded during the
maintenance part of the study”
Comment: there was insufficient informa-
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tion to permit a clear judgement
After email communication: “The clinics
received sealed envelopes containing indi-
vidual treatment codes. The Investigator
kept the envelopes in a secure, limited-ac-
cess location to prevent inadvertent break-
ing of the blind”
Comment: central allocation; allocation
appears to have been adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 557-8): “double-blind” and
“All study personnel at the clinics and the
sponsor staff remained blinded during the
maintenance part of the study”
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
After email communication: “The test
cream and the reference cream used in
the maintenance phase were produced by
Bioglan, Malmö, Sweden. The creams were
packaged in identical plastic pump jars of
500 g and in tubes of 100 g” and “Before
the products were distributed to the pa-
tients, they were also be labelled with the
randomisation number”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 557-8): “double-blind” and
“All study personnel at the clinics and the
sponsor staff remained blinded during the
maintenance part of the study”
Outcomes were investigator-assessed as
well as participant-assessed.
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
After email communication: (see domain
above)
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Blinding of the outcomes assessors, key per-
sonnel, and participants was ensured, and
it was unlikely that the blinding could have
been broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7/172 (4.1%); barrier-strengthening mois-
turiser 3/87 (3.4%), reference cream 4/
85 (4.7%), reasons reported. Intention-to-
treat analysis
Comment: low number of losses to follow-
up, combined with intention-to-treat anal-
ysis, so considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was avail-
able (EudraCT Number: 2011-001068-
23) and the prespecified outcomes and
those mentioned in the Methods section
appear to have been reported
Other bias Low risk The study appears to be free of other forms
of bias.
AD: atopic dermatitis
ADSI: Atopic Dermatitis Severity Index
BHT: butylated hydroxytoluene
BSA: body surface area
CDLQI: Children’s Dermatology Life Quality Index
cis-UCA: cis urocanic acid
DASI: dry skin area and severity index
DFI: Dermatitis Family Impact
DLQI: dermatology quality of life index
EASI: eczema area and severity index
ECG: electrocardiograph
EDTA: ethylenediaminetetraacetic acid
GCS: Global Change Scale
GIS: Global Impression Scale
HI: hydration index
HPA: hypothalamic-pituitary-adrenal
IDQOL: the Infant’s Dermatitis Quality of Life index




MVE: multilamellar vesicular emulsion
NESS: Nottingham Atopic Eczema Severity Score
NSAIDs: non-steroidal anti-inflammatories
OTC: over-the-counter
PPARα: peroxisome proliferator-activated receptor alpha
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PCA: pyrrolidone carboxylic acid
PEG: polyethylene glycol
PGA: Physician Global Assessment
PUVA: photochemotherapy, a type of ultraviolet radiation treatment
POEM: Patient-Oriented Eczema Measure
QoL: quality of life
SCORAD: scoring atopic dermatitis
TEWL: transepidermal water loss
TIS: three item severity score
UVA, UVB: types of ultraviolet light
VAS: visual analogue scale
VCO: virgin coconut oil
VOO: virgin olive oil
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Duggan 2015 After reading full text, appeared to be a report on BATHE trial, BEEP study and CLOTHES trial and no
primary research
Dutronc 2011B Two studies, one RCT in healthy volunteers, second study observational in atopic dermatitis
Schoelermann 2003 Report on two studies, one was a CCT in atopic dermatitis
Szczepanowska 2008 CCT: email communication with investigators confirmed participants were allocated by alternation. “We
included patients consecutively and every second patient was assigned to one group, while the others to the
second treatment group”
Yang 2010 After translation, appeared to be a CCT
Abbreviations
BATHE: Bath Additives in the Treatment of cHildhood Eczema (see Santer 2015)
BEEP: Barrier Enhancement for Eczema Prevention
CCT: controlled clinical trial
CLOTHES: Clothing for the relief of Eczema Symptoms
RCT: randomised controlled trial
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ACTRN12615000782538
Trial name or title A randomised, double blind, placebo controlled comparative trial of ceramide cream and ceramide cleanser
in the management of moderate eczema in adults
Methods Randomised, double-blind, placebo-controlled study, Braeside Vic, Australia
Participants N = 100
Inclusion criteria of the trial
• Male or females over 18 years of age
• A confirmed diagnosis of eczema according to the criteria of Hanifin & Rajka for at least one year, with
moderate severity (score of 10 to 20) as evaluated with the EASI
• Free of any dermatological or systemic disorder which could interfere with the results, at the discretion
of the Investigator
• Free of any acute or chronic disease that might interfere with or increase the risk of study participation.
• Completed a preliminary medical history form
• Read, understood and signed an informed consent document relating to the specific type of study
concerned
• Able to co-operate with the Investigator and research staff, willing to have the test materials applied
according to the protocol, and to complete the full course of the study
Exclusion criteria of the trial
• < 18 years of age
• History of allergies or adverse reactions to moisturisers or the components of the specific products
being tested
• Use of other moisturising products or other topical eczema therapies in the week prior to participation
in the trial
• Use of other moisturising products or other topical eczema therapies during the trial
• Individuals taking any medication (topical or systemic) that might mask or interfere with the test
results, i.e. calcineurin inhibitors, oral corticosteroids
• A history of any acute or chronic disease that might interfere with, or increase, the risk of study
participation
• Excessive hair on the test sites
• Diagnosed with chronic skin allergies
• Pregnant or nursing females
Interventions Intervention
• Ceramide-dominant physiological lipid-based hydrating cleanser and moisturiser for 4 weeks
Comparator
• Placebo (no further information) for 4 weeks
Outcomes Assessments (2): baseline, day 28
Outcomes of the trial (as reported)
• Percentage change from baseline in EASI score
Denotes outcomes prespecified for this review
Starting date Not yet recruiting (website accessed 08-02-2016)
Contact information Dr Kerryn Greive (kerryng@egopharm.com)
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Trial name or title A randomised double blinded placebo controlled study investigating Atopis for the improvement of skin
health in subjects with eczema
Methods Randomised, double-blind, placebo-controlled study in St Rangiora, Christchurch, New Zealand
Participants N = 60
Inclusion criteria of the trial
• Healthy males or females, 16 to 70 years of age
• Mild to moderate eczema; to be determined using the Eichenfield Revised Criteria of Hanifin and
Rajka at screening visit
• Judged by the investigator to be in general good health on the basis of medical history
• Agree to use the study-supplied investigational product as the only body cosmetic applied to irritated
skin
• Agree to stop all dietary supplements including probiotics, dermatological medications and creams for
eczema, for the duration of the study
• Agree not to change their current diet or exercise program for the duration of the study
• Understand the study procedures and sign forms to provide informed consent to participate in the
study and authorization for release of relevant protected health information to the study investigator
• Females of child bearing potential must agree to use appropriate birth control methods for the
duration of the study
Exclusion criteria of the trial
• Clinically significant renal, hepatic, endocrine (including diabetes mellitus), cardiac, pulmonary,
pancreatic, neurologic, hematologic, or biliary disorder
• Known allergy or sensitivity to herbal products
• Use of systemic corticosteroids in the past 30 days
• History of malignancy in the past two years
• Recent history of alcoholism (within 12 months) or strong potential for alcohol or substance abuse
• Participation in a clinical study with exposure to any non-registered drug product within 30 days prior
to the study
• Individual has a condition the investigator believes would interfere with his or her ability to provide
informed consent, to comply with the study protocol or which might confound the interpretation of the
study results or put the person at undue risk, including people who are bed- or wheelchair-bound
• Pregnant or lactating during the duration of the study
• Smoking - must be nonsmoker for at least 12 months prior to screening
Interventions Intervention
• Atopis skin cream, which contains the extract DEC033 at 10% (contains peptilipids and fatty acids),
cetearyl olivate, sorbitan olivate, shea butter, safflower oil, macadamia oil, glycerol, vitamin E, geogard
(preservative), tangerine oil, deionised water. Cream applied topically twice daily to the affected areas for 4
weeks
Comparator
• Placebo twice daily for 4 weeks
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Outcomes Assessments (3): baseline, weeks 2, and 4
Outcomes of the trial (as reported)
• Change in redness - as assessed using SCORAD (VAS) and dermatological examination by the site
investigator
• Change in itching - as assessed using SCORAD (VAS) and dermatological examination by the site
investigator
• Change in severity scoring of atopic dermatitis (SCORAD)
• Change in scaling; VAS
• Change in the number of eczema skin lesions
Denotes outcomes prespecified for this review
Starting date 04-09-2015, follow-up complete (website accessed 08-02-2016)
Contact information Dr Iona Weir (iona@decima.co.nz) and Dr Simon Carson (simon@sctrials.co.nz)
Notes No study results posted
ACTRN12615001343594
Trial name or title Pilot study comparing two moisturisers, Emulsifying ointment B.P. and Epaderm topical ointment in children
with eczema
Methods Randomised, double-blind, controlled within-participant study in Wellington, New Zealand
Participants N = 60
Inclusion criteria of the trial
• Eczema with a severity on SCORAD of ≥ 5 for objective measures only
• Children with eczema aged 0 to 5 years
• Parent/caregiver able to speak enough English to understand the trial and be able to complete the trial
diary
Exclusion criteria of the trial
• Other serious chronic disease that might require immunosuppressive therapy, as decided on a case by
case basis by the principal investigator
• Use of systemic antibacterial therapy 1 week prior to starting study treatment
• Children with co-morbid conditions that would require long term systemic corticosteroid therapy
during study treatment. Systemic steroid use for ≤ 5 days for another reason such as asthma permissible
• Severe eczema requiring regular use of potent topical steroids
• Family unable to comply with study requirements as judged by the investigator, such as the desire to
use other non-study eczema medications, unless medically indicated
• Use of potent topical steroids within 1 month of enrolment (e.g. mometasone, betamethasone,
fluticasone, clobetasol)
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ACTRN12615001343594 (Continued)
Interventions Intervention
• Epaderm ointment (active ingredient Cetomacrogol Emulsifying Wax BP) for 8 weeks
Comparator
• Emulsifying ointment (BP) (active ingredient white soft paraffin and liquid paraffin) for 8 weeks
Outcomes Assessments (5): baseline, weeks 2, 4, 6 and 8
Outcomes of the trial (as reported)
• Change in SCORAD scores
• Differences between SCORAD and EASI
• Assessment of the usefulness of measuring skin temperature in children with skin inflammation due to
eczema by using infrared camera. Mean side skin temperature measurements will be compared with
SCORAD scores on skin treated with the 2 moisturisers
• Comparison skin flora on affected and unaffected skin prior to and after treatment
Denotes outcomes prespecified for this review
Starting date Recruiting (website accessed 08-02-2016)
Contact information Marina.Dzhelali@ccdhb.org.nz and thorsten.stanley@otago.ac.nz
Notes
ChiCTR-IOR-15007139
Trial name or title Effect and efficacy of a linoleic acid-ceramide containing moisturizer as an adjunctive therapy in the treatment
of atopic dermatitis: a randomized controlled trial
Methods Randomised controlled trial in Shanghai
Participants N = 10
Inclusion criteria of the trial
• People with clinically diagnosed atopic dermatitis
• No age limitation
• No limitation on gender
• Participant or legal guardian fully understands the content of the clinical trial, is willing to attend the
research voluntarily and sign the informed consent form
• Physical examination is qualified, participant does not have previous severe systemic disease
Exclusion criteria of the trial
• Other skin diseases
• Physical examination failed to qualify for enrollment
• Pregnant or lactating
• Known allergic history toward drug or moisturiser under study
• Involved in another clinical trial 3 months before enrollment
• Frequently usage of herbal, hypnotics, sedative, stabilisers, or other addictive medication
• Alcoholic, psychotic, or people who cannot follow prescription order
• Utilization of any type of skin moisturiser or topical medication 1 month prior to the screening, or
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during the study period
• Systemic therapies or phototherapy within 3 months of screening or during the study period
Interventions Intervention
• Mometasone furoate 0.1% cream once daily, duration unclear
Comparator
• Mometasone furoate 0.1% cream + moisturiser
Outcomes Assessments unclear
Outcomes of the trial (as reported)
• EASI-50
• EASI
• Normal skin capacitance
• Lesional skin capacitance
• Normal skin TEWL
• Lesional skin TEWL
• Pruritus
Denotes outcomes prespecified for this review
Starting date 2003, completed (website accessed 11-02-2016)
Contact information Xia Li (drlixia@126.com) and Jie Zheng (jie-zheng2001@126.com)
Notes No study results posted. Similar study in chronic eczema is ongoing ChiCTR-IOR-15007140 with 29
participants in each treatment arm. However, unclear if this is atopic eczema
EudraCT2004-002926-23
Trial name or title Evaluation of the impact of the moisturizing milk RV2478B on the use of corticoids and on quality of life,
in a population of children with atopic dermatitis
Methods Open, randomised controlled study in Italy
Participants N = 210
Inclusion criteria of the trial
• Children with atopic dermatitis
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EudraCT2004-002926-23 (Continued)
Outcomes Assessments unclear
Outcomes of the trial (as reported)
• Not specified
Denotes outcomes prespecified for this review
Starting date 2004, completed (website accessed 09-02-2016)
Contact information Not provided, sponsor is Pierre Fabre Médicament
Notes Very little information provided; no study results posted
EudraCT2005-003396-21
Trial name or title Long-term management of atopic dermatitis with the moisturiser V0034 CR. A randomised, placebo-con-
trolled, parallel-groups, double-blind study in infants and children
Methods Randomised controlled trial in Estonia, Finland, Germany, Latvia
Participants N = 300
Inclusion criteria of the trial
• Male or female, aged 3 months to 7 years
• Presenting with atopic dermatitis, out of flare at inclusion
• Atopic dermatitis according to the diagnostic criteria of the UK Working Party (IGA score ≤ 1 at
inclusion)
Exclusion criteria of the trial
• Acute phase of atopic dermatitis with moderate/severe erythema, excoriation, crust, oozing, exudation
• Severe evolutive form of atopic dermatitis requiring systemic corticosteroid treatment and/or antibiotic
or antiviral treatment and/or hospitalisation
• Dermatological disease other than atopic dermatitis liable to interfere with the assessment
• History of serious disease considered by the investigator hazardous for the patient or incompatible with
the study
• Immunosupression
• History of allergy or intolerance to cosmetics
• Use of oral corticosteroids or immunosuppressants within previous month
• Use of antibiotics, topical corticosteroids within previous 15 days
• Use of NSAIDs or antihistamines within previous week
Interventions Intervention
• V0034CR (Dexeryl) cream + Locapred (desonide) 0.1% cream (?)
Comparator
• Placebo + Locapred (desonide) 0.1% cream (?)
Outcomes Assessments (5): baseline, days 7, 14, 21 and 28
Outcomes of the trial (as reported)
To evaluate the overall benefit of a regular treatment by the moisturiser V0034CR in the management of
atopic dermatitis: reduction of corticosteroids consumption, reduction of flares
• Number of days of application of a moderately potent corticosteroid
• Quality of life over the study duration
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• Product effect on the skin dryness and pruritus
• Clinical, local and systemic, safety over the study duration
Denotes outcomes prespecified for this review
Starting date 3-11-2005, completed (website accessed 09-02-2016)
Contact information Not provided, sponsor is Pierre Fabre Médicament, however, see www.fda.gov/iceci/enforcementactions/
warningletters/ucm211391.htm
Notes Not clear from the website if desonide cream was used in both arms. No study results posted
EudraCT2006-000877-30
Trial name or title A 6 week, multi centre study to evaluate the efficacy and safety of E45 complete moisturiser therapy and
E45 itch relief cream in the treatment of mild to moderate atopic eczema compared to a patient’s normal
moisturiser regime defined as the frequent use of moisturisers (not containing lauromacrogols) listed in the
BNF (Harbour Study)
Methods Randomised controlled trial in UK
Participants N = 180
Inclusion criteria of the trial
• Male or female aged 2 to 16 years of age
• Diagnosis of atopic eczema as defined by the UK Working Party criteria and confirmed by a general
practitioner
• Using one of the top 10 moisturisers (excluding lauromacrogols) listed in the BNF
• Diagnosis of atopic eczema defined as mild to moderate by the Rajka and Langeland criteria (score of
3-7.5) and with IGA ≥ 3
• > 2% BSA affected by atopic eczema
• Parental responsibility and written informed consent
Exclusion criteria of the trial
• Pregnant or breast feeding
• Used topical treatments other than moisturisers for the treatment of atopic dermatitis in the 3 days
prior to consent (this includes but is not limited to all topical steroid preparations, tacrolimus,
pimecrolimus, antibiotics)
• Used any light or systemic treatments (including antihistamines) for treatment of atopic dermatitis in
the 28 days prior to consent
• Used systemic corticosteroids for the treatment of any disease in the 28 days prior to consent
• Have or are suspected of previously having any disease (dermatological or other) that might interfere
with the study protocol
• People previously randomised into the study, or who participated in a clinical trial in the 12 weeks
prior to consent
• Used or intend to use any alternative, homeopathic treatments in the 4 weeks prior to consent
• Any previous history of allergy or known intolerance to any of the drugs or formulation constituents
• Those unable in the opinion of the Investigator to comply fully with the study requirements
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Interventions Intervention
• E45 complete moisturiser therapy (group A) for 6 weeks
Comparator 1
• E45 itch relief cream (group B) for 6 weeks
Comparator 2
• Moisturisers (not containing lauromacrogols) listed in the BNF (group C) for 6 weeks
Outcomes Assessments (3): baseline, days 7 and 21
Outcomes of the trial (as reported)
To compare the efficacy of E45 complete moisturiser therapy against an unchanged moisturiser regime along
with the role of E45 anti itch cream in controlling itch. This will be evaluated through validated quality of
life questionnaires, IGA and diary cards
• Change in validated quality of life score (CDLQI) from baseline to week 6, comparing treatment
groups A and C
• Cumulative change in the itch-severity VAS over the course of the study, comparing treatment groups
A and B
• Changes in the quality of life score at weeks 1 and 3; changes in the itch VAS by week; changes in the
DFI questionnaire; changes in the IGA; changes in the itch 4-point grading scale; changes in the SGA
• Number of eczema flares recorded (defined as an IGA ≥ 3)
• Incidence of all adverse events, serious adverse events, and treatment-related adverse events
• Patient satisfaction questionnaire
Denotes outcomes prespecified for this review
Starting date 27-4-2006, ongoing (website accessed 16-2-2016)
Contact information Reckitt Benckiser Healthcare International, no further contact details available
Notes
EudraCT2007-002133-36
Trial name or title A multicenter, randomized, double-blind clinical study to examine the efficacy and safety of Zarzenda in
comparison to Elidel in the management of mild to moderate atopic dermatitis in children and adolescents
Methods Randomised, double-blind, active-controlled study, multicentre in Germany, Spain and Italy
Participants N = 80
Inclusion criteria of the trial
• Mild to moderate atopic dermatitis according to the IGA (IGA 3 or 4)
• History of atopic dermatitis for at least 1 year
• Aged 2 to 17 years at baseline
• Affected BSA: minimum of 5%
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• Participants in whom a treatment with topical corticosteroids is not recommended or is not possible, e.
g. due to: intolerability of topical corticosteroids, lack of efficacy of topical corticosteroids, use in the face
and the neck where the use of topical corticosteroids is not recommended.
• Washout periods to be observed before start of study medication:
◦ ≥ 4 weeks since use of systemic therapy for atopic dermatitis, e.g. systemic corticosteroids
(including inhaled or intranasal > 1 mg/d), cyclosporine A, azathioprine, mycophenolate mofetil, or
phototherapy
◦ ≥ 4 weeks since any vaccination
◦ ≥ 4 weeks since local therapy for atopic dermatitis using tacrolimus or pimecrolimus
◦ ≥ 2 weeks since antihistaminic therapy, unless taken regularly during the previous year
◦ ≥ 2 weeks since local atopic dermatitis therapy using corticosteroids
• ≥ 4 weeks since participation in an investigational drug study
• Willingness to follow all study procedures
• Willingness to avoid excessive exposure of diseased areas to natural or artificial sunlight
Exclusion criteria of the trial
• Pregnancy (in patients with childbearing potential), breast feeding
• Indication for systemic therapy of the atopic dermatitis
• Known sensitivity to Zarzenda, or to any excipients of the formulation or to an extract of the nut
Vitellaria paradoxa (formerly Butyrospermum parkii (shea))
• Known sensitivity to macrolides
• Lymphadenopathy
• Known immune deficiency
• Known hepatic insufficiency
• Known renal insufficiency
• Children with severe excoriations
• Children with clinically active skin infection (e.g. acute and severe impetigo contagiosa)
• Acute herpes simplex, mononucleosis, or mollusca contagiosa infection
• Severe other viral, bacterial, or fungal skin infection (chicken pox, tinea corporis)
• Acute infestations (e.g. head lice, scabies)
• Generalized erythroderma, Netherton’s syndrome
• Any conditions that compromise the child’s ability to understand the patient information, to give
informed consent, to comply with the trial protocol, or to complete the study
• Child is a dependent person, e.g. a relative or family member of the investigator or is a member of the
investigator’s staff
Interventions Intervention
• Zarzenda, dosage and treatment duration unspecified
Comparator
• Pimecrolimus 1% cream, dosage and treatment duration unspecified
Outcomes Assessments (unspecified): baseline and at each visit (information unclear)
Outcomes of the trial (as reported)
• IGA
Denotes outcomes prespecified for this review
Starting date Completed in Germany and Italy, but still ongoing in Spain (website accessed 09-02-2016)
Contact information Not provided, sponsor is INTENDIS GmbH
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Notes Zardenda is another name for Atopiclair. No study results posted
EudraCT2008-003485-25
Trial name or title Impact of the V0034CR 01B moisturiser on atopic dermatitis symptoms in children. A randomised, placebo-
controlled, parallel-groups, double-blind study
Methods Randomised controlled trial in Estonia, France, Germany, Italy, Latvia, Lithuania
Participants N= 550
Inclusion criteria of the trial
• Aged 2 to 7 years
• Atopic dermatitis according to the diagnostic criteria of the UK Working Party
• IGA score ≤1 at inclusion
• Provision of written consent for child’s participation in the study from parent(s) or guardian(s), who
will co-operate with regard to compliance with study-related constraints
Exclusion criteria of the trial
• Acute phase of atopic dermatitis with mild/moderate/severe erythema, excoriation, crust, oozing,
exudation
• Severe form of atopic dermatitis requiring either systemic corticosteroid treatment and/or antibiotic or
antiviral treatment and/or hospitalisation
• Primary bacterial, viral, fungal or parasitic infection
• Ulcerated lesions, acne or rosacea
• Dermatological disease other than atopic dermatitis liable to interfere with the assessment
• History of serious disease considered by the investigator to be hazardous for the patient or
incompatible with the study Immunosuppression
• History of hypersensitivity or intolerance to one of the substances of content of the study drug or
Locapred, or to cosmetics
• Use of oral corticosteroids or immunosuppressants during the previous month
• Use of antibiotics or topical corticosteroids during the previous week
• Use of non-steroid anti-inflammatory drugs or antihistamines during the previous week
• Use of homeopathic treatment during the previous 2 months
• Regular use of food supplements that could, in the opinion of the investigator, modify skin properties
Interventions Intervention (not clear from the study protocol on the website if desonide cream was used in both arms)
• V0034CR 01B (Dexeryl) cream + Locapred (desonide) 0.1% cream (?)
Comparator
• Placebo cream + Locapred (desonide) 0.1% cream (?)
Outcomes Assessments (unspecified): baseline and at each visit (information unclear)
Outcomes of the trial (as reported)
• Mean POEM score measured weekly, over the 12 weeks of treatment
• Impact of the treatment on xerosis: evolution of the SRRC (Scaling, Roughness, Redness, Cracks/
Fissures) score
• Impact of the treatment on the topical corticosteroid use
• Overall efficacy of the treatment by the parents and the investigator
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• Clinical, local and systemic, safety of the treatment over the study duration
Denotes outcomes prespecified for this review
Starting date October 2008, completed in all countries except in France (ongoing) (website accessed 09-02-2016)
Contact information Not provided, sponsor is Pierre Fabre Médicament
Notes No study results posted
EudraCT2008-006844-21
Trial name or title Evaluation of a developmental ‘long lasting’ moisturiser in subjects with dry skin
Methods Randomised, double-blind, controlled, within-participant study in UK
Participants N = 40
Inclusion criteria of the trial
• Eczema sufferers
• Females with essentially ‘non-hairy’ arms and legs, aged 18 to 65 years
• Medically dry skin to arms and lower legs and with baseline Corneometer measurements differing by
≤ 5 units between left and right arms and legs
• Willing to adopt an essentially sedentary lifestyle for the duration of study involvement (i.e. those
willing to refrain from participating in any sports or significant physical activity likely to necessitate
showering/bathing more often than once daily)
Exclusion criteria of the trial
• Any significant concurrent illness or skin disease currently involving arms or legs
• History of skin disease or allergy relevant to the study
• Known allergies to the test products or their ingredients
• Using any topical or systemic medication, or drug, likely to affect the skin response to the test
medicines
• Showing any significant visible skin abnormality or hair growth at the test measurement sites
considered likely to interfere with corneometry
• Participated in an irritation test, on the same skin sites, in the previous month, or a sensitisation test,
on any skin site, during the previous 3 months
• Pregnant or lactating or, if of childbearing potential, are not taking adequate contraceptive precautions
• Concurrent participation in any other safety or efficacy test
• Any irritation, tattoos, scars or birthmarks at the test sites
• Not willing to refrain from removing leg hair (by shaving, waxing, depilation etc.) for at least 48 hours
prior to study participation and for the duration of the study
• Use of oral and topical steroids for any condition within the previous 4 weeks
• Employees of RSSL Pharma or Dermal Laboratories, or an immediate family member (partner,
offspring, parents, siblings or sibling’s offspring) of such employees
Interventions Intervention
• DELP Gel (containing liquid paraffin and isopropyl myristate) for 5 days
Comparator
330Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
EudraCT2008-006844-21 (Continued)
• Doublebase Emollient Gel for 5 days
Outcomes Assessments: unclear
Outcomes of the trial (as reported)
• Difference in effect on skin moisturisation
Denotes outcomes prespecified for this review
Starting date 2008, completed (website accessed 09-02-2016)
Contact information Not provided, sponsor is Dermal Laboratories Ltd
Notes No study results posted
EudraCT2009-010609-35
Trial name or title Is treatment with moisturisers always beneficial? Comparative biophysical and molecular biological studies of
the skin barrier function in patients with atopic dermatitis, ichthyosis vulgaris and X-linked ichthyosis
Methods Randomised, investigator-blinded, controlled study in Sweden
Participants N = 60
Inclusion criteria of the trial
• Participants with atopic dermatitis, ichthyosis vulgaris and X-linked ichthyosis
• 18 to 65 years of age
Exclusion criteria of the trial
• Any other concomitant skin disease
• Pregnancy
Interventions Intervention
• Canoderm cream (urea-containing) for 4 weeks
Comparator 1
• Miniderm cream (glycerol-containing) for 4 weeks
Comparator 2
• Propyless cream (propylene glycol-containing) for 4 weeks
Outcomes Assessments (2): baseline, week 4
Outcomes of the trial (as reported)
• Evaluation of skin barrier function in participants with impaired barrier function
• Improve knowledge of the cause of impaired skin barrier function in participants with atopic
dermatitis, ichthyosis vulgaris and X-linked ichthyosis
Denotes outcomes prespecified for this review
Starting date 2009, ongoing (website accessed 09-02-2016)
Contact information Department of Medical Sciences, Dermatology and Venerology, Uppsala University, Uppsala Sweden, no
further details provided
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Trial name or title Arm immersion test to compare the skin effects of routine bathing with and without the use of an emollient
bath additive
Methods Randomised, investigator-blinded, controlled within-participant study in UK
Participants N = 24
Inclusion criteria of the trial
• 18 to 65 years of age
• History of eczema
• Present with dry skin on the arms and hands
• Prepared to refrain from using moisturisers and moisturising soaps on arms and hands in the week
prior to the study and for the duration of the study
Exclusion criteria of the trial
• Any significant concurrent illness or skin disease at the test sites
• History of other skin disease or allergy relevant to the study
• Known allergies to the test product or its ingredients
• Using any topical or systemic medication or drug likely to affect the skin or its response to treatment
• Eczema visually differing in severity between left/right test sites
• Significant visible skin abnormality at the test site
• Participation in an irritation test, on the same skin site, in the previous month, or a sensitisation test,
on any skin site, during the previous 3 months
• Pregnant or lactating, or likely to become pregnant during time in the study (no safety concerns
regarding these groups using the bath additive - exclusion is simply because it is generally considered
inappropriate for them to take part in clinical trials)
• Participating in any other safety test
• Irritation, tattoos, scars or birthmarks at the test sites
• Use of any unlicensed medicine within the previous 30 days
• Employees of RSSL Pharma or Dermal Laboratories, or an immediate family member (partner,
offspring, parents, siblings or sibling’s offspring) of an employee
Interventions Intervention
• Doublebase Emollient bath additive
Comparator
• No bath additive
Outcomes Assessments unclear
Outcomes of the trial (as reported)
• Skin hydration measured by corneometry
• Skin pH
• Water loss from the skin, measured by TEWL instrument
Denotes outcomes prespecified for this review
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Starting date 2010, not recruiting (website accessed 12-02-2016)
Contact information Sponsor Dermal Laboratories Ltd UK
Notes
EudraCT2012-004621-24
Trial name or title Moisturisers in the management of atopic dermatitis in children: prevention of flares
Methods Randomised, open, controlled study in Lithuania and Estonia
Participants N = 409
Inclusion criteria of the trial
Boys or girls, presenting with the following criteria (V1):
• Aged 2 to 6 years
• Present with atopic dermatitis according to the diagnostic criteria of the UK Working Party
• ≤ 1 documented flare within the previous 6 months treated by corticosteroids
• Present with a current flare
• Objective SCORAD score of 15-40 (grade 3) at inclusion
• Written consent for child’s participation in the study from parent(s) or guardian(s)
• Parent(s) or guardian(s) prepared to comply with study-related constraints
• Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation)
After treatment of the current flare, the following are required for randomisation (V2):
• Objective SCORAD score < 15
• No lichenification, no excoriation, no oozing/crusts, no oedema/papulation
• Erythema intensity < 1 (residual erythema area ≤ 10% of extent)
• Xerosis intensity > 1
• No pruritus, no sleep disorders (< 1 on VAS of SCORAD)
Exclusion criteria of the trial
• Severe form of atopic dermatitis requiring either systemic corticosteroid treatment and/or antibiotic or
antiviral treatment and/or hospitalisation
• Primary bacterial, viral, fungal or parasitic skin infection
• Ulcerated lesions, acne or rosacea
• Dermatological disease other than atopic dermatitis which could interfere with the assessment
• Immunosuppression
• History of serious disease considered by the investigator to be hazardous for the patient or
incompatible with the study
• Use of oral corticosteroids or immunosuppressants during the previous 14 days
• Use of topical corticosteroids during the previous 7 days
• Use of systemic or local antibiotics on the lesions during the previous 7 days
• Use of NSAIDs or antihistamines during the previous 7 days
• Regular use of food supplements that could, in the opinion of the investigator, modify skin properties
(e.g. symbiotics)
• History of hypersensitivity or intolerance to one of the components of the tested or associated
products, or to cosmetics
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Interventions Intervention
• V0034CR for 12 weeks
Comparator 1
• Atopiclair for 12 weeks
Comparator 2
• No treatment for 12 weeks
Outcomes Assessments (4): baseline, days 28, 56 and 84
Outcomes of the trial (as reported)
• Percentage of participants with ≤ 1 flare
Denotes outcomes prespecified for this review
Starting date 2013, completed (website accessed 09-02-2016)
Contact information Pierre Fabre Médicament, Carine Fabre (carine.fabre@pierre-fabre.com)
Notes V0034CR = Dexeryl. A flare will be defined as the following: measurable increased extent or intensity of
lesions in < 2 weeks under continued treatment (in this case: moisturiser or no moisturiser), corresponding
to a significant increase (> 25%) in medical score (SCORAD or last PO-SCORAD) or to the introduction
of a new line of therapy (topical corticosteroid). No study results posted
EudraCT2014-001026-16
Trial name or title Randomised, double-blind, bilateral comparison of two moisturisers in patients with dry skin
Methods Randomised, double-blind, controlled within-participant study in the UK
Participants N = 20
Inclusion criteria of the trial
• Atopic eczema, according to the NICE guidelines (Williams 1994)
• Women aged 16 to 65 years, with an insignificant amount of hair on the lower legs (so as not to impair
the Corneometer measurements)
• Dry skin on the lower legs, i.e. having mean baseline Corneometer readings of < 45 units both at
screening and at the end of the washout/run-in period (prior to randomisation)
• Willing to adopt an essentially sedentary lifestyle for the duration of the study
• Willing to restrict bathing/showering or washing their legs on Tuesday (Day 2) and Thursday (Day 4)
evenings only
• Willing to refrain from applying moisturisers to the lower legs during the washout period, and from
removing lower leg hair for at least 48 hours prior to and during the treatment/testing phase of the study
• Willing to refrain from using sun beds, sun lamps or any skin tanning products during the study, and
to avoid excessive exposure of the test sites to natural sunlight for the duration of the study
• Willing to refrain from using non-study moisturisers or any other topical treatment anywhere on the
lower legs (i.e. from the ankle to the knee) during the study
Exclusion criteria of the trial
• Any significant concurrent illness or skin disease (e.g. eczema flare) currently involving the test sites,
which might interfere with the corneometry measurements
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• Women with a history of intolerance or skin sensitivity to any of the test ingredients
• Use of any topical (on the lower legs) or systemic medication or drug which, in the Investigator’s
opinion, is likely to affect skin response
• Any significant visible skin abnormality or hair growth at the test measurement sites considered likely
to interfere with the corneometry measurements
• Any irritation, tattoos, scars or birthmarks at the test measurement sites that could interfere with the
corneometry measurements
• Women with systemic diseases that, in the opinion of the investigator, might influence their
participation in the trial adversely
• Use of any unlicensed drug within the previous 30 days, or scheduled to receive an investigative drug
other than the study medication during the period of the study
• Participation in an irritation test, on the lower legs, in the previous month, or a positive reaction in a
sensitisation test, on any skin site, during the previous 3 months
• Use of any oral or topical (on the lower legs) antibiotics, corticosteroids or immunosuppressants for
acute conditions in the 4 weeks prior to the screening (Day -7). Women who are taking low dose oral
corticosteroids for long term, chronic conditions (such as arthritis, inflammatory bowel conditions) or using
inhaled corticosteroids (for asthma or COPD) in the long term will be eligible if, in the opinion of the
Investigator, their medication will not have any impact on the results of the trial
• Pregnant or lactating (although there are no particular safety concerns in these participant groups, it is
generally inappropriate for them to participate in clinical trials without overriding justification). Negative
pregnancy testing will not be necessary
• Women of child bearing potential who are not taking adequate contraceptive precautions
• Women considered unable or unlikely to attend the necessary follow-up visits
• Women with another member of the household already enrolled in the study (this is to avoid possible
mix up between assigned treatments)
• Employees of RCR or Dermal Laboratories, or an immediate family member (partner, offspring,
parents, siblings or sibling’s offspring) of such employees
Interventions Intervention
• Doublebase Dayleve gel for 5 days
Comparator
• Zerobase Emollient Cream for 5 days
Outcomes Assessments (16): baseline, days 1 until 5 (3 times a day)
Outcomes of the trial (as reported)
• Area under the curve (AUC) of the change from baseline (i.e. before treatment) on the skin
corneometry measurements collected for each leg
• 3 patient-reported outcomes comparing: a) overall acceptability; b) whether they would use the
product again; and c) which product they preferred
Denotes outcomes prespecified for this review
Starting date 2014, completed (website accessed 09-02-2016)
Contact information Dermal Laboratories Limited, Amanda Wigens, clinical@dermal.co.uk
Notes No study results posted
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Trial name or title Investigating whether topical application of a non toxic molecule improves epidermal pH and barrier function
in atopic dermatitis
Methods Randomised, vehicle-controlled study in UK
Participants Not specified
Interventions Intervention
• Application of gel containing a naturally-occurring chemical onto the skin of one forearm every day for
6 weeks
Comparator
• Application of the same cream/gel without the naturally-occurring molecule on the other forearm
Outcomes Assessments (7): baseline and then weekly up to 6 weeks
Outcomes of the trial (as reported)
• Weekly completion of POEM questionnaire
• Skin condition using SCORAD
• Skin barrier function using TEWL, measured at monthly intervals
Denotes outcomes prespecified for this review
Starting date 01-09-2008, completed (website accessed 8-2-2016)
Contact information Dr Neil Gibbs (neil.gibbs@manchester.ac.uk)
Notes No study results posted
JPRN-UMIN000005158
Trial name or title Randomized controlled trial to evaluate clinical efficacy of once- or twice-daily skin care with moisturiser for
prevention of atopic dermatitis exacerbation
Methods Randomised, investigator-blinded, controlled study in Japan
Participants N = 150
Inclusion criteria of the trial
• People diagnosed with atopic dermatitis according to the diagnostic criteria of Hanifin and Rajka
(Hanifin 1980)
• Atopic dermatitis assessed as moderate or severe within previous year
• People whose skin condition should be maintained without eczema by using twice weekly
betamethasone valerate ointment and twice daily moisturiser at the time of enrollment
• Able to adhere twice-daily skin care treatment
Exclusion criteria of the trial
• Taking oral steroids and/or oral immunosuppressive drugs
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Interventions Intervention
• Once daily skin care for 4 to 6 weeks
Comparator
• Twice daily skin care for 4 to 6 weeks
Outcomes Assessments unclear
Outcomes of the trial (as reported)
• Rates of participants with no recurrence during 28 days of intervention
• Number of no symptom days after start of intervention
• Quality of life of a caregiver (a parent)
• Scoring atopic dermatitis (SCORAD)
• Incidence of skin infection
Denotes outcomes prespecified for this review
Starting date 2011, recruiting (website accessed 12-02-2016
Contact information Yukihiro Ohya, National Center for Child Health and Development, Okura, Setagayaku, Tokyo, Japan
Notes No further details regarding skin care regimen being tested
JPRN-UMIN000010009
Trial name or title Study to evaluate the efficacy of conventional topical therapy for atopic dermatitis based on filaggrin-gene
mutations
Methods Randomised, double-blind controlled study in Japan
Participants N = 30
Inclusion criteria of the trial
• 2 to 15 years of age
• Atopic dermatitis diagnosed according to the diagnostic criteria of Hanifin and Rajika, UKWorking
Party or Japan Society of Dermatology
• Moderate to severe skin lesions
Exclusion criteria of the trial
• Obviously infected lesion in the popliteal and cubital fossa
• Atrophy or telangiectasia in the popliteal and cubital skin caused by the topical steroid application
• Serious underlying disease





Treatment includes steroid ointment and tacrolimus ointment
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Outcomes Assessments unclear
Outcomes of the trial (as reported)
• Amount of change in the score of intensity SCORAD
• 6 criteria including: erythema, oedema/papulation, oozing/crusting, excoriation and lichenification,
scored from 0 to 3 points
• TEWL
• Stratum corneum hydration
• VAS of itch
• Evaluation of presence or absence of flare-ups in the sites which are / are not applied moisturiser for the
sites without eruption
Denotes outcomes prespecified for this review
Starting date 2012, still recruiting (website accessed 12-02-2016)
Contact information Osamu Mizuno (osmizuno@tk9.so-net.ne.jp)
Notes Applying split-plot design, multiple factors randomised. 4 sites at each cubital fossa and popliteal fossa are
used as independent sites. First randomisation factor is presence or absence of filaggrin gene mutation. Second
factor is combination of the usage or non-usage of moisturiser and treatment. Treatment includes steroid
ointment and tacrolimus ointment
JPRN-UMIN000017957
Trial name or title The effect of moisturizer on both sweating function and sensitive skin in patients with atopic dermatitis, a
randomized comparative study
Methods Randomised, double-blinded, placebo-controlled study in Osaka, Japan
Participants N = 25
Inclusion criteria of the trial
• Adult men and women
• Atopic dermatitis
• Itching on the cubital fossa
• Provided written informed consent
• Able to visit clinic 3 times (at 2-weeks intervals) for 4 weeks
Exclusion criteria of the trial
• Most severe cases of atopic dermatitis
• Taking oral steroid
• Taking oral cyclosporine
• Receiving UV therapy
• Trauma on the testing area
• Frequent sun exposure
• Severe pollinosis
• Pregnancy
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• Alcohol drinker
• Person in another drug clinical trial
• Person who got massage or skin treatment within the previous 4 weeks
• Allergy to external treatment
• People thought to be inappropriate
• Related to a person conducting the study
Interventions Intervention
• Ceramide-containing cream applied to forearm twice daily for 4 weeks
Comparator
• Placebo cream applied to forearm twice daily for 4 weeks
Outcomes Assessments unclear
Outcomes of the trial (as reported)
• Barrier function, sweating function, sensitivity of skin
• Skin manifestations, contents of stratum corneum
Denotes outcomes prespecified for this review
Starting date June 2015
Contact information Hiroyuki Murota (h-murota@derma.med.osaka-u.ac.jp)
Notes No study results posted
NCT00180141
Trial name or title Control of therapy with Elidel vs placebo in patients with atopic dermatitis using bioengineering methods
Methods Randomised, double-blind, controlled study in Dresden, Germany
Participants N = 24
Inclusion criteria of the trial
• Age > 18 years
• Atopic dermatitis on both lower arms at least 1% BSA
• ADSI Score ≥ 6
• IIGA Score ≥ 2
Exclusion criteria of the trial
• Systemic therapy with immunosuppressive drugs within the previous 24 weeks
• Phototherapy against atopic dermatitis
• Antibiotic therapy against atopic dermatitis
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NCT00180141 (Continued)
Interventions Intervention




Outcomes of the trial (as reported)
• Not stated
Denotes outcomes prespecified for this review
Starting date April 2005, completed (website accessed 10-02-2016)
Contact information Roland Aschoff, MD Department of Dermatology. Medical Faculty, Technical University Dresden, Germany
Notes No study results posted
NCT00576238
Trial name or title A multi-centre, parallel, randomised study of the skin tolerance of betamethasone creams on atopic eczema
and the influence of moisturiser treatment on the recurrence of eczema
Methods Randomised, double-blind, controlled study in Sweden
Participants N = 55
Inclusion criteria of the trial
• Men and women aged 18 to 65 years
• ’Caucasian’
• Atopic dermatitis diagnosed according to the criteria of Hanifin and Rajka (Hanifin 1980), with
eczematous lesions corresponding to an ADSI score of ≤ 6 on any of the following areas: arms, legs, chest,
abdomen or back
• No serious health conditions that might interfere with the study
Exclusion criteria of the trial
• Eczematous regions exclusively in intertriginous areas or on the face
• Use of topical steroids or any other dermatologic drug therapy (moisturising creams allowed) in the
study area or light therapy within the preceding 2 weeks
• Use of oral steroids within 1 month prior to the study
• Use of concurrent medication e.g. medication that might interfere with study-related activities
• Factors suggesting low compliance with study procedures
• Possible allergy to ingredients in the study medications
• Pregnant or breast feeding
Interventions Intervention
• Topical application of betamethasone valerate according to a fixed schedule for 3 weeks, plus urea 5%
cream twice daily for up to 6 months
Comparator 1
• Topical application of betamethasone valerate (different vehicle) according to a fixed schedule for three
weeks
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NCT00576238 (Continued)
Outcomes Assessments (3): baseline, week 3 and month 6
Outcomes of the trial (as reported)
To study the:
1. compatibility of the skin with the new formulation in comparison to the reference medication
2. effect of maintenance therapy with a moisturiser cream on the possible recurrence of atopic eczema
3. cosmetic acceptance of the corticosteroids
4. safety of corticosteroid treatment
5. safety of maintenance treatment
Denotes outcomes prespecified for this review
Starting date January 2004, completed (website accessed 11-02-2016)
Contact information Principal investigator Berit Berne Hudkliniken, Akademiska sjukhuset, Uppsala, Sweden
Notes No study results posted
NCT00828412
Trial name or title A randomised, investigator-blind, six-week, parallel group, multicenter pilot study to compare the safety
and efficacy of EpiCeram skin barrier emulsion and desonide cream 0.05% in the twice daily treatment of
paediatric subjects with moderate atopic dermatitis
Methods Randomised, investigator-blinded, controlled study in the USA
Participants N = 100
Inclusion criteria of the trial
• Aged ≥ 3 months to < 13 years
• Atopic dermatitis of moderate severity
Exclusion criteria of the trial
• Pregnant or lactating
• Treatment of atopic dermatitis with topical product in the 14 days prior to baseline measurements
• Treatment of atopic dermatitis with systemic product in the 30 days prior to baseline measurements
• Serious or uncontrolled medical condition
• Active infection
• Significant use of inhaled, intranasal, or intraocular corticosteroid
Interventions Intervention
• EpiCeram skin barrier emulsion twice daily for 6 weeks
Comparator
• Desonide 0.05% cream twice daily for 6 weeks
Outcomes Assessments (2): baseline and week 6
Outcomes of the trial (as reported)
• Change from baseline in TIS
• Change from baseline in SCORAD
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NCT00828412 (Continued)
• Pruritus severity score
• Sleep disturbance score
• IGA
• Quality of life index
Denotes outcomes prespecified for this review
Starting date March 2009, completed (website accessed 10-02-2016)
Contact information Promius Pharma LCC, Joanne Fraser (joannefraser@promiuspharma.com)
Notes Few data are available for one outcome
NCT01779258
Trial name or title Moisturisers in the management of atopic dermatitis in children: Prevention of flares
Methods Randomised controlled open-label trial in Estonia, France, Lithuania, Poland, Romania
Participants N = 347
Inclusion criteria of the trial
• Aged between 2 and 6 years
• Atopic dermatitis, with at least one duly documented flare treated by corticosteroids within the
previous 6 months, and presenting with a current flare (objective SCORAD score of 15-40 at inclusion)
• After treatment of the current flare, for randomisation, participants should have an objective
SCORAD score < 15, with Xerosis intensity ≥ 1 and no subjective signs
Exclusion criteria of the trial
• Severe form of atopic dermatitis requiring either systemic corticosteroid treatment and/or antibiotic or
antiviral treatment and/or hospitalisation
• Primary bacterial, viral, fungal or parasitic skin infection, ulcerated lesions, acne or rosacea
• Dermatological disease other than atopic dermatitis that could interfere with the assessment
• Immunosuppression
Interventions Intervention
• Dexeryl: 1 application in the morning, in the afternoon and in the evening
• Locatop: during the run-in period; 1 application in the morning and in the evening for a maximum of
21 days
• Locapred: during the 3-month study treatment; 1 application in the evening in case of flare
Comparator 1
• Atopiclair: 1 application in the morning, in the afternoon and in the evening
• Locatop: during the run-in period; 1 application in the morning and in the evening for a maximum of
21 days
• Locapred: during the 3-month study treatment; 1 application in the evening in case of flare
Comparator 2
• No moisturiser
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NCT01779258 (Continued)
• Locatop: during the run-in period; 1 application in the morning and in the evening for a maximum of
21 days
• Locapred: during the 3-month study treatment; 1 application in the evening in case of flare
Outcomes Assessments: baseline and further time points unclear
Outcomes of the trial (as reported)
• Percentage of participants with at ≤ 1 flare over the 12-week treatment period. A flare is defined as:
measurable increased extend or intensity of lesions in < 2 weeks under continued treatment corresponding
to a significant increase in medical score (> 25%) or to the introduction of a new line of therapy (topical
corticosteroid)
Denotes outcomes prespecified for this review
Starting date February 2013, completed (website accessed 10-2-2016)
Contact information Pierre Fabre Medicament. No further details available
Notes No study results posted
NCT01781663
Trial name or title Efficacy of KAM2904 face cream and KAM3008 body lotion treatment in children with atopic dermatitis
(AD)
Methods Randomised, double-blind, controlled trial in Spain
Participants N = 156
Inclusion criteria of the trial
• Boys and girls between 2 and 12 years of age
• Moderate atopic dermatitis (SCORAD < 40) that is amenable to treatment
• Diagnosis of atopic dermatitis meets Hanifin’s criteria (at least 3 basic features and at least 3 minor
features)
• Atopic dermatitis has been stable for the past 7 days, in the opinion of the investigator
• The child’s parents are able to apply the study product twice a day (each morning and evening) for a
consecutive period of 42 days
• The child’s parents agree that the child will not change his/her lifestyle during the study period
(including: regular body hygiene product (soap), the number of baths and showers per day, the laundry
detergent and fabric softener used to wash clothes)
• The child’s parents agree to use only the test product during the study period
Exclusion criteria of the trial
• Another dermatological disease/condition that could interfere with the clinical evaluation, including
infected atopic dermatitis lesions
• Previous history of allergy to cosmetic products or to any of the ingredients included in the tested
formulations
• Received a topical or a systemic immune-modulator (such calcineurin inhibitors or corticosteroids) for
the treatment of atopic dermatitis, within 14 days prior to start of study
• Underwent phototherapy within 28 days prior to start of study
• Expected to be extensively exposed to the sun during the study
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NCT01781663 (Continued)
• Underwent any experimental treatment within 14 days prior to start of study
Interventions Intervention
• KAM2904 face cream and KAM3008 body lotion for 6 weeks
Comparator
• Petrolatum-based moisturiser for 6 weeks
Outcomes Assessments (4): baseline, week 2, 4 and 6
Outcomes of the trial (as reported)
• Change in SCORAD
• Change in EASI
• Change in the scoring of individual symptoms of atopic dermatitis
• Trend in the change of SCORAD
• Trend in the change of EASI
• Trend in the change of individual symptoms of atopic dermatitis
• Safety of KAM2904 Face Cream and KAM3008 Body Lotion. Measured by the number and severity
of device-related adverse events
Starting date February 2013, completed (website accessed 10-02-2016)
Contact information Miri Sani (mirisani@013.net)
Notes No study results posted
NCT01915914
Trial name or title A randomized, open-label, comparative study to evaluate an intermittent dosing regimen of fluticasone propi-
onate 0.05% cream (twice per week) in reducing the risk of relapse when added to regular daily moisturization
using PHYSIOGEL lotion in paediatric subjects with stabilized atopic dermatitis
Methods Open, 2-phase, randomised controlled study in China
Participants N = 107
Inclusion criteria of the trial
• Boys or girls aged between 1 to 18 years old (including 1 year and excluding 18 years old)
• Atopic dermatitis diagnosed according to criteria of Williams (Williams 1994)
• Mild to moderate atopic dermatitis on the head/neck, trunk, upper limbs or lower limbs and PSGA
scores 2-3 (PSGA score not specified further)
• informed consent provided
• Children eligible for enrolment in the maintenance phase of the study required to achieve treatment
success after receiving fluticasone propionate 0.05% cream twice daily up to 4 weeks in the acute phase
Exclusion criteria of the trial (in the acute phase)
• Dermatitis of only the face, feet or hands
• Involved area > 10% of the BSA
• Diagnosed contact dermatitis at predilection sites of atopic dermatitis
• Atrophy, telangiectasia, extensive scarring lesions in the area or areas to be treated
• Use of topical therapies including, but not limited to: calcineurin inhibitors (topical tacrolimus or
topical pimecrolimus), corticosteroids, antihistamines within 14 days prior to screening
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NCT01915914 (Continued)
• Received nonsteroidal immunosuppressants (e.g. cyclosporine, methotrexate), or UV light treatments
including UVA and UVB, or systemic corticosteroids administrated orally, intramuscularly, or intravenously
within 4 weeks prior to screening
• Pregnant or breast feeding. Women of childbearing potential with a positive urine pregnancy test
performed within 7 days before the start of treatment
• Immunocompromising disease (e.g. lymphoma, AIDS, Wiskott-Aldrich syndrome) or a history of
malignancy (including basal cell carcinoma, squamous cell carcinoma, melanoma)
• Open skin infections (bacterial, viral or fungal) at the application site
• Head lice or scabies
• Presenting with clinical conditions other than atopic dermatitis that may interfere with the valuation
(e.g. generalised erythroderma, toxicoderma, acne, Netherton’s Syndrome, psoriasis)
• Requiring systemic therapy for the treatment of atopic dermatitis, or took systemic therapy including,
but not limited to, antihistamines within 14 days prior to screening
• Accepted any experimental or investigational drug or therapy within 6 weeks prior to screening
• Known hypersensitivity to fluticasone propionate 0.05% cream, or Physiogel lotion, or related drugs
• Non-compliance with general medical treatment, or known to miss appointments, or does not intend
to comply with the protocol for the duration of the study
• Drug abuse, mental dysfunction, or other factors limiting the child’s ability to cooperate fully with
study-related procedures
• Known to be unreliable or may be unable to complete the study
• Any condition or prior/present treatment that would render the child ineligible for the maintenance
phase of the study
• Accepted topical therapies other than fluticasone propionate 0.05% cream and moisturisers during the
acute phase of the study
• Active skin infection (bacterial, viral or fungal)
Interventions Intervention
• Fluticasone propionate 0.05% cream twice weekly combined with regular daily use of Physiogel
moisturiser for 4 weeks
Comparator
• Physiogel moisturiser daily for 4 weeks
Outcomes Assessments: baseline and further time points unclear
Outcomes of the trial (as reported)
• Time to the first relapse of atopic dermatitis during the maintenance phase
• Numbers of participants with recurrence at the end of the maintenance phase
• Number of participants with ’treatment success’ during the acute phase
• Change from baseline in quality of life at the end of the maintenance phase; IDQOL and CDLQI
• Number of participants with post-study assessment of skin emollients using questionnaire and lotion
qualities questionnaire
• Change from baseline in cutaneous atrophy sign score, epidermal thickening/lichenification sign score
and abnormal pigmentation score
Denotes outcomes prespecified for this review
Starting date December 2013, completed (website accessed 10-02-2016)
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NCT01915914 (Continued)
Contact information GlaxoSmithKline. No further details available
Notes No study results posted
NCT02028546
Trial name or title The effect of bathing and moisturizers on skin hydration in atopic dermatitis: an in vivo study
Methods Randomised, investigator-blinded, controlled, cross-over study in Thailand
Participants N = 22
Inclusion criteria of the trial
• Men or women aged 18 to 45 years
• History and physical findings consistent with mild to moderate atopic dermatitis with SCORAD score
≤ 40
• Ceased use of: oral corticosteroids for at least 4 weeks, topical corticosteroids and calcineurin inhibitors
for at least 2 weeks, food supplements e.g. evening primrose oil, wheat extract, flax seed oil sunflower seed
oil, borage oil and fish oil for at least 3 months
Exclusion criteria of the trial
• Medical history of zinc or essential fatty acid deficiency; end stage renal disease; hypothyroidism; HIV;
malignancies; obstructive biliary disease; diabetes mellitus; or radiation or other medical history that may
interfere with the outcome
• Use of drugs that could interfere with the study results, e.g. diuretics, antiandrogens, lipid reducing
agents, isotretinoin, cimetidine
• Unavailable for the duration of the study
• Allergy to any ingredient in the moisturiser or cleanser that will be used in the protocol
• Pregnant or lactating women
Interventions Intervention
• Soaking an arm with tap water for 10 minutes, no moisturiser application regimen
Comparator 1
• Soaking an arm with tap water for 10 minutes, immediate moisturiser application regimen
Comparator 2
• Soaking an arm with tap water for 10 minutes, delay moisturiser application for 30 minutes
Comparator 3
• Wait for 10 minutes without soaking, then apply moisturiser (moisturiser alone)
The same 4 regimens were repeated with soaking an arm with mild cleanser
All regimens were completed in all participants with 2 visits (7 days between visits)
Outcomes Assessments: at baseline and every 30 minutes for 120 minutes after each regimen
Outcomes of the trial (as reported)
• Skin hydration (skin capacitance) measured with a Corneometer, and the TEWL measured with a
Tewameter of various regimens of bathing and moisturiser application
• Skin hydration (capacitance value) measured with a Corneometer, and TEWL measured with a
Tewameter between immediate and delayed (30 minutes) moisturiser application after bathing
• Skin hydration (capacitance value) measured with a Corneometer, and TEWL measured with a
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NCT02028546 (Continued)
Tewameter between water and mild cleanser
Denotes outcomes prespecified for this review
Starting date January 2013, completed (website accessed 11-02-2016)
Contact information Arisa Kaewkes, MSc dermatology Skin center, Faculty of Medicine, Srinakharinwirot University
Notes No study results posted
NCT02286700
Trial name or title Skin effects of a topical amino acid moisturizing cream and desonide in atopic dermatitis
Methods Randomised, double-blind, controlled study in Boston, USA
Participants N = 42
Inclusion criteria of the trial
• Men or women in general good health, aged ≥ 18 years
• Diagnosis of atopic dermatitis based on clinical criteria. Each participant must have < 1 eczematous
target lesion with area ranging from 10 to 500 cm2 of mild to moderate severity with a grade of ≥ 6 on the
TADSI scale, plus presence of itch
• BSA affected by atopic dermatitis lesions: ≤ 5% at start of treatment
Exclusion criteria of the trial
• Pregnant or breastfeeding
• Any condition or therapy that, in the investigator’s opinion, may pose a risk to the participant, or that
could interfere with any evaluation in the study
• Widespread atopic dermatitis requiring systemic therapy
• Diagnosis of allergic contact dermatitis
• Known hypersensitivity to any of the constituents or excipients of the investigational product
• Diagnosed with immunocompromised status
• Use of systemic atopic dermatitis therapy, e.g. systemic corticosteroids, cyclosporine A, azathioprine,
mycophenolate mofetil, or phototherapy in the previous month.
• Use of phototherapy in the previous 2 weeks
• Use of any topical atopic dermatitis therapy such as corticosteroids or topical immuno-modulators in
the previous 2 weeks
• Use of local anti-itch or medical device treatments, e.g. benadryl, Atopiclair, Epicream in the previous
2 weeks
• Use of topical moisturisers on eczema lesions < 24 hours in advance of the baseline visit
• Participation in another clinical research study with an investigational drug in the 4 weeks prior to
randomisation in this study
Interventions Intervention
• Desonide cream 0.05% twice daily for 3 weeks
Comparator
• Amino acid moisturizing cream twice daily for 3 weeks
347Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Outcomes Assessments (4): baseline, week 1, 2 and 3
Outcomes of the trial (as reported)
1. TADSI
2. EASI
3. Static IGA of targeted lesion
4. Total IGA (PGA) and BSA involvement
5. POEM
6. Participants’ assessment of pruritus (VAS); a self-assessment questionnaire
Denotes outcomes prespecified for this review
Starting date November 2014, still recruiting (website accessed 10-2-2016)
Contact information Barbara A Green, RPh (bgreen@neostrata.com) and Justine K Gostomski, MS (jgostomski@neostrata.com)
Notes
NCT02376049
Trial name or title An explorative clinical trial to evaluate an intra patient comparison design of topical agents in adults with
mild to moderate atopic dermatitis
Methods Randomised, double-blind, controlled study in Israel and Canada
Participants N = 30
Inclusion criteria of the trial
• Mild to moderate atopic dermatitis
• 4 comparable target areas (TAs)
• Total sign score (TSS) of at least 5 on all TAs
• Difference in TSS < 2 between the TAs
• Sign score erythema ≥ 2 between the TAs
• TAs at least 2 cm apart
Exclusion criteria of the trial
• Investigator’s opinion
• Fitzpatrick skin type > 5
• Topical (i.e. on the TAs) treatment with prohibited medications
• Systemic treatment with prohibited medications
• Phototherapy within prohibited timeframe
• Use of moisturisers within prohibited timeframe
Interventions Intervention
• Pimecrolimus 1% cream once daily for 14 days
Comparator 1
• Betamethasone dipropionate 0.05% cream once daily for 14 days
Comparator 2
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NCT02376049 (Continued)
• Clobetasol propionate 0.05% cream once daily for 14 days
Comparator 3
• Glaxal Base cream moisturiser once daily for 14 days
Outcomes Assessments (2): baseline and week 2
Outcomes of the trial (as reported)
• TSS change compared to baseline
Denotes outcomes prespecified for this review
Starting date February 2015, completed (website accessed 11-02-2016)
Contact information Principal investigator Emma Guttmann, MD, Icahn Scool of Medicine
Notes No study results posted
NCT02589392
Trial name or title Effect of Cetaphil Restoraderm moisturizer on very dry skin in children with a controlled atopic dermatitis:
a randomised, parallel group study
Methods Randomised, investigator-blinded controlled study in China and the Phillipines
Participants N = 120
Inclusion criteria of the trial
• Boys and girls, aged 2 to 12 years inclusive
• Controlled mild to moderate atopic dermatitis with an IGA score of 0 or 1 within 1 week of successful
treatment with topical corticosteroid
Exclusion criteria of the trial
• Bacterial, viral, fungal or parasite skin infection
• Ulcerated lesions, acne or rosacea
• Immunosuppression
• Washout period from baseline for topical treatment of < 8 days for calcineurin inhibitor
• Washout period from baseline for topical treatment of > 8 days for corticosteroids
• Washout period from baseline for systemic treatment of < 8 days for antihistamines, and < 4 weeks for
immunomodulators
Interventions Intervention
• Cetaphil Restoraderm moisturiser twice daily + Cetaphil Restoraderm Skin body wash once daily for
12 weeks
Comparator
• Cetaphil Restoraderm body wash once daily for 12 weeks
Outcomes Assessments (2): baseline and week 12
Outcomes of the trial (as reported)
• Time to relapse
Denotes outcomes prespecified for this review
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NCT02589392 (Continued)
Starting date May 2015, still recruiting (website accessed 11-2-2016)
Contact information Philippe Martel (philippe.martel@galderma.com) and Stéphanie Leclerc (stephanie.leclerc@galderma.com)
Notes
NTR4541
Trial name or title Efficacy of a skin barrier repair cream (Dermalex Eczema) in atopic dermatitis patients - EDA
Methods Randomised, double-blind, controlled, within-participant study in the Netherlands
Participants N = 100
Inclusion criteria of the trial
• Clinically diagnosed atopic dermatitis
• Mild to moderate atopic dermatitis, according to total SCORAD score (score < 25)
• Aged 18 to 70 years
• Provided written informed consent
• At least 2 symmetrical (i.e. left and right side of the body) skin sites with comparable severity of atopic
dermatitis (measured with the SCORAD-score)
Exclusion criteria of the trial
• Extensive UV exposure in the 14 days before the study or expected during the study
• Skin disease other than atopic dermatitis
• Use of antibiotics in the 4 weeks prior to the study or expected use during the study
• Use of systemic suppressing drugs (e.g. prednisone, methotrexate) in the 4 weeks prior to the study or
expected use during the study
• Severe disorders within the 6 months before the study (e.g. cancer, acute cardiac or circularity
disorders, HIV, infectious hepatitis)
• Investigator’s uncertainty about the willingness or ability of the individual to comply with the protocol
requirements
Interventions Intervention






Outcomes of the trial (as reported)
• Duration (in days) of use of ointments until atopic dermatitis symptoms improve, defined as a decrease
in SCORAD-score of 5 points
• The amount of cream/ointments used (per day and total)
• Change in cytokine levels, lipid profile, TEWL and pH after the different treatments
• Presence of mutations on the filaggrin-gene
Denotes outcomes prespecified for this review
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NTR4541 (Continued)
Starting date May 2014, recruiting (website accessed 12-02-2016)
Contact information SA Koppes (s.a.koppes@amc.nl)
Notes
Ridd 2015
Trial name or title Choice Of Moisturiser in Eczema Treatment (COMET)
Methods Randomised, investigator-blinded, controlled study
Setting
University of Bristol, UK
Date of study
June 2014 to July 2015. Duration 3 months
Participants N = 160
Inclusion criteria of the trial
• Aged 1 month to 5 years
• Eczema as (diagnosed by a doctor or an appropriately qualified health care professional with oversight
from a medically qualified doctor)
Exclusion criteria of the trial









Children will attend appointments for their eczema as normal and use other medications (for example, topical
corticosteroids) as normally directed. Co-prescribing of other leave on moisturisers and bath additives will be
discouraged, but allowed
Outcomes Assessments (4): baseline, months 1, 2 and 3
Outcomes of the trial (as reported)
• Proportion of children approached who were randomised to a study moisturiser and used it for the
duration
• Data completeness of daily, weekly and monthly measures, recorded by parents and collected by
research assistants: EASI; Six Area, Six Sign Atopic Dermatitis severity score (SASSAD); TIS; skin
corneometry; POEM; DFI; Patient Global Assessment; quality of life
• Extent to which the research assistants were kept masked to intervention
• Preliminary data on the clinical effectiveness of the proposed study moisturisers, including the quantity
and frequency of moisturiser application, and evidence of any effect on topical corticosteroid or calcineurin
inhibitor use
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• Qualitative feedback from parents of participants regarding the logistics and acceptability of trial
processes, procedures and paperwork
Denotes outcomes prespecified for this review
Starting date June 2014. Completed (website accessed 8-2-2016)
Contact information Dr Victoria J Wilson (Victoria.Wilson@bristol.ac.uk)
Notes Feasability study. No study results posted
Santer 2015
Trial name or title Bath additives for the treatment of childhood eczema
Methods Open, randomised controlled study
Setting
Multicentre general practitioner practices in England and Wales, UK
Date of study
Unspecified. Duration 1 year
Participants N = 423
Inclusion criteria of the trial
• Children aged > 12 months and < 12 years with eczema (Williams 1994)
Exclusion criteria of the trial
• Inactive or very mild eczema (5 or less on Nottingham Eczema Severity Scale) (Emerson 2000)
Interventions Intervention
• Bath moisturisers plus standard eczema care
Comparator
• Standard eczema care
Standard care includes advice to use leave-on moisturisers regularly, plus intermittent topical corticosteroids
if required
Outcomes Assessments (25): baseline and then weekly up to 16 weeks, thereafter monthly
Outcomes of the trial (as reported)
• POEM score
• Number of eczema exacerbations resulting in healthcare consultations over 1 year
• Eczema severity over 1 year
• Disease-specific and generic quality of life (Child Health Utility 9D (CHU-9D) and DFI)
• Medication use and healthcare resource use
• Cost-effectiveness
Denotes outcomes prespecified for this review
Starting date The recruitment was expected to start in November 2014 (website accessed 8-2-2016)
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Santer 2015 (Continued)
Contact information Kate Martinson, Trial Manager (k.martinson@soton.ac.uk)
Notes Trial registration number: ISRCTN84102309
Abbreviations
ADSI: Atopic Dermatitis Severity Index
BNF: British National Formulary
BSA: body surface area
CDLQI: Children’s Dermatology Life Quality Index
COPD: chronic obstructive pulmonary disease
DELP: Brandname of the gel under research
DFI: Dermatitis Family Impact questionnaire
EASI: eczema area and severity index
IDQOL: Infant’s Dermatitis Quality of Life Index
IGA: Investigator Global Assessment
NSAIDs: non-steroidal anti-inflammatories
UVA and UVB: types of ultraviolet light
POEM: Patient-Oriented Eczema Measure
PO SCORAD: Patient Oriented SCORAD
PSGA: Physician Static Global Assessment
SCORAD: scoring atopic dermatitis
SGA: Subjective Global Assessment
TADSI: Target Lesion Atopic Dermatitis Severity Index
TEWL: transepidermal water loss
TIS: three item severity score
UVA, UVB: types of ultraviolet light
VAS: visual analogue scale
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D A T A A N D A N A L Y S E S
Comparison 1. Moisturisers versus no treatment (i.e. no moisturiser)




participants Statistical method Effect size
1 Change from baseline in
SCORAD
3 276 Mean Difference (IV, Random, 95% CI) -2.42 [-4.55, -0.28]
2 Number of participants
experiencing a flare
2 87 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.23, 0.70]
3 Rate of flare 2 87 Hazard Ratio (Random, 95% CI) 3.74 [1.86, 7.50]
4 Amount of topical steroids used 2 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Amount of topical
corticosteroids first 3-4 weeks
2 222 Mean Difference (IV, Random, 95% CI) -8.25 [-17.22, 0.72]
4.2 Amount of topical
corticosteroids used last 3-4
weeks
1 74 Mean Difference (IV, Random, 95% CI) 0.5 [-4.70, 5.70]
4.3 Total amount of topical
corticosteroids used in 6 to 8
weeks
2 222 Mean Difference (IV, Random, 95% CI) -9.30 [-15.33, -3.27]
5 Change from baseline in quality
of life
2 177 Std. Mean Difference (IV, Random, 95% CI) -0.15 [-0.55, 0.24]
Comparison 2. Atopiclair versus vehicle




participants Statistical method Effect size
1 Number of participants who
experienced good improvement
to total resolution
3 390 Risk Ratio (M-H, Random, 95% CI) 4.51 [2.19, 9.29]
1.1 Number of participants
who experienced good
improvement to total resolution
(low risk of bias)
1 30 Risk Ratio (M-H, Random, 95% CI) 4.0 [1.01, 15.81]
1.2 Number of participants
who experienced good
improvement to total resolution
(unclear risk of bias)
1 142 Risk Ratio (M-H, Random, 95% CI) 8.06 [3.95, 16.42]
1.3 Number of participants
who experienced good
improvement to total resolution
(high risk of bias)
1 218 Risk Ratio (M-H, Random, 95% CI) 3.02 [2.00, 4.56]
2 Change from baseline in itch
measured on a VAS
4 396 Mean Difference (IV, Random, 95% CI) -2.65 [-4.21, -1.09]
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2.1 Change from baseline in
itch measured on a VAS (low
risk of bias)
1 30 Mean Difference (IV, Random, 95% CI) -0.8 [-1.20, -0.40]
2.2 Change from baseline
in itch measured on a VAS
(unclear risk of bias)
2 180 Mean Difference (IV, Random, 95% CI) -3.10 [-4.47, -1.73]
2.3 Change from baseline in
itch measured on a VAS (high
risk of bias)
1 186 Mean Difference (IV, Random, 95% CI) -3.70 [-4.66, -2.74]
3 Number of participants
reporting an adverse event
4 430 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.79, 1.33]
4 Change from baseline in EASI 4 426 Mean Difference (IV, Random, 95% CI) -2.00 [-5.42, -2.57]
4.1 Change from baseline in
EASI (low risk of bias)
1 30 Mean Difference (IV, Random, 95% CI) -3.30 [-5.67, -0.93]
4.2 Change from baseline in
EASI (unclear risk of bias)
2 180 Mean Difference (IV, Random, 95% CI) -4.42 [-7.73, -1.10]
4.3 Change from baseline in
EASI (high risk of bias)
1 216 Mean Difference (IV, Random, 95% CI) -3.62 [-5.06, -2.18]
5 Number of participants
experiencing a flare
3 397 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.11, 0.31]
5.1 Number of participants
experiencing a flare (unclear
risk of bias)
2 181 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.12, 0.57]
5.2 Number of participants
experiencing a flare (high risk
of bias)
1 216 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.07, 0.28]
Comparison 3. Urea-containing moisturiser versus vehicle




participants Statistical method Effect size
1 Change from baseline in skin
capacitance
2 Mean Difference (Random, 95% CI) 1.23 [-7.39, 9.86]
Comparison 4. Glycerin cream versus placebo cream




participants Statistical method Effect size
1 Number of participants
reporting an adverse event
2 385 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.68, 1.19]
355Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 5. Oat-containing cream versus vehicle or no treatment




participants Statistical method Effect size
1 Change in disease severity as
assessed by the investigators
(SCORAD and EASI)
3 272 Std. Mean Difference (IV, Random, 95% CI) -0.23 [-0.66, 0.21]
1.1 Change in disease severity
as assessed by the investigator
(EASI) (low risk of bias)
1 50 Std. Mean Difference (IV, Random, 95% CI) 0.01 [-0.55, 0.56]
1.2 Change in disease severity
as assessed by the investigators
(SCORAD) (high risk of bias)
2 222 Std. Mean Difference (IV, Random, 95% CI) -0.33 [-0.98, 0.32]
2 Change from baseline in quality
of life
3 226 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.37, 0.19]
2.1 Change from baseline in
quality of life (low risk of bias)
1 50 Std. Mean Difference (IV, Random, 95% CI) 0.10 [-0.46, 0.65]
2.2 Change from baseline in
quality of life (high risk of bias)
2 176 Std. Mean Difference (IV, Random, 95% CI) -0.16 [-0.55, 0.24]
Comparison 6. All moisturisers versus vehicle, placebo or no treatment (no moisturiser)




participants Statistical method Effect size
1 Number of participants who
experienced improvement
5 572 Risk Ratio (M-H, Random, 95% CI) 2.46 [1.16, 5.23]
1.1 Number of participants
who experienced improvement
(low risk of bias)
2 80 Risk Ratio (M-H, Random, 95% CI) 1.86 [0.41, 8.31]
1.2 Number of participants
who experienced improvement
(unclear risk of bias)
2 274 Risk Ratio (M-H, Random, 95% CI) 3.11 [0.25, 38.71]
1.3 Number of participants
who experienced improvement
(high risk of bias)
1 218 Risk Ratio (M-H, Random, 95% CI) 3.02 [2.00, 4.56]
2 Change from baseline in itch 7 749 Std. Mean Difference (IV, Random, 95% CI) -1.10 [-1.83, -0.38]
2.1 Change from baseline in
itch (low risk of bias)
3 329 Std. Mean Difference (IV, Random, 95% CI) -0.36 [-1.16, 0.43]
2.2 Change from baseline in
itch (unclear risk of bias)
2 180 Std. Mean Difference (IV, Random, 95% CI) -2.29 [-2.67, -1.91]
2.3 Change from baseline in
itch (high risk of bias)
2 240 Std. Mean Difference (IV, Random, 95% CI) -0.95 [-1.75, -0.16]
3 Number of participants who
expressed treatment satisfaction
3 298 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.77, 2.36]
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3.1 Number of participants
who expressed treatment
satisfaction (low risk of bias)
2 80 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.77, 1.42]
3.2 Number of participants
who expressed treatment
satisfaction (high risk of bias)
1 218 Risk Ratio (M-H, Random, 95% CI) 2.14 [1.58, 2.89]
4 Number of participants
reporting an adverse event
10 1275 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.82, 1.30]
4.1 Number of participants
reporting an adverse event (low
risk of bias)
4 471 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.58, 1.18]
4.2 Number of participants
reporting an adverse events
(unclear risk of bias)
3 314 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.82, 1.42]
4.3 Number of participants
reporting an adverse events
(high risk of bias)
3 490 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.37, 4.96]
5 Change in disease severity as
assessed by the investigators
12 1281 Std. Mean Difference (IV, Random, 95% CI) -0.65 [-0.89, -0.41]
5.1 Change in disease severity
as assessed by the investigators
(low risk of bias)
5 512 Std. Mean Difference (IV, Random, 95% CI) -0.45 [-0.74, -0.15]
5.2 Change in disease severity
as assessed by the investigators
(unclear risk of bias)
2 180 Std. Mean Difference (IV, Random, 95% CI) -0.93 [-1.29, -0.57]
5.3 Change in disease severity
as assessed by the investigators
(high risk of bias)
5 589 Std. Mean Difference (IV, Random, 95% CI) -0.77 [-1.23, -0.30]
6 Number of participants
experiencing a flare
6 607 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.17, 0.62]
6.1 Number of participants
experiencing a flare (low risk of
bias)
1 123 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.48, 1.34]
6.2 Number of participants
experiencing a flare (unclear
risk of bias)
2 181 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.12, 0.57]
6.3 Number of participants
experiencing a flare (high risk
of bias)
3 303 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.12, 0.59]
7 Change from baseline in quality
of life
3 300 Std. Mean Difference (IV, Random, 95% CI) -0.39 [-0.90, 0.12]
7.1 Change from baseline in
quality of life (low risk of bias)
1 123 Std. Mean Difference (IV, Random, 95% CI) -0.81 [-1.18, -0.44]
7.2 Change from baseline in
quality of life (high risk of bias)
2 177 Std. Mean Difference (IV, Random, 95% CI) -0.15 [-0.55, 0.24]
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Comparison 7. Evening primrose oil versus placebo oil




participants Statistical method Effect size
1 Change from baseline in TEWL 1 Mean Difference (Random, 95% CI) -0.34 [-1.44, 0.76]
2 Change from baseline in skin
hydration
1 Mean Difference (Random, 95% CI) 0.34 [-2.54, 3.21]
Comparison 8. Licochalcone versus hydrocortisone acetate (HCA) 1%




participants Statistical method Effect size
1 Change from baseline in itch
(VAS)
2 Mean Difference (Random, 95% CI) -0.48 [-1.46, 0.50]
1.1 Change from baseline in
itch (VAS) (unclear risk of bias)
1 Mean Difference (Random, 95% CI) 0.0 [-0.47, 0.47]
1.2 Change from baseline in
itch (VAS) (high risk of bias)
1 Mean Difference (Random, 95% CI) -1.0 [-1.61, -0.39]
2 Change from baseline in
SCORAD
3 Mean Difference (Random, 95% CI) 0.08 [-1.96, 2.13]
2.1 Change from baseline in
SCORAD (unclear risk of bias)
1 Mean Difference (Random, 95% CI) -2.0 [-3.47, -0.53]
2.2 Change from baseline in
SCORAD (high risk of bias)
2 Mean Difference (Random, 95% CI) 1.12 [-1.38, 3.61]
3 Change from baseline in TEWL 2 Mean Difference (Random, 95% CI) -0.50 [-5.88, 4.87]
3.1 Change from baseline in
TEWL (unclear risk of bias)
1 Mean Difference (Random, 95% CI) -3.0 [-4.71, -1.29]
3.2 Change from baseline in
TEWL (high risk of bias)
1 Mean Difference (Random, 95% CI) 2.51 [-1.21, 6.23]
Comparison 9. Advabase versus MPA cream twice weekly and emollient




participants Statistical method Effect size
1 Rate of flare 1 Hazard Ratio (Random, 95% CI) Totals not selected
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Comparison 10. Vehicle + daily moisturiser versus fluticasone propionate (FP) + daily moisturiser




participants Statistical method Effect size
1 Number of participants
reporting an adverse event
3 718 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.22, 1.14]
2 Number of participants
experiencing a flare
3 718 Risk Ratio (M-H, Random, 95% CI) 2.17 [1.51, 3.11]
3 Rate of flare 3 723 Hazard Ratio (Random, 95% CI) 3.69 [1.80, 7.55]
Comparison 11. Active treatment in combination with a moisturiser versus active treatment only




participants Statistical method Effect size
1 Change in disease severity as
assessed by the investigators
2 192 Std. Mean Difference (IV, Random, 95% CI) -0.87 [-1.17, -0.57]
2 Change in quality of life IDQOL 1 67 Mean Difference (IV, Random, 95% CI) -1.31 [-2.70, 0.09]
3 Change in quality of life DFI 1 67 Mean Difference (IV, Random, 95% CI) -1.03 [-2.47, 0.42]
Analysis 1.1. Comparison 1 Moisturisers versus no treatment (i.e. no moisturiser), Outcome 1 Change
from baseline in SCORAD.
Review: Emollients and moisturisers for eczema
Comparison: 1 Moisturisers versus no treatment (i.e. no moisturiser)
Outcome: 1 Change from baseline in SCORAD





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Giordano-Labadie 2006 35 -15.41 (6.31) 39 -11.5 (4.96) 28.5 % -3.91 [ -6.52, -1.30 ]
Grimalt 2007 78 -19.67 (7.33) 70 -19.51 (6.3) 32.5 % -0.16 [ -2.36, 2.04 ]
Patrizi 2014 28 -5.6 (1.68) 26 -2.4 (3.73) 39.1 % -3.20 [ -4.76, -1.64 ]
Total (95% CI) 141 135 100.0 % -2.42 [ -4.55, -0.28 ]
Heterogeneity: Tau2 = 2.41; Chi2 = 6.25, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Moisturisers versus no treatment (i.e. no moisturiser), Outcome 2 Number of
participants experiencing a flare.
Review: Emollients and moisturisers for eczema
Comparison: 1 Moisturisers versus no treatment (i.e. no moisturiser)
Outcome: 2 Number of participants experiencing a flare








Weber 2015 4/20 15/23 34.7 % 0.31 [ 0.12, 0.77 ]
Wir n 2009 7/22 15/22 65.3 % 0.47 [ 0.24, 0.92 ]
Total (95% CI) 42 45 100.0 % 0.40 [ 0.23, 0.70 ]
Total events: 11 (Moisturiser), 30 (No moisturiser)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 3.26 (P = 0.0011)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Moisturisers versus no treatment (i.e. no moisturiser), Outcome 3 Rate of flare.
Review: Emollients and moisturisers for eczema
Comparison: 1 Moisturisers versus no treatment (i.e. no moisturiser)
Outcome: 3 Rate of flare
Study or subgroup Moisturiser No moisturiser log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Weber 2015 20 23 1.556 (0.565) 39.5 % 4.74 [ 1.57, 14.34 ]
Wir n 2009 22 22 1.163 (0.457) 60.5 % 3.20 [ 1.31, 7.84 ]
Total (95% CI) 42 45 100.0 % 3.74 [ 1.86, 7.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 3.71 (P = 0.00021)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Moisturisers versus no treatment (i.e. no moisturiser), Outcome 4 Amount of
topical steroids used.
Review: Emollients and moisturisers for eczema
Comparison: 1 Moisturisers versus no treatment (i.e. no moisturiser)
Outcome: 4 Amount of topical steroids used





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Amount of topical corticosteroids first 3-4 weeks
Giordano-Labadie 2006 35 24.5 (12.51) 39 38 (18.63) 43.2 % -13.50 [ -20.67, -6.33 ]
Grimalt 2007 78 9.52 (7.1) 70 13.78 (8.87) 56.8 % -4.26 [ -6.87, -1.65 ]
Subtotal (95% CI) 113 109 100.0 % -8.25 [ -17.22, 0.72 ]
Heterogeneity: Tau2 = 35.12; Chi2 = 5.64, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 1.80 (P = 0.071)
2 Amount of topical corticosteroids used last 3-4 weeks
Giordano-Labadie 2006 35 24.6 (9.89) 39 24.1 (12.85) 100.0 % 0.50 [ -4.70, 5.70 ]
Subtotal (95% CI) 35 39 100.0 % 0.50 [ -4.70, 5.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
3 Total amount of topical corticosteroids used in 6 to 8 weeks
Giordano-Labadie 2006 35 49.1 (11.2) 39 62.1 (15.74) 40.9 % -13.00 [ -19.18, -6.82 ]
Grimalt 2007 78 15.99 (9.98) 70 22.73 (10.29) 59.1 % -6.74 [ -10.01, -3.47 ]
Subtotal (95% CI) 113 109 100.0 % -9.30 [ -15.33, -3.27 ]
Heterogeneity: Tau2 = 13.23; Chi2 = 3.08, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 3.02 (P = 0.0025)
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Analysis 1.5. Comparison 1 Moisturisers versus no treatment (i.e. no moisturiser), Outcome 5 Change
from baseline in quality of life.
Review: Emollients and moisturisers for eczema
Comparison: 1 Moisturisers versus no treatment (i.e. no moisturiser)
Outcome: 5 Change from baseline in quality of life







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Giordano-Labadie 2006 35 -0.84 (0.43) 39 -0.41 (1.5) 45.0 % -0.38 [ -0.84, 0.08 ]
Grimalt 2007 49 -2.57 (35.51) 54 -3.41 (26.7) 55.0 % 0.03 [ -0.36, 0.41 ]
Total (95% CI) 84 93 100.0 % -0.15 [ -0.55, 0.24 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.73, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Atopiclair versus vehicle, Outcome 1 Number of participants who experienced
good improvement to total resolution.
Review: Emollients and moisturisers for eczema
Comparison: 2 Atopiclair versus vehicle
Outcome: 1 Number of participants who experienced good improvement to total resolution








1 Number of participants who experienced good improvement to total resolution (low risk of bias)
Belloni 2005 8/15 2/15 18.3 % 4.00 [ 1.01, 15.81 ]
Subtotal (95% CI) 15 15 18.3 % 4.00 [ 1.01, 15.81 ]
Total events: 8 (Atopiclair), 2 (Vehicle)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
2 Number of participants who experienced good improvement to total resolution (unclear risk of bias)
Boguniewicz 2008 58/72 7/70 35.6 % 8.06 [ 3.95, 16.42 ]
Subtotal (95% CI) 72 70 35.6 % 8.06 [ 3.95, 16.42 ]
Total events: 58 (Atopiclair), 7 (Vehicle)
Heterogeneity: not applicable
Test for overall effect: Z = 5.74 (P < 0.00001)
3 Number of participants who experienced good improvement to total resolution (high risk of bias)
Abramovits 2008 108/145 18/73 46.1 % 3.02 [ 2.00, 4.56 ]
Subtotal (95% CI) 145 73 46.1 % 3.02 [ 2.00, 4.56 ]
Total events: 108 (Atopiclair), 18 (Vehicle)
Heterogeneity: not applicable
Test for overall effect: Z = 5.26 (P < 0.00001)
Total (95% CI) 232 158 100.0 % 4.51 [ 2.19, 9.29 ]
Total events: 174 (Atopiclair), 27 (Vehicle)
Heterogeneity: Tau2 = 0.25; Chi2 = 5.63, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 4.08 (P = 0.000045)
Test for subgroup differences: Chi2 = 5.46, df = 2 (P = 0.07), I2 =63%
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Analysis 2.2. Comparison 2 Atopiclair versus vehicle, Outcome 2 Change from baseline in itch measured on
a VAS.
Review: Emollients and moisturisers for eczema
Comparison: 2 Atopiclair versus vehicle
Outcome: 2 Change from baseline in itch measured on a VAS





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Change from baseline in itch measured on a VAS (low risk of bias)
Belloni 2005 15 -1.3 (0.5) 15 -0.5 (0.6) 25.7 % -0.80 [ -1.20, -0.40 ]
Subtotal (95% CI) 15 15 25.7 % -0.80 [ -1.20, -0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.97 (P = 0.000073)
2 Change from baseline in itch measured on a VAS (unclear risk of bias)
Boguniewicz 2008 72 -4.7 (1.7) 70 -0.9 (1.7) 25.3 % -3.80 [ -4.36, -3.24 ]
Patrizi 2008 19 -2.6 (0.9) 19 -0.2 (0.9) 25.2 % -2.40 [ -2.97, -1.83 ]
Subtotal (95% CI) 91 89 50.5 % -3.10 [ -4.47, -1.73 ]
Heterogeneity: Tau2 = 0.90; Chi2 = 11.76, df = 1 (P = 0.00061); I2 =91%
Test for overall effect: Z = 4.43 (P < 0.00001)
3 Change from baseline in itch measured on a VAS (high risk of bias)
Abramovits 2008 129 -5.8 (2.5) 57 -2.1 (3.3) 23.8 % -3.70 [ -4.66, -2.74 ]
Subtotal (95% CI) 129 57 23.8 % -3.70 [ -4.66, -2.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.56 (P < 0.00001)
Total (95% CI) 235 161 100.0 % -2.65 [ -4.21, -1.09 ]
Heterogeneity: Tau2 = 2.41; Chi2 = 88.78, df = 3 (P<0.00001); I2 =97%
Test for overall effect: Z = 3.34 (P = 0.00084)
Test for subgroup differences: Chi2 = 36.76, df = 2 (P = 0.00), I2 =95%
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Analysis 2.3. Comparison 2 Atopiclair versus vehicle, Outcome 3 Number of participants reporting an
adverse event.
Review: Emollients and moisturisers for eczema
Comparison: 2 Atopiclair versus vehicle
Outcome: 3 Number of participants reporting an adverse event








Abramovits 2008 46/145 19/73 32.8 % 1.22 [ 0.77, 1.92 ]
Belloni 2005 0/15 0/15 Not estimable
Boguniewicz 2008 36/72 36/70 64.5 % 0.97 [ 0.70, 1.34 ]
Patrizi 2008 2/20 4/20 2.7 % 0.50 [ 0.10, 2.43 ]
Total (95% CI) 252 178 100.0 % 1.03 [ 0.79, 1.33 ]
Total events: 84 (Atopiclair), 59 (Vehicle)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.46, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Atopiclair versus vehicle, Outcome 4 Change from baseline in EASI.
Review: Emollients and moisturisers for eczema
Comparison: 2 Atopiclair versus vehicle
Outcome: 4 Change from baseline in EASI





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Change from baseline in EASI (low risk of bias)
Belloni 2005 15 -4 (3.9) 15 -0.7 (2.6) 21.0 % -3.30 [ -5.67, -0.93 ]
Subtotal (95% CI) 15 15 21.0 % -3.30 [ -5.67, -0.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0064)
2 Change from baseline in EASI (unclear risk of bias)
Boguniewicz 2008 72 -5.15 (7.24) 70 0.84 (3.52) 26.9 % -5.99 [ -7.85, -4.13 ]
Patrizi 2008 19 -4.3 (3.3) 19 -1.7 (4.7) 18.9 % -2.60 [ -5.18, -0.02 ]
Subtotal (95% CI) 91 89 45.9 % -4.42 [ -7.73, -1.10 ]
Heterogeneity: Tau2 = 4.43; Chi2 = 4.35, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 2.61 (P = 0.0090)
3 Change from baseline in EASI (high risk of bias)
Abramovits 2008 145 -4.38 (3.94) 71 -0.76 (5.52) 33.2 % -3.62 [ -5.06, -2.18 ]
Subtotal (95% CI) 145 71 33.2 % -3.62 [ -5.06, -2.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.94 (P < 0.00001)
Total (95% CI) 251 175 100.0 % -4.00 [ -5.42, -2.57 ]
Heterogeneity: Tau2 = 1.06; Chi2 = 6.10, df = 3 (P = 0.11); I2 =51%
Test for overall effect: Z = 5.50 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.29, df = 2 (P = 0.86), I2 =0.0%
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Analysis 2.5. Comparison 2 Atopiclair versus vehicle, Outcome 5 Number of participants experiencing a
flare.
Review: Emollients and moisturisers for eczema
Comparison: 2 Atopiclair versus vehicle
Outcome: 5 Number of participants experiencing a flare








1 Number of participants experiencing a flare (unclear risk of bias)
Boguniewicz 2008 6/72 20/70 39.3 % 0.29 [ 0.12, 0.68 ]
Patrizi 2008 1/20 7/19 7.1 % 0.14 [ 0.02, 1.00 ]
Subtotal (95% CI) 92 89 46.5 % 0.26 [ 0.12, 0.57 ]
Total events: 7 (Atopiclair), 27 (Vehicle)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.38 (P = 0.00073)
2 Number of participants experiencing a flare (high risk of bias)
Abramovits 2008 8/145 29/71 53.5 % 0.14 [ 0.07, 0.28 ]
Subtotal (95% CI) 145 71 53.5 % 0.14 [ 0.07, 0.28 ]
Total events: 8 (Atopiclair), 29 (Vehicle)
Heterogeneity: not applicable
Test for overall effect: Z = 5.38 (P < 0.00001)
Total (95% CI) 237 160 100.0 % 0.18 [ 0.11, 0.31 ]
Total events: 15 (Atopiclair), 56 (Vehicle)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.90, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 6.24 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.43, df = 1 (P = 0.23), I2 =30%
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Analysis 3.1. Comparison 3 Urea-containing moisturiser versus vehicle, Outcome 1 Change from baseline
in skin capacitance.
Review: Emollients and moisturisers for eczema
Comparison: 3 Urea-containing moisturiser versus vehicle
Outcome: 1 Change from baseline in skin capacitance





IV,Random,95% CI IV,Random,95% CI
Bohnsack 1997 -3.2 (0.96) 49.6 % -3.20 [ -5.08, -1.32 ]
Wilhelm 1998 5.6 (0.6) 50.4 % 5.60 [ 4.42, 6.78 ]
Total (95% CI) 100.0 % 1.23 [ -7.39, 9.86 ]
Heterogeneity: Tau2 = 38.08; Chi2 = 60.42, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours vehicle Favours urea
Analysis 4.1. Comparison 4 Glycerin cream versus placebo cream, Outcome 1 Number of participants
reporting an adverse event.
Review: Emollients and moisturisers for eczema
Comparison: 4 Glycerin cream versus placebo cream
Outcome: 1 Number of participants reporting an adverse event








Boralevi 2014 34/125 42/126 55.0 % 0.82 [ 0.56, 1.19 ]
Lod n 2002 27/68 26/66 45.0 % 1.01 [ 0.66, 1.53 ]
Total (95% CI) 193 192 100.0 % 0.90 [ 0.68, 1.19 ]
Total events: 61 (Glycerin cream), 68 (Placebo cream)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Oat-containing cream versus vehicle or no treatment, Outcome 1 Change in
disease severity as assessed by the investigators (SCORAD and EASI).
Review: Emollients and moisturisers for eczema
Comparison: 5 Oat-containing cream versus vehicle or no treatment
Outcome: 1 Change in disease severity as assessed by the investigators (SCORAD and EASI)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Change in disease severity as assessed by the investigator (EASI) (low risk of bias)
Nebus 2009 25 -4.38 (3.72) 25 -4.4 (3.66) 28.0 % 0.01 [ -0.55, 0.56 ]
Subtotal (95% CI) 25 25 28.0 % 0.01 [ -0.55, 0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
2 Change in disease severity as assessed by the investigators (SCORAD) (high risk of bias)
Giordano-Labadie 2006 35 -15.41 (6.31) 39 -11.5 (4.96) 32.0 % -0.69 [ -1.16, -0.22 ]
Grimalt 2007 78 -19.67 (7.33) 70 -19.51 (6.3) 40.0 % -0.02 [ -0.35, 0.30 ]
Subtotal (95% CI) 113 109 72.0 % -0.33 [ -0.98, 0.32 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 5.19, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 138 134 100.0 % -0.23 [ -0.66, 0.21 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 5.78, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 0.60, df = 1 (P = 0.44), I2 =0.0%
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Analysis 5.2. Comparison 5 Oat-containing cream versus vehicle or no treatment, Outcome 2 Change from
baseline in quality of life.
Review: Emollients and moisturisers for eczema
Comparison: 5 Oat-containing cream versus vehicle or no treatment
Outcome: 2 Change from baseline in quality of life







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Change from baseline in quality of life (low risk of bias)
Nebus 2009 25 -3.59 (3.81) 25 -3.96 (3.81) 23.4 % 0.10 [ -0.46, 0.65 ]
Subtotal (95% CI) 25 25 23.4 % 0.10 [ -0.46, 0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
2 Change from baseline in quality of life (high risk of bias)
Giordano-Labadie 2006 35 -0.84 (0.43) 39 -0.41 (1.5) 32.7 % -0.38 [ -0.84, 0.08 ]
Grimalt 2007 50 -2.57 (35.51) 52 -3.41 (26.7) 43.9 % 0.03 [ -0.36, 0.41 ]
Subtotal (95% CI) 85 91 76.6 % -0.16 [ -0.55, 0.24 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.72, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 0.77 (P = 0.44)
Total (95% CI) 110 116 100.0 % -0.09 [ -0.37, 0.19 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.27, df = 2 (P = 0.32); I2 =12%
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Chi2 = 0.52, df = 1 (P = 0.47), I2 =0.0%
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Analysis 6.1. Comparison 6 All moisturisers versus vehicle, placebo or no treatment (no moisturiser),
Outcome 1 Number of participants who experienced improvement.
Review: Emollients and moisturisers for eczema
Comparison: 6 All moisturisers versus vehicle, placebo or no treatment (no moisturiser)
Outcome: 1 Number of participants who experienced improvement








1 Number of participants who experienced improvement (low risk of bias)
Belloni 2005 8/15 2/15 13.2 % 4.00 [ 1.01, 15.81 ]
Nebus 2009 21/25 19/25 22.6 % 1.11 [ 0.84, 1.46 ]
Subtotal (95% CI) 40 40 35.8 % 1.86 [ 0.41, 8.31 ]
Total events: 29 (Moisturiser), 21 (Control)
Heterogeneity: Tau2 = 0.96; Chi2 = 4.75, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.81 (P = 0.42)
2 Number of participants who experienced improvement (unclear risk of bias)
Boguniewicz 2008 58/72 7/70 19.3 % 8.06 [ 3.95, 16.42 ]
Lod n 2002 57/66 46/66 23.0 % 1.24 [ 1.03, 1.49 ]
Subtotal (95% CI) 138 136 42.4 % 3.11 [ 0.25, 38.71 ]
Total events: 115 (Moisturiser), 53 (Control)
Heterogeneity: Tau2 = 3.25; Chi2 = 47.06, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 0.88 (P = 0.38)
3 Number of participants who experienced improvement (high risk of bias)
Abramovits 2008 108/145 18/73 21.8 % 3.02 [ 2.00, 4.56 ]
Subtotal (95% CI) 145 73 21.8 % 3.02 [ 2.00, 4.56 ]
Total events: 108 (Moisturiser), 18 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 5.26 (P < 0.00001)
Total (95% CI) 323 249 100.0 % 2.46 [ 1.16, 5.23 ]
Total events: 252 (Moisturiser), 92 (Control)
Heterogeneity: Tau2 = 0.63; Chi2 = 75.73, df = 4 (P<0.00001); I2 =95%
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Chi2 = 0.38, df = 2 (P = 0.83), I2 =0.0%
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Analysis 6.2. Comparison 6 All moisturisers versus vehicle, placebo or no treatment (no moisturiser),
Outcome 2 Change from baseline in itch.
Review: Emollients and moisturisers for eczema
Comparison: 6 All moisturisers versus vehicle, placebo or no treatment (no moisturiser)
Outcome: 2 Change from baseline in itch







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Change from baseline in itch (low risk of bias)
Belloni 2005 15 -1.3 (0.5) 15 -0.5 (0.6) 13.1 % -1.41 [ -2.22, -0.60 ]
Boralevi 2014 124 -1.72 (2.01) 125 -1.11 (1.93) 15.4 % -0.31 [ -0.56, -0.06 ]
Nebus 2009 25 -0.78 (0.76) 25 -1.2 (1.01) 14.3 % 0.46 [ -0.10, 1.02 ]
Subtotal (95% CI) 164 165 42.8 % -0.36 [ -1.16, 0.43 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 14.18, df = 2 (P = 0.00083); I2 =86%
Test for overall effect: Z = 0.89 (P = 0.37)
2 Change from baseline in itch (unclear risk of bias)
Boguniewicz 2008 72 -4.7 (1.7) 70 -0.9 (1.7) 14.9 % -2.22 [ -2.64, -1.80 ]
Patrizi 2008 19 -2.6 (0.9) 19 -0.2 (0.9) 12.7 % -2.61 [ -3.50, -1.72 ]
Subtotal (95% CI) 91 89 27.6 % -2.29 [ -2.67, -1.91 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 11.83 (P < 0.00001)
3 Change from baseline in itch (high risk of bias)
Abramovits 2008 129 -5.8 (2.5) 57 -2.1 (3.3) 15.2 % -1.33 [ -1.67, -0.99 ]
Patrizi 2014 28 -1.24 (0.77) 26 -0.76 (1.05) 14.4 % -0.52 [ -1.06, 0.03 ]
Subtotal (95% CI) 157 83 29.6 % -0.95 [ -1.75, -0.16 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 6.20, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 2.35 (P = 0.019)
Total (95% CI) 412 337 100.0 % -1.10 [ -1.83, -0.38 ]
Heterogeneity: Tau2 = 0.87; Chi2 = 105.82, df = 6 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Chi2 = 23.39, df = 2 (P = 0.00), I2 =91%
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Analysis 6.3. Comparison 6 All moisturisers versus vehicle, placebo or no treatment (no moisturiser),
Outcome 3 Number of participants who expressed treatment satisfaction.
Review: Emollients and moisturisers for eczema
Comparison: 6 All moisturisers versus vehicle, placebo or no treatment (no moisturiser)
Outcome: 3 Number of participants who expressed treatment satisfaction








1 Number of participants who expressed treatment satisfaction (low risk of bias)
Belloni 2005 9/15 9/15 28.3 % 1.00 [ 0.56, 1.79 ]
Nebus 2009 18/25 17/25 35.0 % 1.06 [ 0.74, 1.52 ]
Subtotal (95% CI) 40 40 63.3 % 1.04 [ 0.77, 1.42 ]
Total events: 27 (Moisturiser), 26 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
2 Number of participants who expressed treatment satisfaction (high risk of bias)
Abramovits 2008 119/145 28/73 36.7 % 2.14 [ 1.58, 2.89 ]
Subtotal (95% CI) 145 73 36.7 % 2.14 [ 1.58, 2.89 ]
Total events: 119 (Moisturiser), 28 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.96 (P < 0.00001)
Total (95% CI) 185 113 100.0 % 1.35 [ 0.77, 2.36 ]
Total events: 146 (Moisturiser), 54 (Control)
Heterogeneity: Tau2 = 0.20; Chi2 = 11.79, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Chi2 = 10.71, df = 1 (P = 0.00), I2 =91%
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Analysis 6.4. Comparison 6 All moisturisers versus vehicle, placebo or no treatment (no moisturiser),
Outcome 4 Number of participants reporting an adverse event.
Review: Emollients and moisturisers for eczema
Comparison: 6 All moisturisers versus vehicle, placebo or no treatment (no moisturiser)
Outcome: 4 Number of participants reporting an adverse event








1 Number of participants reporting an adverse event (low risk of bias)
Belloni 2005 0/15 0/15 Not estimable
Boralevi 2014 34/125 42/126 22.7 % 0.82 [ 0.56, 1.19 ]
Gayraud 2015 5/65 7/65 4.2 % 0.71 [ 0.24, 2.13 ]
Tan 2010 3/30 1/30 1.1 % 3.00 [ 0.33, 27.23 ]
Subtotal (95% CI) 235 236 27.9 % 0.83 [ 0.58, 1.18 ]
Total events: 42 (Moisturiser), 50 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.39, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
2 Number of participants reporting an adverse events (unclear risk of bias)
Boguniewicz 2008 36/72 36/70 27.0 % 0.97 [ 0.70, 1.34 ]
Lod n 2002 34/66 26/66 22.6 % 1.31 [ 0.89, 1.91 ]
Patrizi 2008 2/20 4/20 2.1 % 0.50 [ 0.10, 2.43 ]
Subtotal (95% CI) 158 156 51.6 % 1.08 [ 0.82, 1.42 ]
Total events: 72 (Moisturiser), 66 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.29, df = 2 (P = 0.32); I2 =13%
Test for overall effect: Z = 0.55 (P = 0.58)
3 Number of participants reporting an adverse events (high risk of bias)
Abramovits 2008 46/145 19/73 17.9 % 1.22 [ 0.77, 1.92 ]
Grimalt 2007 8/91 0/82 0.7 % 15.34 [ 0.90, 261.64 ]
Korting 2010 2/51 4/48 1.9 % 0.47 [ 0.09, 2.45 ]
Subtotal (95% CI) 287 203 20.5 % 1.35 [ 0.37, 4.96 ]
Total events: 56 (Moisturiser), 23 (Control)
Heterogeneity: Tau2 = 0.75; Chi2 = 4.63, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 0.46 (P = 0.65)
Total (95% CI) 680 595 100.0 % 1.03 [ 0.82, 1.30 ]
Total events: 170 (Moisturiser), 139 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.18, df = 8 (P = 0.25); I2 =21%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 1.55, df = 2 (P = 0.46), I2 =0.0%
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Analysis 6.5. Comparison 6 All moisturisers versus vehicle, placebo or no treatment (no moisturiser),
Outcome 5 Change in disease severity as assessed by the investigators.
Review: Emollients and moisturisers for eczema
Comparison: 6 All moisturisers versus vehicle, placebo or no treatment (no moisturiser)
Outcome: 5 Change in disease severity as assessed by the investigators







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Change in disease severity as assessed by the investigators (low risk of bias)
Belloni 2005 15 -4 (3.9) 15 -0.7 (2.6) 5.5 % -0.97 [ -1.73, -0.21 ]
Boralevi 2014 124 -5.3 (5.3) 125 -3.1 (4.7) 10.5 % -0.44 [ -0.69, -0.19 ]
Gayraud 2015 62 -3.7 (3.79) 61 0 (5.66) 9.3 % -0.76 [ -1.13, -0.40 ]
Nebus 2009 25 -4.38 (3.72) 25 -4.4 (3.66) 7.3 % 0.01 [ -0.55, 0.56 ]
Tan 2010 30 -12.67 (7.7) 30 -11.69 (7.7) 7.8 % -0.13 [ -0.63, 0.38 ]
Subtotal (95% CI) 256 256 40.4 % -0.45 [ -0.74, -0.15 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 8.77, df = 4 (P = 0.07); I2 =54%
Test for overall effect: Z = 2.98 (P = 0.0029)
2 Change in disease severity as assessed by the investigators (unclear risk of bias)
Boguniewicz 2008 72 -5.15 (7.24) 70 0.84 (3.52) 9.5 % -1.04 [ -1.39, -0.69 ]
Patrizi 2008 19 -4.3 (3.3) 19 -1.7 (4.7) 6.4 % -0.63 [ -1.28, 0.03 ]
Subtotal (95% CI) 91 89 15.9 % -0.93 [ -1.29, -0.57 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.20, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 5.04 (P < 0.00001)
3 Change in disease severity as assessed by the investigators (high risk of bias)
Abramovits 2008 145 -4.38 (3.94) 71 -0.76 (5.52) 10.1 % -0.80 [ -1.09, -0.50 ]
Giordano-Labadie 2006 35 -15.41 (6.31) 39 -11.5 (4.96) 8.2 % -0.69 [ -1.16, -0.22 ]
Grimalt 2007 78 -19.67 (7.33) 70 -19.51 (6.3) 9.8 % -0.02 [ -0.35, 0.30 ]
Korting 2010 50 -8.9 (4.96) 47 -1.3 (6.4) 8.5 % -1.32 [ -1.76, -0.88 ]
Patrizi 2014 28 -5.6 (1.68) 26 -2.4 (3.73) 7.1 % -1.10 [ -1.68, -0.53 ]
Subtotal (95% CI) 336 253 43.7 % -0.77 [ -1.23, -0.30 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 26.75, df = 4 (P = 0.00002); I2 =85%
Test for overall effect: Z = 3.25 (P = 0.0012)
Total (95% CI) 683 598 100.0 % -0.65 [ -0.89, -0.41 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 44.59, df = 11 (P<0.00001); I2 =75%
Test for overall effect: Z = 5.24 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.39, df = 2 (P = 0.11), I2 =54%
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Analysis 6.6. Comparison 6 All moisturisers versus vehicle, placebo or no treatment (no moisturiser),
Outcome 6 Number of participants experiencing a flare.
Review: Emollients and moisturisers for eczema
Comparison: 6 All moisturisers versus vehicle, placebo or no treatment (no moisturiser)
Outcome: 6 Number of participants experiencing a flare








1 Number of participants experiencing a flare (low risk of bias)
Gayraud 2015 18/62 22/61 21.3 % 0.80 [ 0.48, 1.34 ]
Subtotal (95% CI) 62 61 21.3 % 0.80 [ 0.48, 1.34 ]
Total events: 18 (Moisturiser), 22 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
2 Number of participants experiencing a flare (unclear risk of bias)
Boguniewicz 2008 6/72 20/70 17.2 % 0.29 [ 0.12, 0.68 ]
Patrizi 2008 1/20 7/19 7.2 % 0.14 [ 0.02, 1.00 ]
Subtotal (95% CI) 92 89 24.4 % 0.26 [ 0.12, 0.57 ]
Total events: 7 (Moisturiser), 27 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.38 (P = 0.00073)
3 Number of participants experiencing a flare (high risk of bias)
Abramovits 2008 8/145 29/71 18.7 % 0.14 [ 0.07, 0.28 ]
Weber 2015 4/20 15/23 16.2 % 0.31 [ 0.12, 0.77 ]
Wir n 2009 7/22 15/22 19.4 % 0.47 [ 0.24, 0.92 ]
Subtotal (95% CI) 187 116 54.3 % 0.27 [ 0.12, 0.59 ]
Total events: 19 (Moisturiser), 59 (Control)
Heterogeneity: Tau2 = 0.33; Chi2 = 6.31, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 3.26 (P = 0.0011)
Total (95% CI) 341 266 100.0 % 0.33 [ 0.17, 0.62 ]
Total events: 44 (Moisturiser), 108 (Control)
Heterogeneity: Tau2 = 0.43; Chi2 = 18.45, df = 5 (P = 0.002); I2 =73%
Test for overall effect: Z = 3.43 (P = 0.00059)
Test for subgroup differences: Chi2 = 8.35, df = 2 (P = 0.02), I2 =76%
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Analysis 6.7. Comparison 6 All moisturisers versus vehicle, placebo or no treatment (no moisturiser),
Outcome 7 Change from baseline in quality of life.
Review: Emollients and moisturisers for eczema
Comparison: 6 All moisturisers versus vehicle, placebo or no treatment (no moisturiser)
Outcome: 7 Change from baseline in quality of life







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Change from baseline in quality of life (low risk of bias)
Gayraud 2015 62 -4.4 (2.49) 61 -2.2 (2.88) 34.6 % -0.81 [ -1.18, -0.44 ]
Subtotal (95% CI) 62 61 34.6 % -0.81 [ -1.18, -0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.33 (P = 0.000015)
2 Change from baseline in quality of life (high risk of bias)
Giordano-Labadie 2006 35 -0.84 (0.43) 39 -0.41 (1.5) 31.4 % -0.38 [ -0.84, 0.08 ]
Grimalt 2007 49 -2.57 (35.51) 54 -3.41 (26.7) 34.0 % 0.03 [ -0.36, 0.41 ]
Subtotal (95% CI) 84 93 65.4 % -0.15 [ -0.55, 0.24 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.73, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 0.77 (P = 0.44)
Total (95% CI) 146 154 100.0 % -0.39 [ -0.90, 0.12 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 9.51, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 5.72, df = 1 (P = 0.02), I2 =83%
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Analysis 7.1. Comparison 7 Evening primrose oil versus placebo oil, Outcome 1 Change from baseline in
TEWL.
Review: Emollients and moisturisers for eczema
Comparison: 7 Evening primrose oil versus placebo oil
Outcome: 1 Change from baseline in TEWL





IV,Random,95% CI IV,Random,95% CI
Gehring 1999 -0.39 (0.85) 43.8 % -0.39 [ -2.06, 1.28 ]
Gehring 1999 -0.3 (0.75) 56.2 % -0.30 [ -1.77, 1.17 ]
Total (95% CI) 100.0 % -0.34 [ -1.44, 0.76 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Evening primrose oil versus placebo oil, Outcome 2 Change from baseline in
skin hydration.
Review: Emollients and moisturisers for eczema
Comparison: 7 Evening primrose oil versus placebo oil
Outcome: 2 Change from baseline in skin hydration





IV,Random,95% CI IV,Random,95% CI
Gehring 1999 -0.8 (2.11) 48.3 % -0.80 [ -4.94, 3.34 ]
Gehring 1999 1.4 (2.04) 51.7 % 1.40 [ -2.60, 5.40 ]
Total (95% CI) 100.0 % 0.34 [ -2.54, 3.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Licochalcone versus hydrocortisone acetate (HCA) 1%, Outcome 1 Change
from baseline in itch (VAS).
Review: Emollients and moisturisers for eczema
Comparison: 8 Licochalcone versus hydrocortisone acetate (HCA) 1%
Outcome: 1 Change from baseline in itch (VAS)





IV,Random,95% CI IV,Random,95% CI
1 Change from baseline in itch (VAS) (unclear risk of bias)
Wanakul 2013 0 (0.24) 51.9 % 0.0 [ -0.47, 0.47 ]
Subtotal (95% CI) 51.9 % 0.0 [ -0.47, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Change from baseline in itch (VAS) (high risk of bias)
Angelova-Fischer 2014 -1 (0.31) 48.1 % -1.00 [ -1.61, -0.39 ]
Subtotal (95% CI) 48.1 % -1.00 [ -1.61, -0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.23 (P = 0.0013)
Total (95% CI) 100.0 % -0.48 [ -1.46, 0.50 ]
Heterogeneity: Tau2 = 0.42; Chi2 = 6.51, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Chi2 = 6.51, df = 1 (P = 0.01), I2 =85%
-10 -5 0 5 10
Favours licochalcone Favours HCA 1% cream
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Analysis 8.2. Comparison 8 Licochalcone versus hydrocortisone acetate (HCA) 1%, Outcome 2 Change
from baseline in SCORAD.
Review: Emollients and moisturisers for eczema
Comparison: 8 Licochalcone versus hydrocortisone acetate (HCA) 1%
Outcome: 2 Change from baseline in SCORAD





IV,Random,95% CI IV,Random,95% CI
1 Change from baseline in SCORAD (unclear risk of bias)
Wanakul 2013 -2 (0.75) 33.1 % -2.00 [ -3.47, -0.53 ]
Subtotal (95% CI) 33.1 % -2.00 [ -3.47, -0.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.67 (P = 0.0077)
2 Change from baseline in SCORAD (high risk of bias)
Angelova-Fischer 2014 0 (0.4) 37.8 % 0.0 [ -0.78, 0.78 ]
Udompataikul 2011 2.57 (1.01) 29.1 % 2.57 [ 0.59, 4.55 ]
Subtotal (95% CI) 66.9 % 1.12 [ -1.38, 3.61 ]
Heterogeneity: Tau2 = 2.71; Chi2 = 5.60, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.88 (P = 0.38)
Total (95% CI) 100.0 % 0.08 [ -1.96, 2.13 ]
Heterogeneity: Tau2 = 2.72; Chi2 = 13.47, df = 2 (P = 0.001); I2 =85%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 4.45, df = 1 (P = 0.03), I2 =78%
-10 -5 0 5 10
Favours licochalcone Favours HCA 1% cream
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Analysis 8.3. Comparison 8 Licochalcone versus hydrocortisone acetate (HCA) 1%, Outcome 3 Change
from baseline in TEWL.
Review: Emollients and moisturisers for eczema
Comparison: 8 Licochalcone versus hydrocortisone acetate (HCA) 1%
Outcome: 3 Change from baseline in TEWL





IV,Random,95% CI IV,Random,95% CI
1 Change from baseline in TEWL (unclear risk of bias)
Wanakul 2013 -3 (0.87) 54.7 % -3.00 [ -4.71, -1.29 ]
Subtotal (95% CI) 54.7 % -3.00 [ -4.71, -1.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.45 (P = 0.00056)
2 Change from baseline in TEWL (high risk of bias)
Angelova-Fischer 2014 2.51 (1.9) 45.3 % 2.51 [ -1.21, 6.23 ]
Subtotal (95% CI) 45.3 % 2.51 [ -1.21, 6.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Total (95% CI) 100.0 % -0.50 [ -5.88, 4.87 ]
Heterogeneity: Tau2 = 13.00; Chi2 = 6.95, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 0.18 (P = 0.85)
Test for subgroup differences: Chi2 = 6.95, df = 1 (P = 0.01), I2 =86%
-10 -5 0 5 10
Favours licochalcone Favours HCA 1% cream
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Analysis 9.1. Comparison 9 Advabase versus MPA cream twice weekly and emollient, Outcome 1 Rate of
flare.
Review: Emollients and moisturisers for eczema
Comparison: 9 Advabase versus MPA cream twice weekly and emollient
Outcome: 1 Rate of flare
Study or subgroup Advabase
MPA cream
and
emollient log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Peserico 2008 109 112 1.253 (0.31) 3.50 [ 1.91, 6.43 ]
0.1 0.2 0.5 1 2 5 10
MPA cream + emollient Advabase
Analysis 10.1. Comparison 10 Vehicle + daily moisturiser versus fluticasone propionate (FP) + daily
moisturiser, Outcome 1 Number of participants reporting an adverse event.
Review: Emollients and moisturisers for eczema
Comparison: 10 Vehicle + daily moisturiser versus fluticasone propionate (FP) + daily moisturiser
Outcome: 1 Number of participants reporting an adverse event








Berth-Jones 2003 0/84 0/70 Not estimable
Berth-Jones 2003 0/73 0/68 Not estimable
Glazenburg 2009 5/36 18/39 38.8 % 0.30 [ 0.12, 0.73 ]
Hanifin 2002 26/119 71/229 61.2 % 0.70 [ 0.48, 1.04 ]
Total (95% CI) 312 406 100.0 % 0.51 [ 0.22, 1.14 ]
Total events: 31 (Vehicle + moisturiser), 89 (FP + moisturiser)
Heterogeneity: Tau2 = 0.24; Chi2 = 3.01, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours vehicle + moist’ Favours FP + moisturiser
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Analysis 10.2. Comparison 10 Vehicle + daily moisturiser versus fluticasone propionate (FP) + daily
moisturiser, Outcome 2 Number of participants experiencing a flare.
Review: Emollients and moisturisers for eczema
Comparison: 10 Vehicle + daily moisturiser versus fluticasone propionate (FP) + daily moisturiser
Outcome: 2 Number of participants experiencing a flare








Berth-Jones 2003 54/84 13/70 20.2 % 3.46 [ 2.07, 5.80 ]
Berth-Jones 2003 41/73 27/68 25.8 % 1.41 [ 0.99, 2.02 ]
Glazenburg 2009 29/36 17/39 24.5 % 1.85 [ 1.25, 2.73 ]
Hanifin 2002 79/119 58/229 29.4 % 2.62 [ 2.03, 3.39 ]
Total (95% CI) 312 406 100.0 % 2.17 [ 1.51, 3.11 ]
Total events: 203 (Vehicle + moisturiser), 115 (FP + moisturiser)
Heterogeneity: Tau2 = 0.10; Chi2 = 11.61, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 4.21 (P = 0.000025)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours vehicle + moist’ Favours FP + moisturiser
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Analysis 10.3. Comparison 10 Vehicle + daily moisturiser versus fluticasone propionate (FP) + daily
moisturiser, Outcome 3 Rate of flare.
Review: Emollients and moisturisers for eczema
Comparison: 10 Vehicle + daily moisturiser versus fluticasone propionate (FP) + daily moisturiser
Outcome: 3 Rate of flare
Study or subgroup Vehicle + moisturiser FP + moisturiser log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Berth-Jones 2003 84 70 1.758 (0.318) 24.2 % 5.80 [ 3.11, 10.82 ]
Berth-Jones 2003 78 68 0.642 (0.25) 26.0 % 1.90 [ 1.16, 3.10 ]
Glazenburg 2009 36 39 0.78 (0.325) 24.0 % 2.18 [ 1.15, 4.12 ]
Hanifin 2002 119 229 2.041 (0.261) 25.7 % 7.70 [ 4.62, 12.84 ]
Total (95% CI) 317 406 100.0 % 3.69 [ 1.80, 7.55 ]
Heterogeneity: Tau2 = 0.45; Chi2 = 19.62, df = 3 (P = 0.00020); I2 =85%
Test for overall effect: Z = 3.57 (P = 0.00036)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours FP + moisturiser Favours vehicle + moist’
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Analysis 11.1. Comparison 11 Active treatment in combination with a moisturiser versus active treatment
only, Outcome 1 Change in disease severity as assessed by the investigators.
Review: Emollients and moisturisers for eczema
Comparison: 11 Active treatment in combination with a moisturiser versus active treatment only













N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Msika 2008 17 -26 (7.04) 15 -20 (7.63) 16.8 % -0.80 [ -1.52, -0.07 ]
Msika 2008 17 -24.94 (8.7) 18 -20.98 (6.91) 19.5 % -0.49 [ -1.17, 0.18 ]
Wu 2014 63 -16.67 (2.4) 62 -13.8 (3.21) 63.7 % -1.01 [ -1.38, -0.63 ]
Total (95% CI) 97 95 100.0 % -0.87 [ -1.17, -0.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.75, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 5.75 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours active tx + moist Favours active tx only
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Analysis 11.2. Comparison 11 Active treatment in combination with a moisturiser versus active treatment
only, Outcome 2 Change in quality of life IDQOL.
Review: Emollients and moisturisers for eczema
Comparison: 11 Active treatment in combination with a moisturiser versus active treatment only











N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Msika 2008 17 -4.24 (3.4) 18 -3.17 (3.3) 39.7 % -1.07 [ -3.29, 1.15 ]
Msika 2008 17 -3.53 (2.59) 15 -2.07 (2.6) 60.3 % -1.46 [ -3.26, 0.34 ]
Total (95% CI) 34 33 100.0 % -1.31 [ -2.70, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.068)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours active tx + moist Favours active tx only
Analysis 11.3. Comparison 11 Active treatment in combination with a moisturiser versus active treatment
only, Outcome 3 Change in quality of life DFI.
Review: Emollients and moisturisers for eczema
Comparison: 11 Active treatment in combination with a moisturiser versus active treatment only











N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Msika 2008 17 -3.18 (3.58) 18 -2.67 (3.67) 36.4 % -0.51 [ -2.91, 1.89 ]
Msika 2008 17 -3.65 (3.09) 15 -2.33 (2.11) 63.6 % -1.32 [ -3.14, 0.50 ]
Total (95% CI) 34 33 100.0 % -1.03 [ -2.47, 0.42 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours active tx + moist Favours active tx only
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A D D I T I O N A L T A B L E S
Table 1. Glossary of terms
Term Definition
Adverse events Unwanted side effects of using medication
Allergic contact dermatitis A form of eczema after contact with a substance (an allergen) that produces (elicits) an immune-
mediated response in the skin
Allergic rhinitis ’Hay fever’: inflammation of the nose caused by allergens such as house dust mite, animals,
pollen. Symptoms include sneezing, itchiness in the nose, watery eyes, runny or blocked nose
Ameliorate Improve, to make something (such as a problem) better
Atopy The individual’s genetic predisposition to develop allergic reactions such as eczema, allergic
rhinitis and asthma. Atopy often involves production of IgE antibodies against allergens such
as, for example, house dust mite, animals, grass and tree pollen, and food proteins
Bacteria Also referred to as germs, bacteria are tiny micro-organisms that are invisible to the eye. They are
found everywhere and can be harmful, e.g. causing infections, or helpful, e.g. aiding digestion
of food
Ceramides Lipid (fatty) molecules found in the lipid bilayer of the intercellular matrix (see ‘Intercellular
lipid matrix’ below)
Colonisation The point at which an Infection begins, when an organism successfully enters the body, grows
and multiplies
Control The alternative treatment, placebo, or absence of treatment against which the intervention of
interest in the review is compared
Corneodesmosomes Any of a class of proteins that hold corneocytes (cells in the epidermis, or outer layers of the
skin) together; their degradation leads to desquamation (see ’Desquamation’ below)
DASI Dry skin area and severity index: a tool used to evaluate dryness and severity of dry skin (Serup
1995)
Desquamation Skin peeling
Dizygotic Non-identical twins, i.e. twins formed from two different eggs fertilised by separate sperm
cells, are referred to as dizygotic
DLQI Dermatology Life Quality Index: an assessment tool to evaluate the impact of eczema and its
treatment on quality of life (Finlay 1994)
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Table 1. Glossary of terms (Continued)
EASI Eczema Area and Severity Index: a tool used to measure the extent (area) and severity of eczema
(Hanifin 2001)
Emollients The terms ‘emollients’ and ‘moisturisers’ are often used interchangeably. But, since ’emollient’
sometimes refers to a specific ingredient that soothes the skin, it is more appropriate to use the
term ’moisturiser’. Emollients are included within ointments, creams, lotions, gels, bath oils
and sprays, and are used to keep the skin soft and supple and reduce scaling. Application to
the skin reduces water loss by covering it with a protective film. They can be used frequently
and might ease itching
Epidermis The outermost layers of cells in the skin which consist mainly of keratinocytes that mature to
become corneocytes
Exacerbation Periods of worsening the symptoms and signs of eczema
Excoriation Abrasion, scratched skin
Extensor The opposite site of a flexure point, i.e. the outer side of, for example elbow, knee or wrist
Filaggrin An epidermal barrier protein
Flare Periods of worsening of eczema symptoms and signs, or escalation in use of medication (
Thomas 2015)
Flexural dermatitis Eczema at the flexure points (inner sides) of elbow, knees, wrists, groin and armpits
Gene Part of DNA that encodes a protein involved in body function
Genome-wide linkage study An established tool to map inherited diseases
Humectant Substance or product that is ’water loving’ and draws water towards it
Hygroscopic Absorbing water
Hypersensitivity An exaggerated immune response toward an allergen (for example pollen, house dust mite,
but also for contact allergens such as nickel and fragrances)
IgE (immunoglobulin E) A class of antibody that is important in defence against parasitic disease, and plays a key role
in the disease process of allergic diseases. People with eczema often have an increased level of
IgE in their blood
Immune response The process through which the body identifies and defends itself against bacteria, viruses and
other harmful agents
Intercellular lipid matrix Space surrounding corneocytes with stacked layers of lipids
Lesion A region or area of damaged skin
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Table 1. Glossary of terms (Continued)
Lesional Concerning lesions, or accompanied by lesions
Lichenification Skin thickening
Moisturisers Ointments, creams, lotions, gels, bath oils and sprays that are used to keep the skin soft and
supple and reduce scaling. Application to the skin reduces water loss and covers it with a
protective film. Moisturisers can be used frequently and might ease itching
Monozygotic Identical twins, i.e. twins who develop from a single fertilised egg (zygote) that splits to form
two identical embryos, are referred to as monozygotic (in contrast to dizygotic twins (see above)
)
Objective Something observed and verified by physician or investigator by visible physical signs or
laboratory tests (i.e. based on facts, not emotions or feelings)
Objective- SCORAD Objective - SCORing Atopic Dermatitis is a clinical scoring system, that uses the SCORAD
system and excludes subjective symptoms, which cannot be measured accurately, such as
daytime itching (pruritus) and sleep loss (Kunz 1997)
Occlusive Describes an agent or process that seals something off
Over-the-counter (OTC) medicines Medicines that can be bought without a prescription
Papulovesicular Relating to an eruption of papules (clearly defined (circumscribed), solid elevations of skin
with no visible fluid) and vesicles (small fluid-filled sacs on the skin)
Pathogenesis Origin of disease and how it develops
Pathognomonic biomarker A specific indicator for a disease
Photochemotherapy (PUVA) PUVA is a combination treatment of a drug (psoralen) with ultraviolet A (UVA) light. The
psoralen makes the skin temporarily more sensitive to the ultraviolet light
Phototherapy Treatment with ultraviolet light (UVB or UVA)
Placebo A ’dummy’ or fake medicine that has no expected benefit. In this review placebo means, in
accordance with the terminology used by the investigators, a moisturiser without the ingredient
considered to be the most beneficial, and so, of a different composition than the moisturiser
being studied. Use of placebo treatments allows patients and staff to be blinded, as the placebo
and active treatments appear the same, so it is impossible to tell which has been used
POEM The Patient Oriented Eczema Measure is a self-assessment tool for monitoring eczema severity,
based on signs and symptoms (Charman 2004)
PO-SCORAD The Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD) index is a self-assessment
score for patients to evaluate their eczema, based on subjective and objective criteria from the
SCORAD (see also SCORAD below) (Stalder 2011)
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Table 1. Glossary of terms (Continued)
Preservative A natural or synthetic ingredient added to products such as foods, pharmaceuticals, paints,
biological samples, wood, etc. which help to prevent decomposition caused by microbial
growth or by undesirable chemical changes
Propylene glycol Propylene glycols attract water and by enhancing skin penetration they behave as moisturisers
to improve the appearance of the skin
Protease An enzyme that breaks down proteins (via proteolysis)
Pruritus Itch
Quality of life The general well-being of individuals and societies. Health-Related Quality of Life (HRQoL)
looks at quality of life in relation to health
QoLIAD Quality of Life Index for Atopic Dermatitis (QoLIAD). An assessment tool to evaluate the
impact of eczema and its treatment on quality of life (Whalley 2004)
Remission A temporary or permanent decrease or absence of the symptoms and signs of disease activity
Sensitisation Exposure to an allergen that results in the development of hypersensitivity, i.e. an increased or
disproportionate response to the allergen
SCORAD-index An assessment tool used by clinicians to evaluate the extent and severity of eczema (SCORing
Atopic Dermatitis) (European Task Force on Atopic Dermatitis 1993)
Staphyloccocus aureus A type of bacterium that is often found on the skin
Subjective Something experienced by the participant not perceived by the investigator or physician
TEWL Trans-epidermal water loss (TWL or TEWL) is the quantity of water that diffuses through
and evaporates from the epidermis
Topical corticosteroid Corticosteroids applied to the skin; these are effective in controlling inflammation and used
to treat eczema and many other skin conditions
Urea Urea absorbs water, helps to reduce the amount of water lost though the skin and increases
skin penetration of other substances. It softens the horny layer and also has anti-itch (anti-
pruritic) properties
Vehicle In this review ’vehicle’ means a moisturiser that has the same composition as the studied
moisturiser, but lacks the ingredient that is considered to be the most beneficial
Volar The inside surface of the forearm, i.e. the same side as the palm of the hand
Xerosis Dry skin
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Table 2. Contact with investigators
Study ID Response Additional Comment
Abramovits 2008 Emails sent: 26 June 2014,
7 February 2016, 12 February
2016, 26 February 2016, 12
March 2016, 19 March 2016, to
dra@dermcenter.us
Regarding allocation conceal-
ment and method of blinding
Replies received: 24 March 2016
with responses; 29 March 2016
with additional information
Yes -
Angelova-Fischer 2014 Emails sent: 13 February 2016,




Reply received: 1 March 2016
with response to sequence gener-
ation
Several emails sent regarding allo-




it no need to contact, but this is
recent email for future update of
the review
Not applicable -




Email received: 15 February
2016 with responses
Yes -
Berth-Jones 2003 Emails sent: 13 February 2016,
26 February 2016, to john-
berthjones@aol.com
Regarding method of blinding
Email received: 27 February
2016 with responses
Yes -
Bissonnette 2010 Emails sent: 12 May 2014, 14




tion, allocation concealment and
Yes -
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Table 2. Contact with investigators (Continued)
method of blinding
Replies received: 2 February
2015 and 15 February 2016; re-
ceived all responses and addi-
tional material
Boguniewicz 2008 Emails sent: 14 February 2016,
26 February 2016, 12 March
2016, 19 March 2016, to bo-
guniewiczm@njhealth.org. Also
did not reply to questions about
the Abramovits 2008 study
Regarding allocation conceal-
ment and method of blinding,
EASI scores at day 43 and sub-
jects/care givers assessment of




Boralevi 2014 Emails sent: 15 February 2016,
26 February 2016, 12 March
2016, 26 March 2016, to franck.
boralevi@chu-bordeaux.fr
Regarding P-VAS scores, SCO-
RAD, Objective SCORAD, and
HI at day 28 as well as SDs
Replies received: 31 March 2016









and method of blinding, mean
SCORAD, TEWL, capacitance
and SDs
Replies received: 16 May 2014
and 15 February 2016, received
responses and additional infor-
mation
Yes -
Danby 2011 Emails sent: 15 February 2016,
26 February 2016, 15 March
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Table 2. Contact with investigators (Continued)
allocation concealment, method
of blinding, TEWL values and
SDs after 2 weeks, number of
dropouts, numbers of male/fe-
male and age of participants
Reply received: 22 March 2016
with responses to our questions





ment and method of blinding
Replies received: 24 February
2016 and 12 March 2016
from cbaudouin@expanscience.
com and bernard@clinreal.com,
with responses to our questions
Yes -
Draelos 2008 Emails sent: 16 February 2016,
12 March 2016, 19 March
2016, 26 March 2016, to zdrae-
los@northstate.net
Regarding allocation conceal-
ment and method of blinding
No reply received
Not applicable -
Draelos 2009 Emails sent: 19 February 2016,
12 March 2016, 19 March
2016, 26 March 2016, to zdrae-
los@northstate.net
Regarding allocation conceal-
ment and method of blinding,
more precise baseline data and




Draelos 2011 Emails sent: 19 February 2016,
12 March 2016, 19 March




of blinding, precise baseline data
and data at end of study, means
and SDs, Participant assessments
of target site skin appearance for
Not applicable -
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Table 2. Contact with investigators (Continued)
redness, peeling, dryness, sting-
ing/burning, and overall skin ir-
ritation, sponsoring and declara-
tion of interest
No reply received
Emer 2011 Emails sent: 5 March 2016, 12
March 2016, 19 March 2016,
26 March 2016 to Jason Emer
(email not current anymore),




of blinding, colour version of pdf
and SDs at week 4
No reply received
Not applicable -
Faergemann 2009 Emails sent: 7 March 2016,




of blinding, more precise data
Reply received: 12 March 2015
“it is so long time ago that I per-
formed this study so I do not re-
member. I retired last November
2015 and I do not have assess to
any data now.”
No -




of blinding and incomplete data
Reply received: 14 March 2014
with responses to our questions
Yes -
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Table 2. Contact with investigators (Continued)
Reply received: 26 May 2014
with responses to our questions
Glazenburg 2009 Emails sent :14 March 2016, 19
March 2016, 26 March 2016, 3
April 2016, to a.oranje@inter.nl.
net
Regarding allocation conceal-
ment, method of blinding and











Reply received: 24 June 2015, af-
ter several emails we received re-
sponses to everything we asked
for
Yes -
Hagströmer 2006 Email sent: 17 April 2016,
to lena.hagstromer@karolinska.
se (no longer correct, no more
recent email, so sent again
to lennart.emtestam@medhs.ki.
se, but this is also no longer cor-
rect)
Regarding sequence generation,
allocation concealment and base-
line data for TEWL and cor-
neometry
No recent email addresses could
be found
Not applicable -
Hamada 2008 We could not find a current email
address of any of the authors
listed
Not applicable -
Hlela 2015 Emails sent: 18 March 2016,
26 March 2016, 3-4 February
2016,10 April 2016, to n.khu-
malo@uct.ac.za
Regarding sequence generation
and allocation concealment, fre-
quency of use, precise data after 3
Not applicable -
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Table 2. Contact with investigators (Continued)
months (means and SDs), more
data on adverse events
No reply received
Janmohamed 2014 Emails sent: 19 March 2016, 26
March 2016, 3 April 2016, to a.
oranje@inter.nl.net
Regarding allocation conceal-
ment, method of blinding, exact
data for POEM and quality of
life at baseline, and SCORAD,




Jirabundansuk 2014 Emails sent: 8 January 2016, 24
January 2016, 12 February 2016,






Kircik 2009 Email sent: 19 March 2015, to
wedoderm@yahoo.com
Regarding full text publication
Reply received: 21 March 2015,
Principal investigator could not
remember anymore
No -




of blinding, exact TEWL values
and corneometry with SDs at
week 4
Reply received: 21 March 2016
with responses to some of our
questions, the rest was no longer
accessible
Yes and No We did not receive exact data





Email address is no longer cor-
rect, and further searches showed
Not applicable -
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Table 2. Contact with investigators (Continued)
that he died in 2012. None of the
other authors could be contacted
Laumann 2006 Emails sent: 20 March 2016, 26






of blinding and precise study data
Reply received: 26 March 2016
with responses to our questions
Yes -
Marseglia 2014 Emails sent: 15 April 2016,
19 April 2016, 23 April 2016,




Reply received: 2 May 2016 with
responses to our questions
Yes -
Miller 2011 Email sent: 14 May 2014,
to afleisch@wfubmc.edu. Lat-





Reply received: 14 May 2014
with responses to our questions
Yes -







ment, means and SDs for some
outcomes and clarification about
data losses for the following
outcomes in particular IDQOL,
DFI, IGE
Reply received: 30 June 2014
with additional information
Yes -
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Table 2. Contact with investigators (Continued)
Namazova-Baranova 2012 Email sent: 30 June 2014, to
julia.levina@mail.ru and lsnama-
zova@yandex.ru
Regarding clarification of correct
citation i.e. author string/jour-
nal page numbers to the 2 cita-
tions listed in Included studies,
plus sequence generation, alloca-
tion concealment and method of
blinding
Reply received: 30 June 2014 and
5 July 2014, with responses to
our questions
Yes -
Nebus 2009 Emails sent: 2 January 2016, 5
January 2016, 15 January 2016,
20 January 2016, to Fowler-
joe@msn.com, wwallo@its.jnj.
com, Jnebus@its.jnj.com
Regarding missing data of con-
trol, and clarification regarding
study design, and data regarding
EASI, IGA
Repy received: 20 January 2016
from Dr Nebus with responses
to our questions and additional
documents
Yes -




Reply received: 18 January 2016,
from sminno@gmail.com, with
responses to our questions
Yes -




of blinding, dropouts, EASI,
VAS scores at baseline and day 21
and additional study details
Replies received: 26 March 2016,
and 30 March 2016 with re-
sponses to our questions
Yes -
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Table 2. Contact with investigators (Continued)
Park 2014 Emails sent: 26 March 2016,
3 April 2016, 10 April 2016,




of blinding and precise data of
IGA, VAS, TEWL and corneom-
etry with SD at 4 weeks
No reply received
Not applicable -
Patrizi 2008 Emails sent: 27 March 2016, 3




of blinding and precise data of
EASI at day 43, and data of ap-
praisal patients
Reply received: 12 April 2016,
with responses regarding se-
quence generation, allocation
concealment and blinding, but
not the rest. 14 April 2016
we sent mails to the spon-
sor at PPrioglio@sinclairpharma.
com (no longer working) and
pprioglio@sinclairpharma.it
No further details retrieved
In part -
Patrizi 2014 Email sent 27 March
2016, 3 April 2016 jennifer.the-
unis@pierre-fabre.com
Regarding sequence generation,
allocation concealment, and pre-
cise data of TEWL at day 43, and
to which group drop-out was ran-
domised
Response 7 April 2016 we re-
ceived responses to our questions
Yes -
Peltonen 2014 Email sent 28 March 2016, 3
April 2016, 10 April 2016, 16
April 2016 jarmo.laihia@utu.fi
Regarding allocation conceal-
ment, precise data at baseline,
day 10 and 28 for TEWL, PGA,
EASI, adverse events in Cis UCA
group and in vehicle
Not applicable -
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Table 2. Contact with investigators (Continued)
No reply received
Peserico 2008 Email




of blinding as one group had two
different tubes, precise data at
baseline and week 16 for VAS,
EASI, DLQI and CDLQI
Reply received: 30 March 2016,
saying that cannot help us,
the study was too long ago,
and Schering Dermatology does









ences between publication and
protocol and exact baseline values
for data after 15, 30 and 60 min-
utes for TEWL, and corneome-
try
Reply received: 12 April 2016,
with responses to our questions
Yes -
Simpson 2011 Email sent: 18





garding sequence generation and
allocation concealment, mean re-
duction in EASI and correspond-
ing standard deviations at day 28,
and dropouts
Reply received: 18 July 2014,
with responses to our questions
Yes -
Simpson 2013 Emails sent: 2 April 2016, 10
April 2016, 16 April 2016, 23
April 2016, to simpsone@ohsu.
Yes -
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Regarding exact baseline values
(and SD) at day 28 for dryness
scale, TEWL, and corneometry
Reply received: 2 May 2016, with
responses to our questions and
additional information




of blinding, precise data at base-
line and day 28 for IGA and pa-
tient/family self-assessments
Reply received: 4 April 2016,
with responses to our questions
and additional information
Yes -




Reply received: 16 May 2014,
with responses to our questions
Yes Quasi randomised, exclude
Takeuchi 2012 Emails sent: 3 April 2016, 10
April 2016, 16 April 2016, 23




and allocation concealment, and
SCORAD (mean and SD) at




Tan 2010 Emails sent: 3 April 2016, 10




Reply received: 11 April 2016,
with response to our question
Yes -
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Table 2. Contact with investigators (Continued)




Reply received: 8 April 2016,
with response to our question
Yes -
Udompataikul 2011 Emails sent: 2 July 2014, 7
July 2014, 24 January 2016, 12
February 2016, 8 April 2016, 18
April 2016, to umontree@yahoo.
com (mpatai@yahoo.com is no
longer in use)
Regarding sequence generation,
allocation concealment and stan-
dard deviations (or SEM) of the
SCORAD at baseline, week 2,
week 4 and week 6?
Reply received: 18 April 2016,
with some data but no informa-
tion regarding sequence genera-
tion, or allocation concealment
and there were no data for week
6
In part -




Reply received: 15 April 2016,
with responses to our questions
Yes -





Reply received: 20 April 2016,
with responses to our questions
Yes -
Wu 2014 Emails sent: 5 January 2016,
15 January 2016, 31 January
2016, 12 February 2016, 10
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Table 2. Contact with investigators (Continued)
Åkerström 2015 Emails sent:
10 April 2016, 16 April 2016, to
petra.skare@aconordic.com
Regarding allocation conceal-
ment, method of blinding, SCO-
RAD values at start maintenance
phase and follow-up, item EQ-
5D
Reply received: 18 April 2016,
with responses to our questions
Yes -
Abbreviations
CDLQI: Children’s Dermatology Life Quality Index
DLQI: Dermatology Life Quality Index
EASI: eczema area and severity index
EQ-5D: a measure of health-related quality of life that was developed by the EuroQol group that includes the five dimensions of
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression
HI: hydration index
IGA: Investigator Global Assessment
IGE: Immunoglobulin E
POEM: Patient-Oriented Eczema Measure
P-VAS: Pruritus visual analogue scale
SCORAD: scoring atopic dermatitis
SD: standard deviation
SEM: standard error of the mean
TEWL: transepidermal water loss
Table 3. Comparisons of moisturisers
MOISTURISER VERSUS VEHICLE, PLACEBO OR NO TREATMENT
Moisturisers versus no treatment (i.e. no moisturiser)
Study Intervention Comparator Within-participant? Active treatment allowed?
Grimalt 2007 Exomega lotion (oat)
twice daily 6 weeks
No treatment for 6 weeks No Moderate- and high-po-
tency corticosteroids al-
lowed
Giordano-Labadie 2006 Exomega moisturising
milk (oat) twice daily for
2 months
No treatment for 2
months
No Moderate- and high-po-
tency corticosteroids al-
lowed
Weber 2015 Eucerin Eczema Relief
body cream (oat and lic-
ochalcone) once a day for
6 months + cleanser
Only cleanser for 6
months
No Eucerin Eczema Relief In-
stant Therapy allowed for
active lesions,
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Table 3. Comparisons of moisturisers (Continued)
Wirén 2009 Canoderm (urea 5%)
twice daily 6 months
No treatment 6 months No Permitted only at areas
other than target lesion
Simpson 2013 Cethaphil Restoraderm
Body moisturiser (ce-
ramide precursors etc)
twice daily 27 days
No treatment 27 days Yes No
Patrizi 2014 Emollient balm twice
daily for 28 days




Study Intervention Comparator Within-participant? Active treatment allowed?
Abramovits 2008 Atopiclair three times
daily for 50 days
Vehicle three times daily
for 50 days
No No
Belloni 2005 Atopiclair three times
daily for 21 days
Vehicle three times daily
for 21 days
No Oral medication continued
Boguniewicz 2008 Atopiclair three times
daily for 43 days





Patrizi 2008 3-arm (1st
comparison)
As Atopiclair ’light’ is
not marketed and clearly
less effective, it is not in-
cluded in the compari-




son) will therefore not be
further discussed
Atopiclair three times
daily for 43 days
Vehicle three times daily
for 43 days
No If really needed, low-po-
tency topical corticosteroid
allowed
Other moisturisers versus vehicle or placebo
Urea-containing moisturisers
Study Intervention Comparator Within-participant? Active treatment allowed?
Bohnsack 1997 Laceran (10% urea)
twice daily for 4 weeks
Vehicle twice daily for 4
weeks
Yes No
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Table 3. Comparisons of moisturisers (Continued)
Wirén 2009 Canoderm (urea 5%)
twice daily for 6 months
No treatment for 6
months
No Only at other areas than tar-
get lesion
Wilhelm 1998 Laceran (10% urea)
twice daily for 4 weeks
Vehicle twice daily for 4
weeks
Yes No
Lodén 2002 3 arm (1st
comparison)
Urea saline 4% cream
once daily for 30 days
Placebo (cream base)
cream once daily for 30
days
No Topical steroids allowed
Glycerol-containing moisturisers
Lodén 2002 3 arm (2nd
comparison)
Glycerol 20% once daily
for 30 days
Placebo (cream base)
once daily for 30 days
No Topical steroids allowed
Boralevi 2014 Dexeryl (glycerol 15%)
twice daily for 4 weeks
Vehicle without glycerol
twice daily for 4 weeks
No If really needed, moder-
ate-potency topical corti-
costeroid allowed
Breternitz 2008 Glycerol 20% twice daily
for 4 weeks
Vehicle without glycerol
twice daily for 4 weeks
Yes No
Oat-containing moisturisers
Grimalt 2007 Exomega lotion (oat)
twice daily for 6 weeks
No treatment for 6 weeks No Moderate- and high-po-
tency corticosteroids al-
lowed
Giordano-Labadie 2006 Exomega moisturising
milk (oat) twice daily for
2 months
No treatment for 2
months
No Moderate- and high-po-
tency corticosteroids al-
lowed
Nebus 2009 Oatmeal based occlusive
cream twice daily for 8
weeks




Weber 2015 Eucerin Eczema Relief
body cream (oat and lic-
ochalcone) once a day for
6 months + cleanser
Cleanser only for 6
months
No Eucerin Eczema Relief In-
stant Therapy was allowed
for active lesions
Remaining moisturisers versus vehicle or placebo
Larregue 1996 Ammonium lactate 6%
in water-in-oil emulsion
twice daily for 4 weeks
Vehicle twice daily for 4
weeks
Yes No
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Table 3. Comparisons of moisturisers (Continued)
Korting 2010 Pale sulfonated 4% shale
oil cream three times
daily for 4 weeks
Vehicle three times daily
for 4 weeks
No No
Gayraud 2015 Atoderm In-
tensive cream twice daily
for 6 months
Moisturiser base twice
daily for 6 months
No Topical corticosteroid and
immunomodulators could
be continued
Tan 2010 Triclosan 1% mois-
turiser twice daily for 41
days




Thumm 2000 3 arm
(1st comparison)
Hippophae rhamnoides
10% cream for 4 weeks
Placebo cream for 4
weeks
No No
Thumm 2000 3 arm
(2nd comparison)
Hippophae rhamnoides
20% cream for 4 weeks




Gehring 1999 study 1 Primrose oil amphilic o/
w emulsion twice daily
for 4 weeks
Placebo oil twice daily
for 4 weeks
Yes No
Gehring 1999study 2 Primrose oil amphilic w/
o emulsion twice daily
for 4 weeks
Placebo oil twice daily
for 4 weeks
Yes No
Hamada 2008 Camellia oil spray for 2
weeks
Purified water spray for 2
weeks
No All allowed without chang-
ing
ONE MOISTURISER VERSUS ANOTHER MOISTURISER
Study Intervention Comparator Within-participant? Active treatment allowed?
Patrizi 2008 3 arm (3rd
comparison)
Atopiclair three times
daily for 43 days
Atopiclair ’light’ three
times daily for 43 days
No If really needed, low-po-
tency topical corticosteroid
allowed
Miller 20113 arm (1st
comparison)
Atopiclair three times
daily for 3 weeks
EpiCeram three times
daily for 3 weeks
No No
Miller 20113 arm (2nd
comparison)
Atopiclair three times
daily for 3 weeks
Aquaphor (petrola-
tum 41%, glycerol, lano-
lin etc.), three times daily
for 3 weeks
No No
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Table 3. Comparisons of moisturisers (Continued)




daily for 3 weeks
Aquaphor three times
daily for 3 weeks
No No




glycol etc) twice daily for
4 weeks
Yes No
Nuñez 2013 EpiCeram twice daily for
3 weeks
Oatmeal-contain-
ing cream twice daily for
3 weeks
No No
Kircik 2014 EpiCeram for 4 weeks Eucerin for 4 weeks Yes No
Laumann 2006 MimyX + Eucerin twice
daily for 12 weeks
Eucerin cream twice
daily for 12 weeks
Yes If really needed, low-po-
tency topical corticosteroid
allowed
Draelos 2009 Albolene twice daily for
4 weeks
MimyX twice daily for 4
weeks




Aquacare twice daily for
4 weeks






daily for a year




Åkerström 2015 Canoderm (urea 5%)
twice daily for 6 months
Miniderm (no urea)
twice daily for 6 months
No No
Bissonnette 2010 Urea 5% moisturiser
twice daily for 6 weeks
Urea 10% lotion for 6
weeks
No Topical steroids allowed
Hagströmer 2001 Urea 4% + NaCl in o/w
twice daily for 2 weeks
Urea 4% in o/w twice
daily for 2 weeks
Yes No
Lodén 2002 3 arm (3rd
comparison)
Glycerol 20% once daily
for 30 days
Urea saline 4% cream
once daily for 30 days
No Topical corticosteroids al-
lowed
Faergemann 2009 Propyless (20% propy-
lene glycol) twice daily
for 2 weeks
Fenuril (urea 4% and





daily for 6 weeks
Control moisturiser (?)
twice daily for 6 weeks
No Topical corticosteroids al-
lowed
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Table 3. Comparisons of moisturisers (Continued)
Tripodi 2009 Furfuryl palmitate-en-
riched moisturiser twice




Marseglia 2014 Pro-AMP cream (rham-
nosoft ceramides) twice
daily for 4 weeks
Hydrating cream (glyc-
erol, vaseline, paraffin
twice daily for 4 weeks
No No
Thumm 2000 3 arm
(3rd comparison)
Hippophae rhamnoides
10% cream for 4 weeks
Hipophae rhamnoides
20% cream for 4 weeks
No No
Park 2014 Lactobacillus sakei-con-
taining moisturiser twice
daily for 4 weeks
Control moisturiser for 4
weeks
Yes Topical corticosteroids al-
lowed
Evangelista 2014 Virgin coconut oil twice
daily for 8 weeks
Mineral oil twice daily
for 8 weeks
No No
Verallo-Rowell 2008 Virgin coconut oil twice
daily for 4 weeks
Virgin olive oil twice
daily for 4 weeks
No No
Shi 2015 Bleach bath with mois-
turiser on one occasion
Water bath with mois-
turiser on one occasion
No No
MOISTURISERS VERSUS ACTIVE TREATMENT
Moisturisers versus topical corticosteroids
Study Intervention Comparator Within-participant? Active treatment allowed?
Within-participant studies comparing licochalcone containing moisturiser versus hydrocortisone
Angelova-Fischer 2014 O/W formulation con-
taining licochalcone A
(Glycyrrhiza Inflata root
extract) twice daily for 1
week
Hydrocortisone cream
twice daily for 1 week
Yes No
Udompataikul 2011 Licochalcone twice daily
for 6 weeks
Hydrocortisone cream
twice daily for 6 weeks
Yes No
Wanakul 2013 Licochalcone twice daily
for 4 weeks
Hydrocortisone cream
twice daily for 4 weeks
Yes No
Parallel studies comparing moisturisers versus topical corticosteroids
409Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Comparisons of moisturisers (Continued)
De Belilovsky 2011 Ste-
latopia (2% sunflower oil
distillate, fatty acids, ce-






Sugarman 2009 EpiCeram twice daily for
4 weeks
Fluticasone 0.5% cream
twice a day for 4 weeks
No No (Cetaphil lotion applied
to uninvolved lesions)
Janmohamed 2014 20% petrolatum in ce-
tomacrogol + wet wrap
for 4 weeks
Mometasone furoate 0.
1% + wet wrap for 4
weeks
No No
Gehring 1996 w/o emulsion Excipial
twice a day for 1 week
Hydrocortisone 1% in
w/o emulsion (Excipial)
twice daily for 1 week
No No
Jirabundansuk 2014 Moisturiser containing
spent grain wax, spinose
kernel oil, etc. twice a
day for 4 weeks
Hydrocortisone 1%
cream twice a day for 4
weeks
Yes No
Peserico 2008 Moisturiser (Advabase)
twice a day for 16 weeks
Methylprednisolone
aceponate cream 2 days a
week, on other days used
moisturiser twice a day
for 16 weeks
No No
Moisturiser versus topical immunomodulators
Emer 2011 Eletone
(high lipid) three times
daily for 4 weeks
Pimecrolimus three
times daily for 4 weeks
Yes No
Takeuchi 2012 Moisturiser therapy (?)
for 4 weeks
Tacrolimus for 4 weeks No No
Frankel 2011 Hyalotopic (ce-
ramide) three times daily
for 4 weeks
Pimecrolimus twice a
day for 4 weeks
Yes No
VEHICLE + MOISTURISER VERSUS TOPICAL CORTICOSTEROID + MOISTURISER
Berth-Jones 2003 4 arm
(1st comparison)
Vehicle cream twice




cream twice weekly +
moisturiser for 16 weeks
No No
410Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Comparisons of moisturisers (Continued)
Berth-Jones 2003 4 arm
(2nd comparison)
We did not consider
other possible compar-
isons of the 4 arms im-
portant for this review
Vehicle ointment twice




weekly + moisturiser for
16 weeks
No No
Hanifin 2002 Vehicle twice a week +
moisturiser for 20 weeks
Flutica-
sone propionate 0.05%
cream twice weekly +
moisturiser for 20 weeks
No No
Glazenburg 2009 Placebo ointment twice




weekly + moisturiser for
16 weeks
No No
TOPICAL ACTIVE TREATMENT + MOISTURISER VERSUS TOPICAL ACTIVE TREATMENT ALONE
Study Intervention Comparator Within-participant? Active treatment allowed?
Draelos 2008 3 arm (1st
comparison)
Flu-
ocinonide 0.05% twice a
day + ceramide cleanser+
moisturising cream for 4
weeks
Fluocinonide
0.05% twice a day plus
cleansing bar for 4 weeks
No No
Draelos 2008 3 arm
(2nd comparison)
3rd possible compar-
ison did not include
moisturiser i.e. fluoci-
nonide + cleansing bar
vs fluocinonide + ce-
ramide cleanser
Flu-
ocinonide 0.05% twice a
day + ceramide cleanser+
moisturising cream for 4
weeks
Fluocinonide 0.05%
twice a day plus ceramide
cleanser for 4 weeks
No No
Wu 2014 Moisturising and soften-
ing cream + flumetha-
sone ointment twice a
day for 3 weeks
Flumethasone ointment
twice a day for 3 weeks
No No
Simpson 2011 study D Restoraderm moisturiser
twice a day + topical cor-
ticosteroids for 4 weeks
Routine use of topi-
cal corticosteroids for 4
weeks
Yes No
Hanifin 1998 Desonide 0.05% twice a
day + three times daily
moisturiser for 3 weeks
Desonide 0.05% cream
twice a day for 3 weeks
Yes No
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Table 3. Comparisons of moisturisers (Continued)
Msika 2008 5 arm (1st
comparison)
Desonide 0.05% twice a
day plus moisturiser +
sunflower oil 2% twice a
day for 21 days
Desonide 0.05% twice a
day for 21 days
No No
Msika 2008 5 arm (2nd
comparison)
We did not consider
other possible compar-
isons of the 5 arms to be
important for this re-
view
Desonide 0.05% once
daily plus moisturiser +
sunflower oil 2% twice a
day for 21 days
Desonide 0.05% once
daily for 21 days
No No
Gao 2008 BoPao cream + 10% urea
ointment once a day or
twice a day for 2 weeks




o/w: oil in water
w/o: water in oil
Table 4. Included studies with no usable or irretrievable data
Study ID Interventions & comparisons N Comments
Andersson 1999 5% urea as active substance versus
4% urea and 4% NaCl
50 The data were reported in box-and-whisker plots, and no precise
data were provided, too much estimation
Berents 2015 Emollient + fresh expressed milk
versus moisturiser only
9 None of our outcomes were assessed
Danby 2011 Aqueous cream BP versus Oilatum
Junior Bath additive
38 Poster with limited information. The principal investigator said,
“The study itself was a purely mechanistic study, and not meant to
provide clinical evidence”
Ferreira 1998 Nioleol (10% primrose oil, 8%-9%
γ -linolenic acid) versus
Uriage (borage oil and 24% γ -
linolenic acid) versus
Atopic (35%-40% γ -linolenic
acid) versus Atoderm control mois-
turiser once daily for 12 weeks
23 Unclear how many participants were randomised to each arm
Hagströmer 2006 Proderm versus no treatment 24 No baseline data nor end value data were reported. The data were
reported in box-and-whisker plots, and were not interpretable
Harper 1995 Oilatum Plus versus Oilatum
Emollient
30 Unclear how many participants were randomised to each arm, in-
consistencies in reporting of data
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Table 4. Included studies with no usable or irretrievable data (Continued)
Hlela 2015 Study 1
Emulsifying ointment with aque-
ous cream versus emulsifying oint-




tum versus petroleum jelly
120 Frequency of use during day or week were not reported. There were
quite some inconsistencies in text and figures. Study 2 reported no
end data, just that all scores tended to decline. We mailed inves-
tigators numerous times to clarify study details, but received no
response
Kircik 2009 Midpotency corticosteroid cream
versus midpotency corticosteroid
cream combined with a hydrolipid
cream
6 Poster with limited information, principal investigator was not able
to provide missing study details
Lodén 2001 Glycerol 20% cream versus 4% urea
and 4% NaCl
110 Unclear how many participants were randomised to each arm. The
data all need to be estimated from box-and-whisker plots, too much
estimation
Nho 2014 PPARα activator and ceramide ver-
sus moisturiser without these ingre-
dients
31 Only 5 participants with eczema included, no individual patient
data, not our prespecified outcomes
Peltonen 2014 Cis-urocanic acid 5% emulsion
cream versus control vehicle
14 Data provided need to be estimated from figures (for transepider-
mal water loss (TEWL)), or no precise data were provided other
than that there were no significant differences. We mailed inves-
tigators numerous times to clarify study details, but received no
response
Pigatto 1996 Cream containing 10% urea versus
control cream
70 Unclear how many were randomised to each treatment arm, no
separate data for healthy subjects and atopic subjects
Puschmann 2003 Two different formulations of
polidocanol- and urea-containing
creams against each other
54 Unclear how many were randomised to each treatment arm, no
separate data for healthy subjects and atopic subjects
Shiratori 1977 Urea 10% ointment versus base OR
versus urea 20% ointment
552 The data were confusingly reported in this study and did not lend
themselves to further analysis. As the study was 39 years old we
have not contacted the investigators for data
Table 5. Table of fixed-effect sensitivity analyses
Analysis Comparison MD/RR/HR/SMD 95% confidence interval P value
Analysis 1.1





MD -2.51 -3.66 to -1.37 P < 0.0001
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Pooled data for the first
3 to 4 weeks
MD -5.34 -7.79 to -2.89 P < 0.0001
Moisturisers versus no
treatment
Single study data last 3 to
4 weeks
MD 0.50 -4.70 to 5.70 P = 0.85
Moisturisers versus no
treatment
Pooled data for 6 to 8
weeks
MD -8.11 -11.00 to -5.22 P < 0.00001
Analysis 1.5













RR 4.16 2.96 to 5.86 P < 0.00001
Analysis 2.2
Change from baseline
itch measured on a VAS
Atopiclair versus vehicle
Pooled data







RR 1.04 0.80 to 1.35 P = 0.78
Analysis 2.4










RR 0.18 0.11 to 0.31 P < 0.00001
Analysis 3.1




MD 3.13 2.13 to 4.13 P < 0.00001
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RR 0.89 0.67 to 1.18 P = 0.46
Analysis 5.1
Change in disease sever-




vehicle or no treatment
Pooled data
SMD -0.19 -0.43 to 0.05 P = 0.12
Analysis 5.2




vehicle or no treatment
Pooled data






vehicle, placebo or no
treatment
Pooled data
RR 2.20 1.84 to 2.62 P < 0.00001
Analysis 6.2
Change from baseline in
itch
All moisturisers versus
vehicle, placebo or no
treatment
Pooled data






vehicle, placebo or no
treatment
Pooled data






vehicle, placebo or no
treatment
Pooled data
RR 1.06 0.88 to 1.27 P = 0.56
Analysis 6.5
Change in disease sever-
ity as assessed by the in-
vestigators
All moisturisers versus
vehicle, placebo or no
treatment
Pooled data





vehicle, placebo or no
treatment
Pooled data
RR 0.35 0.26 to 0.47 P < 0.00001
Analysis 6.7
Change from baseline in
quality of life
All moisturisers versus
vehicle, placebo or no
treatment
Pooled data
SMD -0.40 -0.64 to -0.17 P = 0.0006
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Table 5. Table of fixed-effect sensitivity analyses (Continued)
Analysis 7.1





MD -0.34 -1.44 to 0.76 P = 0.55
Analysis 7.2





MD 0.34 -2.54 to 3.21 P = 0.82
Analysis 8.1





MD -0.37 -0.75 to -0.00 P = 0.05
Analysis 8.2





MD -0.12 -0.77 to 0.54 P = 0.73
Analysis 8.3






















RR 2.27 1.91 to 2.71 P < 0.00001
Analysis 10.3






HR 3.67 2.78 to 4.84 P < 0.00001
Analysis 11.1
Change in disease sever-
ity as assessed by the in-
vestigators
Active treatment in com-
bination
with a moisturiser versus
active treatment only
Pooled data
SMD -0.87 -1.17 to -0.57 P = 0.00001
Analysis 11.2
Change in quality of life
IDQOL
Active treatment in com-
bination
with a moisturiser versus
active treatment only
Pooled data
MD -1.31 -2.70 to 0.09 P = 0.07
Analysis 11.3
Change of quality of life
DFI
Active treatment in com-
bination
MD -1.03 -2.47 to 0.42 P = 0.17
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Table 5. Table of fixed-effect sensitivity analyses (Continued)




DFI: dermatitis family impact
EASI: eczema area and severity index




SCORAD: scoring atopic dermatitis
SMD: standardised mean difference
TEWL: transepidermal water loss
VAS: visual analogue scale
Table 6. Table with stratified analyses per domain of risk of bias
MOISURISER VERSUS NO MOISTURISER


















3 141 135 -2.42 (-4.55 to -
0.28)
68% P = 0.03
Sequence generation
Low risk (all tri-
als)
3 141 135 -2.42 (-4.55 to -
0.28)
68% P = 0.03
Allocation concealment
Low risk (all tri-
als)
3 141 135 -2.42 (-4.55 to -
0.28)
68% P = 0.03
Blinding of participants and personnel
High risk (all tri-
als)
3 141 135 -2.42 (-4.55 to -
0.28)
68% P = 0.03
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Table 6. Table with stratified analyses per domain of risk of bias (Continued)
Blinding of outcome assessment
High risk (all tri-
als)
3 141 135 -2.42 (-4.55 to -
0.28)






2 63 65 -3.39 (-4.73 to -
2.05)
0% P < 0.00001
High risk
(Grimalt 2007)
1 78 70 -0.16 (-2.36 to 2.
04)
NA P = 0.89
Selective reporting
Low risk (all tri-
als)
3 141 135 -2.42 (-4.55 to -
0.28)
68% P = 0.03
Other bias
Low risk (all tri-
als)
3 141 135 -2.42 (-4.55 to -
0.28)
68% P = 0.03
ATOPICLAIR VERSUS VEHICLE



















3 232 158 4.51 (2.19 to 9.
29)
64% P < 0.0001
Sequence generation
Low risk (all tri-
als)
3 232 158 4.51 (2.19 to 9.
29)
64% P < 0.0001
Allocation concealment
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2 160 88 3.09 (2.08 to 4.
59)




1 72 70 8.06 (3.95 to 16.
42)
NA P < 0.00001





2 160 88 3.09 (2.08 to 4.
59)




1 72 70 8.06 (3.95 to 16.
42)
NA P < 0.00001





2 160 88 3.09 (2.08 to 4.
59)




1 72 70 8.06 (3.95 to 16.
42)






2 87 85 6.95 (3.69 to 13.
07)




1 145 73 3.02 (2.00 to 4.
56)
NA P < 0.00001
Selective reporting
Low risk (all tri-
als)
3 232 158 4.51 (2.19 to 9.
29)
64% P < 0.0001
Other bias
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Table 6. Table with stratified analyses per domain of risk of bias (Continued)
Low risk (all tri-
als)
3 232 158 4.51 (2.19 to 9.
29)
64% P < 0.0001




















4 235 161 -2.65 (-4.21 to -
1.09)
97% P = 0.0008
Sequence generation
Low risk (all tri-
als)
4 235 161 -2.65 (-4.21 to -
1.09)







3 163 91 -2.25 (-3.83 to -
0.68)




1 72 70 -3.80 (-4.36 to -
3.24)
NA P < 0.00001






3 163 91 -2.25 (-3.83 to -
0.68)




1 72 70 -3.80 (-4.36 to -
3.24)
NA P < 0.00001
Blinding of outcome assessment
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3 163 91 -2.25 (-3.83 to -
0.68)




1 72 70 -3.80 (-4.36 to -
3.24)







3 106 104 -2.33 (-4.13 to -
0.52)




1 129 57 -3.70 (-4.66 to -
2.74)
NA P < 0.00001
Selective reporting
Low risk (all tri-
als)
4 235 161 -2.65 (-4.21 to -
1.09)
97% P = 0.0008
Other bias
Low risk (all tri-
als)
4 235 161 -2.65 (-4.21 to -
1.09)
97% P = 0.0008




















4 251 175 -4.00 (-5.42 to -
2.57)
51% P < 0.00001
Sequence generation
421Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 6. Table with stratified analyses per domain of risk of bias (Continued)
Low risk (all tri-
als)
4 251 175 -4.00 (-5.42 to -
2.57)







3 179 105 -3.36 (-4.47 to -
2.25)




1 72 70 -5.99 (-7.85 to -
4.13)
NA P < 0.00001






3 179 105 -3.36 (-4.47 to -
2.25)




1 72 70 -5.99 (-7.85 to -
4.13)
NA P < 0.00001






3 179 105 -3.36 (-4.47 to -
2.25)




1 72 70 -5.99 (-7.85 to -
4.13)




1 15 15 -3.30 (-5.67 to -
0.93)





2 91 89 -4.42 (-7.73 to -
1.10)
77% P = 0.009
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1 145 71 -3.62 (-5.06 to -
2.18)
NA P < 0.0001
Selective reporting
Low risk (all tri-
als)
4 251 175 -4.00 (-5.42 to -
2.57)
51% P < 0.00001
Other bias
Low risk (all tri-
als)
4 251 175 -4.00 (-5.42 to -
2.57)
51% P < 0.00001
OAT-CONTAINING MOISTURISERS VERSUS VEHICLE OR NO TREATMENT (NO MOISTURISER)



















3 138 134 -0.23 (-0.66 to 0.
21)
65% P = 0.30
Sequence generation
Low risk (all tri-
als)
3 138 134 -0.23 (-0.66 to 0.
21)
65% P = 0.30
Allocation concealment
Low risk (all tri-
als)
3 138 134 -0.23 (-0.66 to 0.
21)
65% P = 0.30
Blinding of participants and personnel
Low risk (Nebus
2009)
1 25 25 0.01 (-0.55 to 0.
56)




2 113 109 -0.33 (-0.98 to 0.
32)
81% P = 0.32
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Table 6. Table with stratified analyses per domain of risk of bias (Continued)
Grimalt 2007)
Blinding of outcome assessment
Low risk (Nebus
2009)
1 25 25 0.01 (-0.55 to 0.
56)





2 113 109 -0.33 (-0.98 to 0.
32)






2 60 64 -0.36 (-1.03 to 0.
32)
71% P = 0.30
High risk
(Grimalt 2007)
1 78 70 -0.02 (-0.35 to 0.
30)
NA P = 0.98
Selective reporting
Low risk (all tri-
als)
3 138 134 -0.23 (-0.66 to 0.
21)
65% P = 0.30
Other bias
Low risk (all tri-
als)
3 138 134 -0.23 (-0.66 to 0.
21)





2 103 95 -0.02 (-0.29 to 0.
26)
0% P = 0.91
Difference





1 35 39 -0.69 (-1.16 to -
0.22)
NA P = 0.004
Change from baseline in quality of life
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3 110 116 -0.09 (-0.37 to 0.
19)
12% P = 0.53
Sequence generation
Low risk (all tri-
als)
3 110 116 -0.09 (-0.37 to 0.
19)
12% P = 0.53
Allocation concealment
Low risk (all tri-
als)
3 110 116 -0.09 (-0.37 to 0.
19)
12% P = 0.53
Blinding of participants and personnel
Low risk (Nebus
2009)
1 25 25 0.10 (-0.46 to 0.
65)





2 85 91 -0.16 (-0.55 to 0.
24)
42% P = 0.44
Blinding of outcome assessment
Low risk (Nebus
2009)
1 25 25 0.10 (-0.46 to 0.
65)





2 85 91 -0.16 (-0.55 to 0.
24)






2 60 64 -0.17 (-0.63 to 0.
29)
39% P = 0.48
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Table 6. Table with stratified analyses per domain of risk of bias (Continued)
High risk
(Grimalt 2007)
1 50 52 0.03 (-0.36 to 0.
41)
NA P = 0.89
Selective reporting
Low risk (all tri-
als)
3 110 116 -0.09 (-0.37 to 0.
19)
12% P = 0.53
Other bias
Low risk (all tri-
als)
3 110 116 -0.09 (-0.37 to 0.
19)
12% P = 0.53
ALL MOISTURISERS VERSUS VEHICLE TO PLACEBO OR NO MOISTURISER





















5 323 249 2.46 (1.16 to 5.
23)









4 257 183 3.10 (0.98 to 9.
82)
95% P = 0.05
Unclear risk (
Lodén 2002)
1 66 66 1.24 (1.03 to 1.
49)





3 185 113 2.19 (0.75 to 6.
39)
95% P = 0.15
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2 138 136 3.11 (0.25 to 38.
71)
98% P = 0.98






3 185 113 2.19 (0.75 to 6.
39)





2 138 136 3.11 (0.25 to 38.
71)
98% P = 0.98






3 185 113 2.19 (0.75 to 6.
39)





2 138 136 3.11 (0.25 to 38.
71)






3 106 106 1.23 (0.94 to 1.
62)




1 72 70 8.06 (3.95 to 16.
42)




1 145 73 3.02 (2.00 to 4.
56)
NA P < 0.00001
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Table 6. Table with stratified analyses per domain of risk of bias (Continued)
Selective reporting
Low risk (all tri-
als)
5 323 249 2.46 (1.16 to 5.
23)
95% P = 0.02
Other bias
Low risk (all tri-
als)
5 323 249 2.46 (1.16 to 5.
23)
95% P = 0.02























7 412 337 -1.10 (-1.83 to -
0.38)
94% P = 0.003
Sequence generation
Low risk (all tri-
als)
7 412 337 -1.10 (-1.83 to -
0.38)










6 340 267 -0.89 (-1.56 to -
0.23)




1 72 70 -2.22 (-2.64 to -
1.80)
NA P < 0.00001
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Table 6. Table with stratified analyses per domain of risk of bias (Continued)








5 312 241 -0.98 (-1.79 to -
0.18)




1 72 70 -2.22 (-2.64 to -
1.80)
NA P < 0.00001
High risk (Patrizi
2014)
1 28 26 -0.52 (-1.06 to 0.
03)
NA P = 0.06








5 312 241 -0.98 (-1.79 to -
0.18)




1 72 70 -2.22 (-2.64 to -
1.80)
NA P < 0.00001
High risk (Patrizi
2014)
1 28 26 -0.52 (-1.06 to 0.
03)







4 192 191 -0.38 (-0.94 to 0.
17)





2 91 89 -2.29 (-2.67 to -
1.91)
0% P < 0.00001
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1 129 57 -1.33 (-1.67 to -
0.99)
NA P < 0.00001
Selective report-
ing
Low risk (all tri-
als)
7 412 337 -1.10 (-1.83 to -
0.38)
94% P = 0.003
Other bias
Low risk (all tri-
als)
7 412 337 -1.10 (-1.83 to -
0.38)
94% P = 0.003


















3 185 113 1.35 (0.77 to 2.
36)
83% P = 0.29
Sequence generation
Low risk (all tri-
als)
3 185 113 1.35 (0.77 to 2.
36)
83% P = 0.29
Allocation concealment
Low risk (all tri-
als)
3 185 113 1.35 (0.77 to 2.
36)
83% P = 0.29
Blinding of participants and personnel
Low risk (all tri-
als)
3 185 113 1.35 (0.77 to 2.
36)
83% P = 0.29
Blinding of outcome assessment
Low risk (all tri-
als)
3 185 113 1.35 (0.77 to 2.
36)
83% P = 0.29
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2 40 40 1.04 (0.77 to 1.
42)




1 145 73 2.14 (1.58 to 2.
89)
NA P < 0.00001
Selective reporting
Low risk (all tri-
als)
3 185 113 1.35 (0.77 to 2.
36)
83% P = 0.29
Other bias
Low risk (all tri-
als)
3 185 113 1.35 (0.77 to 2.
36)
83% P = 0.29

























10 680 595 1.03 (0.82 to 1.
30)








9 614 529 0.96 (0.74 to 1.
24)
16% P = 0.76
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1 66 66 1.31 (0.89 to 1.
91)











7 491 411 1.00 (0.65 to 1.
55)






3 189 184 1.08 (0.82 to 1.
43)
15% P = 0.59








6 400 329 0.94 (0.72 to 1.
24)





2 138 136 1.11 (0.83 to 1.
48)




2 142 130 2.27 (0.06 to 90.
70)
80% P = 0.66
Blinding of outcome assessment
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6 400 329 0.94 (0.72 to 1.
24)





2 138 136 1.11 (0.83 to 1.
48)




2 142 130 2.27 (0.06 to 90.
70)








6 352 350 0.99 (0.70 to 1.
40)





2 92 90 0.95 (0.69 to 1.
30)





2 236 155 3.04 (0.24 to 38.
72)
71% P = 0.39
Selective reporting
Low risk (all tri-
als)
10 680 595 1.03 (0.82 to 1.
30)
21% P = 0.80
Other bias
Low risk (all tri-
als)
10 680 595 1.03 (0.82 to 1.
30)
21% P = 0.80
Change in disease severity as assessed by the investigators
433Emollients and moisturisers for eczema (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.




























12 683 598 -0.65 (-0.89 to -
0.41)
75% P < 0.00001
Sequence generation
Low risk (all tri-
als)
12 683 598 -0.65 (-0.89 to -
0.41)














10 561 481 -0.53 (-0.76 to -
0.30)





2 122 117 -1.15 (-1.43 to -
0.88)
0% P < 0.00001
Blinding of participants and personnel
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7 420 346 -0.53 (-0.77 to -
0.30)




1 72 70 -1.04 (-1.39 to -
0.69)







4 191 182 -0.77 (-1.41 to -
0.12)
88% P = 0.02









7 420 346 -0.53 (-0.77 to -
0.30)




1 72 70 -1.04 (-1.39 to -
0.69)







4 191 182 -0.77 (-1.41 to -
0.12)







8 369 368 -0.66 (-0.96 to -
0.36)
71% P < 0.0001
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2 91 89 -0.93 (-1.29 to -
0.57)





2 223 141 -0.41 (-1.17 to 0.
35)
92% P = 0.29
Selective reporting
Low risk (all tri-
als)
12 683 598 -0.65 (-0.89 to -
0.41)
75% P < 0.00001
Other bias
Low risk (all tri-
als)
12 683 598 -0.65 (-0.89 to -
0.41)
75% P < 0.00001






















6 341 266 0.33 (0.17 to 0.
62)
73% P = 0.0006
Sequence generation
Low risk (all tri-
als)
6 341 266 0.33 (0.17 to 0.
62)
73% P = 0.0006
Allocation concealment
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5 269 196 0.33 (0.15 to 0.
71)




1 72 70 0.29 (0.12 to 0.
68)
NA P = 0.005






3 227 151 0.27 (0.06 to 1.
20)




1 72 70 0.29 (0.12 to 0.
68)




2 42 45 0.40 (0.23 to 0.
70)
0% P = 0.001






3 227 151 0.27 (0.06 to 1.
20)




1 72 70 0.29 (0.12 to 0.
68)




2 42 45 0.40 (0.23 to 0.
70)





3 104 106 0.54 (0.31 to 0.
92)
47% P = 0.02
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2 92 89 0.26 (0.12 to 0.
57)




1 145 71 0.14 (0.07 to 0.
28)
NA P < 0.00001
Selective reporting
Low risk (all tri-
als)
6 341 266 0.33 (0.17 to 0.
62)
73% P = 0.0006
Other bias
Low risk (all tri-
als)
6 341 266 0.33 (0.17 to 0.
62)
73% P = 0.0006


















3 146 154 -0.39 (-0.90 to 0.
12)
79% P = 0.13
Sequence generation
Low risk (all tri-
als)
3 146 154 -0.39 (-0.90 to 0.
12)
79% P = 0.13
Allocation concealment
Low risk (all tri-
als)
3 146 154 -0.39 (-0.90 to 0.
12)
79% P = 0.13
Blinding of participants and personnel
Low risk
(Gayraud 2015)
1 62 61 -0.81 (-1.18 to -
0.44)
NA P < 0.0001
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2 84 93 -0.15 (-0.55 to 0.
24)
42% P = 0.44
Blinding of outcome assessment
Low risk
(Gayraud 2015)
1 62 61 -0.81 (-1.18 to -
0.44)





2 84 93 -0.15 (-0.55 to 0.
24)






2 97 100 -0.62 (-1.04 to -
0.19)
52% P = 0.004
High risk
(Grimalt 2007)
1 49 54 0.03 (-0.36 to 0.
41)
NA P = 0.89
Selective reporting
Low risk (all tri-
als)
3 146 154 -0.39 (-0.90 to 0.
12)
79% P = 0.13
Other bias
Low risk (all tri-
als)
3 146 154 -0.39 (-0.90 to 0.
12)
79% P = 0.13
LICOCHALCONE-CONTAINING MOISTURISERS VERSUS HYDROCORTISONE ACETATE 1% CREAM






















0.08 (-1.96 to 2.
13)
85% P = 0.94
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-0.90 (-2.85 to 1.
05)








2.57 (0.59 to 4.
55)
NA P = 0.01







-2.00 (-3.47 to -
0.53)










1.12 (-1.38 to 3.
61)
82% P = 0.38







-2.00 (-3.47 to -
0.53)










1.12 (-1.38 to 3.
61)










-0.90 (-2.85 to 1.
05)








2.57 (0.59 to 4.
55)
NA P = 0.01
Selective reporting
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Table 6. Table with stratified analyses per domain of risk of bias (Continued)




0.08 (-1.96 to 2.
13)
85% P = 0.94
Other bias




0.08 (-1.96 to 2.
13)
85% P = 0.94
VEHICLE TREATMENT + MOISTURISER VERSUS FLUTICASONE TREATMENT TWICE WEEKLY + MOISTURISER





















4 312 406 0.51 (0.22 to 1.
14)







3 193 177 0.30 (0.12 to 0.
73)
NA P = 0.008
Unclear risk (
Hanifin 2002)
1 119 229 0.70 (0.48 to 1.
04)










2 155 268 0.51 (0.22 to 1.
14)
67% P = 0.10
Blinding of participants and personnel
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2 155 268 0.51 (0.22 to 1.
14)
67% P = 0.10









2 155 268 0.51 (0.22 to 1.
14)




4 312 406 0.51 (0.22 to 1.
14)




4 312 406 0.51 (0.22 to 1.
14)




4 312 406 0.51 (0.22 to 1.
14)
67% P = 0.10




















4 312 406 2.17 (1.51 to 3.
11)
74% P < 0.0001
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3 193 177 2.02 (1.24 to 3.
30)
76% P = 0.005
Unclear risk (
Hanifin 2002)
1 119 229 2.62 (2.03 to 3.
39)





2 157 138 2.17 (0.88 to 5.
37)





2 155 268 2.27 (1.62 to 3.
19)
54% P < 0.00001




2 157 138 2.17 (0.88 to 5.
37)





2 155 268 2.27 (1.62 to 3.
19)
54% P < 0.00001




2 157 138 2.17 (0.88 to 5.
37)





2 155 268 2.27 (1.62 to 3.
19)
54% P < 0.00001
Incomplete outcome data
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Table 6. Table with stratified analyses per domain of risk of bias (Continued)
Unclear risk (all
studies)
4 312 406 2.17 (1.51 to 3.
11)




4 312 406 2.17 (1.51 to 3.
11)




4 312 406 2.17 (1.51 to 3.
11)
74% P < 0.0001





















4 406 312 3.69 (1.80 to 7.
55)







3 177 193 2.84 (1.44 to 5.
61)
76% P = 0.003
Unclear risk (
Hanifin 2002)
1 229 119 7.70 (4.62 to 12.
84)





2 138 157 3.26 (1.09 to 9.
74)





2 268 155 4.16 (1.21 to 14.
31)
89% P = 0.02
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Table 6. Table with stratified analyses per domain of risk of bias (Continued)




2 138 157 3.26 (1.09 to 9.
74)





2 268 155 4.16 (1.21 to 14.
31)
89% P = 0.02




2 138 157 3.26 (1.09 to 9.
74)





2 268 155 4.16 (1.21 to 14.
31)




4 406 312 3.69 (1.80 to 7.
55)




4 406 312 3.69 (1.80 to 7.
55)




4 406 312 3.69 (1.80 to 7.
55)
85% P = 0.0004
NA not applicable; MD mean difference; SMD standardised mean difference; RR risk ratio; HR hazard ratio
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A P P E N D I C E S
Appendix 1. Cochrane Skin Specialised Register (CRS) search strategy
(dermatitis or eczema or neurodermatitis) and (emollient* or moisturis* or moisturiz* or lubricant* or ointment* or cream* or oil* or
bath* or steroid* or corticosteroid*)
Appendix 2. CENTRAL (Cochrane Library) search strategy
#1 MeSH descriptor: [Dermatitis] explode all trees
#2 dermatitis:ti,ab,kw
#3 MeSH descriptor: [Eczema] explode all trees
#4 eczema:ti,ab,kw
#5 MeSH descriptor: [Neurodermatitis] explode all trees
#6 neurodermatitis:ti,ab,kw
#7 MeSH descriptor: [Dermatitis, Atopic] explode all trees
#8 {or #1-#7}
#9 MeSH descriptor: [Emollients] explode all trees
#10 emollient*:ti,ab,kw
#11 (moisturis* or moisturiz*):ti,ab,kw
#12 MeSH descriptor: [Lubricants] explode all trees
#13 lubricant*:ti,ab,kw
#14 MeSH descriptor: [Ointments] explode all trees
#15 ointment*:ti,ab,kw
#16 cream*:ti,ab,kw
#17 MeSH descriptor: [Skin Cream] explode all trees
#18 MeSH descriptor: [Oils] explode all trees
#19 oil*:ti,ab,kw
#20 bath*:ti,ab,kw
#21 MeSH descriptor: [Baths] explode all trees
#22 corticosteroid*:ti,ab,kw
#23 steroid*:ti,ab,kw
#24 MeSH descriptor: [Steroids] explode all trees
#25 {or #9-#24}
#26 #8 and #25







7. exp Dermatitis, Atopic/
8. or/1-7
9. emollient$.ti,ab. or exp Emollients/
10. moisturis$.ti,ab.
11. moisturiz$.ti,ab.
12. lubricant$.ti,ab. or exp Lubricants/
13. ointment$.ti,ab. or exp Ointments/
14. cream$.ti,ab.
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15. exp Skin Cream/
16. exp Oils/ or oil$.ti,ab.
17. bath$3.ti,ab. or exp Baths/
18. corticosteroid$.ti,ab.
19. exp Steroids/ or steroid$.ti,ab.
20. or/9-19
21. randomized controlled trial.pt.
22. controlled clinical trial.pt.
23. randomized.ab.
24. placebo.ab.
25. clinical trials as topic.sh.
26. randomly.ab.
27. trial.ti.
28. 21 or 22 or 23 or 24 or 25 or 26 or 27
29. exp animals/ not humans.sh.
30. 28 not 29
31. 8 and 20 and 30
[Lines 21-30: Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-
maximizing version (2008 revision)]









9. exp emollient agent/
10. emollient$.ti,ab.
11. (moisturis$ or moisturiz$).ti,ab.

















29. (crossover$ or cross over$).tw.
30. placebo$.tw.
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31. (doubl$ adj blind$).tw.
32. allocat$.tw.
33. trial.ti.
34. randomized controlled trial.sh.
35. random$.tw.
36. or/26-35
37. exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
38. human/ or normal human/
39. 37 and 38
40. 37 not 39
41. 36 not 40
42. 8 and 25 and 41
Appendix 5. LILACS search strategy
(dermatitis or eczema or eccema or neurodermatitis or neurodermitis) and (emollient$ or moisturis$ or moisturiz$ or oil$ or bath$ or
cream$ or lubricant$ or steroid$ or corticosteroid$ or emoliente$ or crema$ or esteroide$ or corticoesteroide$ or ointment$)
We searched using the Controlled clinical trials topic-specific query filter and the above terms.
Appendix 6. GREAT search strategy
emollient* or oil* or ointment* or lubricant* or cream* or bath* or moisturis* or moisturiz* or corticosteroid* or steroid*
These terms combined with ’all intervention fields’.
This search was limited to intervention fields only.
F E E D B A C K
Eczema and Moisturisers, 12 April 2017
Summary
A comment was that while agreeing with their conclusion, in reality it is not that simple. Using the amount of creams and emollient
every month that are prescribed would require frequent bathing to get it all off and then renew it. Their skin would not tolerate it,
and it would come out in an eczematous rash. Putting on more than can be massaged in results in the layer left on top attracting dust
and the skin overheating. Little and often as needed is the key. Also, what suits one person’s skin one year, or season, may not the next.
Every skin is different, so I hope moisturisers aren’t restricted. Some of the cheaper creams such as Aqueous Cream and E45 which
contains Lanolin should, in my opinion, not be on the prescription list.
The authors agree with the comments made.
Reply
We are in agreement with the comments made. We have discussed these issues in the Discussion under Overall completeness and
applicability of evidence: “The majority of moisturisers considered in this systematic review included a large array of ingredients
(see Notes sections in Characteristics of included studies), which made it impossible to distinguish clearly between hydrophilic and
hydrophobic moisturisers, or, indeed, between humectant, emollient and occlusive moisturisers. Uncertainty about the exact proportions
of these ingredients in a moisturiser does not permit a clear distinction to be made, especially as the proportions are rarely mentioned in
the labelling or packaging. The quantity of certain ingredients can also affect the way a moisturiser feels on the skin. Some ingredients
in a moisturiser enhance its ability to remain on the skin (e.g. petrolatum), while others (e.g. oils) transfer quickly to clothes or bed
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linen. Temperature can influence the viscosity of moisturisers, which is crucially important for application on the skin, as the higher
the viscosity of the moisturiser, the more difficult it is to smear and spread on the skin, which can cause friction and lead to friction-
related adverse events. Once all of these aspects are taken into account, as well as dryness, day or night-time, the seasons, the weather,
and even the clothes that are worn, people with eczema will express a variety of preferences in different situations. The ideal moisturiser
should be easy to spread on the skin, have no smell, contain no irritating or sensitising ingredients, be cosmetically acceptable without
excessive sticking to clothes and bed linen, and be affordable for people with eczema.
This review does not address the importance of educating people with eczema on how to apply moisturisers, how much to use or how
often to use them. Cork and colleagues demonstrated that correct and adequate instructions in usage ”of the treatments resulted in
an 800% increase in the use of emollients, a reduction in disease severity as assessed with six area, six sign atopic dermatitis severity
score (SASSAD) (89% reduction compared with baseline) and no overall increase in the use of topical steroids“ (Cork 2003a). The
importance of education as part of the management strategy has also been emphasised by several other investigators (Arkwright 2013;
Ersser 2014; Mason 2013; Oakley 2016). Another shortcoming of the studies in this review was the lack of detailed reporting of
adverse events, which meant that we could not conclude which moisturiser might be preferable for avoiding adverse events. None of
the studies reported aspects such as the smell, stickiness or greasiness of the moisturiser, but rather adverse effects such as pruritus,
stinging, smarting or increase in erythema. We are still unable to confirm how often moisturisers need to be applied, although it is
more generally acknowledged that this should be at least once a day and preferably more frequently. Current recommended quantities
of moisturisers range from 250 g to 500 g per week (Moncrieff 2013; NICE 2007; Wollenberg 2016).”
We have also discussed these issues under Implications for practice: “This review does not inform us about the importance of education
in how to apply moisturisers, in particular how often they need to be applied and how much to use. However, since moisturisers reduce
flares, prolong the time to flare, decrease the necessity for topical corticosteroids and increase the efficacy of active treatment, it makes
clinical sense to encourage adherence to moisturiser therapy. This is especially important as moisturiser therapy is time consuming and
often required throughout life, as eczema is a chronic condition.
This review provides no information about which moisturisers might be preferred for different parts of the body, or preferred during
different seasons or personal circumstances, or which moisturisers best fit the actual disease status (acute or chronic) or severity (mild,
moderate or severe). There is no evidence to support a ’one size fits all’ approach. Therefore, clinical decisions about choices of moisturiser
should be based on the available evidence, and take into account the experiences and preferences of the person with eczema.”
The ingredient in the Aequous cream is sodium lauryl sulphate, which is mentioned under Agreements and disagreements with other
studies or reviews.
Contributors
Our Co-ordinating Editor Hywel Williams, our Feedback Editor Urbà González and the lead author Esther van Zuuren in discussion
with co-authors.
W H A T ’ S N E W
Last assessed as up-to-date: 17 December 2015.
Date Event Description
16 August 2017 Amended Further copy-editing amendments.
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H I S T O R Y
Protocol first published: Issue 3, 2016
Review first published: Issue 2, 2017
Date Event Description
10 May 2017 Feedback has been incorporated Authors responded to feedback referring to the text of the review. Please see
Feedback section for details
C O N T R I B U T I O N S O F A U T H O R S
EvZ was the contact person with the editorial base.
EvZ co-ordinated contributions from co-authors and wrote the final draft of the review.
EvZ and ZF screened papers against eligibility criteria.
EvZ and ZF obtained data on ongoing and unpublished studies.
EvZ translated German and French studies.
EvZ and ZF assessed ’Risk of bias’ of the studies.
EvZ and ZF extracted data for the review and sought additional information about papers.
EvZ and ZF entered data into RevMan 5.
EvZ, ZF and RC analysed and interpreted data.
EvZ, ZF and RC worked on the methods sections.
EvZ, ZF, AL and BA drafted the clinical sections of the background and responded to the clinical comments of the referees.
EvZ, ZF, and RC responded to the methodology and statistics comments of the referees.
BA was the consumer co-author and checked the review for readability and clarity, as well as ensuring outcomes are relevant to consumers.
EvZ is the guarantor of the update.
Disclaimer
This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding and Cochrane
Incentive funding to the Cochrane Skin Group. The views and opinions expressed herein are those of the authors and do not necessarily
reflect those of the Systematic Reviews Programme, NIHR, National Health Service or the Department of Health.
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Matthew Ridd (referee of the protocol): “I am chief investigator on a feasibility trial comparing four commonly used emollients in
children with eczema (not yet published but likely to be included in this review). I have recently submitted an application for funding
to take this study to a full trial.”
Sandra Lawton (referee of the protocol): “I have received an honorarium for speaking at meetings from Genus, Almirall, and Thornton
& Ross Ltd, and for reviewing an educational programme for Bayer.”
S O U R C E S O F S U P P O R T
Internal sources
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External sources
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The Parker Institute (RC) is supported by grants from the Oak Foundation, a philantropic/non-profit organisation.
• The National Institute for Health Research (NIHR), UK.
The NIHR, UK, is the largest single funder of the Cochrane Skin Group.
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
We have added ’vehicle’ as comparator under Types of interventions. For clarity, under Effects of interventions we added: “To ensure
consistency with the terminology used by the investigators, we used the wording for placebo or vehicle accordingly. It is important to
know that a placebo is also a moisturiser, but with a different composition and without the assumed effective ingredient; a vehicle has
the same composition as the moisturiser it is compared with, but without the assumed effective ingredient. As both placebo and vehicle
have moisturising properties they might have a beneficial effect on the skin barrier and thus might decrease disease severity.”
The text under Measures of treatment effect, Unit of analysis issues (within-participant studies), Assessment of heterogeneity and
Assessment of reporting biases has been amended slightly to provide improved clarification, but without and substantive change made
to the content.
We removed the last sentence Dealing with missing data “Whenever possible, we used results based on an ITT analysis” as this was
already mentioned in first paragraph.
In the protocol we stated under Assessment of heterogeneity “However, based on the GRADE Working Group approach (GRADE) we
will rate down for very serious inconsistency if the I² is above 75%”. Rating down the quality of evidence also depends on how much
other items have been downgraded. The GRADE Handbook states “Reviewers should grade the quality of the evidence by considering
both the individual factors in the context of other judgments they made about the quality of evidence for the same outcome. In such a
case, you should pick one or two categories of limitations which you would offer as reasons for downgrading and explain your choice
in the footnote. You should also provide a footnote next to the other factor, you decided not to downgrade, explaining that there was
some uncertainty, but you already downgraded for the other factor and further lowering the quality of evidence for this outcome would
seem inappropriate” (Schünemann 2013). Therefore, we have made the following post hoc changes to the protocol; “However, based
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on the recommendations of the Grading of Recommendations Assessment, Development and Evaluation working group (GRADE)
we considered rating down for serious inconsistency if the I² was above 50%, taking into account other considerations for rating down
the quality of evidence.”
The text under Data synthesis has changed slightly as although we planned to undertake meta-analyses using Mantel-Haenszel risk
differences, this was not applicable. In future updates when we can perform meta-analyses we will report results including 95%
confidence intervals and forest plots for both Peto OR and Mantel-Haenszel risk differences so that findings can be compared.
In the Subgroup analysis and investigation of heterogeneity we were not able to conduct our planned stratified analyses, as we had
no studies that addressed disease severity (mild versus severe eczema), atopic versus non-atopic eczema, or presence of filaggrin gene
mutations versus no filaggrin gene mutations and, although some studies were conducted only in children and others only in adults,
none of the comparisons allowed stratified analyses for age for the primary outcomes.
In the Sensitivity analysis section we planned to assess the influence of small-study effects on the results of a meta-analysis, but this
was only applicable in Comparison 1 for the outcome ’amount of active topical treatment used’ (Analysis 1.4). Also in this section we
were not able to perform a stratified analysis to compare study results from preregistered trials (e.g. available on Clinicaltrials.gov) with
those without an available prespecified protocol as planned because none of the studies included in meta-analyses were preregistered.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [therapeutic use]; Eczema [∗drug therapy]; Emollients [chemistry; ∗therapeutic use]; Patient Satisfaction;
Randomized Controlled Trials as Topic; Severity of Illness Index; Symptom Flare Up
MeSH check words
Humans
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